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ABSTRACT	
Cancer is a disease of the genome whereby mutational events that confer a survival advantage to cells are 
selectively retained. Consequently, genome instability and evasion of cell death are fundamental hallmarks 
of cancer. Certain cancers, including epithelial ovarian cancers (EOC), pancreatic ductal adenocarcinomas 
(PDAC) and a subset of sarcomas with complex karyotypes are characterized as being very genomically 
unstable suggesting that such tumours are driven by defects in DNA damage recognition and repair. 
Additionally, these tumours are also characterized by a high frequency of p53 mutation, extensive 
intratumoral heterogeneity and resistance, acquired or intrinsic, to DNA damaging chemotherapeutic 
agents: these tumour types consequently carry a poor prognosis. This highlights the need for detailed 
molecular characterization to identify therapeutic targets and stratification biomarkers. The aim of this 
study is to use a bioinformatic approach to identify commonly amplified genes, that function in DNA 
damage response and apoptotic processes, across the three tumour types, and which confer a poorer 
prognosis in these patients. For target identification, datasets for EOC and PDAC (obtained from 
TCGA) and sarcoma (obtained from GEO, NCBI) were analysed for common copy number aberrations 
(CNA) in 734 genes relating to DNA damage response and apoptosis and confer a poor prognosis in 
progression-free survival (PFS) data in EOC patients. Genes with prognostic significance (p <0.05) using 
the log rank test were picked from the top 100 most frequently amplified loci. Next, the targets were 
functionally validated by siRNA-mediated knockdown, overexpression and/or pharmacological inhibition 
using apoptosis, proliferation and migration assays. Four genes, SGK3, c19orf40, MRPS12 and ZBTB32 
were highlighted as being commonly amplified across all three tumour types, of which only SGK3 and 
c19orf40 were statistically significant in circular binary segmentation CNA calling when looking at PFS 
data in ovarian cancer patients.  
SGK3, a member of the serum/glucocorticoid regulated kinase (SGK) family was interesting as it has 
similar functions and substrates to the AKT kinase family, which we have previously shown to have key 
roles in tumour cell survival in response to therapy. Intra-patient paired sensitive (PEA1) and resistant 
(PEA2) and SKOV3 ovarian cancer cell lines, and Aspc1 and Panc-1 pancreatic cancer cell lines were 
used for validation studies.  siRNA-mediated knockdown of SGK3 did not alter induction of caspase 3/7 
activity in response to chemotherapy, relative to control treatments in all cell lines. In order to account 
for compensatory effects by the other SGK members in the presence of SGK3 knockdown, all three 
SGK members (SGK1, SGK2 and SGK3) were knocked down by siRNA and this also did not increase 
induction of caspase 3/7 activity. Migration, invasion and adhesion assays however, revealed that 
overexpressing SGK3 increases cell motility, invasion and adhesion respectively suggesting SGK3’s role 
in prognosis is via migration/tumour spread rather than response to therapy. Furthermore, there is 
evidence to suggest that SGK3 may act through the CXCR4-CXCL12 signalling axis and inhibiting 
CXCR4 may overcome SGK3 oncogenic effects.  
Additionally, recent data indicated that non-canonical subcellular localisation of key proteins alters 
treatment response. The oncogenic serine/threonine kinase, AKT, has been reported by us to be 
activated by DNAPKcs (PRKDC) in response to DNA damage in the nucleus of DNA damage resistant 
cancer cells and it’s inhibition restores therapeutic response in vitro, in vivo and clinically (Stronach et al, 
2011; Blagden et al 2014). Inhibition of DNAPKcs has also shown to restore cisplatin sensitivity in 
platinum resistant ovarian cancer cell lines. Here, I also show that inhibition of DNAPKcs enhances 
sensitivity to doxorubicin in all ovarian, pancreatic cancer and sarcoma cell lines studied. Further 
cytoplasmic/nuclear signalling changes have been observed indicating the importance of nuclear 
signalling in chemoresistance. We describe here a proteomic approach to capturing novel nuclear 
signalling changes associated with chemo-resistance. Stable isotope labelled populations of intra-patient 
paired ovarian cancer cell lines PEA1 (platinum sensitive) and PEA2 (resistant) and the chemo-resistant 
pancreatic cancer cell line Panc-1 were prepared, seeded overnight and treated with cisplatin (25µM) or 
doxorubicin (1.5µM) for 24 hours with and without an inhibitor of DNA-PK (10µM NU7441; prevents 
DNA damage induced AKT activation). Treatment and control cell populations were mixed and 
fractionated to collect nuclear and cytoplasmic fractions for Stable Isotope Labelling of Amino acids in 
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Cell culture (SILAC)/mass spectrometry analysis. Following established statistical filtering methods, 
common alterations in protein families were observed in nuclear fractions of drug treated resistant cells. 
Seven proteins were differentially expressed, some belonging to serine/arginine rich splicing factor 
protein family (1.3-2.4-fold increase), nuclear ribonucleoprotein family (1.2-fold increase) and DEAD box 
protein families. Protein changes in PRKDC were also observed in the resistant cell lines, which were 
absent in the sensitive PEA1 cells. The application of SILAC proteomics has identified novel protein 
changes in subcellular compartments that correlate with response/resistance to chemotherapy. Functional 
validation of identified some interesting candidate proteins, however further characterization is necessary 
to assess their roles in chemoresistance.  
 
The work presented in this thesis has highlighted several candidates that could have good therapeutic 
potential to either act alone (i.e. SGK3 inhibitors could be effective in preventing certain dynamics of the 
metastatic process, which is a major contributor of poor prognosis in patients) or in combination with 
existing agents (i.e. DNAPKcs inhibitor with doxorubicin in platinum resistant patients). Additionally, 
several targets have also been identified through RPPA and SILAC proteomics, that may have functional 
relevance in chemoresistance, however further characterization of these candidates is needed to fully 
understand their roles.  
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CHAPTER	1:	INTRODUCTION	
1.1	OVARIAN	CANCER	
 
1.1.1	OVERVIEW	
 
Ovarian cancer is the fifth most common cancer in females in Europe and the seventh most common 
worldwide. In 2012, there were 7,029 new cases diagnosed in the UK, with 80-90% of cases epithelial in 
origin, with the most common type being serous carcinoma.  Although recent data from Cancer Research 
UK shows that mortality rates have been decreasing, improvements need to be made to accelerate this 
trend, particularly in the older age groups. Risk factors for this disease include age, where the incidence of 
ovarian cancer increases with age and peaks in women aged 80-84 (Cancer Research UK data: 
(http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-
cancer/incidence#heading-one). Other risk factors include obesity, where people with increasing BMI have 
increased risk of developing ovarian cancer (Calle et al, 2003, McLemore et al, 2009) and parity, where 
parous women have a lower risk of ovarian cancer than nulliparous (never pregnant) women (Pike et al, 
2004). Genetic risk factors associated wth ovarian cancer include hereditary breast and ovarian cancer 
(HBOC) and Hereditary Non-polyposis colorectal cancer (HNPCC/Lynch Syndrome). Patients with 
these syndromes are considered high-risk for ovarian cancer and the distinction between the two relies on 
the genetic mutation responsible for the pathogenesis, where HBOC is caused by germline pathogenic 
variants in BRCA1 or BRCA2 and patients with these aberrations confer an increased risk for breast 
cancer (40-80%), ovarian cancer (11-40%) (Petrucelli et al, 2013) and families that exhibit the 
HNPCC/Lynch syndrome tend to have mutations in mismatch repair (MMR) genes such as MLH1 and 
MSH2 that are found on at least four chromosomes, 2p, 3p, 7p and 2q (Pike et al, 2004). Mutations in 
these MMR genes are associated with an increased risk (9-12%) for ovarian cancer (Watson et al, 2008). 
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1.1.2	CLASSIFICATION	OF	OVARIAN	CANCER	
Historically, all ovarian cancers have been grouped as one. However, majority of ovarian tumour can be 
placed into one of three categories: surface-epithelial stromal tumours, sex cord-stromal tumours and 
germ cell tumours. Each category includes a number of subtypes, however for the purposes of this study, 
the focus will be on a subtype of surface-epithelial stromal tumours. Surface-epithelial stromal tumours 
(or epithelial ovarian cancer, EOC) make up for 60% of all ovarian tumours and 90% of all malignant 
tumours. Morphologically, several subtypes of epithelial ovarian cancer (EOC) have emerged, each with 
distinct histology: high-grade serous ovarian cancer (HGSOC), clear cell carcinoma (CCC), endometrioid 
carcinoma (EC), mucinous carcinoma and low-grade carcinoma. These subtypes vary greatly, with respect 
to presentation, prognosis, response to therapy, site of origin and histology. Their histological differences 
are as detailed in figure 1. Shih and Kurman further classified ovarian cancer into two broad types based 
on genetic and histologic features. Type I is a heterogeneous group, which includes low-grade serous, 
endometrioid, clear-cell and mucinous carcinomas which are typically slow growing whilst type II refers 
to high-grade serous (HGS) cancers, which are typically more aggressive, characterized by ubiquitous 
TP53 mutations (Kobel et al, 2008; Ahmed et al, 2010) and present at an advanced stage with metastasis at 
diagnosis. Additionally, it is thought that the cell types that reflect the differences in underlying molecular 
profiles are thought to be the most relevant histologic prognostic factor in ovarian cancer treated with 
platinum/paclitaxel (Bamias et al, 2012). Type I tumours generally lack TP53 mutations, tend to 
demonstrate a slower growth and are not sensitive to platinum based therapy whereas type II tumours are 
more aggressive in nature, usually present at an advanced stage and are initially sensitive to chemotherapy. 
Studies have also indicated that LGSOC has a significantly better prognosis than HGSOC (Hannibal et al, 
2012).  
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Figure 1: differences in histology between the different subtypes of epithelial ovarian 
cancer. These images represent typical histology of each subtype, however there are variations where for 
example, although typically, high-grade serous subtype has a papillary pattern, it can also present containing 
clear cells and have been mistaken for clear cell carcinomas. Figure adapted from Soslow, 2008.  
 
1.1.2.1	Serous	Carcinomas	
Serous carcinomas make up the most common types of malignant ovarian tumours and tend to be 
aggressive, invasive and typically confer a poor prognosis. Well-differentiated serous tumours display 
large degrees of heterogeneity in appearance. Initially it was thought that serous carcinomas may either be 
high-grade or low-grade, where the low-grade progressed into the high-grade as the tumour became more 
aggressive and invasive. In light of mounting evidence to the contrary, a two tier system, whereby 
tumours are subdivided into high-grade and low-grade has been proposed (Vang et al, 2009). This was 
based on the knowledge that there is evidence showing that the two subtypes have very distinct molecular 
characteristics, etiology and prognosis.  
1.1.2.1.1	Low-Grade	Serous	Ovarian	Cancer	(LGSOC)	
Low grade serous carcinoma (LGSOC, also known as invasive micropapillary serous carcinoma) has also 
been described as a type I pathway ovarian cancer. It is thought to arise from a small atypical proliferative 
serous tumour arising from a serous cystadenoma (APST) as detailed in figure 2, which progresses to 
form a non-invasive micropapillary serous carcinoma (MPSC). Tumour progression results in an invasive 
micropapillary serous carcinoma and invasive implant in the peritoneum. The results are histologically 
identical to low-grade serous ovarian cancer and accounts for 10% of serous carcinomas. They are 
High	grade	serous Low	grade	serous Clear	cell	
Mucinous Endometrioid
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characterized by frequent KRAS, BRAF and HER-2 mutations, which occur in about 68% of LGSOC 
and tend to lack TP53 mutations (~8% cases) (Singer et al, 2005). KRAS and BRAF mutations are 
typically much more common than HER2, however mutations of each of these 3 genes tend to be 
mutually exclusive. Given that the three genes are all upstream of the mitogen-activated protein kinase 
(MAPK) pathway, mutations in any of these genes results in constitutive activation of the MAPK 
pathway, consequently resulting in uncontrolled proliferation (Cho et al, 2009). Additionally, allelic 
imbalances are observed on various chromosomal arms such as 1p, 5q, 8p, 18q and 22q are shared 
between APST and MPSC, however these imbalances are more frequent in MPSC and further increase in 
frequency in LGSOC. This gradual increase in chromosomal instability associated with the LGSOC type I 
pathway is in contrast to HGSOC type II pathway, where high levels of chromosomal instability are 
observed (Singer et al, 2002; Staebler et al, 2002).  
Figure 2: The progression and cytogenetic changes in LGSOC and HGSOC. Picture taken 
from Rosen et al, 2007.  
1.1.2.1.2	High-Grade	Serous	Ovarian	Cancer	(HGSOC)	
A lot less is known about the pathogenesis of HGSOC. The identification of the precursor lesion of 
HGSOC has been somewhat of a mystery, since it always presents at high-stage and the tumour 
development is rapid. Traditionally it is thought to be from surface epithelium of epithelial inclusions in 
the ovary, however more recently, it is now thought that the origin is from the fallopian tube (Berek et al, 
2015). Unlike LGSOC, mutations of K-RAS, BRAF, HER2 occur very infrequently (Singer et al, 2002). 
HGSOC is characterized as having ubiquitous p53 mutations, with extensive DNA copy number changes 
and upregulation and downregulation of other genes. Published reports have supported a role of TP53 
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mutation as an early mutational event in the pathogenesis of HGSOC. Similar to TP53, BRCA has been 
shown to contribute to the pathogenesis of HGSOC either through somatic mutations, promoter 
hypermethylation and isolated loss of heterozygosity, all leading to inactivation of BRCA (Giesler et al, 
2002; Hilton et al, 2002). Additionally, approximately 16% of HGSOC is associated with germline BRCA 
mutations (Risch et al, 2001). Genome-wide analysis of DNA copy number alterations have identified 
significant amplifications and deletions, including homozygous deletions. One particular amplification is 
of Cyclin E1 (CCNE1), occurring in approximately 20% of HGSOC cases, which correlates with poor 
clinical outcome (Etemadomoghadam et al, 2013). Interestingly, CCNE1 amplifications were found to be 
independent of BRCA1/2 mutations and thus do not respond to PARP inhibitors, consequently 
contributing to poor outcome. Homozygous deletions included loci containing Rb1, CDKN2A/B and 
CSMD1 that were not present in either serous borderline tumours or low-grade serous carcinomas.  
1.1.2.2	Development	of	HGSOC	(pathway	II)	from	LGSOC	(pathway	I)	
It has been established that the two pathways of serous ovarian cancer occur independently and 
additionally, it has been observed that when LGSOC does recur, it maintains its low-grade appearance, 
suggesting that HGSOC does not progress from LGSOC. However, on some occasions, it has been 
observed that HGSOC has evolved from LGSOC. For example, 2% of HGSOC were associated with 
serous borderline tumour (Malpica et al, 2004). Dehari et al, also reported 3% of serous carcinomas that 
contained both high-grade and low-grade components. Furthermore, 2 out of the 6 tumours studied 
contained KRAS mutations in both high-grade and low-grade thus establishing a clonal relationship 
between the two grades. However, there was a lack of TP53 mutations, which is typical of HGSOC. 
Interestingly, the HGSOC that arises from LGSOC does not differ morphologically to those that arise 
from the type II pathway. These observations collectively suggest that a very small proportion of 
HGSOC may indeed arise from atypical proliferative serous tumours, a non-invasive micropapillary 
serous carcinoma or low-grade serous carcinoma.  
1.1.3	TREATMENT	AND	NOVEL	THERAPEUTICS	
1.1.3.1	Gold	Standard	Treatment		
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There have been improvements in progression free survival and overall survival over the decades, mainly 
owing to improved surgical techniques and the introduction of cisplatin in the early 1980s followed by 
paclitaxel in the 1990s. Currently, about 70% of patients with EOC present at an advanced stage with 
long-term survival being <25% (Baldwin et al, 2012). The gold standard treatment for EOC patients is 
cytoreductive surgery followed by a combination chemotherapy regimen, usually consisting of a platinum 
agent and a taxol. Neoadjuvant chemotherapy followed by interval debulking surgery is also considered a 
suitable alternative in patients that are unable to have complete resection in the primary debulking surgery 
(Vergote et al, 2010; Sato et al, 2014). Additionally, it is also thought that the size of the metastasis tumour 
and the clinical stage were important factors in determining benefit from treatment. Patients with stage 
IIIC metastatic cancer <45mm in diameter benefited more from primary debulking surgery followed by 
chemotherapy whereas patients with stage IV metastatic cancer >45mm in diameter benefited more from 
neoadjuvant chemotherapy (van Meurs et al, 2013). Initially cisplatin and/or docetaxel were utilized, 
however following several clinical trials, carboplatin and paclitaxel are the optimal combination as they 
have consistently demonstrated equivalent response rates and outcomes to cisplatin with a marked 
reduction in toxicity (du Bois et al, 2003). Paclitaxel is a preferred choice over docetaxel because it has less 
myelosuppressive toxicity (Aabo et al, 1998; Nejit et al, 2000; Hogberg et al, 2001; Vasey et al, 2004). A 
2013 meta-analysis suggested that carboplatin in combination with pegylated liposomal doxorubicin 
(PLD) would be a suitable alternative to carboplatin with paclitaxel. However, this conclusion was based 
on two trials with only 820 women (Lawrie et al, 2013).   
1.1.3.2	Serous	Carcinoma	Treatment	Strategies		
The obvious differences between the HGSOC and LGSOC can be exploited therapeutically because one 
would logically conclude that chemotherapy may affect each subtype differently given the different 
molecular profiles observed between the two subtypes. Indeed, data has shown that the LGSOC does not 
respond as well to conventional platinum-based chemotherapy as HGSOC (Schmeler et al, 2008). In vitro 
data also corroborates this observation where LGSOC frequently showed extreme drug resistance to 
paclitaxel and carboplatin compared with high-grade serous ovarian carcinomas suggesting that the 
identification of newer agents to treat LGSOC would prove highly beneficial. One such option is CI-
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1040, a MAPK inhibitor, which prevents the activation of MAPK pathway, known to play a critical role 
in the development of LGSOC as mentioned earlier. In vitro and in vivo data show that CI-1040 inhibits 
growth of ovarian cancer cell lines harboring KRAS or BRAF mutations (Pohl et al, 2005; Nakayama et al, 
2008).  
1.1.3.3	Relapse	and	Chemo-resistance	
One of the major setbacks of treatment in ovarian cancer is despite the excellent response rates to the 
carboplatin/paclitaxel combination therapy of about 70-80%, the majority of these women eventually 
relapse, at which point treatment options are limited. There has been very little improvement over the last 
two decades in the cure rate; progression free survival (PFS) has not changed after first-line therapy, 
however overall survival (OS) is slightly longer. This may possibly be due to improved patient care and a 
better selection of drugs. Over the last few years, there have been an increasing number of available 
therapies, however, this poses another problem of making decisions on the most appropriate treatment 
and timing of treatment.  
At relapse, most patients are treated with a platinum-based drug, however patients do eventually develop 
hypersensitivity after a couple of cycles of relapse therapy. This can be circumvented by using a slow 
infusion of drug combined with steroids and antihistamines (Lee et al, 2005). Combination treatment of 
carboplatin and paclitaxel was also thought to extend both the PFS and OS of patients with recurrent 
ovarian cancer. The combination of carboplatin with gemcitabine is also commonly used in recurrent 
ovarian cancer but it can cause significant myelosuppression, consequently delaying treatment (Pfisterer et 
al, 2006).  
1.1.4	THE	EVOLUTION	OF	RESISTANCE	
As mentioned above, HGSOC are initially hypersensitive to platinum chemotherapy. There are some 
cases where patients have progressive disease during initial treatment, termed platinum-refractory 
patients, however they account for 14% of cases (SCOTROC1 data, Cooke et al, 2011). Of the patients 
that do respond initially, approximately 75% of them relapse; this group is further classified according to 
likelihood of response with re-treatment with platinum agents. Those who relapse within 6 months of 
initial treatment tend to have response rates of less than 10% and consequently are classified as platinum 
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resistant whereas patients who relapse more than 12 months since initial treatment have 60% response 
rates to further platinum treatment and thus are classified as platinum sensitive (Bookman, 1999; Cooke et 
al, 2011). Patients who relapse between 6-12 months are considered partially platinum sensitive (Kaye, 
2008).  
It is thought that resistant sub-clones are present at the start of treatment and these get selected for when 
a selective pressure is applied (i.e. treatment) due to the higher fitness of these cells compared to the 
sensitive counterparts.  These cells repopulate the tumour bulk due to the lack of competing cells and 
patients harbouring these tumours will relapse and be resistant to further treatment as detailed in figure 3. 
Clinical evidence supports this theory of selection for drug resistance; for example, point mutations 
conferring resistance to imatinib has been reported to be present at presentation in acute lymphocytic 
leukemia and chronic myeloid leukemia (Choi et al, 2007).  
 
 
 
 
 
 
 
 
 
 
Figure 3: The evolution of cancer. Taken with permission from Cooke et al, 2011. 
1.1.4.1	Treatment	of	Platinum-Resistant/Refractory	Ovarian	Cancer	
Patients that relapse within 6 months of platinum treatment represent a heterogeneous group of diseases 
with a low response rate, typically between 10-20%. In these cases, clinicians use non-platinum drugs, 
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however, evidence from non-randomized trials have suggested that dose-fractionated weekly therapy may 
overcome platinum resistance. High response rates with carboplatin and paclitaxel have been observed 
(Cadron et al, 2007; Sharma et al, 2009). A general recommendation can be made for the use of single-
agent liposomal doxorubicin, topotecan, etoposide, gemcitabine or paclitaxel. There is no preferred 
sequence of agents due to absence of biomarkers predictive of response to treatment.  
1.1.5	TARGETED	THERAPY	
In an attempt to address the lack of effective treatments for platinum-resistant patients, research has 
focused on identifying molecular targets that can be therapeutically targeted.  
1.1.5.1	Targeting	Angiogenesis	
EOC is one tumour that is unique from other solid tumours because of its pattern of spread within the 
peritoneum. In this context, angiogenesis is thought to be crucial in the persistence of EOC and that in 
addition to the observation that vascular endothelial growth factor (VEGF) levels are often higher in 
ovarian cancer has led to a research focus in this area. Antiangiogenic agents such as VEGFR tyrosine 
kinase inhibitors (TKIs) as well as antibodies (bevacizumab) have been evaluated in the context as both 
single-agents and in combination with conventional chemotherapy. Bevacizumab, a monoclonal antibody 
that targets VEGF-A has been most widely studied. Phase II trials have shown that single-agent 
bevacizumab treatment in heavily pretreated patients have comparable tumour response rates to those 
seen with standard chemotherapy. Additionally, treatment with bevacizumab has been shown to delay 
tumour progression (Burger et al, 2007; Cannistra et al, 2007).  However, high rates of intestinal 
perforation have been observed in some studies, which have raised concerns over this treatment, so 
patients need to be carefully selected. Bevacizumab has not only been shown to be effective as part of 
front-line therapy and in platinum-sensitive recurrent ovarian cancer, but combining it with either 
pegylated liposomal doxorubicin, weekly paclitaxel or topotecan (the main drugs used in platinum-
resistant setting), significantly improved PFS and objective response rate (Pujade-Lauraine et al, 2014). 
Other antiangionenic drugs that have been evaluated are pazopanib and nintedanib. Pazopanib, which 
inhibits angiogenesis, tumour cell proliferation and metastasis was shown to modestly improve PFS in a 
phase II AGO-OVAR16 clinical trial, however it failed to show any benefit in overall survival and also 
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was associated with adverse toxicity profile, which would limit its approval (McLachlan and Banerjee, 
2015). Nintedanib was thought to be beneficial in combination with carboplatin and paclitaxel by 
significantly increasing PFS in women with advanced ovarian cancer, however this was also associated 
with more gastrointestinal adverse events (du Bois et al, 2016).  
1.1.5.2	Targeting	Epidermal	Growth	Factor	Receptor	(EGFR)	
EGFR is involved in various signaling cascades, promoting survival, growth and proliferation. It tends to 
be overexpressed in up to 70% of EOC, which confers a poor prognosis in these patients. A small-
molecule inhibitor targeting EGFR, erlotinib, was evaluated as maintenance treatment. A phase II study 
found that 44% EOC patients’ treatment with maintenance erlotinib in platinum-resistant or –refractory 
patients achieved stable disease and there was an objective response rate of 6% (Gordon et al, 2005).   
There was preclinical evidence suggesting that EGFR TKIs may potentiate the anti tumour effects of 
chemotherapeutic agents such as carboplatin and that it may beneficially modulate drug resistance, 
suggesting a causal relationship between EGFR and the development of platinum resistance (Cullinane et 
al, 2000). This theory has since been proven where EGFR activation was observed during platinum 
therapy, which contributes to the development of platinum resistance (Granados et al, 2015).  
1.1.5.3	PARP	inhibitors	
Poly (ADP-ribose) polymerase (PARP) inhibition was first introduced in 2005 as a novel cancer 
therapeutic strategy, because it showed synthetic lethality with BRCA inhibition. Synthetic lethality is a 
concept whereby the loss of either gene (out of a pair) is compatible to life, however inhibition of both 
together is detrimental to the cell and results in cell death. The logic behind using this drug in a BRCA 
deficient context will be discussed in detail in section 1.5.3. PARP inhibitors have been evaluated in many 
cancers, including ovarian, where it has had some success. Olaparib is the best studied drug, that has 
activity against PARP-1 and PARP-2. In the context of platinum-sensitive ovarian cancer, a trial showed 
the benefit of olaparib treatment in platinum-sensitive HGSOC that have relapsed where there was in 
increase in PFS from 4.8 months to 8.4 months when compared to the placebo arm (HR=0.35; 95%CI, 
0.25-0.49; p=<0.01) (Ledermann et al, 2012). Olaparib has also shown some activity in platinum-resistant 
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ovarian cancer, where one study showed objective response rates in 30% (6 out of 20 patients) whilst 
other studies have shown objective response rates ranging from 33% - 42% (Audeh et al, 2010; Fong et al, 
2010; Gelmon et al, 2011). These initial reports did indicate that further investigations of olaparib in 
platinum-resistant cancer are warranted. A recent trial by Jonathan Ledermann and colleagues, which 
studied a group of 265 patients with platinum-sensitive epithelial ovarian cancer (including fallopian tube 
cancer and peritoneal cancer) found that olaparib treatment was associated with a statistically significant 
improvement in progression free survival when looking at the group as a whole and when patients were 
stratified according to their BRCA mutation status (8.4 months in olaparib group vs 4.8 in placebo group 
and 11.2 months in BRCA mutant group versus 4.8 in placebo) (Ledermann et al, 2016).  This trial 
provided key evidence which led to the National Institute for Health and Care Excellence (NICE) 
approving olaparib use in third line treatment for patients with relapse platinum-sensitive ovarian cancer, 
fallopian tube cancer and peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease 
has responded to subsequent platinum-based chemotherapy (Tucker et al, 2016; 
http://www.nice.org.uk/guidance/TA381; January, 2016 [accessed 2nd May 2016]).  
1.1.5.4	AKT	inhibitors	
Several studies have reported inhibition of AKT as a therapeutic strategy in several malignancies. AKT, a 
key effector of the PI3K pathway has three isoforms which may have distinct biological relevance. For 
example, in glioma cell lines, downregulation of AKT2 and AKT3 induced caspse-dependent apoptosis 
whereas knockdown of AKT1 did not have the same effect (Mure et al, 2010). Phosphorylation of AKT 
stimulates a number of downstream signals, one of the more important one being tuberous sclerosis 
complex 2 (TSC2), which is a key mediator of the mTOR complex along with tuberous sclerosis complex 
1 (TSC1) (Zhang et al, 2009). AKT also has important roles in the transcriptional regulation of apoptosis. 
Given its important roles in oncogenic signaling and the fact that the AKT/mTOR pathway is frequently 
deregulated in ovarian cancer, it appeared to be a good target for drug development and several studies 
have studied the effect of AKT inhibition in preclinical and clinical studies. One of the first AKT 
inhibitors to be tested was the lipid-based inhibitor perifosine and preclinical studies showed that 
perifosine inhibited ovarian cancer cell proliferation and also potentiated paclitaxel sensitivity in vitro and 
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in vivo (Romero et al, 2012). As a result of this, a phase I trial of perifosine was carried out with docetaxel 
in platinum- and taxane-resistant ovarian cancer. At the maximum tolerated dose administered in 11 
patients, 1 patient (with PTEN-null status) achieved partial response and 3 patients achieved stable 
disease status (Fu et al, 2012). Another ATP-competitive pan-AKT inhibitor, GSK795 was assessed in a 
pharmacodynamics and pharmacokinetic study in advanced platinum-resistant ovarian cancer. Treatment 
with GSK795 showed reduced fluorodeoxyglucose (FDG) metabolism in majority of tumours; 
downregulation of pAKT and the proliferative marker Ki67 was also observed (Gungor et al, 2011). Work 
from our laboratory addressing the effectiveness of GSK795 in ovarian cancer showed that combining 
this agent with platinum-based agent was beneficial in vitro. It was also shown that FDG-PET may be a 
useful pharmacodynamics biomarker to assess the effects of GSK795 on tumour glucose metabolism in 
the clinic (Cheraghchi-Bashi et al, 2015). Results from a phase I study (NCT01653912) evaluating the 
clinical efficacy of another AKT inhibitor GSK2110183 in combination with carboplatin and paclitaxel in 
patients with platinum-resistant ovarian cancer showed an objective response rate of 50% among patients 
treated at the maximum tolerated dose (Blagden et al, 2014). This was considered to be a significant effect 
because all the patients recruited in this trial were platinum-resistant or platinum-refractory, where a 
response rate of 15% is expected, suggesting that AKT inhibition may modulate platinum resistance.  
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1.2	PANCREATIC	CANCER	
1.2.1	OVERVIEW	
Pancreatic cancer is UK’s 9th most common cancer, and despite numerous research efforts into 
pancreatic cancer over the forty years, the 5-year survival still remains low at 3% and is the fifth leading 
cause of cancer death in the UK (Cancer Research UK). Pancreatic cancer can be classified into different 
subtypes based on histology, 85% of which are adenocarcinomas, that tend to be diagnosed at an 
advanced stage and are resistant to chemotherapy, contributing to its poor prognosis and will be the focus 
of this study.  
Pancreatic cancer is the 12th most common cancer in the world, with 338,000 new cases diagnosed in 
2012. The estimated 5-year prevalence worldwide with pancreatic cancer is 4.1 per 100,000 (Ferlay et al, 
2014). Pancreatic cancer is more prevalent in older people with a median age of 71; although the 
incidence is lower in people aged <59 years, the 5-year survival is relatively higher than those over the age 
of 60, where survival drops significantly. The poor survival observed is attributed to the lack of specific 
symptoms and limited diagnostics, resulting in the late detection of the disease at which point curative 
surgery is not an option. Even for the 15-20% of patients who do undergo potentially curative surgery, 
the 5-year survival is still only 20% (Ahrendt et al, 2002). There are improvements in patients who receive 
chemotherapy/radiotherapy in addition to surgery, however resistance to these treatments often occurs, 
at which point the patients receive palliative care.  
1.2.2	CLASSIFICATION	OF	PANCREATIC	CANCER	
The pancreas can support several different tumour types, which can be identified based on their histology 
to various pancreatic-cell lineages. The disease can range from low-grade neoplasms to high-grade lethal 
carcinomas such as invasive pancreatic ductal adenocarcinoma. Broadly, pancreatic cancer lesions can fall 
into two categories: the exocrine tumours and the endocrine tumours. The vast majority of cancers are 
exocrine in type, majority of which are adenocarcinomas but can also include cystic tumours and tumours 
of the acinar cells. Endocrine tumours (also called pancreatic neuroendocrine tumours (PNETS) are 
uncommon and about a third tend to be benign whilst two thirds are malignant, and have a better 
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prognosis compared to the exocrine tumours. Other rarer types of pancreatic cancers are 
pancreatoblastoma, sarcomas of the pancreas and lymphoma. The different tumour types show distinct 
clinical behaviour and molecular profiles. The main tumours based on histology are summarized in table 
1. 
 
 
 
Table 1: Types of pancreatic neoplasms. Adapted from Bardeesy et al, 2002.  
Pancreatic ductal adenocarcinoma (PDAC), which make up majority of the exocrine tumours will be the 
focus of this study. PDAC is an invasive malignant epithelial neoplasm with glandular (ductal) pattern and 
varying degrees of cellular atypia and differentiation, and is one of the most lethal of solid malignancies. 
There are three precursor lesions associated with PDAC: PanINs, IPMNs and MCNs. The precursor 
lesions and genetic events involved PDAC progression are detailed in figure 4.  
 
 
 
 
 
 
 
 
Figure 4: Pancreatic precursor lesions and genetic events involved in pancreatic 
adenocarcinoma progression. The three known pancreatic lesions are PanINs, IPMN and MCN. The genetic 
alterations involved in adenocarcinomas are also seen in the precursor lesions. The genetic lesions can be divided into early 
events and include KRAS mutations and later events, which include events such as p53 loss. Picture taken from Hezel et al, 
2006.  
Tumour&type Histological&features Mutations
Adenocarcinoma Ductal/morphology KRAS,/CDKN2A, TP53,/SMAD4
AcinarAcell/carcinoma Zymogen/granules APC/βAcatenin
Pancreatic/endocrine/ tumour Hormone/ production MEN1
Serous/cystadenoma Ductal/morphology,/ cystic/
growth
VHL
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PanINs are the most widely studied precursor lesions of PDAC and are graded from I-III as shown in 
figure 4. The increasing grade reflects increasing atypia and dysplastic growth, eventually leading to 
adenocarcinoma. The high-grade PanINs transform into PDAC evidenced by areas of invasion beyond 
the basement membrane and an accumulation of genetic alterations as the PanINs progress through 
grades. 90% of PanINs at grade I harbor KRAS mutations, followed by CDKN2A/p16, SMAD4 and 
TP53 mutations in the intermediate and later stages (Hezel et al, 2006; Cowan and Maitra, 2014).    
The less common precursor lesions are MCNs and IPMNs. MCNs are epithelial cystic lesions that 
produce mucin and harbor a ovarian-type stroma with variable degrees of epithelial dysplasia. IPMNs 
resemble PanINs at cellular level but develop larger cystic structures. Interestingly, expression profiling 
has revealed several genetic alterations that are commonly associated with the precursor lesions and 
PDAC, suggesting key shared molecular events (Crnogorac-Jurcevic et al, 2002, Prasad et al, 2005).  
1.2.3	TREATMENT	FOR	PDAC	
1.2.3.1	Gold	Standard	and	Emerging	Treatments	
The gold standard treatment currently is gemcitabine, a nucleoside inhibitor, which is favoured over other 
drugs such as 5-fluorouracil and platinum derivatives due to them being less tolerable. However, it only 
increases overall survival by less than two months in patients with unresectable PDAC. Gemcitabine 
alone treatment has been the gold standard treatment for many years, and has also been the subject of 
combination testing with other drugs in an attempt to improve efficacy, however, most studies failed to 
show any significant benefit of combination treatment when compared to gemcitabine alone (Laethem et 
al, 2011). Although studies showed a statistically significant overall survival benefit of 0.33 months in 
combining a HER1/EGFR inhibitor, erlotinib, with gemcitabine compared to gemcitabine alone, this was 
also accompanied with increased risk of toxicities such as interstitial lung disease and treatment-related 
death suggesting that the clinical value of this combination may be limited (Mikstad et al, 2007).  
Recently, a new gemcitabine-free combination, FOLFIRINOX, which is a drug combination regimen 
including oxaliplatin, irinotecan, leucovorin and 5-FU, was shown to be more superior to gemcitabine 
with a median OS of 11.1 months versus 6.8 months in the gemcitabine alone group (p =<0.001) and a 
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median PFS of 6.4 months versus 3.3 months (p=<0.001). Additionally, the FOLFIRINOX regimen also 
showed a higher response rate of 32% compared to the gemcitabine alone group of 9% (p=<0.001). 
Again, toxicity and safety issues were observed, but despite the uncertainties, FOLFIRINOX may be 
considered a standard of care in patients with metastatic disease who fulfill the following: normal 
bilirubin, good performance status and no cardiac ischaemia (Laethem et al, 2011).  
1.2.3.2	Targeted	Therapy	
1.2.3.2.1	Epidermal	Growth	Factor	Receptor	(EGFR)	
EGFR is highly expressed in PDAC (30-50%) and is thought to be required independent of KRAS 
mutations. Erlotinib is selective inhibitor of the EGFR tyrosine kinase and was the first approved 
targeted therapy in PDAC. A phase III trial showed a significant survival benefit when treated in 
combination with erlotinib and gemcitabine versus gemcitabine alone treatment (Moore et al, 2007). 
However, interestingly, it was also observed that patients developing a skin rash on erlotinib treatment 
had a median OS of up to 10.5 months whereas those that didn’t develop a rash did not benefit from 
further erlotinib treatment. Consequently, it was recommended that if patients did not develop a rash 
within 8 weeks of treatment, that the drug use be discontinued (Moore et al, 2007; Kullman et al, 2009). 
An anti-EGFR antibody, nimotuzumab was also evaluated and showed a significant prolonged OS of 1 
year when combined with gemcitabine compared to gemcitabine alone in a phase II trial (Strumberg et al, 
2013). Further positive trends were also reported for other EGFR inhibitors matuzumab (phase I) and 
panitumumab (phase II) (Graeven et al, 2006; Kim et al, 2011). Recently, KRAS mutational status has also 
been implicated as being able to predict response as it was observed that patients with wild type KRAS 
tumours had significantly better OS in response to erlotinib. However, more studies are needed to 
evaluate whether the associations are prognostic or predictive.  
1.2.3.2.2	Insulin-Like	Growth	Factor	(IGF-1)	
IGF-1 is upregulated in the majority of PDACs. IGF-1 activates several key signaling pathways such as 
PI3K/AKT/mTOR and MEK/ERK pathways, which have key oncogenic roles in most solid tumours 
including PDACs and will be discussed in detail in later sections.  
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A phase II trial investigated the benefit of gemcitabine in combination with erlotinib and cixutumumab, a 
monoclonal anti-IGF receptor antibody compared to gemcitabine plus erlotinib. No significant 
differences in OS and PFS was observed but the experimental arm had increased grade 3/4 toxicities 
(Philip et al, 2012). The combination of gemcitabine with another anti-IGFR antibody, ganitumab or 
conatumumab is currently being evaluated, however the interim analysis suggested a positive trend for the 
6-month OS and PFS for the gemcitabine and ganitumab combination (Kindler et al, 2010). This study 
did not progress to the subsequent phase III trial due to lack of benefit observed during another 
preplanned interim analysis (Kleger et al, 2014).  
1.2.3.2.3	VEGF	
High levels of VEGF are also observed in PDAC and its receptors are widely known for promoting 
angiogenesis and metastasis. Despite this, the combination of gemcitabine and bevacizumab failed to 
improve OS and PFS compared to gemcitabine alone treatment (Kindler et al, 2010). A different 
approach of targeting both the fibroblast growth factor along with VEGF also did not show any benefit 
(VanCutsem et al, 2009).  
Promising phase I/II results were obtained for axitinib, which is a small molecule inhibitor targeting 
VEGFR-1-3, platelet-derived growth factor receptor (PDGFR) and c-kit (CD117). This led to a 
subsequent phase III trial, which concluded that there was no benefit in adding axitinib to gemcitabine 
(Kindler et al, 2011). Similar trends were seen with sorafenib, which targets VEGFR-2-3, PDGFR and 
Ras/Raf/MEK/ERK where despite promising initial results, a significant benefit was not observed with 
gemcitabine with respect to PFS and OS (Kindler et al, 2012). 
1.2.3.2.4	Farnesyltransferase	Inhibitors	
KRAS mutations are very common in PDAC with >80% of cases harboring them. KRAS binding to the 
plasma membrane via farnesylation or geranylgeranylation is a prerequisite for its activation and thus 
disrupting this mechanism has been evaluated as a therapeutic strategy (Rowinsky et al, 1999). Tipifarnib, 
a farnesyl transferase inhibitor, failed to show any benefit in combination with gemcitabine; this could be 
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due to compensatory mechanisms or perhaps certain RAS isoforms do not require farnesylation for 
activation (VanCutsem et al, 2004).  
Additionally, prenyl-binding protein (PDEδ) binds and solubilizes farnesylated RAS-proteins, thereby 
enabling their diffusion into the cytoplasm (Chandra et al, 2012). A small molecule, deltarasin, interefering 
with the binding site of PDEδ was evaluated in vitro and in vivo and it was demonstrated that proliferation 
of PDAC cells were inhibited (Zimmerman et al, 2013).  
1.2.7.2.5	Targeting	the	stroma	as	a	therapeutic	strategy	
Recently, there has been increasing interest in the study of tumour-stromal interactions. This is based on 
the observation that several tumours with identical germline mutations exhibit differences in the 
formation of stroma and additionally, the degree of tumour-stroma interactions were found to be 
predictive of an aggressive phenotype (Neesse et al, 2011). Furthermore, it was also suggested that the 
tumour stroma confers chemo-resistance in PDAC partially through decreased drug penetrance (Carr et 
al, 2016). In pancreatic cancer, the stromal component could account for up to 90% of the tumour 
volume. Depletion of the tumour-stroma was considered as a therapeutic strategy and the first benefit of 
decreased tumour-stroma was demonstrated by Olive et al (2009), where a sonic hedgehog (Shh) inhibitor, 
IPI-926 yielded increased survival with reduced tumour-stroma when compared to controls. Additionally, 
tumour vascularity and gemcitabine delivery was also increased in genetically engineered mouse models 
(GEMM) of PDAC when treated with IPI-926.   
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1.3	SARCOMAS	
1.3.1	OVERVIEW	
 
Sarcomas are malignant tumours that arise from mesenchymal cells and account for <1% of all newly 
diagnosed malignancies. They typically tend to be located in muscle, fat and connective tissues, though 
this is not always the case. Sarcomas have different clinical courses based on their histologic subtype, 
grade and location. The rarity of sarcomas plus many differing subtypes have limited our understanding 
of the biology of these tumours and consequently have impeded efforts to find effective therapeutic 
strategies. This study will focus on a specific subtype within soft tissue sarcomas.  
Soft tissue sarcomas (STS) (all subtypes combined) incidence is slightly different compared to most 
cancers because a large proportion of cases occur in children and younger adults, however the incidence 
is highest in older men and women. In the UK, between 2008-2010, 43% of diagnosed cases were in 
women and men aged 65+ but 9% were diagnosed in <30-year group (Cancer Research UK). The age-
profile of STS varies greatly according to subtype, where for example people aged 60+ years comprise 
74% of vascular sarcoma cases but only 43% of malignant phyllodes tumour cases (Cancer Research UK).   
1.3.2	CLASSIFICATION	OF	STS	
STS can be broadly divided into several groups based on site of tumour and classified as benign or 
malignant as detailed in table 2.  
 
 
 
 
 
 
 
Table 2:  classification of soft-tissue sarcomas. * this is not an extensive list of tumours that fall 
within each category. Information taken from Lauer and Gardner, 2013.  
Soft%tissue%tumours Benign%tumours Malignant% tumours
Adipocytic) tumours Lipoma,)Lipomatosis,)Lipoblastoma,)Angiolipoma,)Pleomorphic) lipoma
Dedifferentiated)liposarcoma,)Myxoid)
liposarcoma,)pleomorphic) liposarcoma
Fibroblastic/myofibroblastic)tumours
Nodular)fascitis,)Proliferative)fascitis,)
proliferative)myositis,)
angiomyofibroblastoma
Adult)fibrosarcoma,)myxofibrosarcoma,)
lowAgrade)fibromyxoid)sarcoma,)
sclerosing)epithelioid)fibrosarcoma
Fibrohistiocytic)tumours Tenosynovial)giant)cell)tumour,)deep)benign)fibrous)histiocytoma reclassified)under)undifferentiated
SmoothAmuscle)tumours Leiomyoma)of)deep)soft)tissue Leiomyosarcoma,)angioleiomyoma
SkeletalAmuscle)tumours Rhabdomyoma,)Haemangioma,)Lymphangioma,)Angiomatosis
pleomorphic) rhabdomyosarcoma,)
sclerosing)rhabdomyosarcoma,)
epithelioid)haemangioendothelioma
Nerve)sheath)tumours
Melanotic)schwannoma,)Neurofibroma,)
Perineurioma,)Hybrid)nerve)sheath)
tumours
Malignant)peripheral)nerve)sheath)
tumour,)malignant)triton)tumour,)
malignant)granular)cell)tumour
Tumours)of)uncertain)differentiation Acral)fibromyxoma,)Deep)angiomyxoma,)intramuscular)myxoma
Synovial)sarcoma,)Epithelioid)sarcoma,)
Extraskeletal)ewing)sarcoma
Undifferentiated/unclassified)sarcomas A Pleomorphic)undifferentiated)sarcoma
 36 
 
Traditionally, these tumours have been classified based on their histologic evaluation, however, in recent 
years, advancements in describing molecular aberrations specific to some subtypes of STS has affected 
the approach to classification as well as provided some insight into the pathogenesis of STS.  
At the molecular level, sarcomas can be divided into two main groups: tumours with relatively simple 
karyotypes (type I) (including subtypes characterized by specific abnormalities such as recurrent 
chromosomal translocations and oncogenic mutations) and tumours with complex karyotypes (Type II) 
(Borden et al, 2003). Majority of STS fall into the type II group and will be subject of investigations in this 
study. The exact mechanism of the accumulation of these complexes is still unknown, however it is 
thought that inactivation of the p53 pathway and abnormalities in telomere function play a critical role in 
driving tumourigenesis (Perot et al, 2010).  
In contrast, the type I sarcomas are characterized by specific recurrent translocations leading to the 
formation of novel chimeric fusion genes and have been identified in approximately one-third of 
sarcomas. These aberrations are thought to be the tumour initiating event. Additionally, these aberrations 
remain even as the tumour progresses and metastasizes into distant sites, making them very attractive 
therapeutic targets. Several mechanisms have been proposed describing how the fusion genes may 
promote tumour growth. It is thought that the most common mechanism is through transcriptional 
dysregulation by encoding chimeric transcription factors that activate downstream targets. Alternatively, 
they could produce chimeric constitutively active tyrosine kinases that cause deregulation of kinase 
signaling pathways, which have been implicated in promoting tumourigenesis in the majority of cancers 
(Lauer and Gardner, 2013).  
Although there is usually one cytogenetic translocation that characterizes a particular subtype of sarcoma, 
other variant cytogenetic translocations may also exist within the tumour. For example, in Ewing 
sarcoma, a t(11;22) translocation results in the EWSR1-FLI1 fusion gene in 90% of cases, however other 
partners for EWSR1 such as ERG (21q22) or ETV1 (7p22) may also create fusion genes (Tanas et al, 
2009).  
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Recurrent genomic amplifications also characterize other subtypes such as well-differentiated liposarcoma 
and dedifferentiated liposarcoma where amplification of 2q14-15 results in amplifications of several genes 
including MDM2 and CDK4. Amplification of MDM2 results in inhibition of p53-dependent cell cycle 
arrest and apoptosis whilst amplification of CDK4 promotes cell proliferation (Kanoe et al, 1998; 
Demicco et al, 2012. These amplifications, in particular the amplification of MDM2 is not exclusive to the 
above mentioned subtypes though as they can also be seen in chondrosarcoma and osteosarcoma.  
Furthermore, oncogenic mutations characterize some sarcomas especially gastrointestinal stromal 
tumours (GISTs), where in over 90% cases, mutations in KIT or PDGFRA are observed resulting in 
constitutive activation of signaling pathways critical for tumourigenesis (Corless et al, 2011).  
1.3.8	TREATMENT	FOR	STS	
1.3.8.1	Surgery	
The most effective single modality of treatment for localized STS is surgery involving a complete 
resection with histologically negative margins of at least 1cm (Dangoor et al 2016). However, on 
occasions, anatomical constraints mean that margins may need to be compromised in order to spare 
critical structures such as major nerves or blood vessels. Sarcoma resections are usually categorized as 
intracapsular, marginal, wide or radical. Usually the local recurrence rate is 100% due to the fact that STS 
manifest in a pseudocapsule and the intracapsular surgery procedure remove tumours from within this 
capsule. Radical resections are associated with the lowest local recurrence rates than other procedures 
when surgery is the sole modality of treatment. When sarcomas are treated with multiple modalities, wide 
excisions are the procedure of choice. In some situations, amputations may be the best surgical option to 
control localized disease.  
In metastatic disease, chemotherapy and radiotherapy are more appropriate choices of treatment, 
however, on occasion surgical resection may be considered appropriate as a palliative procedure. This 
decision takes into account factors such as the patients symptoms, expected morbidity of surgery, the 
subtype of sarcoma and extent of metastasis.  
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1.3.8.2	Radiotherapy		
 
1.3.8.2.1	Adjuvant	Radiotherapy	
Postoperative radiotherapy is used mainly for intermediate or high-grade STS however would also be 
considered for low grade tumours that are large and deep, or incompletely resected. Patients who have 
undergone compartmental resection or amputation do not usually receive adjuvant radiotherapy assuming 
clear margins. The recommended radiation dose post-surgery is 60-66Gy in 1.8-2 Gy fractions (Haas et al 
2012). 
 
1.3.8.2.2	Neo-Adjuvant	Radiotherapy	
Pre-operative radiotherapy is not routinely used in the UK, however may be considered in situations 
where the size of the radiation field required post-surgery will be associated with significant late morbidity 
or if the tumour is borderline operable and pre-surgery radiation would result in it being more operable. 
This may be particularly beneficial in subtypes such as myxoid liposarcoma that are radiosensitive. The 
standard regimen for pre-operative radiotherapy is 50Gy in 1.8-2 Gy fractions, followed by surgery 
approximately 6 weeks following completion of radiotherapy (Davis et al 2005). If tumour margins are 
positive, further radiotherapy may be given post-operatively.  
1.3.8.3	Chemotherapy		
 
1.3.8.3.1	Adjuvant	Chemotherapy	
The benefits of adjuvant chemotherapy are currently unclear and not regarded as standard treatment in 
the UK. However, it may be considered for certain individuals that have chemo-sensitive subtypes 
because a potential benefit cannot be excluded. It can also be considered in cases where radiotherapy 
cannot be administered due sensitivity of adjacent structures such as the spinal cord.  
1.3.8.3.2	Neo-Adjuvant	Chemotherapy	
Patients with high-grade tumours that are considered borderline resectable may receive pre-operative 
chemotherapy. This will be dependent on the histologic subtype of sarcoma and the age of the patient; if 
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the patient has a chemo-sensitive subtype, then pre-operative chemotherapy may be suitable if the 
tumour is adjacent to a critical organ, as this would result in the tumour being suitable for conservative 
surgery.  
1.3.8.3.3	Chemotherapy	in	advanced	disease	
Approximately 50% of patients develop distant metastasis, where prognosis is very poor and treatment is 
often palliative. They have a median survival of approximately 12 months from diagnosis of metastasis.  
Palliative chemotherapy 
The rate of response for chemotherapy for STS can vary depending on the histological subtype and the 
drug choice and range between 10-50%. Generally, younger age, absence of liver metastasis and good 
performance status are all indicators that the patient will respond well to chemotherapy, increasing 
survival time (Glabekke et al, 1999; Karavasillis et al, 2008).  
Single-agent chemotherapy 
The standard first-line treatment in Europe is doxorubicin 75mg/m2 every 3 weeks. The duration of 
treatment varies according to response but a maximum of 6 cycles is recommended due to the risk of 
cumulative cardiotoxicity (Casali et al, 2008). Although 45% are reported to have some clinical benefit 
with the chemotherapy treatment (Karavasilis et al, 2006), response rates still remain low at <20% 
(Bramwell et al, 2003), suggesting that there is an urgent need for more effective agents to treat metastatic 
sarcomas. The standard second-line treatment is ifosfamide, a nitrogen mustard alkylating agent, which 
can also be used as first-line treatment in cases where for example, patients have high risk of cardiac 
complications. The response date for ifosfamide is usually approximately 8%, with higher responses seen 
with increased doses (Palumbo et al, 1997).  
Second-line chemotherapy 
There is no current standard therapy following doxorubicin and ifosfamide failure. Dazarbazine, 
trabectedin, gemcitabine and taxanes are all alternative agents that have some activity. There is most 
evidence for the use of gemcitabine and docetaxel in uterine leiomyosarcoma primarily and in other 
tumour types (Leu et al, 2004; Maki et al, 2007). Trabectedin is also licensed as second-line treatment for 
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all STS however this decision was based on trials with predominantly leiomyosarcoma and liposarcomas 
(Demetri et al, 2009).  
1.3.8.4	Targeted	therapy	
As mentioned before, sarcomas are made up of approximately 60 subtypes, all varying in histology and 
response to treatment, each subtype often having specific genetic lesions and consequently have different 
prognosis. This highlights the need for a better understanding of the inherent biology of each subtype 
and develop a means of stratifying each subtype so that a more tailored clinical management programme 
can be developed to improve outcomes. Currently, very few specific genetic lesions in sarcomas are 
directly targeted by therapeutics.  
One subtype that has had some success with targeted therapy is GIST, where the KIT kinase inhibitor, 
imatinib has given partial responses or stable disease to approximately 80% of patients (Heinrich et al, 
2003). This effect however, is dependent on the specific site of mutation because tumours with activation 
loop mutations are insenstivie to imatinib. Furthermore, it has also been observed that imatinib has no 
effect in tumours with wild-type KIT and PDGFRA genotypes, despite KIT pathway activation.  
Imatinib has also shown effects in dermatofibrosarcoma protuberans (DFSP), which has a COL1A1-
PDGFB fusion, however the effect observed in this subtype was not as durable as seen in GIST. Other 
similar effects were observed with ALK inhibitor in inflammatory myofibroblastic tumours with ALK 
fusions (Mosse et al, 2009) or MET inhibitor in clear-cell sarcomas with ASPL-TFE3 fusions (McGill et al, 
2006; Davis et al, 2006). 
Most other common sarcomas including leiomyosarcoma and high-grade undifferentiated pleomorphic 
sarcoma have shown very little success with existing tyrosine kinase inhibitors (TKIs). Summarized in 
table 3 are a list of targeted agents that produce a response in the different subtypes of sarcoma.  
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Table 3: Targeted agents used for specific subtypes of sarcomas to target specific 
genetic alterations and their approximate response rates (if known). Table taken with 
permission from Taylor et al, 2011.  
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1.4	CHEMOTHERAPY	IN	HGSOC,	PDAC	AND	SARCOMAS	
 
Although several chemotherapeutic agents have been established in the three tumour types being studied, 
this introduction will focus on the use of cisplatin and doxorubicin as they were the main 
chemotherapeutic agents used in this study.  
1.4.1	PLATINUM	COMPOUNDS	
 
Platinum compounds make up a group of drugs including cisplatin (cis-diamminedichloroplatinum(II), 
carboplatin and oxaliplatin, which have had significant clinical success, particularly with cisplatin and has 
been the cause for the evolution of the the platinum compound family. The role of platinum in ovarian 
cancer is well known, with cisplatin and now carboplatin being the main chemotherapeutic agent used; 
cisplatin is also used in combination with doxorubicin in osteosarcomas and malignant fibrous 
histiocytoma of the bone (MFH-B) (Bramwell et al, 1992 and 1999; Nooji et al, 2005). Furthermore, 
although not currently standard treatment, research has suggested that there may be some benefit in 
adding platinum agents (cisplatin or the FOLFIRINOX combination, which contains oxaliplatin) to 
standard therapy in BRCA-associated PDAC patients (Golan et al, 2014). For the purposes of this study, 
we focus on the cisplatin compound. Although there has been a considerable benefit with cisplatin 
treatment in a variety of cancers, patients ultimately relapse with cisplatin-resistant disease, and 
overcoming this remains a significant challenge.   
1.4.1.1	Mechanism	of	action	of	cisplatin	
Cisplatin is a non-cell cycle specific, bifunctional alkylating agent. However, as opposed to classic 
alkylating agents, cisplatin binds to DNA to form intrastrand crosslinks, that changes the confirmation of 
the DNA and affects DNA replication (Enoiu et al, 2012). Cisplatin becomes activated once in the cell. In 
the cytoplasm, the chloride atoms on cisplatin are displaced with water molecules. This hydrolyzes 
cisplatin, making it able to react with any nucleophile including sulfhydryl groups on proteins and 
nitrogen donor atoms on nucleic acids. Cisplatin causes DNA damage by binding to the N7 reactive 
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center on purine residues consequently blocking cell division resulting in death by apoptosis. Cisplatin 
forms both intrastrand cross-links (1,2-intrastrand cross-links of purine bases with cisplatin), and 
interstrand crosslinks. The intrastrand crosslinks include 1,2 intrastrand d-(GpG) and 1,2-intrastrand 
d(ApG) adducts, representing 90% and 10% of adducts respectively. These adducts contribute to 
cisplatin’s toxicity (Dasari et al, 2014). Apoptosis is a controlled cell death, which is energy-dependent 
leading to shrinkage, chromatin condensation and activation of caspases and is the main mechanism of 
cell death induced by cisplatin. Cisplatin-induced genotoxic stress results in the activation of a number of 
signalling pathways, which then act to contribute to apoptosis or chemo-resistance. At least two distinct 
pathways have been highlighted to contribute to cisplatin-mediated apoptosis, one involves p53, while the 
other involves p73, a p53-related protein.  
1.4.1.2	Mechanisms	of	resistance	to	cisplatin	
Most patients that initially respond well to cisplatin eventually develop acquired resistance to the drug. At 
this point, the doses should be increased, but this usually leads to multi organ toxicities at which point 
very little can be done. There are several mechanisms by which resistance to cisplatin can emerge. These 
include decreased drug uptake, drug inactivation by cellular thiols, decreased mismatch-repair activity and 
defects in apoptotic signaling.  
A large amount of anti-cancer agents are associated with multi-drug resistance, whereby drugs are 
effluxed via nonselective members of the ATP-binding cassette (ABC) family such as p-glycoprotein. 
This does not apply to cisplatin where reduced intracellular accumulation occurs mainly due to reduced 
uptake rather than drug efflux. Initially, cisplatin was thought to passively diffuse across the plasma 
membrane however, the copper transporter I (CTR1) is thought to play an important role in the uptake 
of cisplatin. This was based on observations where Ctr1-/- mouse embryonic fibroblasts accumulated less 
cisplatin than the wild-type counterparts, making them resistant to cisplatin cytotoxic effects. Similarly, 
cells treated with copper (CTR1 substrate) were also protected from cisplatin cytotoxicity. Furthermore, 
cisplatin is known to downregulate CTR1 through internalization followed by proteasome-mediated 
degradation (Holzer and Howell, 2006).  
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Cisplatin also binds avidly to cytoplasmic nucleophilic species including glutathione (GSH), methionine 
and other cysteine-rich proteins. These nucleophilic species have a dual role in that they may contribute in 
part to the cytoplasmic effects of cisplatin through the establishment of oxidative stress (Slater et al, 1995) 
but also act as cytoplasmic scavengers, consequently limiting the amount of reactive cisplatin (Kasahara et 
al, 1991). Elevated levels of GSH or the enzyme that mediates the conjugating between cisplatin and 
GSH (glutathione S-transferase P1-1) is observed in cisplatin resistance further corroborating the role of 
these nucleophilic species in promoting cisplatin resistance (Lewis et al, 1988; Peklak-Scott et al, 2008). 
Once cisplatin has bound to DNA and caused inter-and intra-strand DNA adducts, several mechanisms 
can mediate cisplatin resistance from this point. The majority of cisplatin lesions are repaired though the 
nucleotide excision repair (NER) system, which will be discussed later (section 1.5.1.2). Several proteins 
participate in this process including ERCC1 and ERCC4. A correlation between NER proficiency and 
cisplatin resistance has been proposed in multiple preclinical models (Metzger et al, 1998). ERCC1 is also 
involved in interstrand crosslink repair (ICR), where ICR proficiency also appeared to correlate with 
cisplatin resistance. Similarly, ERCC1 was found to be a promising biomarker in predicting the response 
to cisplatin in patients (Olaussen et al, 2009).  
Cisplatin induced DNA lesions can also be recognized by mismatch repair system (MMR), which deals 
with erroneous insertions and deletions. MMR proteins can detect the lesions and would attempt to repair 
them, but would fail and thus transmit a proapoptotic signal (Vaisman et al, 1998). In line with this 
observation, MSH2 and MLH1 (MMR proteins) are often downregulated or mutated in acquired cisplatin 
resistance (Drummond et al, 1996, Brown et al, 1997).  
 
Cisplatin-induced interstrand adducts can eventually lead to double-strand breaks, that employ different 
repair machinery, namely homologous recombination (HR) (Smith et al, 2010). Two critical components 
of the HR pathway are BRCA1 and BRCA2, genes that are frequently mutated in breast and ovarian 
cancers but are also observed in PDAC and some sarcoma subtypes. HR-deficient cancers such as 
HGSOC are known to be more sensitive to crosslinking agents including cisplatin (Bryant et al, 2005). 
Patients that are initially cisplatin-sensitive can develop resistance if secondary mutations occur to re-
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establish the HR machinery, suggesting that this is also an important mechanism of cisplatin resistance 
(Edwards et al 2008; Sakai et al, 2008).  
In addition, post-target resistance to cisplatin can also occur, one main mechanism being through 
inactivation of p53 which occurs in approximately half of all neoplasms. Other mechanisms could include 
defects in signal transduction pathways, which would normally trigger the apoptotic response to DNA 
damage. Several specific proteins within signaling cascades have been implicated in cisplatin resistance 
and will be discussed later.  
1.4.2	DOXORUBICIN		
Among the three tumour types being studied, doxorubicin is most used in the first-line treatment of 
sarcomas. However, it does also have a role in HGSOC, where a pegylated liposomal doxorubicin is used 
in recurrent (platinum-sensitive and platinum-resistant) ovarian cancer and is well tolerated with minimal 
toxicity (Cronin et al, 2013). The use of doxorubicin in PDAC has been limited because it has low 
response rates when used as a single-agent and similar responses are seen when combined with other 
agents like 5-fluorouracil (Schwartz and Casper, 1995). However, recent published reports are suggesting 
that treatment of doxorubicin in combination with a dual mTOR/PI3K inhibitor gives a more effective 
tumour response without the increased toxicity normally associated with doxorubicin treatment (Durrant 
et al, 2015). 
1.4.2.1	Mechanism	of	action	of	doxorubicin	
There are two proposed mechanisms by which doxorubicin acts in the cancer cell: firstly, it is thought to 
intercalate into DNA and disrupt the topoisomerase-II-mediated DNA repair and secondly, it is thought 
to generate free radicals thereby damaging cellular membranes, DNA and proteins (Gewirtz, 1999). 
Doxorubicin is oxidized to semiquinone, which is an unstable metabolite and this is converted back to 
doxorubicin. This conversion process releases reactive oxygen species, which can lead to membrane 
damage and DNA damage thereby triggering apoptosis (Doroshow, 1986). Alternatively, doxorubicin can 
enter into the nucleus and poison topoisomerase-II, also resulting in DNA damage and cell death (Tewey 
et al, 1984). A fully functional topoisomerase-II is essential for DNA replication, transcription, 
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recombination and chromatin modelling. Inhibiting its function results in the creation of permanent 
double-strand DNA breaks resulting in lethal effects (Kubecek et al, 2015).  
1.4.2.2	Mechanism	of	action	of	Pegylated	Liposomal	Doxorubicin	(PLD)	
The active agent of PLD is doxorubicin hydrochloride. The doxorubicin molecules in PLD are 
encapsulated in a bilayer sphere of lipids. A dense layer of polyethylene glycol (PEG) surrounds this 
vesicle. The 100nm size of the liposomes prevents it from entering tissues with tight capillary junctions 
such as the heart and also functions to selectively transport the liposome into the tumour (Waterhouse et 
al, 2001). Tumours generally have abnormal leaky endothelial cells (Jain, 2005), which allows more 
deposition of the PLD into the tumour. The PEG coating on the liposome prevents proteins from 
binding to the lipid bilayer by creating a hydrophilic layer around the liposome that buffers the liposome 
wall from the surroundings. When the liposome leaves the intravascular compartment, it is cleared via the 
lymphatic system in normal tissue; tumours do not have lymphatics so when the liposome is deposited in 
the tumour, it remains there for longer (Green and Rose, 2006).  
 
1.4.2.3	Mechanisms	of	resistance	to	doxorubicin	
Similar to cisplatin, resistance to doxorubicin is a major problem in cancer, limiting its use. The main 
mechanism underpinning resistance to doxorubicin is thought to be due to ABCB1 (MDR1/p-
glycoprotein) and ABCC1 (MRP1) which are involved in promoting efflux of doxorubicin. Another 
mechanism of resistance is the downregulation of TOP2A, which affects treatment response (Thorn et al, 
2011).  
P-glycoprotein (pgp), encoded by the multidrug resistant 1 gene (MDR1), is thought to play a critical role 
in inducing doxorubicin resistance. It has been demonstrated that pgp in the lysosomes actively 
sequesters doxorubicin, a known pgp substrate, into these organelles. Inhibition of cells with a pgp 
inhibitor could prevent the sequestration of doxorubicin in the lysosomes (Yamagishi et al, 2013).  
Altered topoisomerase-II activity is also another mechanism that can cause doxorubicin resistance. These 
alterations could be due to mutations in the topoisomerase-II alpha (TOP2A) gene or decrease of gene 
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copy number. It has been proposed that TOP2A gene amplification and deletion can account for both 
relative chemosensitivity and resistance respectively (Jarvinen et al, 2000).   
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1.5	DNA	DAMAGE	AND	DNA	REPAIR	MECHANISMS:	KEY	PROTEINS	
INVOLVED	AND	A	FOCUS	ON	DRUG	RESISTANCE	
 
Most conventional chemotherapeutic agents are designed to kill cells by inducing DNA damage. Among 
the different types of DNA damage, the most deleterious ones are DNA double-strand breaks (DSBs), 
which are generated by chemotherapeutic agents as well as other sources such as reactive oxygen species. 
Cells have an inbuilt repair machinery to repair these DNA lesions. If left unrepaired, the DSBs can result 
in cell death however if repaired correctly, the cell survives with no adverse effects. If the lesions are 
insufficiently repaired, the surviving cells can acquire genomic alterations contributing to tumourigenesis. 
In order to prevent insufficient repair and maintain genomic integrity, cells have a coordinated network of 
signaling cascades, known as the DNA damage response.  
DNA damaging agents can induce various types of DNA damage including intrastrand and interstrand 
crosslinks, DNA-protein crosslinks and single-strand breaks (SSB) in addition to DSBs. Each type of 
DNA damage is processed by a different mechanism. Figure 5 summarizes the different mechanisms 
employed dependent on the type of DNA damage occurred.  
 
 
 
 
 
 
 
Figure 5: Overview of the DNA damage response. The different types of DNA damage and the 
major pathways and components in each pathway to process each type of damage are shown. The proteins 
marked with the red asterisks indicate proteins being evaluated in clinical trials.  Figure taken from Hosoya 
and Miyagawa, 2014.  
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1.5.1	SINGLE-STRAND	BREAK	(SSB)	REPAIR		
 
When SSBs occur, the ataxia telangiectasia and Rad3-related (ATR) kinase is activated and binds to the 
damaged site (Zou et al, 2003). ATR phosphorylates Chk1 thereby activating it, which in turn regulates the 
stability of the CDC25 phosphatase thus having a role in S and G2/M checkpoints (Zhao et al, 2001).  
1.5.1.1	Base	Excision	Repair	(BER)	
 
SSBs are repaired using base excision repair (BER). BER concentrates on correcting lesions that do not 
create structural distortion of the DNA helix (Robertson et al, 2009) Important proteins in BER include 
PARP-1, XRCC1, DNA ligase IIIalpha and APE1. The core BER enzyme APE1 is also involved in non-
repair activities such as regulating the expression of chemo-resistance genes like MDR1. BER of DNA 
damages comprises of five steps. Firstly, the DNA damaged base is detected and removed by glycosylases 
such as UNG, SMUG1, TDG and MBD4. Once the damaged base is removed, a non-instructional abasic 
site is left behind which can cause transcriptional stalling and so must be cleaved in order for the repair to 
continue. Some glycosylases can cleave this abasic site, however most glycosylases require APE1 to cleave 
the site. Cleavage of the site leaves a SSB. The third step is the binding of SSB by scaffolding proteins 
such as PARP1 and XRCC1, which in turn recruits other BER proteins to complete the repair. The 
fourth step is the insertion of the missing base by POLB, a DNA polymerase. The final fifth step is the 
sealing of the DNA nicks by a DNA ligase (Krokan and Bjoras, 2013).  
This repair process can contribute to chemo-resistance as cancer cells use this mechanism to resist DNA-
damaging chemotherapies and consequently BER proteins have been extensively studied as potential 
therapeutic targets. The most extensively studied protein is PARP-1, which binds the SSB and interacts 
with XRCC1 to recruit other BER proteins. In addition to this, it can also directly regulate proteins, 
particularly histones and transcription factors through PARylation. PARP inhibitors were developed to 
target the DNA repair pathway as a means to overcome chemo-resistance and these studies not only 
highlighted a new therapeutic target, but also demonstrated the concepts and benefits of synthetic 
lethality with BRCA deficiency and PARP inhibition. Briefly, BRCA is an essential component in 
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homologous recombination (HR), a repair mechanism to repair DSBs. Studies found that inhibition of 
SSB through PARP inhibition rendered BRCA deficient (and thus HR deficient) cells exquisitely sensitive 
to PARP inhibition and also to other chemotherapeutic agents. This has been observed in ovarian cancer, 
PDAC and sarcomas (Vormoor et al, 2014; Dalton and Coleman, 2015; Sharbeen et al, 2015).  
1.5.1.2	Nucleotide	Excision	Repair	(NER)	
NER repairs DNA lesions that alter the helical structure of DNA and interfere with DNA replication and 
transcription and is the main repair mechanism following cisplatin-induced DNA damage. Important 
steps of the NER pathway include the recognition of the damage and binding of a multi-protein complex 
at the damaged site and the excision of 24-32 nucleotide DNA fragment containing the damaged link 
with great accuracy followed by removal of the damage-containing oligonucleotide between the two 
nicks. The resulting gap is then filled by a DNA polymerase followed by a ligation step to re-join the 
adjacent nucleotides. There are two types of NER: global genome NER (GGR) and transcription-coupled 
NER (TCR). The initial steps depend on whether the damage is in the actively transcribed strand of a 
gene or if it is elsewhere in the genome (Atanassov et al, 2004). If it is elsewhere in the genome, then 
different proteins are recruited to initiate the GGR mechanism; the damage is recognized by XPC and 
hHR23B based on the extent of DNA structure distortion caused by the damage. It is thought that the 
recruitment of the XPC/hHR23B complex further distorts the DNA helical structure, thus permitting the 
entry of addition protein complexes such as TFIIH along with XPA and RPA to unwind a stretch of 
nucleotides containing the damaged site. XPA is essential for complete unwinding though its exact role 
remains unclear. TCR however is thought to be a more rapid process, which requires all the proteins 
needed for GGR, except for XPC suggesting that the initial recognition mechanism may be different. In 
TCR, CSA and CSB proteins are involved in recruiting TFIIH, XPA and RPA to the damaged site. The 
next step for both GGR and TCR is the recruitment of endonucleases XPG and XPF/ERCC1, where 
XPG cuts on the 3’ side of a junction around 2-8 nucleotides away from the lesion whilst XPF/ERCC1 
cuts on the 5’ side about 15-24 nucleotides away from the lesion. The displacement of the damaged 
oligonucleotide occurs with the help of XPB/XPD helicases following which the resulting gap is filled by 
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DNA polymerase epsilon or delta together with PCNA. The final step is ligation using DNA ligase I 
(Marteijn et al, 2014; Petruseva et al, 2014).  
1.5.2	DOUBLE-STRAND	BREAK	(DSB)	REPAIR	
DSBs are repaired through two main mechanisms: non-homologous end joining (NHEJ) and 
homologous recombination (HR). When DSBs occur, a complex comprising of MRE11-RAD50-NBS1 
(MRN complex) senses the DSB site and binds to it, consequently recruiting ataxia telangiectasia (ATM) 
kinase through its autophosphorylation (Bakkenist et al, 2003; Lee et al, 2005). ATM phosphorylation 
involves many proteins, one of which is Chk2, which in turn phosphorylates CDC25A, leading to cell 
cycle arrest. Phosphorylation of BRCA1 leads to DSB repair and S-phase specific cell cycle arrest. 
Activation of p53 triggers cell cycle arrest in the G1 phase or cell death. Additionally, activation of the 
DNA damage response mediator 53BP1, contributes to the choice of DSB repair pathway, promoting 
NHEJ (Zimmermann et al, 2014).  Other evidence to suggest that NHEJ is the predominant DSB repair 
mechanism and HR is only used when NHEJ fails, is the observation that NHEJ proteins such as 
Ku70/80 and DNA-PKcs are abundantly present in mammalian cells whereas HR proteins are more 
scarce and dependent on the cell cycle. Also, Ku is recruited to the site of DNA damage within minutes 
and the whole NHEJ process takes approximately 30 minutes post damage, whereas Rad-51, an HR 
protein, form foci 2 hours post damage and the whole HR process can take up to 7 hours (Mao et al, 
2008).  
1.5.2.1	Non-Homologous	End	Joining	(NHEJ)	
NHEJ is characterized by the type of repair where the two DSBs are joined by direct ligation. The 
resulting joints tend to have very little homology between the joint ends, resulting in NHEJ being very 
error prone. NHEJ originally referred to the the repair system which had dependence for Ku, DNA ligase 
IV and other associated factors termed canonical-NHEJ (c-NHEJ), however, further research into this 
pathway has shown that homology-independent repair occurs without the need for Ku and DNA ligase 
IV and thus termed alternative-NHEJ (alt-NHEJ). Also, because NHEJ does not rely on a homologous 
template, it is not restricted to a certain phase of cell cycle, unlike the other DSB repair mechanism HR, 
which is active in S and G2 phase (Chiruvella et al 2013). 
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The general mechanism of NHEJ involves the recognition and assembly of the NHEJ complex at the site 
of DNA DSB. This is followed by the bridging of the DNA ends and the promotion of end stability and 
then end processing. Lastly, the joints are ligated followed by the dissolution of the NHEJ complex.  
The initial recognition and binding to the site of DNA damage involves the Ku heterodimer, made up of 
Ku70 and Ku80. Once bound to the DSB ends, it acts as a scaffold to recruit either directly or indirectly 
other NHEJ factors to the damage site. The core NHEJ factors include DNA-PKcs, XRCC4, DNA 
ligase IV and XLF. It is believed that Ku is able to recruit any enzyme required depending on the 
complexity of the DSB (Reynolds et al, 2012). For example, it is thought that contrary to earlier beliefs, 
DNA-PKcs is not required for the recruitment of other NHEJ factors and that in fact simple DSBs can 
be repaired rapidly, only involving Ku, XRCC4, Ligase IV and XLF, whereas complex breaks require 
DNA-PKcs activity and possibly even ATM (Davis and Chen, 2013).  
Once Ku70/80 binds to the DNA ends, it helps to maintain their stability by preventing any non-specific 
processing thus preventing any genomic instability. This is followed by the ligation step, which requires 
processing of the DNA ends to create ligatable ends if applicable. Enzymes that are involved in this 
process include NHEJ-specific Artemis, which has DNA-PKcs dependent and independent functions, 
and APE1, Tdp1 and PNKP (Chappell et al, 2002). Following appropriate end processing, the DNA is 
ligated by DNA ligase IV, alone with XRCC4 and XLF (Ahnesorg et al, 2006).  
1.5.2.2	Homologous	Recombination	(HR)	
HR is the other major DSB repair pathway, which often involves the use of a sister chromatid as a 
template and therefore occurs predominantly in the S and G2 phases of the cell cycle. Because the repair 
mechanism uses a sister chromatid as a template, the genetic information is identical and so the repair 
system can successfully restore the genetic configuration thus making HR pathway error free unlike the 
NHEJ pathway. The first stage involves the DSB recognition and processing by endonucleases to a 3’-
OH single stranded (ss) tail. Rad51 is then recruited to the ssDNA to search for a homologous sister 
chromatid to exchange genetic information and DNA synthesis follows. Following strand invasion and 
synthesis, at least three different routes can be used. In the double-strand break repair model (DSBR), the 
second end of the DSB can be engaged to stabilize the D-loop structure leading to formation of double 
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Holliday junctions, which are then resolved in a crossover or non-crossover mode or dissolved to 
generate non-crossover products (Krogh et al, 2004). In a second route, the invading strand is displaced 
from the D-loop and anneals with its complementary strand or with the complementary strand 
associating with the other end of the DSB. This route is known as the synthesis-dependent strand-
annealing mode of homologous recombination (SDSA) (Nassif et al, 1994). The choice of route employed 
is dependent on whether the cells are undergoing mitosis or meiosis; SDSA is preferred over DSBR 
during mitosis whereas during meiosis, the DSBR mechanism is employed creating crossover products 
through resolution of the holliday junctions. A third route, called break-induced replication (BIR), can 
occur where the D-loop structure assembles into a replication fork and copies the entire chromosome 
arm (Malkova et al, 1996).  
1.5.2.3	Fanconi	Anemia	(FA)	pathway	
FA is a disorder that is characterized by sensitivity to DNA-crosslinking agents. It is used to repair mainly 
interstrand-crosslinks (ICLs), and have common components such as BRCA2 and PALB2 with HR and 
NER. The FA repair pathway constitutes an anchor complex that recognizes the ICLs created by DNA 
damaging agents such as cisplatin; a multisubunit ubiquitin ligase, which monoubiquitinates its two 
substrates and recruits several repair proteins. The FA pathway is genetically complex and is made up of 
16 complementation groups and associated genes, which can be grouped into three categories: the FA 
core complex, the ID2 complex and the downstream proteins that have a DNA repair function. The FA 
pathway is activated during the S phase of the cell cycle or in the presence of ICLs and other DNA 
damage. The crucial component in FA is FANCM, which forms a heterodimeric complex with a Fanconi 
Anemia Associated Protein (FAAP), FAAP24, which initially recognizes the ICL and recruits the rest of 
the FA core complex to the site of damage. The FA core complex is then recruited to the site of the 
damage through its interaction with MHF1-MHF2-FANCM complex; the FA core complex is made up 
of 8 FA proteins namely FANCL, FANCA, FANCB, FANC, FANCE, FANCF, FANCG and FANCM 
along with newly identified FAAPs, FAAP100, FAAP24 and FAAP20. Once the core complex is 
recruited to the site of DNA damage, FANCL, an E3 ligase along with UBE2T ubiquitinates the ID2 
complex, made up of FANCI and FANCD2. Following the ubiquitination of the ID2 complex, 
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FANCP/SLX4 and FANCQ/XPF form a complex with XPF to ‘unhook’ the ICL by making incisions 
(Zhang and Walter, 2014). This unhooking then allows one duplex to be repaired by translesion 
polymerases, whilst the other strand uses the HR repair pathway using the already repaired strand as a 
template. Other FA proteins are also implicated in HR repair following the unhooking step (Long et al, 
2014). Finally, the NER machinery is recruited to clear any residual DNA adducts before the gap is 
resealed by DNA polymerases (Dietlein et al, 2014).  
1.5.3	TARGETING	DNA	DAMAGE	RESPONSE	AND	REPAIR	TO	COMBAT	CHEMO-
RESISTANCE		
As briefly mentioned earlier, most chemotherapeutic agents target DNA and thus cause significant DNA 
damage, leading to cell cycle arrest and cell death. Additionally, DNA lesions that do persist in the cell 
cycle into S phase, can interfere with replication fork progression, resulting in DSB formation, which are 
the most deleterious lesions. There are several DNA repair mechanisms that are employed to repair the 
DNA depending on the nature of damage as discussed in the previous section. This efficient repair 
system is a major setback in successful cancer therapy as DNA repair pathways tend to have increased 
activity in tumour cells, thus contributing to resistance to chemotherapeutic agents (Chabner et al, 2005). 
This is further supported by observations that cells defective in specific DNA repair pathways are 
exquisitely sensitive to drugs that produce lesions which are reliant on the defective repair pathway for 
repair. Figure 6 summarises the DNA lesions caused by the different chemotherapeutic agents and the 
repair mechanisms active to repair the lesions. Each repair mechanism can be pharmacologically inhibited 
to increase the efficacy of chemotherapeutic agents.  
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Figure 6: Summary of the DNA lesions caused by various DNA damaging agents used 
in cancer treatment. Each lesion is repaired by a specific repair pathway for that lesion but can also act 
complementarily. The size of the boxes indicating the repair pathways are relative to their contribution in repairing the 
specific DNA lesion. A) ionizing radiation causes DSBs, which are predominantly repaired by the NHEJ pathway. B) 
monofunctional alkylators and bifunctional alkylators such as cisplatin (C) interfere with DNA synthesis by inducing base 
modifications. The main repair pathways utilized here are BER and NER. D) antimetabolites interfere with DNA 
synthesis causing replication lesions. The repair pathways utilized here apart from BER are not fully known. E) 
topoisomerase inhibitors which act on either topoisomerase-I or –II (such as doxorubicin), trap them in a transient cleavage 
complex with DNA, thus interfering with replication and creating DNA breaks. F) Replication inhibitors result in 
indirect DSB formation and are primarily repaired by HR. Figure taken from Helleday et al, 2008 (reused with 
permission form Macmillan Publishing Ltd).  
 
Recent efforts in making cancer therapies more effective, have increasingly focused on DNA damage 
response (DDR) and DNA repair pathways. It is known that abrogation of the DDR pathway results in 
increasing genomic instability, which contributes to tumourigenesis. However, tumours also rely on 
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efficient repair pathways to overcome chemotherapeutic agent-induced DNA damage; this may explain 
why only isolated repair pathways tend to be dysregulated in cancers. To compensate for the specific 
dysregulated/inactivated pathway, other DDR and repair pathways may be induced, which is thought to 
be responsible at least in part for the limited efficacy of conventional cytotoxic agents (Muller et al, 1998). 
This is particularly relevant for HGSOC and PDAC, which have been shown to be DDR/repair pathway 
defective as shown in figure 7, and so could be exploited for effective therapies. Additionally, 
dysregulation of the DNA repair machinery has also been implicated in sarcoma development (Helman 
and Meltzer, 2003).  
Figure 7: Ovarian cancer and PDAC are characterized as being DDR defective . Cancers 
sub-classified based on molecular phenotypes. Pa = PDAC. Data for figure was obtained from Cowley et al, 
2013.  
 
Efforts to target SSB repair inhibition resulted in what is probably the most well-known target in SSB 
repair, PARP, which was briefly discussed in section 1.1.5.3. The rationale behind the use of PARP 
inhibitors stemmed from the knowledge of the basic repair mechanisms of SSB and DSB repair pathways 
and an effort to employ a synthetically lethal approach. This, in combination with cell based screens, led 
to the observation that BRCA deficient cells are very sensitive to PARP inhibition (Bryant et al, 2005; 
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Farmer et al, 2005). This is relevant in breast and ovarian cancer and to a certain degree in PDAC, where 
BRCA is frequently inactivated (Hilton et al, 2002; Cassidy et al 2014). Additionally, approximately 50% of 
HGSOC cases are thought to be HR deficient (The Cancer Genome Atlas Research Network, 2011), 
which is a key determinant of platinum sensitivity and thus provides a basis for the use of PARP 
inhibitors.  
PARP inhibitors (PARPi) were found to have activity in ovarian cancer patients with a germline BRCA 
mutation, but interestingly were also found to have activity in HGSOC without any germline BRCA 
mutation (Gelmon et al, 2011). This was thought to be due to deficiencies in other HR components such 
as ATM and ATR, which would render the cells HR-deficient and thus PARPi sensitive – the same effect 
seen with BRCA deficiency (McCabe et al, 2006).  This phenomenon was termed “BRCAness”. Olaparib 
is the most well studied PARP inhibitor, which showed that 41% of patients with a germline BRCA 
mutation had an objective response according to RECIST whereas 24% of non-BRCA associated patients 
also had an objective response. Also, the non-BRCA associated responders tended to be associated with 
platinum sensitivity (Liu et al, 2014).  
PARPi also have a role in pancreatic cancers, where BRCA mutations account for up to 17% of inherited 
pancreatic cancer. A phase II trial assessing olaparib monotherapy in metastatic pancreatic cancer showed 
an 83% partial or complete response by RECIST criteria (Lowery et al, 2011).  
1.5.3.1	DNA-PKcs	as	a	therapeutic	target	
NHEJ is a major mechanism of DSB repair as discussed in section 1.5.2.1. One of the major regulators of 
this pathway is a serine/threonine kinase, DNA-dependent protein kinase (DNA-PK). The enzyme acts 
as a scaffold protein to align broken ends and recruits other repair effectors. DNA-PK, along with ATM 
and ATR belong to the phosphatidyl inositol 3-kinase-like (PIKK) protein kinase group and the three 
kinases are collectively capable of phosphorylating and acting on 700+ proteins. DNA-PK is known to 
phosphorylate protein substrates including Ku70/80, RPA and autophosphorylation. The protein kinase 
activity of DNA-PK can also be regulated by PARP independently of the Ku70/80 complex. DNA-PK is 
also thought to have a role in HR, where phosphorylation of certain sites (Thr 946 and Ser1004), 
specifically promote HR and simultaneously inhibit NHEJ, thus protecting certain DNA ends from 
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NHEJ repair (Neal et al, 2011). In addition to its roles in DNA repair, DNA-PK is also known to 
phosphorylate AKT, a major effector of the PI3K pathway, which will be discussed in a later section, at 
serine 473 in response to platinum therapy, consequently inhibiting cisplatin-mediated apoptosis, thus 
promoting chemo-resistance (Stronach et al, 2011). Specifically, the kinase activity of DNA-PKcs is 
thought to be responsible for the resistance to DNA damaging agents. Additionally, DNA-PKcs has been 
found to correlate with response to treatment, where upregulation of DNA-PKcs correlated with 
resistance to various treatments in a number of cancers (Shintani et al, 2003; Beskow et al, 2009; 
Bouchaert at al, 2012). Furthermore, frequent DNA-PKcs amplifications are observed in HGSOC, which 
correlates with higher DNA-PKcs gene expression and poorer patient outcomes using in-house and 
publically available datasets (Curry E, unpublished data).  
Because of its significant role in the repair of DNA DSBs and its role in mediating chemo-resistance and 
other important cellular functions which have not been discussed here but have been extensively 
discussed in Goodwin and Knudsen (2014), its therapeutic potential has been widely studied. Synthetically 
lethal interactions were observed with DNA-PKcs and DDR proteins such as ATM, MSH3 and other 
HR-related proteins, suggesting that DNA-PKcs inhibitors may be effective in treating DDR defective 
tumours such as HGSOC, PDAC and complex karyotypic sarcomas. The original DNA-PKcs inhibitors 
were not very successful for clinical consideration due to lack of specificity and poor pharmacokinetics, 
however, newer drugs such as NU7441 and NU7026 with improved specificity and pharmacokinetics 
have been used to explore the effect of DNA-PKcs inhibition in several tumours (Davidson et al, 2013).  
NU7026 is an ATP-competitive DNA-PKcs inhibitor which displays a 60-fold greater potency against 
DNA-PKcs than PI3K and is inactive against the other PIKK family enzymes ATM and ATR (Willmore 
et al, 2004). Studies utilizing this drug have shown accumulation of DNA damage, inhibition of growth 
resulting in apoptosis in PDAC cells, even in the absence of DNA-damaging agents (Li et al, 2012). 
NU7441 is more potent than NU7026, with at least 100-fold selectivity for DNA-PKcs compared to 
ATM and ATR. Several studies utilizing this drug has shown enhanced chemotherapeutic effects in many 
cancer cell types (Zhao et al, 2006; Travecchio et al, 2012). Specific DNA-PK inhibitors have been shown 
to have synergistic effect in combination with chemotherapeutic agents in vitro, with NU7441 resensitizing 
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platinum resistant cells to cisplatin treatment in a panel of HGSOC cell lines (Stronach et al, 2011). 
Several clinical trials are underway assessing the effect of DNA-PK inhibition, including trials consisting 
of dual-targeting inhibitors such as a dual inhibitor of DNA-PK and mTOR currently in phase 1 trial 
(NCT01353625) for advanced solid tumours and haematologic malignancies, and a dual PI3K and DNA-
PK currently also in phase I trials for solid malignancies (NCT01280487 and NCT01682473).  
Collectively, this highlights the potential clinical benefits of utilizing inherent molecular phenotypes such 
as DDR defects that are shared with several tumour types.  
1.6	GENOMIC	INSTABILITY	IN	CANCER	
Cancer is a disease of the genome, which involves several complex multi-step processes to fully display its 
lethal nature. This complexity in progression also reflects the several natural defense barriers in place that 
need to be evaded for cancer to develop. Given that DNA are the building blocks that several cellular 
defense barriers are reliant on and that a rare mutational event must occur to breach each of these 
barriers, one would then postulate that the occurrence/progression of cancer must be a rare event. Yet, as 
of 2015, Cancer Research UK, using the most accurate calculation method to date, puts our risk of 
developing cancer at 1 in 2. This reflects a gradual increase in incidence over decades. It was reasoned 
that there must be a drastic increase in mutational rate – that cell populations at risk of becoming 
malignant must be more prone to mutations compared to genomes of normal cells, a term known as 
‘mutator phenotype’. There are several lines of evidence to suggest that genetic instability is present in 
many cancer types and these will be discussed here.  
The ability of cells to replicate its genetic material with high fidelity is one of the most important 
processes in maintaining genomic integrity. This coupled with efficient DNA-damage sensors and repair 
mechanisms are essential in maintaining an efficient process in chromosomal duplication and segregation 
to prevent mutations and DNA rearrangements. We know that cancer cells generally accumulate several 
mutations, which give them a selective growth or survival advantage compared to normal cells and this 
increases its evolutionary fitness. Over time, these cells will outgrow and dominate the surrounding local 
tissue consequently giving rise to a tumour. There are several forms of genomic instability, ranging from 
 60 
point mutations to chromosomal deletions and amplifications and these can be divided into several 
categories depending on what stimulates such instabilities. Most cancers tend to have chromosomal 
instability (CIN), a type of genomic instability, where large genomic deletions and amplifications occur 
changing chromosome number, or large changes to chromosomal structure occur. Chromosomal 
instability occurs at a high frequency in multiple cancers and is associated with an aggressive tumour, 
typically conferring drug resistance and poor prognosis (Gordon et al, 2012; McGranahan et al, 2012). 
This is usually caused by failures in DNA repair, mitotic chromosomal transmission or impaired spindle 
mitotic checkpoint. Although it has been well established that many epithelial tumours exhibit 
asymmetrical segregation of chromosomes at the metaphase-anaphase transition resulting in aberrant 
distribution of genetic material to daughter cells (Steinbeck, 1998), there is evidence to suggest that one 
such mechanism may not be enough to observe chromosomal instability. One group examining several 
cell lines with specific genetic abnormalities observed that cells homozygous for mutant BRCA1 or 
BRCA2 show structural aberrations in metaphase chromosomal spreads, consistent with ongoing 
structural instability.  
Although CIN is the predominant type of genomic instability that is prevalent in many tumour types, 
other forms of genomic instability include microsatellite instability (MSI), where mutations result in large 
expansion and contractions in microsatellite sequences and it has been well documented that MSI is a 
characteristic feature of many colorectal cancers, accounting for at least 15% of all colorectal cancers 
(Boland et al, 2010). Other types of genomic instability also include instability occurring as a result of base 
substitutions, micro-insertions or micro-deletions, which are mainly associated with replication errors, 
impairment of base excision repair (BER) and mismatch repair (MMR) or error-prone translation 
synthesis (Aguilera et al, 2008).  
Addressing the ‘mutator phenotype’ mentioned above, it is thought that repetitive cycles of mutagenesis 
and selection mimics Darwinian evolution in cancer cells. Most mutations that accumulate are thought to 
be ‘passenger’ mutations that do not contribute towards the cells’ selective growth or survival advantage. 
It has been a long held concept that ‘driver’ mutations are beneficial to cancer cells as they facilitate all the 
hallmarks of cancer that contribute towards tumour progression (Hanahan and Weinberg, 2011). 
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Oncogenes are defined as driver genes, in which a mutation results in activation or altered/new functions 
favourable in promoting tumourigenesis. The same can be said for tumour suppressors, where 
inactivating mutations drive tumour progression. The types of mutations can vary from gene to gene; for 
example, while oncogenes tend to be affected by focal amplifications or missense mutations, tumour 
suppressors tend to be affected by focal deletions or frameshift mutations. There are however exceptions 
to these such as p53, which frequently have missense mutations (Kern et al, 2006) or truncations that 
confer gain-of-function activity (Ruark et al, 2013).  The activating/inactivating mutation differs between 
various genes so the types of mutations would need to be assessed for each driver gene to better 
understand its role and how we may exploit it. To further complicate matters, for each driver gene, the 
activating mutation may differ between cancer types and between samples within a cancer type. Driver 
mutations are also considered to have such a high impact on fitness of cells that they are known to not 
occur in the germline DNA of populations. Despite this, driver mutations can be inherited, a classic 
example being the BRCA1 and BRCA2 gene mutations in familial breast and ovarian cancers (Hoffmann 
et al, 2000). This demonstrates that it is possible for cancer genes to be present in the germ-line DNA for 
decades before cells harboring them become cancerous. Interestingly, some drivers may only have that 
function during certain stages of tumourigenesis. For example, inactivating mutations of TGF-β drive 
early stages of tumourigenesis by inhibiting TGF-β induced growth arrest, whereas activating mutations 
of the same gene promote angiogenesis and invasion during later stages of tumourigenesis (Akhurst et al, 
2001).  
It would thus stand to reason that there would be great benefit in identifying more driver mutations to 
better characterise each tumour on a patient-to-patient level. The problem however, is that there are far 
more passenger mutations than there are drivers. It is estimated that 5-8 drivers are required for cancer 
development (Stratton et al, 2009; Armitage and Doll, 1954). However, samples from 11 tumour types 
had on average 200 somatic mutations, of which only 2 to 6 mutations were predicted to be drivers 
(Kandoth et al, 2013). The presence of so many passenger mutations would prove challenging to 
functionally test all mutations detected by next generation sequencing. This can be circumvented by 
identifying driver mutations based on their mutation frequency or based on the prediction of the 
functional impact of the mutation. Another possible trait of a driver gene would be that it is 
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evolutionarily conserved across species because if a gene is conserved, it is very likely very important to 
the core mechanisms of cells so mutations in such a gene could be detrimental.  
1.6.1	INTER-TUMOUR	AND	INTRA-TUMOUR	HETEROGENEITY	
As mentioned above, genomic instability is very common in several cancer types, particularly with the 
more aggressive phenotypes; and as genomic instability increases, so does the genetic diversity between 
patient samples and sometimes, even within the same patient subject to the microenvironment and 
therapeutic context. Various instability mechanisms can take part during the development in a tumour, 
often a different mechanism being employed in different patients for different tumour types. This extent 
of variability is usually addressed by trying to classify different subgroups with distinct molecular 
alterations based on mutation patterns, copy number changes or patterns of genomic instability (Lengauer 
et al, 1997). This classification is usually used as the basis for identifying relevant treatment options. For 
examples, molecular classification of breast cancers, selectively highlight HER2 amplified tumours as 
being eligible for Herceptin treatment, which would otherwise not be beneficial in other tumour subtypes 
(Weigelt and Reis-Filho, 2009).  
Although the diverse mechanisms by which genomic instability occurs, it is appreciated that it wouldn’t 
necessarily translate to a huge phenotypic variation because ultimately the same pathways would be 
affected irrespective of the route taken to cause the genomic aberration. For example, impairment of the 
G1-S transition, common in most cancers, could be observed through several mechanisms, some of 
which being promoting proliferation and destabilizing the genome through DNA replication stress.   
 
1.6.2	Genomic	instability	in	HGSOC	
HGSOC has been characterized has being largely genomically unstable, with ubiquitous p53 mutations 
and inter- and intra-tumour genetic heterogeneity, where HGSOC can be further grouped into 
‘immunoreactive’, ‘differentiated’, ‘proliferative’ and mesenchymal’ subtypes, all of which have distinct 
gene expression signatures (Bayani et al, 2002). Furthermore, HGSOC is characterized by a large number 
of DNA copy number alterations, including chromosomal amplifications, which are one of the main 
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mechanisms that lead to the activation of oncogenes and the development of drug resistance. One study 
showed significant copy number gains and losses across all chromosomes in HGSOC when compared to 
LGSOC and the normal tissue counterparts. Chromosomal instability (CIN) index was used to compare 
changes in DNA copy number between samples. CIN was based on counting the number of discreet 
DNA fragments showing either gains or losses in each sample. Compared to the normal sample, both 
LGSOC and HGSOC demonstrated a higher CIN index; when comparing LGSOC and HGSOC, 
although the LGSOC did have a high CIN index in some chromosomes, the HGSOC generally had a 
higher CIN index and also had a high CIN index in all the chromosomes as shown in figure 8 (Kuo et al, 
2010).  
Figure 8: Genome-wide chromosome instability (CIN) index in ovarian serous tumours. 
A) the CIN index for all the chromosomes of each tumour plotted using a colour gradient where black = low 
CIN index and red = high CIN index. B) details the genome-wide CIN index for each tumour, where **=p 
<0.01, ***=p<0.001. C) comparing the cin index in matched normal vs tumour pairs showed that the 
tumours consistently had a higher CIN index. SBT = serous borderline tumour, LG = low grade tumour, 
HG = high grade tumour. Figure taken with permission from Kuo et al, 2009.  
 
250K SNP array analysis highlighted several frequently amplified regions in HGSOC including the loci at 
ch3q, ch12p and ch19p (Kuo et al, 2009). Interestingly, CIN can be used to describe numerical 
chromosomal instability (N-CIN), which refers to amplifications and deletions, and structural aberrations 
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of chromosomes (S-CIN), which is also though to occur to a high degree in primary ovarian carcinomas 
(Bayani et al, 2008).  
1.6.3	Genomic	instability	in	PDAC	
PDAC is also characterized by genomic instability and complexity. Some of the main genetic events are 
loss of p53, KRAS mutations and defects in mitotic spindle apparatus. These genetic aberrations and 
other nuclear abnormalities appear in PanIN-2 and PanIN-3 lesions, suggesting that genomic instability is 
triggered at these stages and then increases as the tumour progresses. Regions that are consistently altered 
involving gains are 3q, 5p, 7p, 8q, 11q 12p, 17q and 20q, detected by comparative genomic hybridization 
(CGH) (Hezel et al, 2006). Additionally, recurrent and highly focal chromosomal amplifications have been 
detected in PDAC but occurring at low individual prevalence, suggesting that the known genetic lesions 
only represent a small proportion of mechanisms driving this heterogeneous disease. Even the known 
genetic lesions can manifest in different ways, for example, although KRAS mutations are very common 
in PDAC, they can have different mutations and sometimes multiple KRAS mutations have been 
detected in the same PDAC (Yamano et al, 2000). Several genes amplified either have known inhibitors to 
target them (HER2, MET, FGFR1) or are known to be amplified in other tumour types such as PIK3CA 
and PIK3R3, also amplified in ovarian cancer (Cancer Genome Atlas Network, 2011; Waddell et al, 2015).  
1.6.4	Genomic	instability	in	type	II	sarcomas	
As mentioned in section 1.3.3, sarcomas can broadly be divided into two types: the simple karyotypic 
sarcomas which include known defining translocation or amplification of a particular locus and account 
for 20% of sarcomas, or type II sarcomas that are genomically complex, usually with multiple 
chromosomal rearrangements, amplifications and deletions. The type II sarcomas tend to develop in 
older patients as secondary cancers following radiation exposure, a known risk factor. Genes typically 
dysregulated belong to the cell cycle (RB1, INK4A, p53) and DNA repair. Frequent amplifications were 
observed on chromosomes 1,5,8,12,13,17,19 and 20 and often correlate with poor prognosis, large 
tumour size and metastatic dissemination (Jain et al, 2010). Although specific defects have not been 
identified in human sarcomas, a mouse model of the disease was developed. In this model, NHEJ defects 
were observed due to inactivation of ligase IV and the STS were characterized by significant copy number 
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aberrations such as amplifications of oncogene containing regions that correspond to the human 
sarcomas, suggesting that genetic diversity that results from copy number changes is an important step in 
sarcoma tumourigenesis (Helman and Meltzer, 2003).  
1.7	RESISTANCE-PROMOTING	SIGNALLING	PATHWAYS	
Major signalling pathways are almost always altered in all cancers as these pathways promote cell growth 
and differentiation and are interconnecting, increasing the complexity of understanding how these 
pathways work together. There are several pathways that all have important roles in tumourigenesis and 
in promoting resistance thus making them attractive therapeutic targets. The signalling pathways relevant 
to the studies in this thesis will be discussed here.  
1.7.1	THE	PI3K/AKT/MTOR	PATHWAY	
The PI3K pathway is one of the major signalling transduction pathways, that receives several upstream 
inputs from epidermal growth factor (EGF), tumour growth factor (TGF) and epidermal growth factor 
receptor (EGFR) to name a few. It is a major effector pathway of the GTPase protein RAS, that is 
frequently altered in several malignancies. The RAS/RAF/ERK pathway interacts with the PI3K pathway 
at several levels: from RAS activating PI3K (Rodriguez-Viciana et al, 1996), to PI3K activating C-RAF 
(Wandzioch et al, 2004) and then ERK phosphorylating TSC2 (Ma et al, 2005). There are three classes of 
PI3K, with each having their own substrate specificities; the class IA PI3K will be discussed here as this 
class is the most widely implicated in its contribution in cancer. The class IA PI3Ks catalyse the 
phosphorylation of inositol-containing lipids, namely phosphatidylinositols (PtdIns). The class I PI3K 
proteins are comprised of a catalytic p110 subunit (PIK3CA) and a regulatory p85 subunit (PIK3R), 
which mediates the activation and localization of the enzyme. The regulatory subunits of class IA PI3Ks 
are encoded by one of three genes (a, b, and g), which can also undergo alternative splicing. The direct 
binding of the enzyme to the phosphotyrosine residues of the growth factor receptors leads to the 
allosteric activation of the catalytic subunit and resulting phosphorylation of phosphatidylinositol 4,5-
bisphosphate (PIP2) to the active second messenger PIP3. This results in the activation of PDK1 at the 
plasma membrane. The p85 regulatory subunit is a phosphoprotein substrate of many cytoplasmic and 
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receptor tyrosine kinases; p85 associates with active tyrosine kinases either through direct interaction 
through its SH2 domain or indirectly through intermediate phosphoproteins such as insulin receptor 
substrates, IRS1 and IRS2 (Vivanco and Sawyer, 2002).  
AKT is a major effector of the PI3K pathway and regulates a number of downstream targets to control 
growth and survival. At the membrane, PDK1 phosphorylates AKT on T308, which results in its partial 
activation. Phosphorylation of AKT at S473 by mTORC2 results in its full activation. DNA-PKcs can 
also activate AKT at S473 (Stronach et al, 2011). AKT has three isoforms which share significant 
homology and also substrate specificities such as PRAS40, but also have distinct substrates. AKT 
regulates cell growth and proliferation through its effects on TSC1/TSC2 complex and mTORC 
signalling and phosphorylation of p21 and p27. mTOR phosphorylation by AKT leads to the 
phosphorylation of its subsequent targets, S6K1 and 4E-BP-1 (Hemmings and Restuccia, 2012). AKT 
promotes cell survival though negative regulation of pro-apoptotic proteins such as Bad, or inhibition of 
pro-apoptotic signals generated from downstream transcription factors such as FoxO (Zhang et al, 2011). 
AKT also phosphorylates GSK3, leading to the de-repression of cell-cycle activating molecules including 
MYC and cyclin D1 (Helman and Meltzer, 2003). AKT is also known to contribute to other phenotypes 
such as cell invasion and migration through its phosphorylation of vimentin and paladin. Phosphatase 
and tensin homologue (PTEN) is a lipid phosphatase that antagonizes the PI3K pathways by the removal 
of the D3 phosphate from PIP3 thereby limiting or terminating the PI3K signalling in cells (Cantley and 
Neel, 1999).  
In HGSOC the PI3K/Ras pathway is altered in about 45% of cases as detailed in figure 9, with frequent 
amplifications in PIK3CA, RAS and AKT2.  
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Figure 9: Altered pathways in HGSOC. Retinoblastoma (RB) and PI3K/RASA pathways are 
identified as being frequently altered in HGSOC. n=316. Figure taken with permission from the Cancer 
Genome Atlas Research Network, 2011.  
Data from TCGA suggests that the PI3K pathway is altered in about 34% of HGSOC patients, however 
if accounted for downstream mTOR targets, then the pathway is altered in approximately 63% of cases, 
highlighting the importance of this pathway in promoting survival/evading apoptosis and promoting 
resistance to treatment. The mTOR kinase intercepts signals from several pathways, including the 
MAPK/ERK pathway in addition to the PI3K pathway. There are two mTOR complexes, complex 1 
(mTORC1) and complex 2 (mTORC2). Phosphorylation of mTORC1 promotes mRNA translation and 
oncogenic protein synthesis and there are reports suggesting that hyperactivation of mTOR results in the 
selective translation of pro-survival (surviving, Mcl1), angiogenesis (VEGF-A) and DNA repair response 
(BRCA1, 53BP1) proteins (Musa and Schneider, 2015). mTORC2 is thought to play an important role in 
activating AKT through phosphorylation (Sarbassov et al, 2005). Although there are mTORC1 inhibitors 
such as rapamycin, studies indicate that perhaps inhibition of both complexes are required for therapeutic 
efficacy as without inhibition of mTORC2, AKT is still activated, stimulating pro-survival oncogenic 
signalling and thus would be capable of overcoming the effects of mTORC1 inhibition.  
In PDAC, the mutations in PI3K frequently observed in other tumour types are not present, however 
PTEN is lost in approximately 75% of cases (Asano et al, 2004). Additionally, it has been suggested that 
the activation of the PI3K pathway is necessary and sufficient to maintain oncogenic RAS-transformed 
xenograft tumours, after the elimination of RAS (Lim and Counter, 2005), which has great significance in 
PDAC, given its reliance on RAS in driving tumourigenesis in the majority of PDAC cases. AKT2, a 
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PI3K effector is also amplified in 10-20% of PDAC, further demonstrating the importance of this 
pathway in PDAC. Furthermore, Eser et al, have demonstrated that inhibition of PI3K pathway 
effectively blocks carcinogenesis and tumour progression in KRASG12D driven PDAC (Eser et al, 2013).  
Many sarcomas have also been shown to have activated growth factor signalling pathways, presumably 
through activating mutations in growth factor receptors. Interaction with the p85 subunit of PI3K leads 
to the activation of the p110 catalytic subunit, triggering the signalling cascade, leading to the activation of 
AKT as mentioned above. Additionally, one of the most frequent somatic mutations are in the PIK3CA 
gene in sarcomas with complex karyotypes, making it an attractive pathway for therapeutic intervention 
(Kim et al, 2012). This was further supported by observation that inhibiting PI3K pathway using BKM120 
as a single agent delayed tumour growth in a mouse model of high-grade soft-tissue sarcoma and had 
increased benefits in combination with doxorubicin, although not statistically significant (Kim et al, 2012). 
Furthermore, the complexity of this pathway and cross-talk with other pathways was further 
demonstrated when studies suggested that BKM120 acted in synergy with a MEK1/2 inhibitor, 
trametinib or an IGF1R inhibitor, NVP-AEW541 or an mTORC1 inhibitor rapamycin in vitro in STS cell 
line models (Anderson et al, 2015).  
1.7.2	AKT-INDEPENDENT	ONCOGENIC	SIGNALLING	
Historically, PI3K was known to promote tumourigenesis primarily through the AKT family, however, 
multiple alternative oncogenic pathways such as LKB1 and MYC converge downstream of AKT (Shaw et 
al, 2004) suggesting that there is great potential for redundancy in its ability to drive tumourigenesis.  
Interestingly, it has been observed that AKT activation only correlates weakly with activating mutations in 
the alpha catalytic subunit of PI3K (Stemke-Hale et al, 2008), suggesting the possibility of alternative 
PI3K effectors. Additionally, cell lines harboring activating mutations in PIK3CA or KRAS showed 
reduced anchorage-independent growth and increased apoptosis with PDK1 knockdown, however when 
AKT expression was introduced, it was unable to rescue the cells from the PDK1 knockdown, suggesting 
a PDK-dependent, AKT-independent signalling mechanism was responsible for the phenotypes seen.  
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1.7.3	SERUM	GLUCOCORTICOID	KINASES	(SGKS)	
Similar to the AKT family, the SGKs are members of the AGC family of serine/threonine kinases, 
comprised of three family members which are highly homologous, SGK1, SGK2 and SGK3. They are 
products of three different genes, located on different chromosomes but their activations are PI3K-
dependent. The SGKs share significant homology with the AKT family, particularly in the catalytic 
domain sequence, consequently sharing substrates and similar functions (Kobayashi et al, 1999). The SGK 
kinases consist of an N-terminal, a catalytic domain and a C-terminal hydrophobic domain. The three 
SGKs have different variants, which affect their substrate specificities; SGK1 has four variants, SGK2 
has two variants (alpha and beta) and SGK3 also has two variants, variant 1 and variant 2, which results in 
a shorter protein due to the lack of an alternate in-frame exon. SGKs have been involved in several 
pathophysiological conditions in addition to cancer, such as hypertension (Busjhan et al, 2002), fibrosis 
(Klingel et al, 2000) and diabetes (Lang et al, 2000).  
SGK activity is regulated through posttranslational modification, mainly through phosphorylation and 
dephosphorylation via PI3K.  
1.7.4	SERUM	GLUCOCORTICOID	KINASE	3	(SGK3)	
1.7.4.1	Activation	and	regulation	
Similar to AKT and the other SGKs, SGK3 is activated at T320 in the catalytic domain in a class I PI3K-
dependent manner by PDK1, however, the serine activating kinase in the hydrophobic motif has not yet 
been determined. Both mTORC2 and to a lesser extent, mTORC1 have been proposed as the 
phosphorylators of the serine residue. Evidence has pointed to mTORC2 phosphorylating the serine 
residue of AKT and SGK1, given their sequence similarities in the hydrophobic motif, it was thought that 
it may also phosphorylate the serine residues on SGK2 and SGK3. SGK3 is different from the other 
SGK members in that it has a phox-homology (PX) domain instead of a pleckstrin-homology (PH) 
domain. This PX domain is thought to be important in targeting SGK3 to PtdIns(3)P (PI3P)-rich 
endosomal vesicles; it is the specificity and binding to PI3P by SGK3 on the PX domain that targets it to 
the endosomes. This step is thought to be important for its activity, as mutations in the PX domain 
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showed abrogation of the PI3P binding and endosomal location of SGK3 along with decreased SGK3 
activity (Xu et al, 2001), suggesting that the endosomal localization of SGK3 is required for its full 
activation. Additionally, it is thought that this localization is important so that the serine phosphorylating 
kinase in the hydrophonic motif can co-localize with SGK3 in the endosomes resulting in complete 
activation of SGK3 (Tessier and Woodgett, 2006b). There is currently no evidence to suggest that 
mTORC2 localizes in the endosomes, casting doubt on its suitability for SGK3 activation at the 
hydrophobic motif. Although it is thought that SGK3 is activated exclusively in a class I PI3K-dependent 
manner, interestingly, the class III PI3K catalytic subunit hVPS34 resides in the endosomes, suggesting a 
possible interaction between the two to contribute to hVPS34-dependent regulation of protein synthesis 
via mTOR/S6K1 (Bruhn et al, 2013).  More studies are required to investigate this further. 
SGK3 is thought to be involved in regulating a lot of cellular processes similar to that of AKT. The idea 
that SGK3 may be able to drive malignant transformation in the absence of AKT stemmed from the 
observation that PIK3CA mutant tumour cells with low AKT activity had a reliance on SGK3 for 
anchorage independent growth (Vasudevan et al, 2009).  
The importance of SGK3 in mediating the pathogenesis of certain cancers has already been established; 
for example, amplifications in SGK3 are more common than AKT in hepatocellular carcinomas (HCC), 
suggesting that in certain contexts, when comparing to AKT, SGK3 may have an important functional 
significance in the biology of that particular tumour. A positive role for SGK3 in HGSOC, PDAC or 
sarcomas has not yet been determined. In fact, a report failed to demonstrate a role for SGK3 in 
mediating PI3K signalling in a panel of ovarian cancer samples with low AKT activity with only 36% of 
cases showing SGK3 activation in the presence of high PIK3CA and low phosphorylated AKT (De 
Marco et al, 2013).   
1.7.4.2	SGK3	and	cell	proliferation	and	cell	growth	
SGK3 regulates p27kip1 via the FOXO transcription factors, which it shares with other SGK and AKT 
members. SGK3 acts on FOXO3 specifically via SGK3-dependent phosphorylation of FOXO3a at 
multiple sites, consequently preventing FOXO3 from localizing to the nucleus making it unable to act on 
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its targets. The FOXO proteins act on different components of the cell cycle such as cyclin D1, CDK4 
and retinoblastoma (Ho et al, 2008). Additionally, GSK3b is also another SGK3 substrate; GSK3b 
phosphorylates cyclin D1, marking it for proteosomal degradation (Takahashi-Yanaga et al, 2008). SGK3 
prevents this by phosphorylating GSK3b, thus inactivating it in a manner similar to that of AKT 
consequently allowing cyclin D1 to continue its role in cell cycle.  
Few studies have conclusively shown a role for SGK3 in cell growth regulation, however, Bruhn et al have 
suggested a role for SGK3 in increasing growth signals through TSC2, PRAS40 and S6 phosphorylation 
(Bruhn et al, 2010). Furthermore, inhibiting PDK1 or SGK3 attenuates cell growth by inducing G1 phase 
cell cycle arrest in melanoma cells (Scortegagna et al, 2015).  
1.7.4.3	SGK3	and	cell	survival	
SGK3 was first highlighted in the context of cell survival as it was identified as one of the factors that 
mediates IL-3-dependent survival of hematopoietic cells in a genetic screen (Liu et al, 2000). As 
mentioned above, SGK3 negatively regulates FOXO3a, which is also a proapoptotic factor and can also 
increase the level of BAD, attenuating BCL-2 mediated cell death (Liu et al, 2000). Flightless-I (FL-II) has 
also been identified as being an SGK3 substrate and its activation results in enhanced activation of 
estrogen receptor (ER) and it has also been proposed to be a survival factor (Xu et al, 2009), thus further 
confirming the role of SGK3 in mediating survival.  
1.7.4.4	SGK3	and	cell	migration	
Few studies have demonstrated a role for SGK3 in cancer cell migration. It has been proposed that 
SGK3 may mediate migration through its substrate GSK3b, as GSK3b alters b-catenin dynamics leading 
to the formation of adherens and tight junctions in mammary epithelial cells. Recently, Gasser et al, have 
demonstrated that SGK3 mediates INPP4B-dependent PI3K signalling which has effects on breast 
cancer cell proliferation, migration and invasion further confirming a role for SGK3 in tumours that have 
oncogenic PIK3CA suppressed AKT activity (Gasser et al, 2014). SGK3 is also thought to indirectly 
positively regulate chemokine receptor, CXCR4 through the negative regulation of the CXCR4 degrader 
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AIP4. CXCR4 has been implicated in promoting cell migration, invasion and adhesion in breast cancer 
(Muller et al, 2001; Gassmann et al, 2009). To date, there has been no conclusive evidence to link SGK3 in 
promoting these phenotypes in HGSOC, PDAC and sarcomas.  
1.7.5	PATHWAY	REDUNDANCIES	IN	CANCER:	PROBLEMS	WITH	RESISTANCE	AND	
TARGETED	THERAPY	
Although only the PI3K pathway has been discussed here, several other signalling pathways such as the 
MAPK pathway, Wnt/b-catenin pathway and NF-kB pathway act in concert with each other to promote 
tumorigenesis and contribute to acquired resistance in cancers, and have been the focus for therapeutic 
intervention to tackle chemo-resistance. In order for cellular processes to be adaptive and dynamic, there 
are cross-talks and feedback inhibition across the different signalling pathways. This however poses a 
major problem in chemo-resistance and cancer therapies. For example, when a signalling pathway is 
blocked by a targeted inhibitor, the pathway is often disrupted resulting in upregulation of parallel 
circuits. Additionally, the complexity of this issue is even more apparent with the observations of the 
existence of cross-talk and feedback loops at multiple levels of the pathway, where signalling can be 
altered/activated downstream of the inhibited target. A classic example of this is in colorectal cancers, 
with frequent mutations in the PI3K and MAPK pathways where downstream substrate MEK was 
targeted.  It was observed that clinical benefit with the MEK inhibitor was limited and resistance is 
inevitable due to driving mutations in KRAS increasing signalling through the ERK1/2 pathway thereby 
completely bypassing MEK, and further upregulation of the Wnt and PI3K pathway (Temraz et al, 2015). 
Redundancy of a pathway or target can also occur where other effects with similar functions/substrate 
specificities can compensate for the lack of the inhibited target as seen with AKT and SGK families.  
1.8	EMT	AND	POOR	PROGNOSIS	IN	CANCER	
In addition to chemo-resistance, metastasis is also a major contributor of poor prognosis and is the main 
cause of cancer mortality. Metastasis occurs through processes including invasion, intravasation, 
transport, extravasation and colonization. EMT has been shown to play a critical role in promoting this 
aggressive phenotype. Several studies have demonstrated a correlation between EMT factors and 
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prognosis in various cancers (Xu et al, 2014; Xia et al, 2015; Ahmad and Gadgeel, 2016). However, the 
EMT process has been difficult to identify in human cancers, because the cells undergoing EMT will 
appear to be morphologically similar to surrounding stromal fibroblasts. Additionally, given that the 
distant metastases are always epithelial in origin, suggested that the EMT process is dynamically regulated 
(Tsai and Yang, 2013). Additionally, it was proposed that EMT can undergo reversible conversion termed 
mesenchymal to epithelial transition (MET) once disseminated throughout the body and colonizing 
distant sites and consequently would explain the epithelial morphology of the metastases (Thiery, 2002). 
EMT is thought to occur in three distinct contexts; it is important for tissue regeneration and fibrosis, it 
occurs during embryogenesis and organ development and it occurs in the context of cancer progression 
(Lamouille et al, 2014). The classic role of EMT is thought to be its contribution in promoting 
dissemination of the tumour cells from the solid tumour and then subsequent breakdown of the 
basement membrane to allow for migration of the tumour cells by maintaining the mesenchymal status of 
the metastasizing cell. However, this can only be achieved when all component pathways of the network 
are activated. Additionally, EMT can also promote resistance by affecting response to therapy, thus also 
contributing to poor prognosis. The degree of EMT during different stages of the tumour progression are 
dependent on the imbalance of several associated activated oncogenic network pathways (Craene and 
Berx, 2013). It is thought that EMT is regulated by four interconnected networks and that modulation of 
any of the networks will have significant effects on the others. These regulatory networks are at 
thetranscriptional level, the expression of small non-coding RNAs, differential splicing and translational 
and post-translational control. The steps involved in EMT are detailed in figure 10. 
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Figure 10: The steps involved in EMT. 1. Disassembly of the epithelial cell-cell contacts such as adherens 
junctions, tight junctions and desmosomes. 2. The loss of cell polarity through disruption of Crumbs, partitioning defective 
(PAR) and Scribble polarity complexes. 3. Repression of epithelial gene expression and promotion of mesenchymal gene 
expression. 4.Cells acquire invasive and motility capabilities by forming lamellipodia, filopodia and invadopodia by 
expressing matrix metalloproteinases (MMPs), that degrade ECM components. Figure taken from Lamouille et al, 2015 
with permission from Macmillan Publishers Ltd.  
  
1.8.1	CHANGES	IN	GENE	EXPRESSION	DURING	EMT	
During EMT, expression of epithelial genes are repressed and the cells promote gene expression 
programming to induce expression of genes relating to promoting adhesion and interaction of cells with 
the ECM. The gene expression profiles however are dependent on the extent of mesenchymal 
differentiation occurring in the cells.  
The characteristic gene expression changes are those involving the cadherins, where induction of EMT 
promotes the repression of E-cadherin to reinforce the destabilization of adherens junctions. Other 
similar genes repressed encode claudins, occludin and desmoplakin (Huang et al, 2012). The repression of 
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genes encoding epithelial proteins is also accompanied by an activation of gene expression of proteins 
which promote mesenchymal adhesion. Specifically, the downregulation of the expression of E-cadherin 
is accompanied by an increase in the expression of N-cadherin, a process which is thought to alter cell 
adhesion (Wheelock et al, 2008). N-cadherin is essential in the EMT process as it connects to the 
cytoskeleton through a-catenin and b-catenin and interactions with other signalling mediators such as 
PDGF and FGFRs.  
The expression of genes encoding proteins involved in cellular polarity are also altered, which contributes 
to EMT. Cytokeratin expression is repressed whilst vimentin activation is activated consequently 
changing the intermediate filament composition, which is important because they target different proteins 
to the membrane. For example, keratins but not vimentin direct E-cadherin to the membrane (Toivola et 
al, 2005). There are changes in expression of the genes encoding the integrins; EMT downregulate 
epithelial a6b4 integrin and upregulates a3b1 integrin, which binds laminin and is required for 
progression through EMT. Additionally EMT also upregulates a5b1 integrin, which increases adhesion 
to fibronectin, which is also activated and promotes cell migration during EMT (Maschler et al, 2005).  
The changes in integrins also correlates with the changes in expression of proteases such as MMPs, which 
enhance ECM component degradation and enables tumour cell invasion (Nistico et al, 2012).  
1.8.2	TRANSCRIPTIONAL	REGULATION	OF	EMT	
The best characterized EMT transcription factors (EMT-TFs) belong to the SNAIL, ZEB and TWIST 
families. The presence of these EMT-TFs are thought to result in the characteristic cadherin switch, 
where E-cadherin is lost and N-cadherin is gained along with vimentin (Craene and Berx, 2013). These 
transcription factors are activated early in EMT, so are considered to have central roles in EMT 
progression.  It was originally thought that EMT-TFs are associated with only promoting the 
mesenchymal phenotype and that the default phenotype is the epithelial phenotype. However, studies are 
emerging suggesting that epithelial transcription factors such as GRHL2, ELF3 and ELF5 may also be 
involved in the phenotype as they are actively downregulated in EMT and when overexpressed in 
mesenchymal cells, drive MET (Chung et al, 2016).  
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1.8.3	EMT	REGULATION	AT	RNA	LEVEL	
Another characteristic feature of EMT is the significant changes in the splicing of many mRNAs, which 
generates various protein isoforms in mesenchymal cells compared to the epithelial cells. One of the 
significant changes that occurs during EMT is the downregulation of the expression of epithelial splicing 
regulatory protein I (ESRP1) and ESRP2, which are important in regulating the splicing of many gene 
transcripts. This downregulation results in mesenchymal protein isoforms, which then affect adhesion, 
motility and signalling pathways (Warzecha et al, 2010). An increase in splicing factor Ser-Arg-rich splicing 
factor 1, SRSF1 also occurs which promotes EMT by splicing the mRNA encoding the RTK RON1 
(Goncalves et al, 2009).  
Additionally, micro-RNAs (miRNAs) that inhibit translation by binding to mRNAs or promoting their 
degradation are also known to regulate the epithelial phenotype and EMT including regulating the activity 
of the key EMT-TFs (Lamouille et al, 2013). For example, miR-29b and miR-30 repress SNAIL1 
expression, so increased miR-29b can reverse EMT and decrease cell invasion (Ru et al, 2012). In addition 
to acting on EMT-TFs, miRNAs also affect genes that define epithelial or mesenchymal phenotypes, for 
example, increased miR-9 expression represses E-cadherin and promotes a mesenchymal phenotype (Ma 
et al, 2010).  
1.8.4	SIGNALLING	PATHWAYS	IN	EMT	
Several key signalling pathways act cooperatively to regulate EMT. One of the main and most 
characterized families involved in inducing EMT is TGFb, where increased expression of TGFb 
members promotes epithelial plasticity response and progression of EMT (Katsuno et al, 2013). This can 
occur in a SMAD-dependent and a SMAD-independent manner. TGFb can also activate the PI3K/AKT, 
MAPK and JNK pathways. Several growth factors such as EGF, FGF, VEGF that act via RTKs can 
induce EMT by activating the MAPK pathway and increasing EMT-TFs and regulators of cell motility 
and invasion such as Rho GTPases and S6 kinase protein. The growth factor receptor transactivation by 
TGFb can also activate the PI3K/AKT pathway, which can promote EMT through indirect promotion 
of EMT-TFs expression (Chaudhury et al, 2010) or by inhibiting GSK3b, which prevents GSK3b-
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induced SNAIL1 degradation (Zhou et al, 2004). The Wnt pathway also promotes EMT through 
inactivation of GSK3b to stabilize b-catenin, which translocates to the nucleus to promote a gene 
expression programme favouring EMT. IL-6 can also promote EMT through JAK-STAT3 induced 
SNAIL1 expression (Lamouille et al, 2014).  
Given the wide range of signalling pathways involved in regulating EMT, crosstalk between pathways is 
inevitable. It is accepted that EMT and MET are not solid states and there can be partial EMT states 
suggesting that there can be multiple ways these pathways can interact that are dependent on the 
particular microenvironment at the time. TGFb interacts with other signalling pathways, often through 
SMAD to promote EMT however, there is conflicting evidence showing that SMAD-mediated TGFb 
interaction with HGF actually inhibitis TGFb-induced EMT which is unlike the interactions observed 
with TGFb and other growth factors, which promote EMT (Lekushi et al, 2010).  
Although TGFb can promote EMT in SMAD-dependent and SMAD–independent manners, there 
appears to be cross-talk between the two pathways. This observation stemmed from studies showing that 
although PI3K signalling can act independently of SMAD signalling, inhibition of PI3K activity can 
abrogate EMT and reduce SMAD2 phosphorylation (Bakin et al, 2000).  
With so many pathways being activated at any single time, it is important to understand the signalling 
mechanisms and the key components that integrate these pathways as they may be attractive targets for 
therapeutic intervention. One such protein, GSK3b, is central to many of these pathways; for example, 
GSK3b prevents the aberrant activation of EMT by targeting EMT-TFs such as SNAIL1 and SMAD 
proteins for degradation. GSK3b is inhibited by Wnt and AKT thus preventing GSK3b from negatively 
regulating EMT and consequently stabilizing SNAIL1 (Fuentealba et al, 2007).  
1.8.5	CELL	MIGRATION	IN	CANCER		
Cells need to be able to invade and migrate in order to change their position within tissues. In order for 
cells to disseminate into the circulation and then metastasize to distant organs, cells adopt migratory 
mechanisms which are not too dissimilar to those that occur in normal cells during physiological 
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processes such as wound healing. For cells to migrate, the cells must modify its stiffness and shape and be 
able to interact with the surrounding tissue. This occurs through several steps: firstly, the cells become 
polarized and elongate, consequently forming a pseudopod. This pseudopod then attaches to the 
extracellular matrix (ECM), which acts as a substrate. This results in contraction of either the leading edge 
of the cell of the entire cell body, which generates traction force that results in the forward movement of 
the cell body (Friedl and Wolf, 2003).  
Tumour cells within a tumour can migrate collectively and individually, often both simultaneously. 
Differences in extracellular protease activities, cadherin mediated cell-cell adhesion and cell polarity to 
name a few define the type of cell migration and invasion. In collective cell migration, tumours exhibit 
high expression of integrins and E-cadherin. The process of EMT or collective amoeboid transitions 
(CAT) trigger the transition from collective cell migration to single cell migration. In cancers, various 
types of cell migration can occur with different degrees and combinations at any given time.  
1.8.6	SINGLE	CELL	MIGRATION	
The most primitive and perhaps even effective form of cell migration is amoeboid migration, which is 
single cell migration, mimicking the features of the single-cell behavior of the amoeba Dictyostelium 
discoideum (Friedl and Wolf, 2003). These cells utilize non-integrin pattern recognition receptors to bind to 
the extracellular structures. In higher eukaryotes, this type of cell movement is utilized by hematopoietic 
stem cells and certain tumour cells. These cells use a ‘crawling’ movement, driven by short and weak 
interactions with the ECM substrate. The changes in shape occur by cortical filamentous actin, which 
provides stiffness to the cell body and mediates cell dynamics (Friedl, 2010). Single-cell migration is very 
shape-driven, which allows cells to glide through rather than degrade the ECM barrier. The ellipsoid 
shape of the cells requires actin polymerization along the plasma membrane as this stiffens and contracts 
the cell cortex; these dynamics are controlled by small GTPase RHoA and its effector ROCK (Kardash et 
al, 2010). Amoeboid cells have the ability to move freely through many different organs, allowing it to 
have great capacity for dissemination, either through recirculation within the blood and lymphatic system 
or in connective tissue.   
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1.8.7	COLLECTIVE	CELL	MIGRATION	
Collective cell migration is the second main mode of cell movement. In contrast to single cell migration, 
collective cell migration are characterized by three hallmarks: firstly, the cells maintain their cell-cell 
junctions, regulated by adherens junction proteins such as cadherins and integrins; secondly, the 
organization of the actin cytoskeleton results in the generation of the traction and protrusion force that 
results in the cell movement, and thirdly, as cells migrate collectively, they direct proteolytic breakdown of 
the ECM, thereby generating a migratory path (Friedl and Gilmour, 2009).  
The guidance of collective cell migration involves the coordination between two distinct populations: the 
leader and the follower cells. The leader cells essentially receive guidance signals as they are localized at 
the front of the moving group of cells and they instruct the population through chemical or mechanical 
signalling, where the cell-cell junctions are at the rear. The leader cells acquire a leading edge towards the 
substrate (i.e. ECM) and secure front-rear polarity and guidance along tissue structures. To penetrate the 
ECM as a cell collective, the leading cells generate an invasion path that use B1 integrin-mediated focal 
adhesions and local expression of MT1-MMP to cleave the collagen fibers and orient them so that they 
form tracks that the follower cells can utilize (Haeger et al, 2015). The downstream intracellular signals 
that define and regulate the leader cells are cell-type and context specific but include MAPK/ERK 
signaling, focal adhesion kinase (FAK) signaling, PI3K/AKT signaling pathways and Rho GTPases 
(Haeger et al, 2015).  
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Figure 11: collective and individual cell migration. In collective cell migration, tumours express 
high levels of E-cadherin and integrins. Processes such as epithelial-mesenchymal transition (EMT) and 
collective-amoeiboid transitions (CAT) act as triggers between the two migrations types. During EMT, 
tumour cells acquire a mesenchymal phenotype and detatch from the tumour and migrate by the mesenchymal 
mechanism, which involves molecular changes such as increase in proteases and integrins and a decrease in 
RhoA. During CAT, integrins are down-regulated and tumour cells detatch from the tumour mass and move 
by the amoeboid mechanism, which involves a decrease in protease and integrin expression and changes in the 
activity of GTPases such as the activation of RhoA. These two movement types are very plastic and can 
switch from one to another depending on the extracellular matrix type and the intracellular regulation. Figure 
adapted from Krakhmal et al, 2015. 	 	
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1.9	CONCEPT	AND	AIMS	OF	PROJECT	
1.9.1	CONCEPT	
We have thus far established that tumours such as HGSOC, PDAC, and complex karyotypic sarcomas all 
are defined as being genomically unstable and thus carry a very poor prognosis, making them very 
attractive tumour types to study together.  They frequently harbor p53 mutations and their genomes are 
constantly mutated and rearranged to facilitate the tumour formation and evasion of death.  The constant 
genetic changes also inherently highlights the problem with current cancer therapies; as the cell continues 
to evolve, it may no longer be dependent on a particular function that the therapeutic agent targets 
resulting in loss of effectiveness.  Previous data have already shown common markers of poor prognosis 
shared between the three tumour types; for example, it has been shown that Trop-2, a marker of 
aggressive phenotypic tumours, are overexpressed in EOC, PDAC and carcinosarcomas and thus serve as 
a marker of poor prognosis in these tumours (Fong et al, 2008, Bignotti et al, 2010, Raji et al, 2011). We 
therefore aim to exploit the commonalities these tumours appear to share to see if we can further identify 
targetable markers that have prognostic significance, in particular in relation to response to DNA 
damaging chemotherapy. 
Recent technological advances have revolutionized the way we subgroup tumours and our general 
understanding of cancer genetics. Transcriptional profiling, copy number variation (CNVs) and next 
generation sequencing (NGS) have revised the classification of many tumour types into more relevant 
subgroups, providing useful prognostic information. CNVs are an important source of variation in the 
genome that can be detected routinely by single nucleotide polymorphism (SNP) arrays and array 
comparative hybridization (aCGH) (Pang et al, 2010). SNP arrays offer great robustness, high resolution 
and are able to detect copy number variations such as submicroscopic deletions and amplifications 
(Nowak et al, 2009).  The large genomic instability and structural variation that characterizes cancer cells 
are features that would make CNV interesting to study with respect to cancer initiation and progression. 
Ultimately, a detailed characterization of the genetic defects present in most cancers is necessary to be 
able to understand it better at the molecular level. This requires computational analysis that can firstly 
identify addition or deletion events and then identify whether these events are causal or functionally 
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neutral (Taylor et al, 2008).  This project aims to look at existing datasets, which is why SNP array data 
will be analysed instead of next generation sequencing analysis as there are many publicly available SNP 
array datasets with corresponding clinical data.  
It is known that each cancer is characterized by several somatic mutations, of which only a subset 
contributes to tumour progression. Even though genome-wide sequencing studies have identified 
hundreds of mutations within a tumour, it is still difficult to ascertain which of these mutations contribute 
to the pathogenesis. It is therefore of great interest to identify these 'driver' mutations that characterize 
each cancer.  Some of these mutations may be useful in determining prognosis or treatment choice whilst 
other driver mutations may in fact be druggable and could potentially further advance treatment options 
(Dancey et al, 2012). Some mutations may also be predictive of drug response in one form of cancer (i.e. 
BRAF V600E and vemurafenib in melanoma; Chapman et al, 2011) and there may be a likelihood that 
other tumours from different origins harboring the same mutations may confer the same 
sensitivity/resistance to the drug. This however needs to be explicitly tested as previous studies have 
shown that this may not always be the case. For example, Herceptin is sensitive in HER2+ breast and 
gastric cancers, however this response is not observed in HER2+ ovarian or endometrial cancers 
(Bookman et al, 2003; Fleming et al, 2010). If a functional consequence of an identified mutation is similar 
across several tumour types, then the therapeutic implications are huge.  
The incredibly complex genomic rearrangements observed in cancers such as pancreatic adenocarcinomas 
(PDAC), epithelial ovarian cancers (EOC) and a subtype of sarcomas makes it very difficult to 
understand their molecular biology but also highlights possible targets that could be identified and further 
validated. Previous studies have identified and highlighted CNVs that may predispose one to a particular 
cancer. For example, a recent paper by Huang et al (2012) was one of the first studies to suggest an 
association between germline CNV and pancreatic cancer risk; a common 10,379bp deletion at 6q13 was 
found at a higher frequency in patients with sporadic pancreatic cancer compared to the controls. 
Interestingly, further studies showed possible involvement in long-range regulation of the tumour 
suppression gene, CDKN2B. Similarly, studies in ovarian cancer have shown that amplification of 
CCNE1 (cyclin E) is strongly associated with treatment-resistance in ovarian carcinomas. Furthermore, 
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the identification of this relationship has suggested potential for therapeutic exploitation, where patients 
carrying this CCNE1 amplification could potentially benefit from cyclin-related targeted treatments 
(Etemadmoghadam et al, 2009). Work carried out in Dr. Stronach’s lab has highlighted AKT signalling to 
be a key driver in cancer cell survival following chemotherapy. Further studies have also identified DNA-
PKcs to be the activating kinase and thus suggests a link between DNA repair pathways and cancer cell 
survival (Stronach et al, 2011). Further studies looking at the gene loci of DNA-PKcs identified frequent 
chromosomal amplifications, which was significantly associated with poor progression free survival. 
These examples highlight the potential benefits of carrying out such analysis to further identify markers of 
poor prognosis and validate them as potential therapeutic targets.  
1.9.2	AIMS	
The broad aims of the project were: 
1. To analyze publically available datasets for HGSOC, PDAC and a subset of type II sarcomas 
with complex karyotypes for copy number amplifications in genes relating to DDR/repair and 
apoptosis and correlate these results to the response to chemotherapeutic agents. Highlighted 
candidates would then be functionally validated and their therapeutic potential would be 
assessed.  
2. To focus on a key component in DNA repair, DNA-PKcs, which has been implicated in 
contributing to poor prognosis in these tumour types through DNA repair and through the 
PI3K signalling (via AKT) and to further characterize the functional mechanisms behind its role 
in poor prognosis and signalling dynamic changes that occur with its inhibition using proteomic 
analyses 
3. To further address the second aim by investigating nuclear specific changes in response to 
chemotherapeutic agents to attempt to identify biomarkers of chemo-resistance and examine 
how this nuclear/cytoplasmic shuttling dynamic changes with DNA-PKcs inhibition in 
combination with chemotherapeutic agents.  
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CHAPTER	2:	MATERIALS	AND	METHODS	
2.1	GENOMIC	ANALYSIS	TO	IDENTIFY	COMMON	COPY	NUMBER	
AMPLIFICATIONS	
2.1.1	Datasets	used	for	study	
For target identification, four datasets were used; two for ovarian cancer, one for pancreatic 
cancer and one for sarcoma. Two datasets were used for high-grade serous (HGS) ovarian 
cancer, one was produced using a SNP6 array and processed using circular binary 
segmentation (CBS) algorithm whilst the other dataset was produced using array 
comparative genomic hybridization (aCGH) analysing the same tumours. The pancreatic 
ductal adenocarcinoma (PDAC) dataset was produced using SNP6 arrays and processed 
using the CBS algorithm. All three datasets were obtained from the Cancer Genome Atlas, 
TCGA (https://tcga-data.nci.nih.gov/tcga/tcgaCancerDetails.jsp?diseaseType 
=OV&diseaseName=Ovarian%20serous%20cystadenocarcinoma for ovarian and 
https://tcga-data.nci.nih.gov/tcga/tcgaCancerDetails.jsp?diseaseType 
=PAAD&diseaseName=Pancreatic%20adenocarcinoma for pancreatic cancer). The sarcoma 
dataset was obtained from Gene expression omnibus (GEO, NCBI, 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE21124 ) and was produced using an 
Affymetrix Mapping 500K SNP array. The ovarian cancer datasets had copy number, gene 
expression and clinical data. Both the pancreatic cancer and sarcoma datasets had copy number 
and gene expression data only.  
2.1.2	Analysis	inclusion	criteria	
As mentioned above, only high-grade serous ovarian cancer and pancreatic ductal 
adenocarcinomas were included in the analysis; only type II sarcomas were included as they 
typify genomic instability and poor prognosis and are therefore comparable with HGS ovarian 
cancer and PDACs. The TCGA ovarian cancer dataset was enriched by selecting primary grade 3 
tumours only. Primary tumours were selected from the pancreatic cancer dataset. The copy 
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number analysis was restricted to 734 genes relating to DNA damage/repair and/or apoptosis. 
The list of the genes are detailed in Supplementary figure 1. The gene list was collated by using 
“DNA damage”, “DNA repair” and “apoptosis” keywords on the PANTHER Gene Ontology 
database (http://www.pantherdb.org ) and GO databases (http://geneontology.org/page/go-
enrichment-analysis ) and selected all the genes identified by these keywords.  
2.1.3	Data	analysis		
The analysis was carried out using the statistical computing program, ‘R’. The four datasets were 
analysed for common copy number amplifications across the three tumour types. The 
threshold for amplifications was considered to be copy number >2.5. Kaplan Meier survival 
plots were produced and group differences were tested for significance using the log-rank test, 
obtained from the survival package (using the survdiff function) in ‘R’. Although the log rank test 
is used to test whether there is a difference between the survival times of different groups, it 
doesn’t allow for other variables that may account for the differences to be taken into account 
(i.e. univariate), therefore the cox proportional hazards model was used to calculate the hazard 
ratio (i.e. multivariate) using the coxph function from the survival package in ‘R’. The genes in 
each dataset were sorted by amplification frequencies, and the top 100 most amplified genes were 
compared within the three datasets and the commonly amplified genes were then cross-
referenced to the HGS ovarian cancer PFS data survival analysis p-value determined using a log-
rank test to assess how significant the differences in relapse free survival was with the particular 
gene amplification.  To show that copy number amplifications correlate with an increase in gene 
expression, linear regression analysis was carried out using the lm function from the limma 
package in ‘R’. 
2.2	CELL	LINE	FEATURES	AND	CONDITIONS	
Four cell lines were previously derived from patients with ovarian adenocarcinoma before 
platinum treatment (PEA1) or after platinum-based therapy but in the platinum sensitive 
timeframe (PEO1) and after clinically platinum resistant relapse (PEA2, PEO4) were used 
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for a number of experiments within this study (cells were kindly supplied by Simon 
Langdon, University of Edinburgh, UK). Their characteristics are detailed below.  
Patient 
no. 
Cell 
Line 
Morphology Time of collection 
1 PEA1 Poorly differentiated serous 
adenocarcinoma 
Before any treatment 
 PEA2  Relapse after cisplatin and 
prednimustine 
2 PEO1 Poorly differentiated serous 
adenocarcinoma 
After cisplatin, 5-fluorouracil 
and chlorambucil 
 PEO4  After clinical resistance 
developed to above agents 
 
 
 
 
Figure 12: The characteristics of the isogenic ovarian cancer paired cell lines (A). 
Diagram obtained from Cooke et al, 2010 showing the time at which the cell lines for each isogenic pair were 
obtained with respect to time of treatment (B).  
Other ovarian carcinoma cell lines used were SKOV3 and IGROV1, both purchased from 
ECACC, OVCAR4 and 59M, which were kindly provided by Haonan Lu (Imperial College 
London).  
All the ovarian cancer cell lines except for 59M were cultured in RPMI-1640 (Sigma), 
supplemented with 10% fetal calf serum (FCS) (First Link), 2mM L-Glutamine (Invitrogen), 
50µg /ml streptomycin and 50units/ml penicillin (Invitrogen) and were cultured at 37°C with 5% 
CO2. 59M was cultured in DMEM, with same supplements as stated above.  
The pancreatic epithelioid carcinoma cell lines, Panc-1 and Aspc1 were purchased from ECACC 
and cultured in DMEM (Sigma), and RPMI (Sigma) respectively, and supplemented with 10% 
fetal calf serum (FCS) (First Link), 2mM L-Glutamine (Invitrogen), 50µg/ml streptomycin and 
 87 
50units/ml penicillin (Invitrogen). Cells were cultured at 37°C with 5% CO2. The pancreatic 
cancer cell line TKCC6 was established following spontaneous immortalisation of primary cells 
and kindly provided by Professor Andrew Biankin (University of Glasgow, UK). TKCC6 was 
cultured in DMEM/F12 media (Invitrogen), supplemented with 10% FCS (First Link), 2mM L-
Glutamine (Invitrogen), 15mM Hepes (Invitrogen), 10ng/ml hEGF, 40ng/ml hydrocortisone 
(Thermo Scientific), 0.12% glucose solution (Invitrogen) and 0.1IU/ml insulin at 37°C with 5% 
CO2.  
Leiomyosarcoma cell line SK-UT-1 was purchased from ATCC and cultured in DMEM (Sigma), 
supplemented with 10% fetal calf serum (FCS) (First Link), 2mM L-Glutamine (Invitrogen), 
50µg /ml streptomycin and 50units/ml penicillin (Invitrogen)and cultured at 37°C with 5% CO2. 
Cell Line Morphology TP53 status PIK3CA status PTEN status 
SKOV3 Epithelial Truncated Missense mutation WT 
IGROV1 Epithelial Missense mutation Missense mutation Missense mutation and 
frameshift deletion 
OVCAR4 Epithelial Missense mutation WT WT 
59M  Frame shift deletion WT WT 
Panc-1 Epithelial Missense mutation - - 
Aspc1 Epithelial Frame shift deletion - - 
SK-UT-1 Epithelial Missense mutations Missense mutation Frameshift del/ins 
 
Table 4: Genotypic characteristics of cell lines studied 
 
2.3	GROWTH	FACTORS,	CYTOTOXICS	AND	INHIBITORS	
The cytotoxic agents cisplatin (1mg/ml), doxorubicin (2mg/ml) and gemcitabine (38mg/ml) 
were obtained from Hammersmith hospital pharmacy.   
Inhibitors used were NU7441 (DNAPKi) (Selleck Chem) at 10µM, API-2 (AKTi) at 20µM, 
GSK650394 (SGKi) (Selleck Chem) at 20µM, AMD3100 (CXCR4i) (Sigma) at 3µM.  
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2.4	PLASMIDS	
p3xFLAG-CMV-10-SGK3wt was purchased from Addgene, deposited by Jim Woodgett 
(Addgene plasmid # 24650). pcDNA.31+ - FAAP24 wt was generated using RNA from PEA2 
ovarian cancer cell line as detailed in section 2.6.  
2.5	SITE-DIRECTED	MUTAGENESIS	
p3xFLAG-CMV-10-SGK3-S486A, p3xFLAG-CMV-10-SGK3-S486D, p3xFLAG-CMV-10-
SGK3-T320A and p3xFLAG-CMV-10-SGK3-T320D mutant constructs were generated from 
the wild-type p3xFLAG-CMV-10-SGK3wt construct using site-directed mutagenesis to prepare 
constitutively active and null versions of the two main phosphorylation sites required for full 
SGK3 activation using the following primers: 
Mutant Primer sequence 
S486A sense 5’ CGTTGGTTTCGCTTATGCACCTCCTTC 3’ 
anti-sense 3’ GAAGGAGGTGCATAAGCGAAACCAACG 5’ 
S486D sense 5’ CGTTGGTTTCGATTATGCACCTCCTTC 3’ 
antisense 3’ GAAGGAGGTGCATAATCGAAACCAACG 5’ 
T320A sense 5’ GACACCACTACCGCATTTTGTGGGACACC 3’ 
antisense 3’ GGTGTCCCACAAAATGCGGTAGTGGTGTC 5’ 
T320D sense 5’ GACACCACTACCGACTTTTGTGGGACACC 3’ 
antisense 3’ GGTGTCCCACAAAAGTCGGTAGTGGTGTC 5’ 
Table 5: Details of primer sequences used for the site-directed mutagenesis of wild-
type SGK3. 
The mutagenesis was carried out using the Agilent Lightning Site-Directed Mutagenesis kit 
according to the manufacturer’s instructions. Briefly, samples were made up with 100ng template 
DNA (p3xFLAG-CMV-10-SGK3wt), 125 ng of the relevant primers for desired mutation as 
indicated above, dNTP mix, QuikSolution reagent, and QuikChange Lightning enzyme (all from 
the kit). The cycling parameters are outlined as below: 
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Cycles Temperature Time  
1 95°C 2 minutes 
18 95°C 
60°C 
68°C 
20 seconds 
10 seconds 
30 seconds/Kb of plasmid length 
1 68°C 5 minutes 
Table 6: Cycling parameters for site-directed mutagenesis 
 
Following the amplification, the parental supercoiled ds-DNA was digested using methylation 
dependent Dpn I restriction enzyme and incubated at 37°C for 5 minutes. The Dpn I treated 
samples were then transformed using 45µl XL-10 Gold Ultracompetent cells (Agilent) with 2µl 
b-mercaptoethanol on ice for 30 minutes followed by heat shock for 30 seconds at exactly 42°C 
followed by a 2 minute incubation on ice. Super optimal broth with catabolite repression (SOC) 
media was added to the cells and incubated for 1 hour at 37°C at 225rpm. Competent cells were 
plated at different volumes (50µl, 150µl and 300µl) onto lysogeny broth (LB) agar plates 
supplemented with ampicillin at 100µg/ml and incubated at 37°C overnight. The following day, 
at least 6 colonies for each mutant were selected for plasmid DNA extraction to check if the 
SDM was successful, assessed by sequencing. Briefly, the colonies were picked using a pipette tip 
and added to 5ml of 2YT media supplemented with ampicillin at 100µg/ml and incubated 
overnight at 37°C. The plasmid DNA was extracted and purified using the QIAprep spin mini 
prep kit (QIAGEN) according to the manufacturers protocol. 100ng/µl of DNA was sent for 
sequencing carried out by Beckman Coulter Genomics to confirm successful mutagenesis. 
Positive colonies were then picked (one for each mutation) based on sequencing data and DNA 
was extracted using a QIAGEN plasmid midi kit according to the manufacturers protocol. The 
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resulting DNA was then sent for sequencing again to confirm positive mutagenesis before 
initiating experiments.  
2.6	FAAP24	GENE	CLONING	
FAAP24 was amplified using cDNA from PEA2 ovarian cancer cell line using primers with 
incorporated restriction sites for BamHI and XhoI. Primers used were sense 5’ 
GCTAGGATCCATGGAAAAGAACCCCCCTGATGATACG 3’ and antisense 3’ 
TAGTCTCGAGTCACCTGGGCTGCGTGAAGAAGG 5’.  
PCR amplification was carried out using Phusion High-Fidelity DNA Polymerase (New  England 
Biolabs Inc. (NEB)) using 100ng DNA template in a 20µl reaction volume consisting of 1x 
Phusion High-Fidelity buffer, 200µM dNTPs, 0.5µM sense and antisense primers respectively, 1 
units/50µl Phusion DNA polymerase and nuclease-free water. The cycling parameters for this 
reaction are as detailed below: 
Step Temperature Time 
Initial denaturation 98°C 30 seconds 
35 cycles 98°C 
55°C 
72°C 
10 seconds 
30 seconds 
30 seconds/kb 
Final Extension 72°C 10 minutes 
Hold 4°C  
Table 7: Cycling parameters for FAAP24 PCR amplification 
Amplification of the single amplified product (600bp) was verified by gel electrophoresis on a 1% 
agarose gel. Once verified, the remainder PCR product was purified using the QIAGEN PCR 
purification kit according to the manufacturer’s instructions. The concentration was assessed by 
260 absorbance using a NanoDrop ND-1000. The purified FAAP24 PCR product and the 
pcDNA 3.1+ vector were both digested using 10 units of BamHI and XhoI restriction enzymes 
in 1x NEB buffer (New England Biolabs) for 2 hours at 37°C. This was followed by vector 
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dephosphorylation to prevent vector re-ligation using Antarctic Phosphatase (NEB) according to 
manufacturers instructions. Briefly, 1/10th volume of 10x Antarctic Phosphatase reaction buffer 
was added to 1-5µg of digested vector followed by 5 units of the Antarctic Phosphatase. This was 
incubated for 15 minutes at 37°C followed by heat inactivation for 5 minutes at 70°C.  The 
digested PCR product and the dephosphorylated vector were then ligated using a 3:1 ratio 
respectively, using the T4 DNA ligase (Promega) according to the manufacturer’s instructions. 
Briefly, the amount of PCR product and vector to be ligated was calculated using the following 
calculation: 
  
The PCR product and the dephosphorylated vector were ligated using a 3:1 ratio respectively 
along with 1µl of 10x ligase buffer and 1U T4 DNA ligase and nuclease-free water to a final 
volume of 10µl. The ligation reaction was incubated at 4°C overnight. 
The ligation reaction was then transformed into Alpha-select gold efficiency competent E. coli 
cells (Bioline, USA) according to the manufacturer’s instructions. Competent cells were plated 
onto lysogeny broth (LB) agar plates supplemented with ampicillin at 100µg/ml and incubated at 
37°C overnight. Following the overnight incubation, at least 6 resulting colonies were selected for 
plasmid DNA extraction to check for the presence of the insert without mutations, assessed by 
sequencing. Briefly, the colonies were picked using a pipette tip and added to 5ml of 2YT media 
supplemented with ampicillin at 100µg/ml and incubated overnight at 37°C. The plasmid DNA 
was extracted and purified using the QIAprep spin mini prep kit (QIAGEN) according to the 
manufacturers protocol. 100ng/µl of DNA was sent for sequencing carried out by Beckman 
Coulter Genomics to confirm successful mutagenesis. One positive colony was then selected 
based on sequencing data and DNA was extracted using a QIAGEN plasmid midi kit according 
to the manufacturers protocol. The resulting DNA was then sent for sequencing again for 
confirmation before initiating experiments.  
2.7	DRUG	TREATMENTS	
ng of  vector x kb size of  insert
kb size of  vector 
x Molar ratio of  insert = ng of  insert
vector
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Cells were treated with 10µM DNAPK inhibitor (NU7441), 20µM AKT inhibitor (API-2), 3µM 
CXCR4 inhibitor (AMD3100), 10µM SGK inhibitor (GSK650394) unless stated otherwise. 
Doses of chemotherapeutics used were 25µM for cisplatin, 1.5µM for doxorubicin, 10µM for 
gemcitabine and 10µM for bleomycin. These concentrations were determined based on previous 
IC50 data/experiments established in the lab. Equimolar concentrations were used in all cell lines 
where the concentration used was chosen to induce a biological response but not too significant 
to be toxic on its own given that some experiments used combination treatments. Where cells 
were treated with combination drugs (i.e. an inhibitor in combination with a chemotherapeutic 
agent), the inhibitor was added to the cells and incubated at 37°C for 1 hour prior to the addition 
of the chemotherapeutic agent. Following the 1hour incubation, the media was removed and 
replaced with fresh medium containing the chemotherapeutic agent and the inhibitor at the 
appropriate concentration.  
2.8	3-(4,	5-DIMETHYLTHIAZOL-2-YL)-2,	5-DIPHENYL	TETRAZOLIUM	
BROMIDE	(MTT)	PROLIFERATION	ASSAY	
Cell proliferation was assessed using MTT reagent, which relies on the reduction of tetrazolium 
salts. Generally, the MTT substrate is added to the cells in culture at a final concentration 
between 0.2-0.5mg/ml and incubated for any time between 1-4 hours. The quantity of formazan, 
assumed to be directly proportional to the number of viable cells is measured by 
spectrophotometric means by recording changes in the absorbance at 570nm. The principle 
behind this assay relies on the idea that metabolically active viable cells are able to convert MTT 
into a purple coloured formazan product, which has an absorbance around 570nm. Dead cells do 
not have this MTT to formazan conversion ability and thus the colour remains yellow and thus 
the purple colour conversion serves as a crude marker of viable cells.  
For these studies, the MTT reagent (Sigma) (3mg/ml in PBS) was added to cells in a 96-well plate 
to a final concentration of 0.5mg/ml. The plate was incubated for 3 hours at 37°C to allow the 
formazan crystals to form. The reaction was then stopped with 10%SDS/0.01%HCl solution in a 
1:1 ratio. The crystals formed were dissolved overnight at 37°C. Absorbance was measured on a 
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spectrophotometer at 570nm wavelength. All experiments were performed in triplicates and were 
normalised to untreated or vehicle control conditions after correcting for background reading.  
2.9	CASPASE-GLO	3/7	ASSAY	
Caspase-Glo 3/7 assay (Promega) measures the activity of cleaved caspase 3 and caspase 7, 
which play are major effectors of apoptotic cell death. The assay is made up of a luminogenic 
caspase 3/7 substrate containing DEVD-aminoluciferin and a thermostable luciferase. Adding 
the reagent to the cells results in cell lysis, which releases active, cellular caspase-3 or -7, which 
then cleaves the DEVD substrate from aminoluciferin. This allows the oxidation of the luciferin 
by the luciferase, which produces light, which is measured. The luminescent signal is 
proportional to caspase-3/7 activity.  
Cells were cultured in white 96-well plates and treated accordingly (described section 2.7) prior to 
casapse-3/7 assay. After appropriate incubation time with treatment, caspase-glo 3/7 reagent was 
added to cells in 1:1 (v/v) ratio and incubated at room temperature for an hour. The 
luminescence was then measured on a LUMIstar Optima luminometer (BMG Labtech). Similar 
to the MTT assay, all experiments were performed in triplicates and were normalised to untreated 
control or vehicle control after correcting for background reading.  
2.10	PROTEIN	EXTRACTION	FROM	CELLS	
Cells ready for protein extraction were typically at log phase growth. The 
radioimmunoprecipitation cell lysis buffer RIPA (Santa Cruz Biotech) was used with the addition 
of 200mM PMSF, 100mM sodium orthovanadate and protease inhibitor cocktail in DMSO all at 
1:100 just prior to addition to cells. Cells were washed twice, on ice, in cold PBS and trypsinised 
with the pellet collected for cell lysis. Depending on size of plate cells were harvested from, 40-
90µl RIPA cell lysis buffer was added to pellet and vortexed at the highest speed for 15 seconds. 
This step was repeated every 5 minutes for a total of 40 minutes. Samples were kept on ice for 
the duration of the 40-minute incubation. Following 40 minutes, cells were centrifuged at 4°C for 
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10 minutes at the highest speed (15,000 rpm) and supernatant collected and stored at -20°C until 
further use.  
2.11	NUCLEAR/CYTOSOLIC	FRACTIONATION	OF	CELL	LYSATES	
Cells were seeded in duplicates in 6-well plates to reach 50-70% confluency. Following overnight 
incubation to allow cells to adhere, they were treated with either leptomycin B (LMB) at 1nM or 
5nM alone, cisplatin at 25µM or in combination with LMB at the two doses for 24 hours, plus a 
no treatment vehicle (methanol) control. The plates were then washed twice with cold PBS, 
trypsinised and centrifuged to collect the pellet. 
For the SILAC study as described in section 2.14, the different arginine and lysine labelled cells 
were seeded in 100mm dishes until 70% confluent and then each labelled cell population were 
treated with either doxorubicin and cisplatin alone or in combination with the DNAPK inhibitor, 
NU7441. Fractionation was carried out using the BioVision Nuclear/Cytosolic Fractionation kit 
according to the manufacturers protocol. Briefly, after cell pellets were collected, 200µl of cytosol 
extraction buffer A (CEB-A) containing DTT at 1:1000 and Protease inhibitor cocktail at 1:500 
were added and incubated on ice for 10 minutes after vigorous mixing. This was followed by the 
addition of 11µl of cytosol extraction buffer B (CEB-B), vortexing for 15 seconds and incubation 
on ice for 1 minute. The tube was centrifuged at for 5 minutes using a microcentrifuge tube 
(15,000 x rpm). The supernatant was the cytoplasmic extract and this was collected in a separate 
ice-cold tube and appropriate labelled. To extract the nuclear fraction, the cell pellet was 
resuspended in 100µl of ice-cold nuclear extraction buffer with DTT (1:1000) and protease 
cocktail inhibitor (1:500) added to it and incubated on ice for 40 minutes with intermittent 
vortexing. The tube was centrifuged at full speed (15,000 x g) for 10 minutes and the resulting 
nuclear fraction (supernatant) was transferred to a separate tube. All centrifugations were done at 
4°C. Subcellular protein was then quantified using the Pierce BCA protein assay as described 
below. The fractionation efficiency was confirmed via western blotting as described in section 
2.15 using lamin A/C as a nuclear marker and b-tubulin or vinculin as a cytosolic marker.  
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2.12	BCA	ASSAY	FOR	PROTEIN	QUANTIFICATION	
Protein concentrations of all studies were quantified using the BCA protein assay kit (Pierce), 
according to the manufacturer’s instructions.  
A bovine serum albumin (BSA) standard was prepared ranging from 25µg/ml to 2000µg /ml. 
5µl of each sample was added to each well in duplicate in a 96-well plate. The working reagent of 
BCA and copper sulphate were mixed according to the manufacturer’s protocol at a 1:50 ratio 
and 200µl per well was added. The plates were then incubated at 37°C for 30 minutes and the 
optical density was read on a spectrophotometer at 562 nm wavelength. The standard curve was 
plotted (absorbance vs concentration) and the line of best fit was calculated using PRISM 6.0. 
Concentrations of samples were determined using the y-intercept of the line.  
2.13	REVERSE-PHASE	PROTEIN	ARRAY	(RPPA)		
2.13.1	Experimental	design	and	drug	treatments	
Protein samples were prepared for RPPA analysis as follows. Cells were seeded and treated 
according to experimental design in 6-well plates.   
For Doxorubicin and NU7441 combination treatments, ovarian cancer paired PEA1 and PEA2 
cells and pancreatic cancer Panc-1 cells were seeded and after adhering overnight, they were 
treated with doxorubicin, NU7441 alone and in combination. Other conditions included 
treatment with API-2 alone and in combination with doxorubicin and an untreated control.  
For the SGK3 studies, two sets of experiments were conducted. For one set of experiments, 
ovarian cancer SKOV3 cells were seeded and allowed to adhere overnight, after which cells were 
transfected with 30nM SGK3 siRNA, a non-targeting siRNA control or 0.4µg p3xFLAG-CMV-
10-SGK3wt overexpression construct and a p3xFLAG-CMV-10 empty vector control. Protein 
was collected for baseline signalling changes 48 hours after transfection. In another set of 
experiments, following 24-hour incubation post transfection, cells were serum starved for 18 
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hours and then cells were stimulated with 0.5% serum for 30 minutes and protein was collected 
at 0min and 30min serum stimulation for the control and SGK3 construct.  
Following relevant treatments/transfections, cells were washed with PBS twice, and 80µl of 
RPPA lysis buffer was added to cells and incubated levelled on ice for 20 minutes with 
intermittent shaking every 5 minutes. The lysis buffer was made up of 1% Triton X-100, 50mM 
HEPES, pH 7.4, 150mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM Na 
pyrophosphate, 1mM Na3VO4, 10% glycerol, containing freshly added 25 x protease inhibitors 
(Roche Applied Science) and 100 x phosphatase inhibitors (Calbiochem). Cells were then scraped 
off the wells and collected into ice-cold 1.5ml microcentrifuge tubes. The cell lysates were 
centrifuged for 10 minutes at 15,000 rpm at 4°C. The supernatant was transferred to new ice-
cold 1.5ml microcentrifuge tubes. Protein concentration was determined by BCA assay reaction 
and the concentration was adjusted to 1-1.5µg/µl. The samples were then mixed with 4x SDS 
sample buffer without bromophenol blue and boiled for 5 minutes. Samples were stored in -80°C 
until sent for processing. RPPA samples were run and analysed at the MD Anderson Cancer 
Centre (MDACC).  
2.13.2	Experimental	processing	and	running	
For the experimental running and analysis at MD Anderson Cancer Centre, cellular proteins were 
diluted in five 2-fold serial dilutions in dilution buffer (lysis buffer containing 1% SDS). Serial 
diluted lysates were arrayed on nitrocellulose-coated slides (Grace Biolab) by Aushon 2470 
Arrayer (Aushon BioSystems). 5808 array spots were arranged on each slide including the spots 
corresponding to positive and negative controls prepared from mixed cell lysates or dilution 
buffer, respectively. 
Each slide was probed with a validated primary antibody plus a biotin-conjugated secondary 
antibody. Only antibodies with a Pearson correlation coefficient between RPPA and western 
blotting of greater than 0.7 were used in reverse phase protein array study.  
The signal obtained was amplified using a Dako Cytomation–catalyzed system (Dako) and 
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visualized by DAB colorimetric reaction. The slides were scanned, analyzed, and quantified using 
a customized-software Microvigene (VigeneTech Inc.) to generate spot intensity. Each dilution 
curve was fitted with a logistic model (“Supercurve Fitting” developed by the Department of 
Bioinformatics and Computational Biology in MD Anderson Cancer Centre, 
“http://bioinformatics.mdanderson.org/OOMPA”). This fits a single curve using all the samples 
(i.e., dilution series) on a slide with the signal intensity as the response variable and the dilution 
steps are independent variable. The protein concentrations of each set of slides were then 
normalized by median polish, which was corrected across samples by the linear expression values 
using the median expression levels of all antibody experiments to calculate a loading correction 
factor for each sample. The sample running and processing was all performed at the MDACC. 
2.13.3	RPPA	analysis	
The RPPA data was normalised, median centered and analysed in Microsoft Excel. As mentioned 
above, a new normalization algorithm was implemented on these samples to allow for better 
protein loading correction and antibody variant adjustments. The correction factor was 
determined for all samples so that any sample with a correction factor below 0.25 or above 2.5 
were considered outliers and excluded from analysis. To assess the signalling changes occurring 
with SGK3 modulation, the protein changes in SGK3 overexpressed condition were divided by 
the empty vector control to get a fold change in protein expression. Proteins showing a fold 
change of <1.2 or >0.8 were excluded as they were considered to likely not be biologically 
relevant despite statistical significance. Statistical significance of protein expression levels were 
determined using t-test (p<0.05).   
2.14	SILAC	LABELLING	AND	TREATMENTS	
For SILAC, Panc-1 pancreatic cancer cell line and isogenic PEA1 (sensitive) and PEA2 
(resistant) ovarian cancer cell lines were grown in RPMI containing 10% dialyzed FCS (Silantes) 
and unlabelled L-Arginine and L-Lysine (SILAC light), or L-[U-13C6,14N4] arginine and L-
[2H4]lysine (SILAC heavy) or L-[U-13C6,15N4]arginine and L-[U-13C6,15N2]lysine (SILAC 
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extra heavy) (all obtained from Silantes). Cells were grown at 37°C, 5% CO2. After five cell 
doublings in the culture dish, cells were then propagated for experiments. 3 x 105 cells from each 
label were seeded into a 100mm dish and the following day, the ‘light’ label received DMSO 
control, the ‘heavy’ labelled was treated with either doxorubicin at 1.5µM or cisplatin at 25µM 
and the ‘extra heavy’ labelled were treated with either doxorubicin with NU7441 (10µM) or 
cisplatin with NU7441 (10µM). Cells were treated for 24hours, following which all three cell 
populations were detached using mild cell dissociation buffer (Sigma) and mixed in a 1:1:1 ratio. 
Cells were then fractionated to collect nuclear and cytoplasmic fraction for mass spectrometry 
analysis. In order to confirm appropriate incorporation, untreated labelled cells were fractionated 
and sent for analysis.	 Mass spectrometry analysis was carried out at the University of British 
Colombia, Vancouver as part of a collaboration (Dr Juergen Kast). The samples were run on a Q 
STAR XL mass spectrometer. The incorporation test confirmed successful incorporation with at 
least 95% labelling of all three cell populations. The data was analysed in Mascot Distiller and 
MaxQuant software and the heavy/light/extra heavy ratios were standardised and normalised to 
1. To identify truly differentially expressed proteins, the frequency distribution of each dataset 
was assessed using the log2(H/L or EH/L) ratios and fit with a Gaussian distribution curve. The 
principle behind this is that we hypothesize the treatment imposed on the heavy labeled SILAC 
cells does not result in systematic protein expression changes, so that the majority of the 
log2(H/L or EH/L) ratios would conform to the gaussian distribution, and those that don't 
conform to the gaussian distribution are truly differentially expressed as a result of the treatment. 
Any proteins with a peptide score of less than 30 or less than two number of peptides identified, 
or with high standard deviations where two or more peptides were identified, were excluded 
from the analysis. Fold changes of <1.2 and >0.8 were also excluded because that they were not 
thought to be biologically relevant changes. 
2.15	WESTERN	BLOTTING	
Protein samples were diluted to 10µg with dH2O, 0.2M DTT and 5x sample buffer (Laemmli 
Sample Buffer: 0.125M TrisCl, 4% SDS, 20% glycerol, 0.02% bromophenol blue) and denatured 
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at 95°C for 5 minutes. Each sample was separated by electrophoresis using 7-15% SDS-
polyacrylamide gels (120V for approximately 1.5-2 hours and electroblotted on a nitrocellulose 
membrane (median pore size 0.2µM) (Bio-Rad) at 100V for 90 minutes. The membranes were 
then blocked in either 5% milk/tris buffered saline with 0.1% Tween-20 (TBST) or in 5% bovine 
serum albumin (BSA)/TBST depending on type of antibody being probed (phosphorylated or 
total antibody) for 1 hour on a shaking platform at room temperature. The primary antibodies 
were incubated overnight at 4°C on a rocking platform. This was followed by 3 washes, 10 
minutes each of TBST. Secondary antibodies were incubated for 1 hour at room temperature on 
a shaking platform. This was followed by 4 x 10 minute washes in TBST. Membranes were then 
developed with an enhanced chemiluminescent (ECL) system (Millipore) according to the 
manufacturers instructions. Table no. 8 summarises the antibodies used with their conditions.  
Antibody/Company Size 
(kDa) 
Primary conditions Secondary conditions 
p-AKT S473 (CS) 60 1:1000, 5%Milk/TBST Goat anti-rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
p-AKT T308 (CS) 60 1:1000, 5% Milk/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
p-SGK3 S486 (SC) 65 1:1000, 5% BSA/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
Total SGK3   (CS) 61 1:1000, 5% Milk/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
p-DNAPK S2056 (AB) 460 1:1000, 5% Milk/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
Total DNAPK (CS) 460 1:1000, 5% Milk/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
GSK3b (CS) 46 1:1000, 5% Milk/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
p-GSK3b S21/9(CS) 46 1:1000, 5% BSA/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
FOXO3a (CS) 82-97 1:1000, 5% Milk/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
P27 (CS) 27 1:1000, 5% Milk/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
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Vinculin (CS) 135 1:1000, 5% Milk/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
p-PRAS40 (CS) 40 1:1000, 5% BSA/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
P21 (SC) 21 1:1000, 5% Milk/TBST Goat anti mouse Ig/HRP 
1:1000, 5% Milk-TBST 
Slug 30 1:1000, 5% Milk/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
CXCR4 (AB) 37 1:1000, 5% Milk/TBST Rabbit anti goat Ig/HRP 
1:1000, 5% Milk-TBST 
AIP4 (CS) 105 1:1000, 5% Milk/TBST Goat anti rabbit Ig/HRP 
1:1000, 5% Milk-TBST 
Table 8: details of the primary and secondary antibodies used, and their 
concentrations for western blotting. Antibody manufacturers are as follows: cell signalling (CS), 
Abcam  (AB), Santa Cruz (SC) 
2.16	IMMUNOFLUORESCENCE	MICROSCOPY	
1.3mm thick round coverslips were treated with 10% HCl for 30 minutes and then washed 
thoroughly with distilled water and then washed in 50%, 70% and 100% ethanol. Cells were 
seeded at a density dependent on cell type as detailed in table 7 and incubated for up to three 
days to allow for growth and attachment on cover slips. Cells were then treated with LMB at 
1nM and 5nM followed by cisplatin at 25µM or DMSO only (vehicle) or left completely 
untreated for a secondary antibody only control in a total volume of 1 mL and left for either 4 
hours or 24 hours.  
For SGK3 studies, cells were treated with cisplatin at 25µM or doxorubicin at 1.5µM with and 
without a DNAPK inhibitor, NU7441 for 1 hour and 4 hours.  
Paraformaldehyde (PFA) fixation 
Cells were then washed in PBS 3 times and fixed in paraformaldehyde (PFA) at 37°C for 30 
minutes and permeabilised by adding 1% Triton-X in PBS for 5 minutes at room temperature.  
Methanol fixation 
Cells were washed in PBS 3 times and fixed in ice cold 100% methanol for 10 minutes at -20°C.  
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For p21 staining, cells were blocked overnight at 4°C using blocking buffer made up of 2% FCS, 
1% BSA in PBS. Primary antibody diluted in blocking buffer was added to the cells and 
incubated overnight at 4°C. Cells were washed three time for five minutes each prior to 
secondary antibody incubation. The secondary antibody was diluted to 1:1000 and incubated on 
coverslips for 1 hour at room temperature. After secondary incubation, coverslips were washed 5 
times, for 5 minutes each in PBS and mounted with mounting medium containing DAPI 
(VectaShield).  
For all other staining, cells were blocked for 30 minutes in a buffer consisting PBS/0.05% 
saponin/2% FCS. Primary antibodies (diluted in the blocking buffer) were added at 
concentrations detailed in table 9 and incubated for 1 hour at room temperature in a wet 
chamber. Cells on coverslips were washed 3x with the PBS/0.05% saponin/2% FCS buffer 
followed by the addition of the secondary antibody for 1 hour at room temperature in a dark, wet 
chamber. Cells were there thoroughly washed in wash buffer twice followed by PBS for a further 
three times. Coverslips were mounted with Prolong gold onto 1.0-1.2mm thick superfrost glass 
slides (VWR) and sealed with nail varnish. Images were captured using the SP5 Confocal Laser 
Scanning Microscope and analysed using Fiji software.  
Antibodies Concentration Fixation 
method 
Secondary used 
pSGK3 S486 1:50 Methanol Goat anti-rabbit IgG Alexa 
Fluor 488 
P21 1:100 PFA Goat anti-rabbit IgG Alexa 
Fluor 488 
CXCR4 1:100 Methanol Donkey anti-goat IgG Alexa 
Fluor 546 
pDNAPK 1:100 Methanol Goat anti-mouse IgG Alexa 
Fluor 633 
Anti-flag 1:100 Methanol Goat anti-mouse IgG Alexa 
Fluor 488 
AIP4 1:100 Methanol Goat anti-rabbit IgG Alexa 
Fluor 488 
 
A	
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Table 9: Summary of the antibodies used for IFM (A), and the cell lines used and 
their seeding densities for IFM (B) 
2.17.1	siRNAs	used	
All siRNAs and relevant reagents were purchased from Dharmacon (Thermo Scientific). The 
siRNAs used are summarised in table below: 
    
SGK3 
(SMARTpool) 
ACGAGCAGGACUAAACGAA 
AUAUUAUGGCUGAACGUAA 
GCAUUGGGUUACUUACAUU 
CACAUUGGCUGCUAGUUAA 
30nM Dharmafect Reagent 1 
FAAP24 
(SMARTpool) 
GCAUCCAGCAACUGAGUAA 
CGGGUUAGAAAUUCCAAUA 
CCAAAGAGCCCAGUAAGAA 
CCAGUUGGUUCAAGAGCAA 
25nM Dharmafect Reagent 1 
SGK1 
(SMARTpool) 
UCAUGGAGAUUAAGAGUCA 
GUCCAAUCCUCAUGCUAAA 
GGAUGGGUCUGAACGACUU 
GGAGCUGUCUUGUAUGAGA 
33.3nM Dharmafect Reagent 1 
SGK2 GAAAGAGCCUUAUGAUCGA 33.3nM Dharmafect Reagent 1 
Cell line Seeding density 
SKOV3 1 x104 cells/well 
PEA2 5 x 104 cells/well 
Panc-1 5 x104 cells/well 
SKOV3 Empty 1 x 104 cells/well 
SKOV3 DNAPKcs shRNA 1 x 104 cells/well 
B	
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(SMARTpool) GGGAUGACCUGUACCACAA 
GAGAUUAAGAACCAUGUAU 
GUUCUACGCUGCUGAGGUG 
MRPS12 
(SMARTpool) 
CCAUCAGGACCACUAUUAA 
GUCCCUAACUUGUGGCCCA 
GCGUCAAGCUCACCGUUGU 
CGUUUACCCGCAAGCCGAA 
25nM Dharmafect Reagent 1 
ZBTB32 
(SMARTpool) 
GAUAUGGCAUUCCCUUCUA 
CAGAGAAACCCUCAAGGAA 
GAAGAGGCAUGCUGGAGGG 
GGAGUGCUCACGUGGUUGA 
25nM Dharmafect Reagent 1 
FANCM 
(SMARTpool) 
GGGUAGAACUGGCCGUAAA 
GAGAGGAACGUAUUUAUAA 
AAACAGACAUCGCUGAAUU 
GCAUGUAGCUAGGAAGUUU 
25nM Dharmafect Reagent 1 
SRSF6 # 9 
SRSF6 # 10 
CGCAGUAGAUCUCGAAGUA 
UGAAGUAACCUAUGCGGAU 
50nM Dharmafect Reagent 1 
ROA1 # 10 
ROA1 # 11 
GGGAAUGAAGCUUGUGUAU 
CAACUUCGGUCGUGGAGGA 
50nM Dharmafect Reagent 1 
NCL # 5 
NCL # 6 
GCAAAGAAGGUGGUCGUUU 
GAUAGUUACUGACCGGGAA 
50nM Dharmafect Reagent 1 
DDX5 # 5 
DDX5 # 6 
GCAAAUGUCAUGGAUGUUA 
CAACCUACCUUGUCCUUGA 
50nM Dharmafect Reagent 1 
HSP7C # 6 
HSP7C # 7 
GCGCAUUGAUACUAGAAAU 
GAACCAUCCCGUGGCAUAA 
50nM Dharmafect Reagent 1 
CXCR4 # 6 GAAGCAUGACGGACAAGUA 50nM Dharmafect Reagent 1 
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CXCR4 # 8 UAACUACACCGAGGAAAUG 
AIP4 # 7 
AIP4 # 8 
GUUGGGAACUGCUGCAUUA 
CAACAUGGGACGUAUUUAU 
50nM Dharmafect Reagent 1 
Table 10: Details of the siRNAs used with their concentrations and transfection 
reagents  
2.17.2 Optimization of transfection 
Prior to experiments assessing the functional role of SGK3 and FAAP24, cell lines were 
transfected with the relevant siRNAs at the concentrations indicated in table 16, and cells were 
lysed for protein extraction 24-72 hours after transfection. These protein lysates were then run 
on a western to check for optimal transfection time point for the relevant assays used. For the 
siRNAs used for the SILAC study (SRSF6, NCL, DDX5, ROA1, HSP7C), knockdowns were 
confirmed at mRNA level using primers as detailed in section 2.19 (table 12).  
2.17.3 Transfection of siRNA in ovarian, pancreatic cancer and sarcoma cell lines 
Cells were seeded in 6-well plates at their optimal seeding density (as described in table 11) so 
that they were approximately 60% confluent after overnight incubation. Cell lines were 
transfected with the corresponding siRNAs (Table 16). Cells were transfected for 24-48 hours 
and then washed twice with PBS, trypsinised and counted on the haemocytometer and reseeded 
either in triplicates in a clear 96 well plate for MTT assay and in a white 96-well plate for the 
caspase-glo 3/7 assay, or in cell culture inserts for the migration assays, or in transwell matrigel 
chambers for the invasion assay.  Cell densities for each assay are listed in table 17. Cells were 
also reseeded in 6-well plates for protein/RNA extraction to validate protein/mRNA 
knockdown.   
Cell line Initial 
Density 
Cells/well 
6-well for 
protein/RNA 
cells/well 
96 well for 
caspase/MTT 
cells/well 
Cell culture 
insert for 
migration 
Transwell 
matrigel 
invasion 
chamber 
Doubling 
time 
(hours) 
PEA1 1 x105 1 x105 0.5 x104 5 x104 N/A 37 
PEA2 1.5 x105 1.5 x105 7 x104 5 x104 N/A 66 
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PEO1 1.5 x105 1.5 x105 1 x104 N/A N/A - 
PEO4 1.5 x105 1.5 x105 1 x104 N/A N/A - 
IGROV1 1 x105 1 x105 0.3 x104 3 x104 N/A 20 
SKOV3 1 x105 1 x105 0.3 x104 3 x104 1 x105 35 
Panc-1 1 x105 1 x105 0.5 x104 N/A N/A 52 
Aspc1 1 x105 1 x105 0.5 x104 5 x104 N/A 38 
SK-UT-1 1 x105 1 x105 0.5 x104 5 x104 N/A 22 
Table 11: Seeding and re-seeding densities for the cell lines used pre and post 
transfection along with their doubling times 
2.18	OVEREXPRESSION	OF	SGK3	WILD-TYPE	AND	MUTANTS	AND	FAAP24	
2.18.1 Optimization 
The cell lines being transfected with overexpression constructs were transfected with 0.4µg 
mammalian expression vectors (test gene containing and matched empty vector control) and its 
corresponding empty vector at the same concentration for 24, 48 and 72 hours and protein was 
collected for western blotting to see which time point gave the highest overexpression of the 
protein of interest. Effectene transfection kit (Qiagen) was used and the protocol was followed 
according to the manufacturer’s instructions.  
2.18.2 Transfection of overexpression constructs 
Cells were seeded in 6-well plates at their optimal seeding density (as described in table 9 for 
initial seeding density) so that cells are 60-80% confluent on the day of transfection. Cell lines 
were transfected with the relevant gene in an expression vector (as detailed in section 2.4 and 2.5) 
and the corresponding empty expression vector as control. Cells were either transfected for 24 
hours or 48 hours depending on the conditions determined for gene overexpression. For 
downstream experiments, cells were then re-seeded in a 96-well plate for drug treatments; 3D 
invasion assays for spheroids; cell culture inserts for migration assays; transwell matrigel invasion 
chambers for invasion assays and 6-well plates for protein and/or RNA extraction using the 
same densities as detailed in table 9. 
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2.19	QUANTITATIVE	RT-PCR	ANALYSIS	
Knockdown of SGK1, SGK2 and MRPS12 and candidates identified in the SILAC study were 
confirmed by qRT-PCR. Primers were constructed using the Roche UniversalProbe Library 
Assay Design Centre (https://lifescience.roche.com/shop/en/au/overviews/brand/universal-
probe-library ) making sure that all primer sets were designed to meet parameters required such 
as be exon-spanning for specificity, have a GC content of >40%,  have a melting temperature Tm 
between 58-60°C and have an amplicon length between 50-150 bases. RNA was extracted using 
the QIAGEN RNeasy kit according to the manufacturer’s instructions. cDNA was generated by 
reverse transcription reaction. Reverse transcription reaction was carried out using Moloney 
Murine Leukemia Virus Reverse Transcriptase (MMLV-RT) kit (Promega). Briefly, 0.5µg/µl of 
oligoDT15 (Promega) was added to 1µg of RNA and made up to a total volume of 13.7µl. The 
samples were heated at 65°C for 5 minutes followed by 4°C for 5 minutes. Following this, 6.3µl 
of a master reverse transcription mix consisting of 1 x MMLV buffer, 0.4mM dNTPs and 3U/µl 
of MMLV-reverse transcriptase was added to each sample. The samples were incubated at 37°C 
for 1 hour, followed by 5 minutes at 95°C. Thermal cycling was carried out on an MJ PTC200 
(MJ Research, Minnesota, USA).  
The resulting cDNA was then diluted 1:5 with distilled DNAse/RNase free water and mixed 
with relevant primers as listed in table 10, at a final concentration of 0.2µM to a volume of 10µl 
and quantitative RT-PCR was performed using 5µl SYBR Green PCR master mix in a Step One 
PCR system (Life Technologies) in 96-well MicroAmp optical plates (Life Technologies) and 
sealed with MicroAmp Optical adhesive film (Life Technologies). PPIA (sense: 5’-
CTGCACTGCCAAGACTG-3’ and antisense 5’-GCCATTCCTGGACCCAAA-3’) was used as 
the endogenous control. Quantification of transcripts were carried out using the standard curve 
method. Five-fold serial dilutions of pooled cDNA samples were used to construct a standard 
curve for each primer set. Gene expression data was normalised to the endogenous PPIA. All 
primers were synthesised by Eurofins Genomics with a minimum of HPSF purification. Details 
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of other qPCR primers used for the assessment of the role of SGK3 in transcriptionally 
regulating EMT markers are detailed in the table below: 
Gene Sequence 
SGK1 sense: 5’- GACAGGACTGTGGACTGGTG-3’ 
antisense: 5’-TTTCAGCTGTGTTTCGGCTA-3’ 
SGK2 sense: 5’-TCCAGTCAGAGGACCATGA-3’ 
antisense: 5’-AGCAATGATCAGGCAGCTCT-3’ 
MRPS12 sense: 5’-AGTCTCTTATCCCCTACCACAGG-3’ 
antisense: 5’-TGGAGCAGGTAGCCCAGA-3’ 
ROA1 
 
sense: 5’- GCTCAACCCTCCAATGAAGA-3’ 
antisense: 5’-GTCAGCTTGCTCCTTTCTGC-3’ 
HSP7C sense: 5’-AAGGGGACATACATCAAGCAGT-3’ 
antisense: 5’-AGCTGTAGCGTATGGTGCTG-3’ 
DDX5 sense: 5’-GGTTTCCAAACTTCTTTCCAGA-3’ 
antisense: 5’-GCCATGTCGGGTTATTCG-3’ 
NCL sense: 5’-TCTTGGGGTCACCTTGATTT-3’ 
antisense: 5’-CCACTTGTCCGCTTCACA-3’ 
SRSF6 sense: 5’-TGCCAGATGTTCTCCGACT-3’ 
antisense: 5’-GACGGCTACAGCTACGGAAG-3’ 
E-cadherin Sense: 5’-TGGAGGAATTCTTGCTTTGC-3’ 
Antisense: 5’-CGCTCTCCTCCGAAGAAAC-3’ 
VEGFA Sense: 5’- TCTCCGCTCTGAGCAAGG-3’ 
Antisense: 5’- TGCCCGCTGCTGTCTAAT-3’ 
Snail Sense: 5’ -CTTCTCGCCAGTGTGGGT-3’ 
Antisense: 5’-CAAGATGCACATCCGAAGC-3’ 
Slug Sense: 5’-CACAGTGATGGGGCTGTATG-3’ 
Antisense: 5’- CACATACAGTGATTATTTCCCCG-3’ 
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Table 12: Primers used for confirming knockdown for SGK1, SGK2, MRPS12, 
ZBTB32, SILAC studies and primers used for assessing the role of SGK3 in 
transcriptional regulation of EMT markers 
 
2.20	CELL	CYCLE	ANALYSIS	BY	FLOW	CYTOMETRY	
To assess the proportion of cells in each phase of the cell cycle, propidium iodide staining of cells 
was utilised. Briefly, cells were either treated or transfected accordingly and following the 
appropriate incubation period, cells were trypsinised, washed in PBS twice and then centrifuged 
at 300 x g for 5 minutes. Supernatant was then removed and cells were fixed in 1ml 70% ethanol, 
added drop-wise, with continuous agitation of the cells by vortex to prevent cellular aggregation 
and were stored at 4°C until ready for analysis. For analysis, cells were centrifuged at 800 x g for 
10 minutes to remove the ethanol and washed in PBS twice. Cells were then re-suspended in 
0.1mg/ml RNase-PBS, 0.01mg/ml PI and were incubated for 1hour at 37°C. Cells were then 
analysed for forward scatter (FSC), side scatter (SSC) and DNA content using the CellQuest Pro 
software on FACScalibur flow cytometer (Beckton Dickinson). Data acquired was analysed 
further using FlowJo v 10 software.  
2.21	LONG-TERM	CELL	SURVIVAL	ASSESSMENT	BY	CLONOGENIC	ASSAY	
To assess long-term cell survival benefit from a drug treatment or gene expression, clonogenic 
assays were set up. Following appropriate treatment/transfection of cells and incubation period, 
cells were washed in PBS, trypsinised and neutralized in the relevant full media containing 10% 
FCS. Cells were counted on a haemocytometer and cells were diluted to create single cell 
Fibronectin 1 Sense: 5’-GCAAGTCTCTTCAGCTTCAGG-3’ 
Antisense: 5’-AGCGGACCTACCTAGGCAAT-3’ 
Zeb-1 Sense: 5’-TTTTTGGGCGGTGTAGAATC-3’ 
Antisense: 5’-TGGAAATCAGGATGAAAGACAA-3’ 
Twist Sense: 5’-CATCTTGGAGTCCAGCTCGT-3’ 
Antisense: 5’-GAGCAAGATTCAGACCCTCAA-3’ 
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suspensions for re-seeding. Appropriate cell numbers were seeded according to the doubling 
time of each cell lines as detailed in table 11. For SKOV3 and IGROV1 cells, 500 cells/well were 
seeded into 6-well plates, each condition plated in triplicates in an individual experiment. The 
plates were then incubated at 37°C, 5% CO2 for colony formation. Incubation time varied 
between 1-3 weeks depending on the cell line. To fix and stain colonies following the appropriate 
incubation period, media was aspirated from cells and plates were washed twice with PBS, and 
cells were fixed and stained with 0.01% (w/v) crystal violet in 70% ethanol and left for 15 
minutes. The crystal violet was then removed and plates allowed to air dry before manually 
counting the number of colonies present in each condition. A group of >30 cells was considered 
to be one colony.  
2.22	COLLECTIVE	MIGRATION	WOUND	HEALING	ASSAY		
In order to assess cells migratory capacity, overnight migration assays were set up. Cells were set 
up and transfected as detailed in sections 2.17.3 and 2.18.2. Following 24hours of transfection, 
cells were re-seeded either into 8-well µ-slides, or 24-well black with clear flat bottom µ-plates 
(Ibidi, Thistle Scientific), containing cell culture inserts firmly fitted into each well being used. 
The optimal seeding densities for each cell line are listed in table 17. Cells were also reseeded for 
protein extraction at the assay end-point to confirm knockdown or overexpression. Following a 
further 24-hour incubation, the migration assay was set up, (48 hours post transfection). On the 
day of the assay, the complete media was replaced with serum free media and cells were 
incubated for 4 hours. Following this, media was then removed and replaced with serum free 
media and a membrane dye (diluted 1:3000) and incubated for 45 minutes at 37°C, 5% CO2.. 
Media containing the dye was removed along with the cell culture inserts, and fresh media with 
reduced serum (0.5%) was added to the wells for the overnight assay. The assay was carried out 
on the SP5 Confocal Laser Scanning microscope (Leica) at 37°C, 5% CO2 , where the 633 laser 
was used to visualise the membrane dye and 3 positions per insert were imaged over 15 hours to 
assess the gap closure. The data was quantified using Fiji software. Protein lysates were collected 
at the end of the assay to assess overexpression at protein level via western blotting.  
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2.23	SINGLE-CELL	RANDOM	MIGRATION	
In order to assess single cell migration compared to collective migration, ovarian cancer SKOV3 
cells were seeded at 10,000 cells/well in 8-well chamber slides following 24-hour transfection 
with SGK3 wild-type, S486A, S486D, T320A and T320D mutant constructs. On the day of the 
assay, cells were serum starved for 4 hours. Following this, media was removed and replaced with 
serum free media containing the DNA dye, Hoechst 33342 (diluted 1:250,000) and incubated for 
45 minutes at 37°C in 5% CO2 environment. The media containing the dye was replaced with 
media with reduced serum (0.5%) for the overnight assay. The cells were visualised using the 
DAPI UV laser and 3 positions were marked per condition and single cell movement was 
monitored over 15 hours. The data was analysed according to various parameters used for 
assessing single cell migration namely persistence, displacement, distance and velocity using the 
track mate function in the Fiji image software. Protein lysates were collected at the end of the 
assay to assess overexpression at protein level via western blotting  
2.24	TRANSWELL	MIGRATION	AND	INVASION	ASSAYS	
For this assay, 8µm pore, matrigel coated transwell inserts were obtained from BD Biosciences. 
Cells were transfected with appropriate gene of interest for 24-48 hours. The inserts were 
rehydrated with 500µl serum free media for 2 hours at 37°C, 5% CO2. 1x105 transfected cells in 
500µl were added to the upper chamber of the insert with 750µl of 0.5%-1% FCS added to the 
well of the insert and invasive migration was allowed for 22 hours at 37°C in 5% CO2 
environment. The following day, cells in the inner well of the insert were then scrubbed to 
remove non-invading cells and were then washed in PBS once and fixed in 100% ice-cold 
methanol at -20°C for 10 minutes. Following this, cells were then washed in PBS twice and then 
mounted with prolong gold containing 4′,6-diamidino-2-phenylindole (DAPI) for quantitative 
measures using immunofluorescence imaging on the SP5 Confocal Laser Scanning microscope 
(Leica). For quantitation, the number of DAPI nuclei was averaged per 20x field of view, 
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counting five fields per chamber. The DAPI-stained nuclei were counted in Fiji software. Each 
experiment had duplicate inserts per condition, with at least three independentreplicates.  
2.25	3D	TUMOUR	SPHEROID	INVASION	ASSAY	
In order to assess the role of SGK3 in invasive migration in a more physiological setting, 3D 
tumour spheroid invasion assays were implemented according to Vinci et al, 2012. Briefly, cells 
were transfected as required and 100µl at 0.5x104 cells/well were seeded into ultra low 
attachment round bottom plates (Corning) and incubated for 24hours at 37°C, 5% CO2 to allow 
spheroid formation. After 24 hours, 50µl media in each well was diluted serially with serum free 
media until the total concentration of serum in the media was reduced to 0.03% and incubated 
overnight. The day before the assay, Matrigel matrix with reduced growth factors and free of 
phenol red (BD Biosciences) was left on ice at 4°C to thaw overnight. All steps using matrigel 
were performed on ice. On the day of the assay, 50µl of media was removed and replaced with 
50µl of matrigel matrix using ice-cold pipette tips to each well and left at 37°C for 1 hour to 
allow the matrigel to solidify. Then, 100µl of media containing 0.5% serum was added to wells 
and invasion was measured over 24-72 hours using bright field microscopy imaging (Nikon 
Microscope) to take images at 10x field view. The invasion was assessed through cells ‘sprouting’ 
from the spheroid through the matrigel, which would be evident visually. The perimeter was 
assessed and highlighted in Fiji Software to show the level of invasion.   
2.26	ADHESION	ASSAY	TO	COLLAGEN	I	
Cells were seeded and transfected with SGK3 wt, S486A, S486D, T320A and T320D mutant 
plasmids and the empty vector control. Following 24 hours, cells were serum starved for 18 
hours. 96-well plates were coated with rat-tail collagen I (BD Biosciences) at 10µg/cm2 for 1 
hour at 37°C. Following this, the plate was incubated with a blocking buffer made up of 0.5% 
BSA diluted in serum free medium for 1 hour at 37°C. Cells were trypsinised, centrifuged to 
remove the trypsin and resuspended in serum free medium. The blocking buffer was removed 
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and the wells were washed with washing buffer made up of 0.1% BSA diluted in serum free 
media. For the cell-substratum adhesion assay 100µl of cell suspension at 2x105 cells/ml diluted 
in 0.1% BSA in medium were added to the wells and incubated for 30 minutes at 37°C in a 5% 
CO2 atmosphere to allow cells to adhere to the surface. Following the incubation, wells were 
washed three times with washing buffer and medium supplemented with 10% fetal calf serum 
was added to the wells and cells were allowed to recover for 2 hours. For quantification, medium 
was removed and cells were washed once in PBS and fixed in 4% paraformaldehyde for 10 
minutes at room temperature. This was followed by the addition of 0.4% crystal violet solution 
and incubation for a further 15 minutes. The crystal violet solution was then removed and plates 
were thoroughly washed in PBS until it ran clear. The crystal violet stained cells were then 
dissolved in 30% acetic acid and plate was read at 590nm on a spectrophotometer. All the 
conditions were normalised to collagen coated empty wells for background correction. The fold 
change in adhesion with SGK3 overexpression or knockdown was calculated by comparing 
adhesion to the corresponding controls (empty vector and non-targeting respectively).  
2.27	IMMUNOPRECIPITATION	
To assess any interaction between proteins, the relevant antibodies were cross-linked and 
immunoprecipitated using the immunoprecipitation (IP) kit (Thermo Scientific) according to the 
manufacturers guidelines. Briefly, the antibody was coupled to the protein A/G plus agarose. 
This was followed by crosslinking the bound antibody. Lysates were collected in the IP Lysis 
buffer (0.025M Tris, 0.15M NaCl, 0.001M EDTA, 1% NP-40, 5% glycerol; pH 7.4) provided in 
the kit along with 100x protease inhibitor (Calbiochem). 550µl of cold lysis buffer was added to a 
10cm3 dishes on ice and were incubated on a shaker for 1 hour at 4°C. Following this, cells were 
scraped from the dish and centrifuged at full speed for 10 minutes. The lysates were pre-cleared 
according to the kit’s protocol using the control agarose resin. Around 1mg of lysate was added 
to the cross-linked antibody and this was incubated overnight at 4°C in an orbital shaker. 
Following the overnight incubation, the sample was washed several times with IP lysis/wash 
buffer followed by a conditioning buffer (neutral pH buffer). The IP was eluted in elution buffer 
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provided. At least two elutions were carried out to ensure the antigen had completely eluted. The 
antibody-coupled resin was then preserved for further short-term use at 4°C. The samples were 
prepared by adding 5x sample buffer to make 1x final solution and were boiled at 95°C for 5 
minutes. Samples were then run along with an isotype control and empty beads control on a SDS 
gel as detailed in 2.15. 
2.28	DATA	ANALYSIS	AND	STATISTICAL	ANALYSIS	
All results shown are representative of three biologically independent experiments, each done in 
triplicate unless otherwise stated. Within each experiment, technical replicates were disregarded if 
one such replicate was judged to have markedly deviated from the remaining two. All data 
presentation and statistical tests were carried out on Prism 6.0 software (GraphPad Software 
Inc.). 
CHAPTER	3:	TARGETING	GENOMIC	INSTABILITY	TO	IDENTIFY	
COMMON	COPY	NUMBER	AMPLIFICATIONS	THAT	CORRELATE	
WITH	POOR	PROGNOSIS	IN	OVARIAN	CANCER,	PANCREATIC	
CANCER	AND	A	SUBSET	OF	SARCOMAS	
	 3.0	INTRODUCTION		
It is well known that molecular aberrations may drive cancers, resulting in poor prognosis in some cases. 
A more complete understanding of the genetic alterations that define cancer subtypes, linked to prognosis 
could aid in individualizing tumour therapies.  
Currently many of the treatments available are limited due to the development of chemoresistance in 
many types of cancers, which confers a poor prognosis. Although targeted therapies are becoming 
increasingly sought after, tumour heterogeneity makes it difficult to predict which patients would benefit 
most from targeted therapies or conventional cytotoxic therapy thus impeding targeted therapy 
implementation. A solution to this would be to identify any new therapeutic potential targets that could 
either serve as prognostic markers or that could be druggable. Additionally, the presence of some 
mutations may be predictive of drug response in a particular type of cancer (i.e. BRAF V600E and 
vemurafenib in melanoma; Chapman et al, 2011).  
The incredibly complex genomic rearrangements observed in cancers such as pancreatic adenocarcinomas 
(PDAC), high grade serous (HGS) ovarian cancer and sarcomas makes it very difficult to understand their 
molecular biology but also highlights that possible targets could be identified. Previous studies have 
identified copy number variations (CNVs) that may predispose one to a particular cancer (e.g myc 
amplifications and BRCA loss; Nesbit et al, 1999, Welcsh et al, 2001). Further studies have also shown that 
amplification of CCNE1 (cyclin E) is strongly associated with treatment-resistance in ovarian carcinomas. 
Furthermore, the identification of this relationship has suggested potential for therapeutic exploitation, 
where patients carrying this CCNE1 amplification could potentially benefit from cyclin-related targeted 
treatments (Etemadmoghadam et al, 2009).  
One of the biggest challenges in cancer therapy is the emergence of resistance. For example, in ovarian 
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cancer, resistance to platinum therapy is common. Dr. Stronach’s lab has identified AKT as a driver of 
chemoresistance. It was shown that DNA-PK mediated pro-survival AKT activation following DNA 
damage (Stronach et al, 2011). Additionally, we have also shown that DNA-PK is amplified in ovarian 
cancer and this is linked to poor prognosis thus suggesting a link between DNA repair pathways and 
cancer cell survival (unpublished data, manuscript in preparation). This identifies novel mechanisms of 
resistance that require further understanding. This also suggests that a better understanding of DDR 
could uncover further mechanisms leading to poor prognosis. Studying common genomic alterations in 
multiple tumour types typified by poor outcome and genomic instability may identify key drivers and 
potential therapeutic targets. This project focuses on identifying genes of prognostic relevance relating to 
DNA damage response (DDR) and apoptosis.  
3.1	AIMS	
Several cancers have been highlighted as being largely genomically unstable and frequently harboring p53 
mutations including epithelial ovarian cancers (EOC), pancreatic ductal adenocarcinomas and certain 
sarcomas (Helman and Meltzer, 2003). Parallels can be drawn with EOC and sarcomas in that both can 
be divided mainly into two groups, Type I and type II, with type II tumours being more aggressive and 
genetically unstable (Zhan et al, 2013). Previous studies have already identified common markers of poor 
prognosis between the three tumour types (Fong et al, 2008, Bignotti et al, 2010, Raji et al, 2011). We 
therefore aim to exploit the commonalities these tumours appear to share to identify targetable markers 
that may have prognostic significance. The aims of the study are to analyse genome copy number datasets 
of sarcomas, PDACs and EOCs to find commonly amplified genes among these tumours, correlate 
patient prognosis with CNVs in genes related to DNA repair and apoptosis, and to establish functional 
mechanisms behind poor outcomes in these tumours. Furthermore, the data generated may identify novel 
therapeutic targets for single agent treatment or enhance the effects of existing agents in combination 
therapies.  
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3.2	CNV	ANALYSIS	FOR	TARGET	IDENTIFICATION	IN	PDAC,	HGSOC	AND	COMPLEX	
KARYOTYPE	SARCOMAS		
For target identification, three datasets were analysed for CNV alterations:  high grade serous (HGS) 
ovarian cancer (n=477), pancreatic ductal adenocarcinoma (PDAC) (n=57) and a sarcoma dataset 
(n=207) with a focus on complex karyotype sarcomas (n=138). The sources of datasets are detailed in 
chapter 2. Only high grade serous tumours (stage 3 and 4), primary pancreatic ductal adenocarcinomas 
and type II sarcomas were included as they typify genomic instability and poor prognosis and are 
therefore comparable with each other. The CNVs were called and normalised using circular binary 
segmentation (CBS) (Olshen et al, 2004). The CNVs in each dataset were analysed and ranked based on 
amplification frequencies; the top 100 genes were selected in each dataset and analysed for commonly 
amplified genes, with >2.5 set as the amplification consideration cut-off. The commonly amplified genes 
were then cross-referenced to the progression free survival (PFS) survival analysis p-value, assessed by 
log-rank test to assess statistical significance of gene amplification on poor prognosis. Survival analysis 
was only performed in the HGS ovarian cancer dataset because clinical data was only available for this 
dataset. 
Out of 734 genes related to DNA damage response/repair and apoptosis, the results showed that whilst 
the majority of the gene amplifications observed were restricted to one particular cancer, there were 
several genes that overlapped with two cancers (figure 13A) however, four gene amplifications were 
common across all three tumour types as detailed in figure 13B. Furthermore, from the genes found to be 
commonly amplified across pancreatic cancers, ovarian cancers and sarcomas, only two genes (C19orf40 
and SGK3) were found to be statistically significant following PFS analysis in the HGS ovarian cancer 
dataset.  
 
 
 
 
 117 
 
  
 
 
 
 
 
 
 
 
 
Figure 13: Venn diagram (A) showing the distribution of genes amplified in the HGS 
ovarian cancer, pancreatic ductal adenocarcinoma and type II sarcoma datasets. Four genes 
were commonly amplified across the three tumour types. Details of the four genes are detailed in B.  
Kaplan Meier (KM) survival plots were produced and group differences were tested for significance using 
the log-rank test. Although the log rank test is used to test whether there is a difference between the 
survival times of different groups, it cannot be used to adjust for variables known to affect survival such 
as disease duration and age, therefore cox regression analysis was utilised to calculate the hazard ratio (i.e. 
multivariate) to determine the difference between the amplified and non-amplified samples.  
The KM plots show a clear difference in survival between amplified versus non-amplified cases with 
C19orf40 (figure 14A) and SGK3 (figure 14B) amplifications compared to MRPS12 (figure 14C) and 
ZBTB32 (figure 14D).  
 
A	
Gene Frequency in+
Sarcoma
Frequency in+
PDAC
Frequency+in+
EOC
PFS EOC
C19orf40 16% 7% 25% 0.0022
SGK3 9% 7% 26% 0.038
ZBTB32 12% 7% 25% 0.098
MRPS12 6% 7% 32% 0.075
B	
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Figure 14: Kaplan Meier (KM) plots showing the survival disadvantage of patients 
with C19orf40 (A), SGK3 (B), MRPS12 (C) and ZBTB32 (D) amplifications in 
HSGOC dataset. Both log rank test and Cox proportional hazards ratios were calculated in ‘R’ program 
using functions detailed in chapter 2. The p-values for the hazard ratios were 0.004, 0.04, 0.08 and 0.1 for 
C19orf40, SGK3, MRPS12 and ZBTB32 respectively.  
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To show that copy number amplifications correlate with an increase in gene expression, linear regression 
analysis was carried out. C19orf40 had one gene expression probe, which also showed a significant trend 
in increased copy number resulting in increased gene expression (figure 15A). There were four gene 
expression probes for MRPS12, all showing a significant trend of increased copy number correlating with 
increased gene expression (Figure 15B-E). There was one gene expression probe for SGK3, also showing 
increased gene expression with increasing copy number (figure 15G). ZBTB32, also with one gene 
expression probe however, did not show this trend (figure 15F). 
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Figure 15: scatter plots showing the relationship between copy number and gene 
expression for C19orf40 (A), MRPS12 (B-E), ZBTB32 (F) and SGK3 (G) using linear 
regression analysis. 	
A
B
C D
E F
G	
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3.3	VALIDATION	OF	COMMONLY	AMPLIFIED	GENES	
Following the identification of the commonly amplified genes, each of the four genes were validated in 
the laboratory to assess their functional importance in contributing to poor prognosis in these tumour 
types. SGK3 was extensively studied and results are detailed in chapter 4. The validations for c19orf40, 
MRPS12 and ZBTB32 are detailed here.  
The genes were validated by transient knock down using siRNA to assess their effect on viability and 
apoptosis as they belonged to a group of genes relating to DNA damage repair and apoptosis.  
3.3.1	c19orf40	validation	
C19orf40, also known as Fanconi-Anemia Associated Protein member 24 (FAAP24), is a member of the 
fanconi anemia core complex, which has an important role in the DNA damage response (Ciccia et al, 
2007). FAAP24 was knocked down in isogenic paired cell lines, PEA1 (platinum sensitive) and PEA2 
(platinum resistant) and its effect on apoptosis and viability following treatment with chemotherapeutic 
agents was assessed using the caspase 3/7 glo assay and MTT assay respectively. The results were 
represented as a fold-change in induction of caspase 3/7 normalised to MTT. In addition to knockdown 
by siRNA, FAAP24 was also overexpressed using a mammalian expression vector and the effect of 
overexpression on apoptosis and viability was also determined.  
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Knocking down FAAP24 does not appear to alter caspase 3/7 induction compared to the relative 
controls (figure 16A-B). Similar results are observed in the FAAP24 overexpressed cells compared to the 
empty vector control (figure 16C-D), suggesting that FAAP24 is not involved in cell survival in patients. 
 
 
 
 
 
 
Figure 16: knockdown and overexpression of FAAP24 does not affect apoptosis in 
ovarian cancer cell lines PEA1 and PEA2. Apoptosis and viability was determined using caspase 3/7 glo 
assay and MTT assay respectively. Cells were transfected with 50nM of FAAP24 for knockdown (A-B) and 0.4µg 
DNA for the overexpressions and following 48 hour transfections (C-D), cells were re-seeded and treated with doxorubicin 
or cisplatin for 24 hours before the assay was implemented. Knockdows and overexpressions were confirmed by western 
blotting (E).  
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FAAP24 is known to be involved in maintaining genome stability and is a binding partner of FANCM, a 
fanconi anemia (FA) protein, which is thought to be involved in repairing interstrand crosslinks, forming 
part of the FA core complex. Together, they are thought to be involved in ATR-mediated S phase 
checkpoint activation. Therefore, it is possible that knocking down both FAAP24 and FANCM may 
confer increased sensitivity to cytotoxic agents. Below is a proposed model (figure 17) to suggest that 
there may be benefit in knocking down both components (Wang et al, 2012). To test this, both FAAP24 
and FANCM were knocked down in PEA1 and PEA2 cells.  
 
 
 
 
 
 
 
 
 
Figure 17: Rationale for knocking down FANCM and FAAP24 simultaneously. Figure taken 
with permission from Wang et al, 2012, showing the rationale for knocking down both FAAP24 and FANCM. 
Although the FANCM-FAAP24 complex has coordinated functions, they also have distinct functions that need to be 
blocked simultaneously to have any phenotypic effect. Although knocking down FAAP24 or FANCM individually may 
prevent FANCD2 monoubiquitination and either interstrand crosslink repair (if FANCM is knocked down) or 
activation of ATM-dependent checkpoint, both individual functions need to be knocked down to have the best effect. 
	
It appears that knocking down FAAP24 in combination with FANCM does not have a benefit when 
compared to FANCM alone as FANCM alone induces more apoptotic signal when compared to the non-
targeting control, compared to either FAAP24 or the combination knockdown but this effect is only seen 
in the resistant PEA2 cells; FANCM knockdown does not appear to have an effect alone or in 
combination with FAAP24 in the sensitive PEA1 cells (figure 18).  
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Figure 18: There is no benefit in knocking down FANCM and FAAP24 simultaneously 
to increase apoptotic signal in PEA1 and PEA2 cells.  
Caspase 3/7 glo assay normalised to MTT in FAAP24 and FANCM knockdown cells in response to 
treatment with either cisplatin (25µM) or doxorubicin (1.5 µM) for 24 hours.  
 
3.3.2	MRPS12	validation	
Although the bioinformatic analysis identified two genes that when amplified were significantly associated 
with poor prognosis in the HGSOC dataset, four genes were identified as being commonly amplified in 
EOC, PDAC and a subset of sarcomas (type II sarcomas with complex karyotypes). The other two genes, 
MRPS12 and ZBTB32 were found not to be statistically significant when the PFS data for the HGS 
ovarian cancer patients was studied, however trends towards poor prognosis were observed. To 
investigate if MRPS12 had biological relevance in poor prognosis, preliminary validation experiments 
were undertaken.  
Preliminary experiments knocking down MRPS12 by siRNA in PEA1 and PEA2 cells were performed 
and the results showed that knocking down MRPS12 in PEA1 and PEA2 does not affect caspase 3/7 
activity in both cell lines (figure 19), however the exception to this is with cisplatin treatment in PEA1 
cells there appeared to be a significant difference in induction of caspase 3/7 in the MRPS12 knockdown 
(1.5-fold difference). Knockdown was confirmed by qPCR. This suggests that MRPS12 may affect 
sensitivity to cisplatin treatment, however this was only seen in the sensitive PEA1 (figure 19A).   
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Figure 19: Knockdown of MRPS12 in PEA1 and PEA2 cells. Knockdown of MRPS12 significantly 
alters caspase 3/7 induction in cisplatin treated PEA1 cells. No other significant alteration was observed with MRPS12 
knockdown in PEA1 doxorubicin treated (A) and PEA2 cells with any treatment (B). Knockdown of MRPS12 was 
confirmed at mRNA level in both PEA1 (C) and PEA2 (D). Statistical significance was carried out on three independent 
experiments using a Student’s T-test.  
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one of the other identified targets, c19orf40. ZBTB32 was knocked down using siRNA in PEA1 and 
PEA2 cells.  
The results showed that knockdown of ZBTB32 did not alter apoptosis in the PEA1 cells with either 
doxorubicin or cisplatin treatment (figure 20A) however it did significantly alter apoptosis in cisplatin 
treated cells in the cisplatin resistant PEA2 cells by 2.8-fold compared to the cisplatin treated non-
targeting control (figure 20B). The doxorubicin treated PEA2 cells were not significantly altered 
compared to the non-targeting control.  
Figure 20: Knockdown of ZBTB32 in PEA1 and PEA2. Knockdown of ZBTB32 significantly alters 
cisplatin treated PEA2 cells, inducing 2.8-fold more apoptosis compared to the cisplatin treated control (B). Knockdown for 
ZBTB32 was confirmed at mRNA level in PEA1 (C) and PEA2 (D). Statistical significance was carried out using a 
Student’s T-test. i 
	
3.4	DISCUSSION	
The aims of this study were to bioinformatically identify molecular contributors of poor prognosis by 
looking at copy number changes in multiple tumour types that share characteristic features of being 
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driven by p53 aberrations, genomic instability and typically conferring poor prognosis. The presence of 
highly complex genome rearrangements in these tumours strongly suggests that such tumours are 
fundamentally driven by defects in DNA repair and the DNA damage response. Furthermore, the 
analysis of genome copy number changes allows for the identification of common chromosomal gains 
and losses, which strongly hint as to the genomic location of tumour driver gene loci. For the analysis, 
genes relating to DDR/apoptosis were selected and the analysis was focused on copy number 
amplifications. Out of 734 genes examined, only four were highlighted as being commonly amplified 
across HGS ovarian cancer, PDAC and a subset (type II) of sarcomas with complex karyotypes. The 
basis for initially selecting the two main targets, SGK3 and FAAP24, was that they were statistically 
significant when looking at PFS in the ovarian cancer patients. The selection was made only on the basis 
of the ovarian cancer PFS data (using log rank test for statistical significance); the clinical data for the 
other tumour types was not available for analysis. The copy number of the genes identified were also 
analysed for their correlation with overall survival (OS) however no significant trends were observed 
(supplementary figure 2). SGK3, MRPS12, ZBTB32 and c19orf40 gene expression was also interrogated 
for its correlation with PFS however there were no significant correlations for any of the genes 
interrogated (SGK3 p=0.88; MRPS12 p=0.83; ZBTB32 p=0.86; c19orf40 p=0.46).  Interestingly, out of 
the four commonly amplified genes identified, three of them (c19orf40, MRPS12 and ZBTB32) are on 
the same chromosomal locus that are also shared by known cancer associated genes such as AKT2, and 
ERCC1 which are known to confer poor prognosis in several tumour types (Miwa et al, 1996; Thompson 
et al, 1996; Smith et al, 2013). Additionally, 19q13 amplifications were highlighted as being associated with 
high grade and stage in pancreatic cancer and ovarian cancer (Kuuselo et al, 2010; Shih et al, 2011), 
suggesting that given that the three genes amplified genes identified in this analysis are in the highly 
amplified region of chromosome 19, it is possible that the genes highlighted in this analysis may be 
passenger events.  One possible way to address this issue would be to exclude amplification of potential 
‘driver’ genes such as AKT2 and observe the effects of amplification of these candidate genes in this 
setting.  
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Following the identification of the genes commonly amplified, validation studies were carried out in the 
laboratory using proliferation and apoptosis assays to determine the functional relevance of these genes in 
poor prognosis.  
3.4.1	FAAP24	validation	
FAAP24, in addition to SGK3, initially appeared to be a promising target because it was found to be the 
most statistically significant target identified and its role in being part of the core complex in the Fanconi 
Anemia (FA) syndrome made it well placed to potentially play a role in poor prognosis in cancer. The FA 
pathway is known for being essential in DNA damage repair and consequently important in maintaining 
genomic stability (Kee and D’Andrea, 2010). It is thought that mutation or silencing of genes core to the 
FA pathway can lead to the inability for DNA repair to occur efficiently, consequently leading to genomic 
instability and causing hypersensitivity to DNA damaging agents.  To date, the most frequently reported 
gene studied in the FA pathway is FANCD2, which when monoubiquitinylated causes translocation to 
nuclear foci for DNA repair to continue (Guo et al, 2014), and this is indicative of drug resistance. 
FAAP24 is thought to be the binding partner of FANCM, another FA gene forming part of the Fanconi 
Anemia core complex that is required for normal levels of FANCD2 ubiquitylation and for resistance to 
DNA crosslinking agents. The FANCM-FAAP24 complex is thought to be directly involved in 
checkpoint signaling in addition to its repair functions (Ashour et al, 2015).  
The studies reported here showed that transiently knocking down FAAP24 by siRNA did not resensitize 
cells to either cisplatin or doxorubicin. This contrasts with a report suggesting the siRNA knockdown of 
FAAP24 results in a 2-3-fold sensitivity to cisplatin and mitomycin C compared to the respective control 
in HeLa cells (Ciccia et al, 2007). It is important to bear in mind that our results are from experiments 
performed in one isogenic paired cell line and that the effects that other groups have reported may be 
dependent on the presence of other genomic abnormalities that may not be present the cell lines we used. 
Interrogation of this gene in other more suitable cell line models would be necessary to make conclusions 
regarding the role of FAAP24 in contributing to poor prognosis. Given its potential role in checkpoint 
signaling, future studies could also focus on the mechanism by which FAAP24 induces ATR activation, 
which results in the phosphorylation of FANCM by ATR on S1045 (Ashour et al, 2015).  
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3.4.2	MRPS12	validation	
MRPS12, a mitochondrial ribosomal protein of the S12 family was also identified as being commonly 
amplified across the three tumour types studied. Although this finding was not statistically significant 
using the copy number calls generated using the SNP6 microarray processed by CBS, it was statistically 
significant when the array comparative genomic hybridization (aCGH) method was employed.  
MRPS12 is encoded by nuclear genes and is involved in protein synthesis in the mitochondria. There is 
functional relevance of ribosomal proteins in tumourigenesis; it is known that both tumour suppressors 
and oncogenes modulate ribosome protein biosynthesis and initiation of ribosome translation in various 
models (Ruggero et al, 2003). An example is MYC, a proto-oncogene product, which regulates mature 
ribosome biogenesis and its overexpression results in the increase of activity and expression of ribosomal 
components, suggesting that this could be an important mechanism by which MYC regulates growth and 
thus contributes to tumourigenesis (Boon et al, 2001). PTEN has also been shown to have similar 
functions in the regulation of ribosome biogenesis (Coelho et al, 2005), suggesting that perturbation in the 
ribosome biogenesis function may be an important factor, that contributes to carcinogenesis.   
The amount of ribosomes produced is a limiting factor for cell growth. It is known the amount of 
ribosomes produced controls the G1-S transition phase of the cell cycle, which is considered to be the 
critical restriction point, after which cells are destined to undergo division independent of cell growth. It 
has been reported that inhibition of ribosomal RNA (rRNA) transcription through the depletion of 
POLR1A, caused cell cycle arrest (Donati et al, 2011). Therefore, targeting factors of rRNA transcription 
complex looks like a promising strategy for chemotherapeutic treatment in p53 proficient and deficient 
tumours. Our results showed that knocking down MRPS12 by siRNA enhanced sensitivity to cisplatin 
treatment in the PEA1 cells. These studies must be carried out in other suitable cell lines, and future 
studies that address how modulation of MRPS12 affects the cell cycle would also prove beneficial before 
conclusions can be drawn regarding its contribution to poor prognosis.  
3.4.3	ZBTB32	validation	
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ZBTB32 is a zinc finger and BTB domain containing 32, whose function has not fully been characterized 
and very little is known about it. It is thought to be a repressor of GATA3 by preventing it from binding 
to DNA (Yoon et al, 2012). GATA3 has particular significance in breast cancer because it is thought to 
prevent metastasis by maintaining a luminal phenotype; loss of GATA3 is thought to correlate with poor 
prognosis in these patients. The preliminary validations carried out as part of this study did not show a 
significant difference between control and knockdown in the PEA1, however the PEA2 cells showed a 
significant induction of apoptosis with cisplatin treatment. This was thought to be an interesting 
observation, as this appeared to be a resistance-specific effect as enhanced sensitivity to cisplatin was not 
observed in the platinum sensitive PEA1 cells, suggesting that ZBTB32 may have a role in contributing to 
poor prognosis. Due to time constraints, further characterization of this gene was not possible, however, 
the data here suggests that further characterization of this gene would prove beneficial in determining its 
role as a suitable biomarker and therapeutic target. Future studies could focus on further elucidating the 
mechanism by which ZBTB32 represses GATA3 and to identify further targets that ZBTB32 may affect 
to get a better understanding of how and why the effects are observed.  
3.4.4	Other	highlighted	targets	
Although this study focused on commonly amplified genes across the three tumour types, several genes 
were identified as being amplified in all three tumours either alone or with one other tumour type. Of 
note, PRKDC (the gene that encodes DNA-PK) and AKT2 were highlighted as being commonly 
amplified across PDAC and sarcoma tumour types. This is corroborated by published data suggesting 
that AKT2 amplifications correlated with poor prognosis in osteosarcoma and colon carcinoma (Roy et al, 
2002; Zhu et al, 2014).  
Interestingly, among the other highlighted targets that were not common across the three tumour types 
but are worth mentioning are FANG and FANCI (highlighted in the pancreatic only group) and FANCB 
(highlighted in the sarcoma only group) because they additionally highlight the importance the FA 
pathway may have in contributing to poor prognosis in ways that remain to be elucidated. Additionally, 
SGK2 was also highlighted in the analysis in the ovarian cancer only group, again highlighting the 
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importance that AKT-independent effectors that are similar to AKT may have in the context of 
contributing to poor prognosis as will be discussed in the next chapter.  
Overall, the analysis in this chapter highlights several interesting genes that have shown to correlate with 
poor prognosis (using PFS in the ovarian cancer dataset).   It is important to appreciate the limitations of 
the analysis carried out; for example, when working with patient data, one must bear in mind that the data 
generated is from a combination of both normal and tumour DNA (from the patient biopsies) and thus 
would impact the interpretation of the data.   This is why very large datasets are required to reduce the 
impact of these and other clinical variables.   Additionally, although these interesting genes were 
highlighted, some of which appeared to show interesting results with the initial validation studies, one of 
the limitations of the approach taken to validate these genes was the cell line models used. In all the cell 
line models used, although the cell lines picked were based on the presence of high protein expression 
relative to the other cell lines, the presence of the amplicons were not verified in the models used and this 
could also impact the data generated. More robust validations using verified cell line models would be 
necessary moving forward to properly assess the role of these genes in poor prognosis. 
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CHAPTER	4:	INVESTIGATING	THE	ROLE	OF	SGK3	IN	DRIVING	POOR	
PROGNOSIS	IN	MULTIPLE	TUMOUR	TYPES	
4.0	INTRODUCTION	
It is well established that the PI3-K pathway is frequently dysregulated in multiple human cancers 
and has roles in regulating many aspects of cancer such as angiogenesis, cell growth, migration, 
proliferation and cell survival (Hanahan and Weinberg, 2011; Furman and Rommel, 2014). This 
makes it a very attractive pathway to exploit for cancer therapy. One of the most important targets 
downstream of the PI3-K pathway is AKT, which is also a key mediator of the PI3-K pathway 
function. The activation of AKT can result in inhibition of apoptosis and stimulation of cell survival 
and proliferation (Yamaguchi et al, 2001)) and this is thought to be the dominant tumour-promoting 
mechanism illustrated by the PI3-K pathway. Many cancers display frequent AKT activation, which 
has been shown to correlate with poor prognosis in some tumours (Wang et al, 2014). Although PI3-
K, a lipid kinase is a major regulator of AKT activation in response to various stimuli, other diverse 
groups of kinases (e.g. DNAPKcs) have also been found to directly activate AKT to stimulate 
various processes such as survival, growth and proliferation as mentioned earlier. Furthermore, even 
though AKT is widely recognised as being a key effector in driving malignant transformation, studies 
have reported that in some tumours (breast and ovarian), AKT activation only weakly correlated with 
activating mutations in the PI3-K catalytic subunit (Bruhn et al, 2013), suggesting the existence of 
other key AKT-independent, PI3-K dependent mediators of tumourigenesis.  
The SGK family are potential candidates that may be responsible for the AKT-independent 
oncogenic signalling. The SGK family of kinases share similar substrate specificities to the AKT 
family including TSC2 and PRAS-40 (Bruhn et al, 2013) so it may not be surprising that they may 
provide a potential parallel alternative pathway to PI3-K/AKT signalling. Recent studies have shown 
that mutant PI3K can induce tumourigenesis through AKT-independent, SGK-dependent 
mechanisms (Bruhn et al, 2013).  The SGK family consists of three highly homologous but distinct 
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isoforms, SGK1, SGK2 and SGK3, of which SGK1 is the most widely studied, and are all three 
activated in a PI3-K dependent manner. Similar to AKT isoforms, SGK1 SGK2 and SGK3 activity 
is regulated through post-translational modifications.  
 
This chapter focuses on the functional validations of SGK3 using different phenotypic assays to assess its 
role in contributing to poor prognosis in ovarian cancer, pancreatic cancer and sarcomas.  
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4.1	SGK3	IS	AMPLIFIED	ACROSS	SEVERAL	TUMOUR	TYPES		
In order to assess whether the analysis that showed SGK3 amplifications in ovarian and pancreatic 
cancers and sarcomas extended into other tumour types, publically available datasets were analysed 
for SGK3 aberrations in a range of solid tumours and hematological malignancies using the freely 
available www.cbioportal.com tool. The results showed that SGK3 aberrations, specifically 
amplifications were present in multiple tumour types with an increased frequency in breast tumours 
from multiple datasets (Figure 21A). On occasion deletions were observed, however these events 
were not common. Additionally, when focusing on the tumour types involved in this study from 
multiple datasets, amplifications were the most common aberration in all three tumour types. There 
were some deletions and mutations, however they accounted for <1% in each dataset (Figure 21B) 
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Figure 21: graph showing the frequency of SGK3 aberrations in a range of cancers (A) and 
in several datasets focusing on ovarian cancer, pancreatic cancer and soft-tissue sarcomas 
(B). Information shown from www.cbioportal.com. The source of the datasets were indicated in 
brackets next to the tumour type.  
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4.2	KNOCKDOWN	OF	SGK3	BY	SIRNA	DOES	NOT	RESENSITIZE	CELLS	TO	
CHEMOTHERAPY	
SGK3 was one of the most significant genes highlighted from the bioinformatics analysis, where 
high copy number gains correlated with poor prognosis in ovarian cancer patients. Analysis also 
revealed that SGK3 was commonly amplified across three tumour types: high-grade serous ovarian 
cancer, pancreatic ductal adenocarcinoma and type II complex karyotype sarcomas. To validate these 
results, siRNA-mediated knockdown specific for SGK3 was investigated in isogenic-paired HGS 
ovarian cancer lines PEA1/PEA2 and PEO1/PEO4; pancreatic cancer cell line Aspc1, and sarcoma 
cell line, SK-UT-1. Given that the genes studied were related to DNA damage response/repair and 
apoptosis, it was hypothesized that the genes would influence response to chemotherapy, hence 
functional validations were initiated with apoptosis assays. Using the caspase 3/7 glo assay 
(promega), apoptosis was measured and presented as a fold change in induction of caspase 3/7 (a 
marker of apoptosis), normalised to cell numbers, inferred by MTT assay. Knockdown of SGK3 was 
implemented to assess if combining it with a chemotherapeutic agent would enhance apoptotic 
effect, particularly in cell lines already resistant to chemotherapy. SGK3 knockdown in PEA1 and 
PEA2 cells showed no difference in response to chemotherapy (doxorubicin and cisplatin treatment) 
when assessed by induction of caspase 3/7 activity normalised to viability compared to the non-
targeting control (figure 22A and 22B).  Similar results were observed in the second isogenic pair 
PEO1 and PEO4 cells (figure 23A and 23B) as well as sarcoma cell line, SK-UT-1 (figure 24).  A 
small effect was observed with SGK3 knockdown in pancreatic cancer cell line Aspc1 (figure 25) 
with cisplatin, however this was only seen in this particular cell line.  Knockdown for SGK3 in all cell 
lines were confirmed at protein level (figure 26).  
 
 
 
 
 
 
 137 
 
 
 
 
 
 
Figure 22:  Knocking down SGK3 does not alter apoptosis in PEA1 and PEA2.  
Apoptosis assay using caspase 3/7 glo kit normalised to cell viability (MTT) in ovarian isogenic paired cell lines PEA1 
and PEA2 following doxorubicin 1.5µM (A) and cisplatin 25µM (B) treatment after 24 hours. Knockdown was 
confirmed at protein level as detailed in figure 30. Data shown are the mean values ± SEM of three independent 
experiments.  
 
Figure 23: Knocking down SGK3 does not alter apoptosis in PEO1 and PEO4.  
Apoptosis assay using caspase 3/7 glo kit normalised to cell viability (MTT) in the ovarian isogenic paired cell lines PEO1 
and PEO4 following doxorubicin 1.5µM (A) and cisplatin 25µM (B) treatment after 24 hours. Knockdown was 
confirmed at protein level as detailed in figure 30. Data shown are the mean values ± SEM of three independent 
experiments.  
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Figure 24: SGK3 knockdown does not alter apoptosis induction in sarcoma cell line, SK-UT-
1. Apoptosis assay using caspase 3/7 glo kit normalised to cell viability (MTT) in sarcoma cell line SK-UT-1 following 
doxorubicin 1.5µM and cisplatin 25µM treatment after 24 hours. Knockdown was confirmed at protein level as detailed in 
figure 30. Data shown are the mean values ± SEM of three independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: SGK3 knockdown does not alter apoptosis induction in pancreatic cancer line, 
Aspc1. Apoptosis assay using caspase 3/7 glo kit normalised to cell viability (MTT) in sarcoma cell line Aspc1 following 
doxorubicin 1.5µM and cisplatin 25µM treatment after 24 hours. Knockdown was confirmed at protein level as detailed in 
figure 30. Data shown are the mean values ± SEM of three independent experiments.  
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Figure 26: Confirmation of SGK3 knockdown by western blotting. Western blots showing knockdown 
for SGK3 in both isogenic ovarian cancer cell lines at protein level. Vinculin was used as loading control.  
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4.3	KNOCKDOWN	OF	ALL	SGK	ISOFORMS	IS	NOT	SUFFICIENT	TO	RESTORE	
SENSITIVITY	TO	CHEMOTHERAPEUTIC	AGENTS	
Previous work studying AKT isoforms in the laboratory indicated that all isoforms of AKT needed 
to be knocked down to see the optimal effect in inducing apoptosis in response to chemotherapy 
treatment (Koseoglu et al, 2007).  Given that other members of the SGK family (SGK1 and SGK2) 
share similar substrates and functions to SGK3, all three members were knocked down together to 
account for any compensatory effects by the other members. Knocking down all three members of 
the SGK family did not alter caspase 3/7 induction normalised to MTT with either doxorubicin or 
cisplatin treatments in ovarian cancer cell lines PEA1, PEA2 (Figure 27) and pancreatic cancer cell 
line TKCC6 (Figure 28B). A small effect was observed in pancreatic cell line Panc-1 (Figure 28A) 
however this effect was not significant and not observed in other cell lines studied.  
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Figure 27: Knockdown of all SGK family members does not alter apoptosis induction in 
ovarian cancer isogenic paired cell lines PEA1 and PEA2. Apoptosis assay using caspase 3/7 glo kit 
normalised to cell viability (MTT) following doxorubicin 1.5µM (A) and cisplatin 25µM (B) treatment after 24 hours. 
Knockdown of SGK3 was confirmed at protein level and SGK1 at mRNA level as detailed in figure 33. Data shown are 
the mean values ± SEM of three independent experiments.  
 
 
 
 
Figure 28: Knockdown of all SGK family members does not alter apoptosis induction in 
pancreatic cancer cell lines Panc-1 (A) and TKCC6 (B). Apoptosis assay using caspase 3/7 glo kit 
normalised to cell viability (MTT) following doxorubicin 1.5µM and cisplatin 25µM treatment after 24 hours. 
Knockdown of SGK3 was confirmed at protein level and SGK1 at mRNA level as detailed in figure 33. Data shown are 
the mean values ± SEM of three independent experiments.  
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Figure 29: Knockdown confirmation of SGK members. SGK3 knockdown was confirmed at protein 
level in all cell lines studied (A-B). SGK1 knockdown was confirmed in PEA1 (C), PEA2 (D), Panc-1 (E) and 
TKCC6 (F) at mRNA level using qPCR.   
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4.4	KNOCKDOWN	OF	SGK3	AFFECTS	LONG	TERM	SURVIVAL	IN	SPECIFIC	GENOMIC	
CONTEXTS	
Previous data showed that knockdown of SGK3 does not appear to affect apoptosis in most cell 
lines studied following 24-hour treatment of DNA damaging agents. It is becoming clear now in the 
era of personalized medicine that the effect of any particular gene or drug is usually relevant only in 
specific context be it cellular, genomic or environmental. Most of the cell lines used have active AKT 
(Stronach et al, 2011) and given that SGK3 and AKT have similar functions, it is possible that SGK3 
may not have biological significance in these cell types. To address this, a cell line with high 
endogenous SGK3 and simultaneous low AKT levels, IGROV1 was studied. This was based on cell 
line data obtained from the Sanger Institute, which showed that IGROV1 had high SGK3 copy 
number and low AKT1, AKT2 and AKT3 gene expression and copy number when compared to 
other pancreatic and ovarian cancer cell lines.  
Knocking down SGK3 in IGROV1 did not increase apoptosis induction compared to control in 
cells treated with chemotherapeutic agents after 24 hours (figure 30A) or 48 hours (figure 30B), 
similar to previous data observed.  
Following the short-term apoptosis assays, long-term survival effects were also assessed by 
clonogenic assays. We observed that knockdown of SGK3 significantly reduced long term survival in 
IGROV1 cells (p=0.0002) (figure 31A-B).  
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Figure 30: Knockdown of SGK3 does not alter apoptosis induction in IGROV1 cells after 24 
hours (A) or 48 hours (B) of treatment with either doxorubicin or cisplatin. Apoptosis assay using 
caspase 3/7 glo kit normalised to cell viability (MTT) following doxorubicin 1.5µM and cisplatin 25µM treatment. Data 
shown are the mean values ± SEM of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: SGK3 knockdown affects long term survival in IGROV1 cells. Long term survival was 
assessed by clonogenic assay. IGROV1 cells were seeded at 500 cells/well following transfection with SGK3 siRNA and 
colonies were allowed to form for 10 days. A colony was defined as a cluster of 50 or more cells. When counted, the SGK3 
knockdown condition appeared to have significantly less colonies (A and B). SGK3 knockdown was confirmed at protein 
level at both 24h (C) and 48h (D) time points. Data shown are the mean values ± SEM of three independent experiments 
and a visual image also representative of three individual experiments. P-value was determined using a Student’s t-test.   
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4.5	KNOCKDOWN	OF	SGK3	DOES	NOT	AFFECT	THE	CELL	CYCLE	
It was observed that knockdown of SGK3 affected long term survival assessed by clonogenic assay. This 
assay determines a cells ability to proliferate indefinitely, thereby retaining the ability to form large and 
multiple colonies. The effect of SGK3 modulation (if any) on the cell cycle was investigated. Cell cycle 
analysis was carried out by quantitation of DNA content using propidium iodide dye staining and flow 
cytometry. Both knockdown and overexpression of SGK3 does not appear to affect cell cycle in IGROV-
1 and SKOV3 (figure 32A and 32B).  
 
 
Figure 32: Knockdown and overexpression of SGK3 does not appear to affect cell cycle in 
IGROV-1, SKOV3. Cells were transfected with p3xFLAG-CMV-10-SGK3wt and the corresponding empty vector 
along with SGK3 siRNA and following 48 hours transfection, cells were fixed in ethanol and stained with propidium 
iodide to assess DNA content. Data shown are the mean values ± SEM of three independent experiments.   
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4.6	OVEREXPRESSION	OF	SGK3	ENHANCES	SURVIVAL	IN	OVARIAN	AND	
PANCREATIC	CANCER	AND	SARCOMA	CELL	LINES	
It was observed that knockdown of SGK3 does not alter apoptotic signal in ovarian cancer, pancreatic 
cancer and sarcoma cell lines. Following this, we wanted assess the effects of overexpressing SGK3 on 
viability and apoptosis. If SGK3 were involved in poor prognosis, then we would expect SGK3 
overexpression to make a sensitive cell line resistant to chemotherapeutic agents.  
Studies addressing this showed that overexpression of SGK3 enhanced survival in all cell lines studied. 
Although both ovarian cancer isogenic paired cell lines PEA1 and PEA2 showed the same trend of 
enhanced survival, this effect was only significant in the resistant PEA2 (figure 33B) cell line, not in the 
sensitive PEA1 (figure 33A). Although the effect was only significant in the isogenic resistant cell line 
PEA2 with doxorubicin (p=0.0156) and cisplatin treatment (p=0.0094), similar trends were observed in 
other resistant ovarian cancer cell lines such as SKOV3 (figure 33C), pancreatic cancer cell line Aspc1 
(figure 33D) and sarcoma cell line SK-UT-1 (figure 33E).  
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Figure 33: SGK3 overexpression enhances survival in ovarian cancer cell lines, PEA1 (A), 
PEA2 (B) and SKOV3 (C); pancreatic cancer cell line Aspc1 (D) and sarcoma cell line SK-
UT-1 (E). Overexpression of SGK3 for all experiments were confirmed at protein level (F). Apoptosis assay using 
caspase 3/7 glo kit normalised to cell viability (MTT) in ovarian cancer, pancreatic cancer and sarcoma cell lines mentioned 
above following doxorubicin 1.5µM and cisplatin 25µM treatment after 24 hours. Data shown are the mean values ± 
SEM of three independent experiments. P-value was determined using Student’s t-test. Graphs without any p values indicate 
non-significance.  
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4.7	SGK3	MODULATION	AFFECTS	MIGRATORY	CAPACITY	OF	OVARIAN	CANCER	
CELLS	
The data shown here suggests that SGK3 knockdown does not significantly alter apoptosis however may 
affect long term survival in cells with high endogenous levels of SGK3 and simultaneous low levels of 
AKT. In keeping with this trend, overexpressing SGK3 appeared to enhance survival in most cell lines 
studied.  The potential role of SGK3 in other phenotypes was investigated. Previous published research 
suggested a role for SGK1 in motility (Zarrinpashneh et al, 2013) and more recently SGK3 in motility in 
breast cancer (Gasser et al, 2014) however its role in ovarian cancer or pancreatic cancer cell migration is 
currently unknown. To address this, 15-hour overnight wound healing assays were undertaken to assess 
the effect of SGK3 overexpression on the migratory capacity of ovarian and pancreatic cancer cell lines. 
The results showed that overexpressing SGK3 increased the migratory capacity in all cell lines studied 
compared to the empty vector control, however the effect was most significant in the resistant ovarian 
cancer cell lines PEA2 (p=<0.01) (figure 34B), and SKOV3 (p= <0.05) (figure 34C). Visually it is also 
clear that overexpressing SGK3 enhances the migratory capacity of the cells, particularly in the SKOV3 
cells (figure 34E), where at the 15h endpoint, the cells in the empty control condition have not migrated 
sufficiently to completely close the gap created whereas the SGK3+ condition has closed the gap.  
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Figure 34: Overexpression of SGK3 significantly increases the migratory capacity of 
resistant ovarian cancer cell lines PEA2 (B) and SKOV3 (C) and to a lesser extent in PEA1 
(A) and pancreatic cancer cell line Aspc1 (D). End point images (E) of the ‘wound’ created by the cell 
culture inserts also clearly show that in the resistant PEA2 and SKOV3, the cells in the SGK3+ condition migrate faster 
to close the ‘gap’. *** p=<0.001; ** p= <0.01; * p=<0.05 Data shown are the mean values ± SEM and visual 
representation of three independent experiments.  
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Given that the SGK3 overexpression appeared to have the most significant effect in SKOV3 cells, this 
cell line was used to further characterize this effect and the potential role of SGK3 in migration and other 
phenotypes. If SGK3 was indeed directly responsible for the enhanced migratory effect seen, then 
conversely knocking it down should slow down the cells migratory capacity. This was addressed in 
experiments, where SGK3 was overexpressed and knocked down with effects compared to the relative 
controls. Whilst overexpressing SGK3 increased migratory capacity (figure 35A), knocking down SGK3 
did have the reverse effect, where the cells moved significantly slower than the control counterpart (figure 
35B). This effect can also clearly be seen visually in figure 35C, where the gap in the SGK3 knockdown 
condition has not fully closed compared to the non-targeting control, which has clearly closed at the 15-
hour end point of the assay.  
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Figure 35: Overexpressing SGK3 increases migratory capacity (A), whilst knocking it down 
decreases its migratory capacity (B, C). Overexpressions and knockdowns of SGK3 were confirmed at protein 
level for all experiments (D). *** p=<0.001; ** p= <0.01; * p=<0.05.  P value was calculated using multiple t-test. 
Data shown are the mean values ± SEM and visual representation of three independent experiments. 
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4.8	SGK3	OVEREXPRESSION	INCREASES	SINGLE	CELL	MIGRATION	
 
Although it has been shown here that SGK3 modulates collective migration, another mode of migration, 
single-cell migration, has an equally important role in cancer metastasis. Single cell migration allows cells 
to position themselves in secondary growths and can transiently pass through tissue, thereby facilitating 
the metastatic process. To see if SGK3 modulation also has a role in single-cell migration, random cell 
tracking assays were set up and analysed using the Fiji software TrackMate function. The results indicate 
that SGK3 overexpression does significantly increase single-cell migration as determined by set 
parameters such as increased velocity, distance travelled, speed, displacement and persistence (figure 36A-
E). The only parameter that didn’t significantly change, was the persistence of the single cells, which is the 
ratio of displacement to distance, however there was a general trend of slightly increased persistence in 
the SGK3+ cells. 
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Figure 36: SGK3 overexpression increases single-cell migration. Overnight random cell tracking under 
reduced serum conditions following SGK3wt transfection revealed a role for SGK3 in promoting the displacement of cells 
(A), speed (B), the distance they travelled (C) and the velocity (D) and the persistence (E) of the cells. Visually, cell tracking 
shows that in the SGK3+ cells, each individual cell had a bigger path to track and was associated with increased migration 
as indicated by the colours of the path around each cell (F). Statistical significance was calculated using student’s T-test with 
<0.05 used as the cut off for significance. Data shown are the mean values ± SEM and visual representation of three 
independent experiments. 
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4.9	SGK3	OVEREXPRESSION	INCREASES	OVARIAN	CANCER	2D	AND	3D	CELL	
INVASION	
Cancer cell metastasis is the leading cause of mortality from cancer. In order for metastasis to occur, cell 
invasion and migration are essential prerequisite steps. Metastasis begins with the invasion of cancer cells 
to the stroma and migration towards the bloodstream. We have already established a role for SGK3 in 
cancer cell migration so the potential role of SGK3 in tumour cell invasion was explored. SKOV3 was 
used for these studies as we observed the most significant effect in migration studies in this cell line. 
Using matrigel coated invasion chambers, we observed that overexpressing SGK3 significantly increases 
tumour cell invasion compared to the empty control (p=<0.0001) (figure 37A). This effect is also clear 
visually, where there is a clear difference between the number of DAPI stained nuclei invaded through 
the matrigel in the empty control compared to SGK3 overexpression (figure 37B). To investigate this 
finding further in a more physiological setting, 3D spheroid invasion assays were carried out to see if 
similar effects were observed. We observed that after 24-hour incubation of the SKOV3 spheroids with 
matrigel, the SGK3+ condition had visible signs of invasion as indicated by the sprouts visible in figure 
37C. This is clearly absent in the empty vector control (also figure 37C). Sarcoma cell line SK-UT-1 
spheroids also showed the same trend, where overexpressing SGK3 increased invasion, however signs of 
dead cells were more visible in the SK-UT-1 empty vector compared to the SKOV3 spheroids. 
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Figure 37: SGK3 overexpression increases 2D and 3D ovarian cancer cell invasion. 2D invasion 
assessed by matrigel coated 8µM pore invasion chambers (BD Biosciences). Transfected cells were serum starved 18 hours 
prior to adding to the invasion chamber and then incubated at 37°C for 22 hours before scrubbing the non-invading cells, 
fixing and staining the cells. The number of cells invaded in each condition were counted and represented as a number (A). 
3D invasion was assessed by forming spheroids post transfection and then adding a layer of matrigel to the spheroids and 
incubating for 24 hours to measure the invasion through the matrigel that would be visible through ‘sprouting’ of cells as can 
been seen in the SGK3+ SKOV3 spheroid (C) and SK-UT-1 spheroid (D). SGK3 overexpression was confirmed at 
protein level (E).  p value was calculated using a student t-test. Data shown are the mean values ± SEM and visual 
representation of three independent experiments. 
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4.10	SGK3	OVEREXPRESSION	INCREASES	OVARIAN	AND	PANCREATIC	CANCER	
CELL	ADHESION	TO	COLLAGEN	I	
The metastatic potential of a cancer cell is determined by its ability to exit the bloodstream, to colonize 
distant organs and to grow in distant organs. Critical in this metastatic cascade, are the cell-cell 
interactions that facilitate adhesion in the vasculature of distant organs. We have shown that SGK3 
modulation affects cancer cell migration and invasion. Metastatic tumour cells tend to adhere to 
extracellular matrix (ECM) components such as collagen I, laminin and fibronectin, mediated by 
molecules such as integrins in order to move into the sub-endothelial stroma and then subsequently grow 
at new sites (Valastyan et al, 2011). Here, we investigated the effect of SGK3 modulation on adhesion to 
one of the ECM components, collagen I. The results indicated that SGK3 overexpression significantly 
increases adhesion in the ovarian cancer cell lines, SKOV3 (p=0.0017) (figure 38A), PEA2 (p=0.0096) 
(figure 38B) and IGROV1 (p=0.0006) (figure 38C) with differences of at least a 1.5-fold increase in the 
SGK3 overexpressed condition compared to the empty vector in all cell lines (SKOV3, PEA2, IGROV1. 
Furthermore, knocking down SGK3 also appears to decrease adhesion in the SKOV3 cell line (p=0.0002) 
(figure 38A).   
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Figure 38: Overexpression of SGK3 increases ovarian cancer cell lines adhesion to collagen 
I. Following appropriate coating of 96-well plates with Collagen I, adhesion assay was carried out in SGK3 knocked down 
and overexpressed cells as detailed in chapter 2. There was a significant increase in adhesion to collagen I in ovarian cancer 
cell lines, SKOV3 (A), PEA2 (B) and IGROV1 (C) overexpressing SGK3. Furthermore, a decrease in adhesion to 
collagen I was also observed in cells knocked down with SGK3 in SKOV3 cells (A).  SGK3 knockdown and 
overexpressions were confirmed at protein level (D). Data shown are the mean values ± SEM of three independent 
experiments. 
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4.11	SGK3	MAY	HAVE	PLEIOTROPIC	EFFECTS	ON	MIGRATION	DEPENDENT	ON	ITS	
PHOSPHORYLATION	STATUS	
The effect of SGK3 modulation on migration has been clearly demonstrated. However, it is currently 
unclear if SGK3 phosphorylation is driving this, and if so which site is responsible for the phenotypes 
seen. In order to identify the site responsible, the two main phosphorylation sites, serine at residue 486 
(S486) and threonine at residue 320 (T320), known to be required for full SGK3 activation (Tessier and 
Woodgett, 2006) were investigated. Mutant forms of the phosphorylation sites were generated, where an 
activating and inactivating mutation were introduced. The two phosphorylation sites studied were serine 
at residue 486 (S486) and threonine at residue 320 (T320) and these were compared to the SGK3 wild-
type (WT) and empty vector for control.  
The results revealed that mutating the S486 site affected the rate of migration, where surprisingly, a 
constitutively active S486 (S486D) appeared to slow the rate of migration compared to SGK3 WT whilst 
the S486 inactive mutant (S486A) appeared to enhance migratory capacity even more compared to the 
SGK3 WT (figure 39A). Whilst both mutant forms of SGK3 migrated faster than the empty vector 
control, the differences between the two forms are visible.  
Inactivating the T320 site (T320A) appeared to return the migratory capacity of these cells to the same 
level as the empty vector as seen in figure 39B, however the activating T320 mutation (T320D) did not 
cause the cells to migrate at a rate faster than the SGK3 WT (figure 39B).  
Collectively, it would appear that SGK3 has pleiotropic effects on migration, where an inactivating 
mutation of one of the sites (S486) that are required for full SGK3 activation appears to enhance the rate 
of migration compared to the WT however the opposite is seen with the inactivating mutation of T320, 
which appears to slow the rate of migration to levels comparable with the empty vector control.  
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Figure 39: Inactivating mutations of the two phosphorylation sites required for SGK3 
activation reveal pleiotropic effects of SGK3 on migration. 15-hour wound healing assay using cell 
culture inserts to assess the migratory capacity of cells with SGK3 phosphorylation site modulation. Activating and 
inactivating mutations of SGK3 S486 (A) show that the inactivating mutation of S486 enhances migratory capacity 
whereas inactivating mutation of SGK3 T320 (B) decreases migratory capacity. Overexpressions were confirmed using 
western blotting (C)  
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4.12	SGK3	INTERACTS	WITH	AIP4	AND	CXCR4	
A role for SGK3 in several phenotypes/events contributing to metastasis such as invasion, migration and 
adhesion has been established, which ultimately is the main cause of poor prognosis in most cancer 
patients. In order to better understand these findings, we need to uncover the responsible mechanism. 
This could also further aid in patient stratification to exploit SGK3 therapeutically (if possible) for better 
patient outcomes.  
Here, one such mechanism through which SGK3 may be modulating the phenotypes observed is 
proposed: through the CXCL12-CXCR4 signalling axis. It is well established that the CXCL12-CXCR4 
signalling axis has been implicated in contributing to metastasis in several cancers including ovarian 
cancer (Wang et al, 2011), pancreatic cancer (Shen et al, 2013) and sarcomas (Krook et al, 2014). SGK3’s 
role in this pathway is thought to be through the interaction with the E3 ubiquitin ligase, AIP4, which 
degrades CXCR4. AIP4 is involved in controlling the degradation of membrane-bound receptors, by 
promoting their lysosomal sorting (Slagsvold et al, 2006). More specifically, it has been shown that the 
degradation of CXCR4 was dependent on the activity of AIP4 (Marchese et al, 2003). Given that SGK3 
and AIP4 are known to localize in the endosomes, it was shown that SGK3 was able to interfere with 
AIP4-mediated lysosomal degradation of CXCR4 through its phosphorylation and subsequent inhibition 
(Slagsvold et al, 2006).  
To investigate this as a possible mechanism through which SGK3 is involved in these phenotypes, it was 
important to observe if SGK3 interacted with AIP4 and CXCR4 in our systems as this would be 
indicative of a potential role for SGK3 through CXCR4. To address this, immunoprecipitation studies 
were performed. Three cell lines were studied, two ovarian cancer cell lines SKOV3, with low 
endogenous SGK3 levels and IGROV1, with high endogenous SGK3 levels along with a sarcoma cell 
line SK-UT-1, which had moderate levels of SGK3. Immunoprecipitation experiments showed that 
SGK3 does interact with CXCR4 in all cell lines based on SGK3 immunoprecipitation and probing for 
CXCR4 on a western blot. Furthermore, in IGROV1 cells, SGK3 appears to interact with both AIP4 and 
CXCR4 as shown when all three antibodies are immunoprecipitated and probed for the expression of the 
other proteins (figure 40A). Additionally, here we show that modulation of SGK3 does affect CXCR4 
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protein levels as shown in figure 40B, where overexpression of SGK3 in SK-UT-1 and SKOV3 cell lines 
results in an increase in CXCR4 protein levels and correspondingly, knockdown of SGK3 in IGROV-1 
shows decreased CXCR4 levels compared to the non-targeting control (figure 40B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40: SGK3 interacts with CXCR4 and AIP4 and modulation of SGK3 affects CXCR4 
protein levels. Ovarian cancer (SKOV3 and IGROV1) and sarcoma (SK-UT-1) cell lines were lysed for protein and 
1mg lysates were mixed with the cross-linked antibody to allow for interaction with protein A/G support overnight at 4°C 
followed by elution for western blot detection (A). The same cell lines were transfected with an SGK3 overexpression 
construct or siRNA and following 72 hours, cells were lysed and the protein collected were run on a western blot to detect 
how SGK3 modulation affects CXCR4 levels (B).  
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4.13	SGK3	MODULATES	ITS	EFFECT	ON	MIGRATORY	PHENOTYPE	THROUGH	CXCR4	
4.13.1	AIP4	knockdown	increases	migration	and	increases	CXCR4	protein	levels	
In order to address whether SGK3 promotes increased migration and invasion through CXCR4 via AIP4, 
we first looked to characterize whether this effect was through AIP4 using AIP4 siRNA. If SGK3 is 
positively regulating CXCR4 by inhibiting its AIP4-mediated lysosomal degradation, then using an AIP4 
siRNA alone should yield similar effects seen with SGK3+ because both events would result in increased 
CXCR4 levels. We observed that although not statistically significant, knockdown of AIP4 using two 
siRNAs increased the rate of migration compared to the non-targeting control (figure 41A) to levels 
similar to SGK3+, however the two siRNAs did result in slightly different migration rates, even though 
both siRNAs appeared to knock down AIP4 at protein level (figure 41A). Furthermore, we also observed 
that combining SGK3 overexpression with AIP4 knockdown resulted in enhanced migratory capacity 
when compared to AIP4 knockdown alone (figure 41B). This is possibly through complete depletion of 
AIP4 resulting in even higher CXCR4 levels. We also show that knocking down AIP4 does increase 
CXCR4 protein levels as expected in figure 41D.  
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Figure 41: Knockdown of AIP4 increases migration compared to non-targeting in SKOV3 
cells. SKOV3 cells were transfected accordingly and seeded in cell culture inserts for overnight wound healing migration 
assays (A and B). Knockdowns and overexpressions were confirmed at protein level via western blotting (C). The effect of 
AIP4 knockdown on CXCR4 was also determined via western blotting (D). 
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4.13.2	CXCR4	knockdown	slows	down	the	migratory	capacity	of	cancer	cells		
Given that we have established that knockdown of AIP4 does have a differential migratory capacity when 
compared to the SGK3 overexpressions, and also increases CXCR4 protein levels, we wanted to observe 
the effects of knocking down CXCR4 on the migratory capacity of these cells when compared to SGK3 
overexpression. The results indicate that knocking down CXCR4 slows down migration compared to 
SGK3 overexpression. Although both siRNA oligonucleotides show the same trend in slower migratory 
capacity, this effect is particularly significant in the CXCR4 # 8 compared to the SGK3 overexpression 
(p=<0.05) (figure 42A). Although there are differences between the two oligonucleotides, both appear to 
diminish the migratory capacity when comparing to the SGK3 overexpressed condition.  
Although CXCR4 knockdown by siRNA does show a trend towards slowing down migratory capacity of 
SKOV3 cell, to see if this effect was more apparent with inhibition of CXCR4, a specific inhibitor, 
AMD3100, was utilised. Repeating the migration assays with this CXCR4 inhibitor showed that inhibiting 
CXCR4 did indeed significantly slow down migratory capacity of SKOV3 cells (p=<0.05) (figure 43A), 
returning them to similar levels seen with the empty vector.  
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Figure 42: Knockdown of CXCR4 slows down the migratory capacity of SKOV3 cells 
compared to empty vector. SKOV3 cells were transfected accordingly and seeded in cell culture inserts for overnight 
wound healing migration assays (A). Knockdowns and overexpressions were confirmed at protein level via western blotting 
(B) 
 
 
 
Figure 43: CXCR4 inhibition significantly slows migratory capacity of SKOV3 cells. SKOV3 
cells were transfected accordingly and seeded in cell culture inserts for overnight wound healing migration assays (A). 
Inhibition of CXCR4 and overexpression was confirmed at protein level via western blotting (B). 
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4.14	SGK3	MAY	MEDIATE	TRANSCRIPTIONAL	REGULATION	OF	MARKERS	KNOWN	
TO	BE	INVOLVED	IN	EPITHELIAL-MESENCHYMAL	TRANSITION	(EMT)	
A role for SGK3 in several phenotypes such as migration, invasion and adhesion, all of which are thought 
to be important events in metastasis have now been established here. A process termed epithelial to 
mesenchymal transition (EMT) is thought to be critical in promoting tumour metastasis through tumour 
invasion and migration. Previous published data has tentatively indicated a possible role for SGK 
members in being involved in transcriptional regulation of EMT markers (Cheng et al, 2010; Dhasarathy et 
al, 2011). To investigate this further, we sought to see if SGK3 was involved in transcriptional regulation 
of EMT markers as this may explain its role in the phenotypes mentioned. Several known EMT markers 
were assessed by qPCR to assess the expression differences between SGK3 overexpression when 
compared to the empty vector control. The results indicate that SGK3 is involved in transcriptional 
regulation of certain markers of EMT. Of all the markers assessed, Fibronectin 1 (FN1) (p=0.0039) 
(figure 44A), Slug (p=0.0016) (figure 44B), b-catenin (p=0.0027) (figure 44D), E-cadherin (p=0.0011) 
(figure 44E) and snail (p=0.0032) (figure 44G) were significantly differentially expressed when SGK3 was 
overexpressed compared to the control, which will be discussed in more detail later. Of interest, SGK3 
overexpression also resulted in increased CXCR4 mRNA levels (figure 44C) in addition to protein levels 
shown previously however this effect was not significant due to variation between experiments however 
similar trends were seen in all experiments.   
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Figure 44: SGK3 transcriptionally regulates several EMT related markers. RNA was extracted 
from cells overexpressing SGK3 and the empty vector control. Following cDNA synthesis, qPCR was carried out to test for 
fibronectin 1 (A), slug (B), CXCR4 (C), b-catenin (D), E-cadherin (E), MMP2 (F) and Snail (G). SGK3 
overexpression was confirmed at protein level (H).  
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4.15	REVERSE	PHASE	PROTEIN	ARRAY	(RPPA)	HIGHLIGHTS	POTENTIAL	
MEDIATORS	DRIVING	PHENOTYPES	SEEN	THROUGH	SGK3	
 
Although it is likely that CXCR4 may be driving the phenotypes observed with SGK3 modulation, it is 
also likely that there are other important mediators responsible that have yet to be identified. To elucidate 
what other proteins are involved in this signalling cascade, reverse phase protein array (RPPA) was carried 
out to observe differences in protein expression between SGK3 overexpression compared to the empty 
vector control with and without serum modulation.   
SKOV3 ovarian cancer cells were serum starved following transfection for 24 hours and then protein 
lysates were collected before serum stimulation (0h) and at 30 minutes following 0.5% serum stimulation. 
The samples were probed with 297 antibodies by tyramide-based signal amplification approach and 
visualized by DAB colorimetric reaction. The baseline changes were analysed at each time point and the 
fold change difference between the time points for serum-independent changes observed using 1.2-fold 
change as a cut-off. At 0h, several proteins were significantly up-regulated compared to the empty vector 
such as HES1, Connexin-43, HER2, pHER2 and PARP1 (table 13). Although the changes in the other 
proteins were not statistically significant, this was due to variation between the three individual 
experiments, even though the same trend was observed within each experiment and so are included in 
this analysis. There were no downregulated proteins by ≤0.8-fold as this was the cut-off set for 
downregulated protein inclusion. At 30 minutes after serum stimulation, a number of proteins were up-
regulated (table 14), however these were not statistically significant again due to variation between 
experiments but were included because each experiment showed similar trends of up-regulation. When 
comparing fold change ratio between 30min/0h in the SGK3 overexpressed versus the empty vector 
control, fewer proteins are up-regulated however, interestingly, most of the proteins listed as upregulated 
such as fibronectin, vimentin and rheb (table 15) are implicated in EMT and general motility which 
corroborates our theory of SGK3 involvement in these processes.  
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Table 13: Upregulated proteins in SGK3 overexpressed cells compared to the empty vector 
control, analyzed from RPPA at 0h prior to serum stimulation following 48-hour transfection 
of appropriate constructs.  
Fold changes are averages of three independent replicates. Statistical significance was calculated using Student’s T-test using 
≤0.05 as a cut off for significance. Ns= not significant. The proteins that were not significantly altered were included as they 
showed similar trends within each independent replicate; the variation in the fold-changes resulted in them not being 
statistically significant. 
	
	
	
	
	
	
	
	
	
	
 
Table 14: Upregulated proteins analysed from RPPA at 30 minutes after serum stimulation 
following 48-hour transfection of p3xFLAG-CMV-10-SGK3wt and p3xFLAG-CMV-10 empty 
	
0 
ho
ur
s
Up	regulated	
proteins
Fold	change p-value
Myosin-IIa_pS1943 1.80721995 ns
HES1 1.604589306 <0.0001
Connexin-43 1.583122971 0.0045
Fibronectin 1.496226924 ns
HER2 1.410822261 0.0452
XPF 1.360318118 ns
Bcl2 1.2993809 ns
HER2_pY1248 1.295124745 0.05
VHL-EPPK1 1.292861222 ns
PREX1 1.292283395 ns
PARP1 1.274692115 0.05
ARID1A 1.265492033 ns
SCD 1.246577347 ns
EGFR_pY1068 1.240448311 ns
PAR 1.231828573 0.0303
Gab2 1.214276568 ns
NDRG1_pT346 1.206789446 0.0216
S6 1.205710288 ns
Upregulated	proteins Fold	change
Myosin-IIa_pS1943 3.330384777
PAR 1.557315841
EMA 1.516294822
Pdcd4 1.325521315
Syk 1.32512366
ATP5A 1.316165149
Myosin-11 1.308738293
VHL-EPPK1 1.303120765
ARID1A 1.287436474
p70-S6K1 1.253165564
PTEN 1.207573083
PARP1 1.20157503
PRAS40 1.201316842
30
 m
in
ut
es
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vector constructs. Fold changes are averages of three independent replicates. The proteins were not significantly altered 
(using student’s t-test) but were included as they showed similar trends within each independent replicate; the variation in the 
fold-changes resulted in them not being statistically significant.  
 
	
	
	
	
	
	
	
 
Table 15: Upregulated proteins analyzed from RPPA represented as a fold change ratio 
between 30 minutes after serum stimulation over 0h prior serum stimulation following 48-
hour transfection of p3xFLAG-CMV-10-SGK3wt and p3xFLAG-CMV-10 empty vector 
constructs. Fold changes are averages of three independent replicates. The proteins were not significantly altered (using 
student’s t-test) but were included as they showed similar trends within each independent replicate; the variation in the fold-
changes resulted in them not being statistically significant. 
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Upregulated	
proteins
Fold	change
Myosin-IIa_pS1943 1.78441107
5
VHL-EPPK1 1.67029198
8
Akt_pT308 1.25814617
6
Fibronectin 1.23229641
4
Vimentin 1.21736148
1
Rheb 1.21194276
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4.16	DISCUSSION	
4.16.1	Role	of	SGK3	in	apoptosis/survival	
The bioinformatic analysis described in chapter 3 assessed the common copy number amplifications in 
genes relating to DNA damage/repair and apoptosis, and highlighted SGK3 as being significantly 
associated with poor prognosis (using progression free survival data from ovarian cancer patients). This 
study aimed to assess the role of SGK3 in contributing to poor prognosis in solid tumours through 
functional validation using several phenotypic assays. Given that the gene set studied in the 
bioinformatics analysis related to DNA damage response/repair and apoptosis, validation studies were 
commenced using apoptosis (caspase 3/7 glo) and viability (MTT) assays to assess the effect of 
modulating SGK3. These apoptosis assays normalized to cell viability didn’t show any changes in 
apoptosis or viability when SGK3 was knocked down transiently by siRNA. This was evident in the range 
of cell lines studied of ovarian cancer, pancreatic cancer and sarcoma. This was surprising given that 
SGK3 was first discovered in the context of it being an antiapoptotic factor in a screen for IL-3 
dependent survival factors (Liu et al, 2000). Previous work carried out in the laboratory has shown that 
the AKT pathway is active in most of the cell lines studied, particularly the platinum resistant ovarian 
cancer cell lines (PEA2, PEO4, SKOV3). Given that SGK3 is downstream of the PI3K pathway, parallel 
to AKT, and other SGK members share similar substrates to SGK3, it was thought that perhaps the 
other SGK members were compensating for the lack of SGK3. It was previously observed that knocking 
down all members of AKT were needed to see consistent apoptotic effect (Stronach et al, 2011). In light 
of this and to account for any compensatory effects by other SGK members, all three members of the 
SGK family, SGK1, SGK2 and SGK3 were simultaneously knocked down. This too did not significantly 
alter the apoptotic signal in response to chemotherapy treatment. The caspase 3/7 glo assay was used, 
where the induction of caspase 3/7 is used as a marker of apoptosis as caspase 3 plays a key role in the 
initiation of cellular events that result in apoptosis. Caspase 3 and caspase 7 share the same substrate 
(DEVD) so they are usually detected together as it is difficult to differentiate the caspase responsible for 
the cleavage activity. It is possible that perhaps there may have been an apoptotic effect that was caspase 
independent as this assay would not reflect that; this appeared a possibility when we observed decreased 
levels of anti-apoptotic BCL2 with SGK3 knockdown by western blot in PEA1, PEO1 and PEO4 
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(Supplementary figure 3). However, this seems unlikely given that there was no decrease in viability 
observed by MTT assay. If there was a decrease in the MTT assay and no change in the apoptosis assay 
when analysed individually, then there may have been a possibility of an alternative mode of cell death 
such as caspase independent apoptosis or autophagy. Other researchers have observed decreased viability 
with SGK1, thought to be occurring through autophagy (personal communication at conference, V 
Runzuglia), so to address the possibility of autophagy playing a role with SGK3 knockdown, protein 
lysates of SKOV3 and SKUT-1 with SGK3 knockdown and overexpression were probed for autophagy 
marker LC3BI to LC3BII conversion and no change was observed with SGK3 modulation 
(Supplementary figure 4). This result would need further verification however because there is extensive 
literature surrounding the limitations of using LC3 conversion as an autophagy marker.  For example, the 
conversion of LC3BI to LC3BII is an indication of its conjugation to PE and its presence on 
autophagosomes. This is thought to directly correlate with the level of autophagy occurring. However, 
LC3BII can also get degraded by autophagy itself which complicates the interpretation of the data 
(Mizushima and Yoshimori, 2007).  
To fully investigate the role of SGK3 in survival, a potential role for SGK3 in long term survival was 
investigated, as the assays discussed above were used to assess short-term survival. In addition to this, it 
was also important to assess the role of SGK3 in a more specific genotypic context. It is known from 
previous published data that the platinum resistant isogenic cell lines, PEA2 and PEO4 and the resistant 
pancreatic cell line Panc-1 have active AKT so perhaps modulating SGK3 may not have an effect as AKT 
and SGK share functions and substrates. It was important to find a cell line that had high endogenous 
levels of SGK3 and simultaneous low AKT levels. One such ovarian cancer cell line IGROV1 was 
identified and used for further studies. The clonogenic assay was utilised to assess the long-term survival 
with SGK3 knockdown. Interestingly, it was observed that although SGK3 knockdown did not have any 
effect in short-term survival (at 24 or 48 hours) in the IGROV1, it significantly affected long term 
survival, with markedly less colonies forming in the SGK3 knockdown condition. This suggests that 
SGK3 may play a role in proliferation. In light of this finding, we sought to determine the effect that 
SGK3 may have on the cell cycle. This was determined using propidium iodide staining to assess DNA 
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content and flow cytometry analysis. The results showed that modulating SGK3 did not appear to 
significantly affect the cell cycle at any stage in the cell lines studied (IGROV1 and SKOV3).  
The role of SGK3 knockdown in survival has been extensively studied; the effects of overexpression of 
SGK3 on survival were also investigated. As mentioned earlier, one could expect that if SGK3 had been 
involved in poor prognosis, then overexpression of SGK3 would make a sensitive cell line resistant to 
chemotherapy. Interestingly, it was observed that overexpressing SGK3 enhanced survival in all cell lines 
studied. This effect was most significant in the platinum resistant PEA2 cell line compared to the 
sensitive counterpart PEA1 and the SKOV3 untreated, however similar trends were observed across all 
the cell lines. This enhanced survival effect appears to be independent of DNA damage as this effect was 
also observed in the untreated control.  
4.16.2	Role	of	SGK3	in	migration,	invasion	and	adhesion	
We also wanted to know if SGK3 was involved in other phenotypes that may explain its contribution to 
poor prognosis in patients. Several studies have been published that indicate a wide range of functions for 
SGK members, SGK1 in particular is the most well studied SGK and research has indicated a role for 
SGK1 in motility and migration (Lang et al, 2010; Schmidt et al, 2012) in cancers. Recently, SGK3 has also 
been implicated in increased migration in breast cancer (Gasser et al, 2014). However, a role for SGK3 in 
motility in ovarian cancer, pancreatic cancer and sarcomas is currently unknown. To investigate this 
further, wound healing assays were carried out, where transfected cells (with SGK3 overexpression 
constructs) were seeded in cell culture inserts so that all ‘gaps’ created were of equal width (500µm). The 
migration assays showed that cells that overexpressed SGK3 tended to migrate faster than the empty 
vector control. Although all cell lines showed the same trend, this effect was significant and more obvious 
in the resistant PEA2 and SKOV3 ovarian cancer cell line. As the SKOV3 cell line showed the biggest 
effect with SGK3 overexpression, it was selected for further studies. We wanted to show that modulating 
SGK3 by overexpression or knockdown would show either increased or decreased migration respectively 
to show that this was an SGK3 specific effect. Knockdown and overexpression in SKOV3 consistently 
showed significant decreased or increased migration respectively. Migration assays in IGROV1 and Panc-
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1 was attempted, however due to the clustered morphology of the cells, this was not possible as they are 
not ideal cell lines to study motility.  
This finding that SGK3 can modulate the migratory capacity of ovarian cancer cells is a significant result 
because the ability of cancer cells to spread by migrating and invading adjacent tissue resulting in distant 
metastasis is a hallmark of cancer and major contributor to poor prognosis in patients. In epithelial 
carcinomas, cells are organized into multicellular units that are easily distinguished from the surrounding 
stroma. The border of these tumours is typically dominated by collective cell invasion. On the other 
hand, single-cell migration is thought to be the dominant mode of dissemination of tumours whose cells 
migrate constitutively as single cells such as lymphomas and leukaemias (Thiery et al, 2009). However, in 
epithelial tumours, the mode of migration is not restricted to just one type. Each migration type, although 
driven by distinct molecular mechanisms, may transition between each other or undergo conversion to 
the other state; there is a degree of phenotypic plasticity as cells interconvert between individual and 
collective migration.  To assess the role of SGK3 in single cell migration, random migration assays were 
set up to track the path of a single cell, measuring parameters such as displacement, speed, distance, 
velocity and persistence of cells using Fiji software. We observed that overexpression of SGK3 was able 
to increase all the parameters of the single cells with the exception of persistence. Although the difference 
in persistence is not statistically significant, there was a general trend of increased migratory persistence in 
the SGK3 overexpressed cells. This perhaps indicates that SGK3 may contribute towards the EMT 
process, as we know that SKOV3 cells can adopt mesenchymal features depending on the stressor 
(Rohnalter et al, 2015), so it is possible that in the context of single cell motility, SGK3 overexpression 
causes it to behave like a mesenchymal cell, where increased directional persistence is a key phenotype. 
This was also evident in the physical morphology of the single cell, which visually appeared more 
mesenchymal as the time course progressed. Cells that have undergone EMT migrate through the 
environment as a collective front, from which single cells disperse to create micrometastasis. Given that 
single cell migration and collective migration have distinct molecular mechanisms that regulate it, it is 
interesting that SGK3 is able to increase the motility dynamics in both contexts.  
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Given the clear contribution that SGK3 has in promoting migration its role in promoting invasion to 
enable and propagate the metastatic process was explored. To address this, 2D (matrigel Boyden 
chambers) and 3D (spheroid) assays were utilized. It was observed that overexpressing SGK3 
significantly increased 2D migration through matrigel under reduced serum conditions. To investigate the 
invasive process in a more physiological condition, tumour spheroids were grown from SKOV3 cells 
overexpressing SGK3 and the corresponding empty vector control and following spheroid formation, 
matrigel was added to the wells and the invasion was assessed by the ability of the spheroids to invade 
through the matrigel over a 24-hour incubation period. The 3D assay explores the role of ECM 
architectures in important processes like invasion and often 2D assays do not translate when the 
microenvironment and other physiological conditions are taken into consideration. We visually observed 
a clear difference with SGK3 overexpression, where the spheroids were able to invade through the 
matrigel more than the empty vector control; the outline of the cells sprouting is visible in the SGK3+ 
condition, which is clearly absent in the empty vector control. Ideally, the assay would have continued 
beyond 24 hours; this was attempted at 48 and 72 hours, however the spheroids were dying post 24 hours 
due to serum starvation followed by reduced serum conditions that were required of the assay. Also, 
given the transient nature of the transfection, 24 hours after matrigel addition was the ideal time point to 
ensure SGK3 was still being overexpressed and the cells were not dying.  Interestingly, the SGK3 
overexpressed cells always tended to form smaller spheroids compared to their control counterparts. 
Also, particularly in the SK-UT-1 cell line, the spheroids in the empty vector tended to have lots of dead 
cells as evident in figure 37D where the cells breaking away are indicative of cell death based on their 
morphological features; this is clearly less visible in the SGK3 overexpressed, in keeping with the idea 
with SGK3 overexpression enhances survival as seen with the apoptosis assays. This assay was attempted 
in other cell lines such as IGROV1 and Panc-1, however they either failed to form spheroids or formed 
very loose spheroids, which when matrigel was added, dispersed the cells and so the assay could not be 
completed.  
In addition to migration and invasion, cell adhesion also plays an important role in the metastatic process. 
The metastatic behaviour of cancer cells is thought to be dependent partly on the cell’s ability to adhere 
to host tissue structures such as adjacent stromal tissues and endothelial cells (Terranova et al, 1986). The 
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adhesive capacity of cells and the expression of cell adhesion proteins such as laminin and fibronectin can 
be modulated by various components. To see if SGK3 is one such component, adhesion assays were set 
up to determine the role of modulating SGK3 on adhesion to collagen I, a major component of the 
extracellular matrix (ECM). We observed that overexpression of SGK3 significantly increased cell 
adhesion to collagen I in several ovarian cancer cell lines studied; this effect was specific to the collagen 
coating as we observed that no cells were able to adhere in the uncoated wells, presumably due to the 
short incubation time (30 minutes). We also observed SGK3 knockdown cells decreased SKOV3 cells 
ability to adhere to collagen I. Although we observed that modulating SGK3 significantly altered the 
adhesive capability of the cell, is it known that cells may preferentially use one particular 
adhesion/migration mechanism, dependent on the environmental conditions. Consequently, it would be 
interesting to see the effects (if any) SGK3 modulation would have on other ECM components such as 
laminin, fibronectin and collagen IV. It has already been shown that PI3K pathway modulates adhesion 
to collagen IV, which is the primary collagen component of the basement membrane (Matsuoka et al, 
2012). They proposed that this was occurring through AKT signaling and also show that inhibition of the 
PI3K pathway using LY294002 prevented this effect on adhesion. Here, it is more specifically shown that 
modulating SGK3, also downstream of the PI3K pathway affects the ability of cells to adhere to an ECM 
component, collagen I.  
To further show that the effects being observed are specific to SGK3 and to see if this effect was 
dependent on a particular phosphorylation site, site-directed mutagenesis studies were carried out, where 
the two main phosphorylation sites required for SGK3 activation, Serine at 486 (S486) and Threonine at 
320 (T320) were mutated to generate constitutively active site and null function sites. It was observed that 
SGK3 may have opposing effects on migration dependent on the phosphorylation status of each of the 
sites. Mutating the S486 site gave unexpected results; it was anticipated that constitutively active forms of 
the SGK3 phosphorylation sites would mimic, if not enhance the phenotypes seen with the SGK3wt 
construct, it was observed that a constitutively active form of S486 prevented the increased migration 
seen with the SGK3wt construct and the S486 inactive construct enhanced migration more than the 
SGK3wt (figure 39A). Whereas the T320 mutant construct showed that the constitutively active form 
resulted in increased migration compared to the empty but not quite to the same level as the SGK3wt 
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suggesting that other other factors may be necessary to mimic the SGK3wt result. The SGK3-T320 
inactive construct however slowed the migratory capacity of the cells, returning it to the same level as the 
SGK3wt construct (figure 39B). Focusing on the S486 site, similar effects were observed when studying 
adhesion to collagen I, where the S486 constitutively active site reduced adhesion, whereas the S486 
inactive mutant resulted in the same fold increase in adhesion as the SGK3wt (Supplementary figure 5). 
This data collectively suggests that SGK3, when phosphorylated at the S486 phosphorylation site, may act 
to suppress the migratory and invasive effects.  The exception to this was the single cell migration 
analysis, where the constitutively active S486 increased the displacement, velocity, speed and distance 
travelled, similar to the SGK3wt compared to the empty vector control. The inactive S486 behaved like 
the empty vector with respect to quantification of the single cell tracking using the mentioned parameters 
(Supplementary figure 6). This is plausible as collective and single cell migration have distinct molecular 
mechanism that although might overlap, still remain distinct mechanisms.  
4.16.3	Possible	mechanisms	behind	SGK3	modulation	of	migration,	invasion	and	adhesion	
Given that it is now established that SGK3 can modulate migratory, invasive and adhesive phenotypes, 
which are all important processes in metastasis, it was important to investigate what signalling cascades 
resulted in this phenotype. The involvement of PI3K pathway via AKT/PKB in modulating tumour 
migration and invasion is known (Kim et al, 2001; Xu et al, 2013; Li et al, 2015). Furthermore, reports 
show that a chemokine receptor-ligand CXCR4-CXCL12 signalling axis promotes tumour invasion and 
EMT by inducing AKT phosphorylation (Lv et al, 2015), however very little is known about SGK3. As 
mentioned before, the CXCR4-CXCL12 signalling axis is well known in promoting invasion and 
migration (Guo et al, 2015) and its overexpression correlates with metastatic potential of tumour cells 
(Balkwill, 2004). Consequently, overexpression of CXCR4 is associated with poor outcome in a number 
of cancers (Otsuka et al, 2011; Zhao et al, 2015). An E3 ubiquitin ligase, AIP4, has been suggested to be 
involved in controlling the degradation of membrane-bound receptors, including CXCR4 by targeting it 
for lysosomal degradation and in fact, its degradation was dependent on AIP4 activity (Marchese et al, 
2003a, 2003b). The characteristic PX domain of SGK3 results in its endosomal location, where it is 
activated and it has been reported that SGK3 co-localises and interacts with AIP4 and consequently 
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attenuates its function as an E3 ubiquitin ligase (Slagsvold et al, 2006). It was therefore hypothesized that 
SGK3 was mediating its migration and invasion effect through CXCR4. These studies were initiated by 
first showing that AIP4/CXCR4 and SGK3 interact, using immunoprecipitation studies.  The studies 
focused primarily on the IGROV1 cells as opposed to SKOV3, which were primarily utilized for all other 
studies because they had high endogenous SGK3 levels, so higher levels were immunoprecipitated in 
IGROV1 to assess protein interactions, with the results showing that SGK3 did interact with CXCR4.  
 To investigate this further, AIP4 was knocked down in the first instance. The rationale behind this was 
that AIP4 knockdown cells would migrate at a rate similar to SGK3wt overexpression as knockdown of 
AIP4 would result in more CXCR4 expression as a result of decreased targeting of CXCR4 for lysosomal 
degradation. From the migration assays, it was observed that AIP4 knockdown resulted in a faster 
migration rate compared to non-targeting control as did the SGK3wt overexpression compared to the 
empty vector (figure 41A), which had similar migration rates to the non-targeting so it was a fair 
comparison between the two transfections. The difference in migration rates between the AIP4 
knockdown and SGK3wt overexpression is not surprising because there will be other mechanisms at 
play, which regulate CXCR4 expression such as HER2 overexpression, which will be discussed in detail 
further on.  
It was then hypothesized that knocking down AIP4 in combination with SGK3wt overexpression should 
increase migration faster than either transfection alone because both scenarios result in increased CXCR4 
expression, and as expected, combining the two transfections did increase the the rate of migration 
compared to the two individually. The graph in figure 41B shows the empty vector and the non-targeting 
controls; a combination of both the controls were also included in the experiment and they behaved 
similar to the two controls alone so for simplicity this was not added to the graph due to the number of 
conditions already on the graph. Although these experiments were not statistically significant, this was 
due to scale variation between experiments, even though similar trends were observed in each 
experiment.  
As the experiments with AIP4 appeared to follow our hypothesis, CXCR4 was then knocked down using 
siRNA. The resulting lack of CXCR4 should slow down migration if these phenotypes are being 
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implemented through the CXCR4-CXCL12 signalling axis. The results indicate that knockdown of 
CXCR4 does slow down migration when compared to the SGK3wt overexpression. However, there 
appears to be a noticeable difference between the behavior of the two siRNAs used in this study (figure 
42A). This could be due to transfection efficiency differences between the two oligonucleotides, however, 
the siRNA (#8) that is slowing down the migration rate most effectively has less knockdown compared 
to the other siRNA (#7) when compared on a western blot (figure 42B). For more clinical relevance, a 
specific CXCR4 inhibitor, AMD3100 was utilized for these studies. Interestingly, AMD3100 treatment 
slowed down migratory capacity of SKOV3 cells compared to the SGK3wt overexpressed cells, returning 
the migration rate to levels comparable with the empty vector control. Additionally, it was also observed 
that treating the empty vector control with AMD3100 increased migration compared to the untreated 
empty vector control, though not to the same level as SGK3wt overexpression. This could be due to 
ineffective CXCR4 inhibition in the empty vector condition as is visible in the western blot in figure 43B.  
Collectively, the data indicates that SGK3 is modulating increased migration and possibly invasion at least 
in part through the CXCR4-CXCL12 signalling axis because inhibiting this pathway does adversely affect 
the rate of migration, however there are likely other pathways through which SGK3 is modulating these 
phenotypes as inhibiting the CXCR4 pathway did not result in complete impairment of the migratory 
capacity of the cells.  
Although all reports propose a role for AIP4 in regulating proteosomal degradation of CXCR4 protein, a 
role for SGK3 was also thought to be entirely due to its positive regulation of CXCR4 protein by 
preventing its degradation. However interestingly, it has been observed that both SGK3 and AIP4 appear 
to regulate CXCR4 at transcriptional level too. It is observed that SGK3 overexpression increases 
CXCR4 mRNA level in addition to protein level (figure 44C) and knockdown of AIP4 also appears to 
decrease CXCR4 levels however this effect is not significant (Supplementary figure 7).  
4.16.4	Role	of	SGK3	in	transcriptional	regulation	of	EMT	markers	
These studies focused on the role of SGK3 in regulating several proteins and how it may affect the 
degradation of key effectors of invasion and migration. To address if SGK3 was also involved in the 
transcriptional regulation of any markers of EMT, qPCR analyses was undertaken. The results showed 
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that SGK3 does indeed significantly transcriptionally regulate several EMT markers such as fibronectin, 
slug, snail, b-catenin and E-cadherin, though perhaps not in the way that would be expected. SGK3 
overexpression results in loss of E-cadherin, which is known to be a critical step in inducing EMT. This 
decrease in E-cadherin could be occurring through FOXO3a, which is known to downregulate E-
cadherin expression during EMT (Belguise et al, 2007); an increase in FOXO3a protein levels are 
observed with SGK3 overexpression (Supplementary figure 8), so perhaps this promotes E-cadherin 
downregulation. N-cadherin mRNA expression was also assessed as this should increase due to the 
cadherin switch during EMT, but there appeared to be no significant change with SGK3 overexpression 
(Supplementary figure 9). Snail was also upregulated, which is another marker that is upregulated during 
EMT. E-cadherin loss is usually accompanied by b-catenin loss, and b-catenin is also thought to play a 
crucial role in the onset and progression of EMT.  Given that loss of E-cadherin was observed with 
SGK3 overexpression, one would expect for b-catenin levels to decrease too as a marker of the onset of 
EMT, as reported by Cai et al, 2014 and Lv et al, 2015 and indeed it does significantly decrease too with 
SGK3 overexpression.  
 
A significant decrease in fibronectin mRNA expression was also observed, which was unexpected given 
other findings supporting the role of SGK3 in promoting EMT. Fibronectin (FN1) is considered a 
mesenchymal marker and is generally thought to be upregulated during EMT. FN1 downregulation in 
cancer cells can occur with FN1 induction in tumour-associated stroma cells at the same time. The 
presence of leukocytes in the perimeter of a tumor may suggest a direct role in invasion and migration as 
the dislodgement of intercellular contacts between carcinoma cells mediated by FN1 suppression could 
accelerate cellular migration and metastasis (Beier et al, 2007). There are reports on both stimulatory and 
inhibitory effects mediated by FN1 so this downregulation observed at mRNA level should be 
interpreted with caution. In order to corroborate this data, the RPPA results generated were interrogated 
to see if the effects observed at mRNA level correlated at protein level. Information for b-catenin, E-
cadherin and slug were available within the dataset, however the effects observed here were not seen at 
protein level within the RPPA dataset (discussed in the next section) in the SGK3 overexpressed 
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condition compared to the empty vector control further emphasizing that these results should be 
interpreted with caution and perhaps further work addressing this is required before conclusions can be 
drawn.  
4.16.5	RPPA	analysis	
In order to consider the broader signaling effects following SGK3 overexpression, reverse-phase protein 
arrays were carried out, looking for differences between SGK3 overexpression compared to the empty 
vector control. The proteins studied focused on PI3K signalling and some apoptosis/EMT mediators. 
Although most of the candidate proteins modulated were not statistically significant, this was more due to 
variations in the up-regulation fold change between each experiment despite each experiment showing at 
least a 1.2-fold change, therefore due to consistent high expression compared to the control in each 
experiment, these were included. At 0h baseline, prior to serum stimulation, several proteins are 
upregulated in the SGK3 overexpressed condition. Of interest are the top 3 overexpressed proteins 
phospho-Myosin-IIa-S1943, HES1 and connexin-43. 
 Myosin-IIa has been implicated in increasing invasiveness and motility in poor prognosis tumours. 
Myosin II has different isoforms, where switching occurs (not too dissimilar from the cadherin switching 
during EMT). For example, in breast cells, Myosin IIc tends to be expressed in luminal cells, whereas 
Myosin IIb tends to be up regulated in myoepithelial cells, which tend to have more mesenchymal 
characteristics. It is thought that TGFb induced EMT results in an isoform switch from Myosin IIc to 
Myosin IIb and increased phosphorylation of myosin heavy chain IIa on sites known to regulate filament 
dynamics (S1916, S1943). This transition is thought to be a critical stage in EMT and contributes to 
increased invasive behavior (Beach et al, 2011). It was proposed that phosphorylation of Myosin IIa 
results in redistribution of myosin II from posterior to anterior regions, where it can facilitate adhesion 
and alter cell invasion capability. It is also thought that Myosin II represents a point of convergence of 
signal transduction pathways that drive glioma invasion so it is possible that the same applies to ovarian 
and pancreatic cancer. Many studies discuss the role of myosin II isoform switching during TGFb 
induced EMT; the PI3K pathway is a known non-smad pathway contributing to TGFb induced EMT 
and is also thought to regulate TGFb/activin signalling (Zhang et al, 2009), so perhaps SGK3 serves as a 
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mediator in regulating these crosstalks between the two pathways, in a manner similar to that proposed 
for mTORC2 by Yu et al, 2015.  
HES1 (hairy enhancer of split-1) is a transcriptional target of the Notch pathway and its expression 
correlates with activated Notch. However, its expression is not restricted to the Notch pathway as it can 
be elevated by other signals such as Hedgehog, Ras and MAPK pathways (Stockhausen et al, 2005; 
Ingram et al, 2008) Various roles have been proposed for HES1 in different tumour types, from 
promoting proliferation in rhabdomyosarcoma (Ramskold et al, 2012) to promoting invasion by 
suppressing the metastasis inhibitor Deltex1 in osteosarcoma (Zhang et al, 2008) and through the STAT3-
MMP14 pathway in colorectal cancer (Weng et al, 2015). Additionally, HES1 has been reported to be a 
bad prognostic marker in medulloblastoma and ovarian cancer.  
Connexin-43 also is associated with promoting invasion and migration in several tumour types such as 
prostate cancer (Zhang et al, 2015), gliomas (Lin et al, 2002) and breast cancer (Stoletov et al, 2013) and 
have been suggested as a therapeutic target to benefit patients with metastatic disease. High expression of 
connexin 43 has also been associated with poor progression free survival in invasive urothelial bladder 
cancer (Poyet et al, 2015).   
When analyzing the RPPA dataset at 30 minutes after serum stimulation, interestingly, Myosin-IIa-pS1943 
was the most differentially upregulated protein along with epithelial membrane antigen (EMA) also 
known as MUC1. It is aberrantly expressed in majority of breast carcinomas and is known to interact with 
b-catenin, HER2 receptors and GSK-3b in a  complex that promotes disassembly of adherens junctions 
and the invasion of cells (Schroeder et al, 2003). Consequently the interactions between MUC1 and b-
catenin are higher in metastatic tumours. Other reports have also suggested that MUC1 promotes 
migration and invasion of hepatocellular carcinoma (HCC) cells via JNK-mediated phosphorylation of 
SMAD2 (Wang et al, 2015).  
Other proteins upregulated included Syk, which is an interesting protein because it has pleiotropic effects 
dependent on the isoform activated.  The two isoforms in question are Syk (S) and Syk (L). Syk (S) 
promotes EMT and enhances invasiveness, whereas Syk (L) inhibits metastasis in HCC (Hong et al, 2014). 
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Some reports have also implicated Syk in cell motility and progression of squamous cell carcinomas of the 
head and neck, where high Syk expression significantly correlated with poor survival in these patients 
(Luangdilok et al, 2007).  
Next, the fold changes between the time points for each condition (i.e. SGK3 overexpressed and empty 
vector control) were examined to account for serum-independent changes, however the primary goal of 
this experiment was to assess signalling changes with SGK3 overexpression irrespective of serum 
dependent/independent changes. Interestingly, it was observed that the although no proteins were 
upregulated with a significant fold change difference, the majority of the top targets were those implicated 
in either motility, invasion or collectively EMT (such as vimentin, rheb, fibronectin). Also, Myosin IIa-
pS1943 was again the top candidate on the list, suggesting that although further validation is needed, 
there is a high possibility that this protein and its specific phosphorylation site is important in facilitating 
the role SGK3 has in poor prognosis. Another interesting protein that was highlighted in this analysis was 
pAKT-T308 which was upregulated with SGK3 overexpression, suggesting that the AKT pathway and 
SGK pathway may have complementary roles as effectors of PI3K.  
Collectively, the RPPA has highlighted several upregulated proteins with SGK3, most of which have roles 
in migration, invasion and promoting metastasis and EMT in some tumours. This reinforces the theory 
for the potential role of SGK3 in mediating these processes in ovarian and pancreatic cancer. Although 
these analyses comprised of three independent biological experiments, further functional validations are 
required to assess the roles these proteins have with respect to SGK3 and the signalling cascade that 
follows. However, as a perspective, it endorses SGK3 involvement in metastatic processes. In particular, 
it would be interesting to investigate myosin-IIa-pS1943 and assess its precise role with SGK3; as 
mentioned before, perhaps there is a feedback loop given the existing known crosstalk between TGFb 
signalling and PI3K, where SGK3 phosphorylates phosphor-myosin-IIa-S1943 as its upregulation at the 
protein level correlates with SGK3 overexpression in any context of analysis.  
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4.16.6	Summary	
Overall, the data presented here indicates that SGK3 plays a role in regulating invasive and migratory 
phenotypes, promoting metastasis and EMT. This is likely occurring in part through the transcriptional 
regulation of EMT markers by SGK3 and partly through the CXCR4-CXCL12 signalling axis, through 
SGK3 positively regulating its protein levels and potentially mRNA too. Processes that govern metastasis 
and EMT require a convergence and crosstalk between several key pathways such as the PI3K/b-
catenin/MAPK pathways so it is unsurprising that we do not yet have a full picture of all the interactions 
between SGK3 and other mediators but some are becoming apparent. For example, from the knowledge 
that SGK and AKT family have similar functions and substrate specificities, coupled with the observation 
of upregulation of pAKT with SGK3 overexpression in the RPPA indicates that they work 
complementarily. There are possible links between complementary functions between HER2 and SGK3 
too. As mentioned earlier, SGK3 is able to prevent loss of CXCR4 (presumably through inhibition of 
ubiquitination and subsequent proteosomal degradation) thus allowing the CXCR4 signalling cascade to 
continue. Similar mechanisms have been proposed for HER2, where it has been suggested that CXCR4 
overexpression is mediated by HER2 overexpression and HER2 activates the PI3K pathway causing 
enhanced translation of CXCR4 mRNA via the activation of PDK1 and AKT/PKB (Li et al, 2004; 
Slagsvold et al, 2006). Given that we see upregulation of CXCR4 mRNA with SGK3 overexpression too, 
it is possible that perhaps HER2 is involved in mediating this process. Additionally, HER2 is also known 
to inhibit ubiquitin-dependent lysosomal degradation of CXCR4 by a mechanism that remains to be 
characterized (Li et al, 2004). This might again suggest a role for HER2 and SGK3 to work 
complementarily.  
Although the data generated here clearly shows a role for SGK3 in metastasis, there are some limitations 
within the study that need to be considered. For example, bulk of the work in elucidating the role of 
SGK3 was carried out in SKOV3 cells. SKOV3 cell lines have come under scrutiny in the last few years 
with several studies suggesting that they may be a poor choice to model HGSOC because they do not 
resemble HGS tumours at a molecular level (Domcke et al, 2013; Cunnea and Stronach, 2014). However, 
they are still accepted as a useful cell line to study ovarian cancer and furthermore harbor an activating 
PIK3CA mutation and so would be relevant to this studies. It would be useful to carry out these studies 
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in other more appropriate cell line models that reflect the biology of HGS tumours more accurately. 
Additionally, with respect to the experiments conducted, it would be beneficial in the future to use 
CRISPR genome editing to knock out SGK3 and subsequently knock in the mutant forms of SGK3 to 
decipher the role of SGK3 without any endogenous SGK3 affecting the results. This may possibly 
enhance the clear effects already being observed with SGK3 modulation.  
Overall, there is compelling evidence to suggest that inhibiting SGK3 may have potential to inhibit the 
metastatic process; this is very important and may prove especially beneficial for tumours such as ovarian 
cancer, which is typified by peritoneal dissemination, which is the primary cause of poor prognosis.  
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CHAPTER	5:	DNA-PKCS	INHIBITION	RESTORES	SENSITIVITY	TO	
DOXORUBICIN:	A	POTENTIAL	THERAPEUTIC	STRATEGY	IN	
PLATINUM	RESISTANT	PATIENTS	
5.1	Introduction	and	Aims	
DNA-PKcs is a serine/threonine kinase that plays an important role in the DNA damage response and in 
maintaining genome stability. Its expression is thought to correlate with poor response to DNA-
damaging agents in a range of cancers implicating it as a survival mechanism in tumours. Work in the 
laboratory has shown that DNA-PKcs amplification is associated with poor prognosis in ovarian cancer 
patients (unpublished data). DNA-PKcs was also shown to promote metastatic phenotypes such as 
invasion and migration and its inhibition delays the formation of metastasis in vivo (Goodwin et al, 2015).  
DNA-PKcs inhibition has also been shown to resensitize platinum resistant cells to cisplatin treatment 
via AKT inhibition (Stronach et al, 2011) as it activates AKT by phosphorylation at S473 residue. The 
mechanism of resensitization is thought to occur through inhibition of AKT-mediated BAD 
phosphorylation. DNA-PKcs also undergoes autophosphorylation, which is thought to be an important 
mechanism in maintaining its activity (Meek et al, 2007). The relationship between DNA-PKcs 
autophosphorylation and AKT phosphorylation at S473 has not yet been elucidated. 
The aims of this chapter are to understand if DNA-PK phosphorylation predicts AKT phosphorylation 
in response to DNA damage, initially by using cisplatin, and then expanding the investigations to other 
DNA damaging agents such as doxorubicin and gemcitabine. The broader effects of DNA-PKcs in 
mediating poor prognosis and its therapeutic potential will also be investigated.   
5.2	DNA-PKcs	autophosphorylation	occurs	with	cisplatin	and	gemcitabine	
treatment	in	a	time-dependent	manner	
To address if DNA-PKcs autophosphorylation predicts phosphorylation to AKT at S473, isogenic paired 
cell lines PEA1 (platinum sensitive) and PEA2 (platinum resistant) were treated with DNA damaging 
agents such as cisplatin (25µM), doxorubicin (1.5µM) and gemcitabine (10µM) over a time course of 1 
hour, 4 hours, 8 hours and 24 hours. At every time point, protein lysates were collected to run on a 
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western blot to probe for pDNA-PKcs at S2056, which is thought to be the autophosphorylation site for 
DNA-PKcs and pAKT at S473, which DNA-PKcs phosphorylates.  
The results showed that as previously described in Stronach et al, 2011, pAKT S473 was only detected in 
the resistant PEA2, in keeping with the observation that the activation of AKT is a resistance specific 
mechanism. pDNA-PKcs increases in a time dependent manner in the PEA1 cell line. The expression of 
pDNA-PKcs is present in equal amounts at each time point in the PEA2 in both the control and cisplatin 
treated cells; this correlates with consistent pAKT S473 expression in the PEA2 at 4, 8 and 24hours with 
cisplatin treatment (figure 45).  
Similar to cisplatin treatment, treating cells with gemcitabine (10µM) showed AKT activation (determined 
by pAKT S473 expression) only in the resistant PEA2 cells with a decrease in expression at 8 hours in 
both the untreated and treated samples. pDNA-PKcs expression however increases in a time dependent 
manner with it peaking at 24 hours in the gemcitabine treated samples. There is slight expression in the 
untreated samples, however the expression appears more prominent in the gemcitabine treated samples. 
Additionally, although pDNA-PKcs is also present in both the PEA1 and	PEA2 gemcitabine treated cells, 
it is more prominent in the resistant PEA2 cells (figure 46). There does not appear to be a correlation 
between the pDNA-PKcs and pAKT S473 expression in the gemcitabine treated cells.  
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Figure 45 pAKT473 is activated in resistant PEA2 cell line in response to cisplatin 
treatment.  
PEA1 and PEA2 cell lines were treated with cisplatin (25µM) and protein collected at 1h, 4h, 8h and 24h and run on a 
western blot at the same time to probe for pDNA-PKcs S2056 and pAKTS473. Vinculin was used as loading control. 
This is a representation of two independent experiments.  
 
 
 
	
	
	
	
	
Figure 46: pAKT S473 is activated in resistant PEA2 cell line in response to gemcitabine 
treatment. 
PEA1 and PEA2 cell lines were treated with gemcitabine (10µM) and protein collected at 1h, 4h, 8h and 24h and run 
on a western blot to probe for pDNA-PKcs S2056 and pAKTS473. Vinculin was used as loading control. This is a 
representation of two independent experiments.  
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Interestingly, with doxorubicin treatment, there was an induction of pAKTS473 in the sensitive PEA1 
cells, which was not previously observed with other DNA damaging agent treatments. Both the pAKT 
and pDNA-PKcs expression increased with increasing time, with it peaking at 24 hours in the PEA1 cells. 
In the PEA2 cells, there was a strong induction of pDNA-PKcs at all time points; the expression was 
slightly higher at 24hours with doxorubicin treatment. However, interestingly, a time-dependent decrease 
was observed in pAKT expression, with its expression nearly diminished at 24 hours with doxorubicin 
treatment despite strong pDNA-PKcs signal observed at the same time point (figure 47).  
	
	
	
	
	
	
	
	
	
 
 
Figure 47: pAKTS473 expression decreases in resistant PEA2 cell line in response to 
doxorubicin treatment in a time-dependent manner.		
PEA1 and PEA2 cell lines were treated with doxorubicin (1.5µM) and protein collected at 1h, 4h, 8h and 24h and run 
on a western blot to probe for pDNA-PKcs S2056 and pAKTS473. Vinculin was used as loading control.  
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5.3	DNA-PKcs	inhibition	significantly	sensitizes	cells	to	doxorubicin	treatment	
Given the interesting result observed with the doxorubicin treated cells in figure 47, isogenic paired cell 
lines PEA1 and PEA2 were treated with doxorubicin in combination with a DNA-PKcs inhibitor, 
NU7441 to assess if DNA-PKcs inhibition would affect sensitivity to doxorubicin treatment. To address 
this, cells were treated with NU7441 (10µM) and incubated for an hour prior to the addition of 
doxorubicin for a further 24 hour incubation. Apoptosis assays were utilised and data was presented as an 
induction of caspase 3/7 activity normalized to cell viability, assessed by MTT assay. The results showed 
that treating cells with NU7441 in combination with doxorubicin significantly sensitized cells to 
doxorubicin inducing up to 60-fold induction in apoptosis in some cell lines such as PEA2 (figure 48A). 
This was representative across all ovarian cancer, pancreatic cancer and sarcoma cell lines studied. Based 
on previous work carried out in the laboratory, inhibition of DNA-PKcs sensitized cells to cisplatin 
treatment and this was thought to be due to inhibition of AKT activation, mediated by DNA-PKcs 
phosphorylation of AKT S473. Inhibition of AKT using a pan-AKT inhibitor, API-2, also produced the 
same sensitization effect. However, inhibition of DNA-PKcs with NU7441 in combination with 
doxorubicin treatment resensitizes cells to a much greater degree than observed with cisplatin treatment, 
suggesting other mechanisms may contribute to this phenotype observed. To investigate if the 
sensitization effect of the doxorubicin combination with NU7441 was due to inhibition of the AKT 
pathway, the doxorubicin and API-2 (AKT inhibitor) combination was also assessed within the same 
experiment. Interestingly, when cells were treated with doxorubicin and API-2, the cells did not sensitize 
to doxorubicin to the same degree, suggesting that the doxorubicin-mediated resistance is modulated by 
DNA-PKcs but through an AKT-independent mechanism. Additionally, when studying the isogenic 
paired cell lines PEA1 (platinum sensitive) and PEA2 (platinum resistant) and a second pair, PEO14 
(platinum sensitive) and PEO23 (platinum resistant) the resistant cells were more sensitive to DNA-PKcs 
inhibition, however this did not appear to be a resistance specific mechanism because similar results were 
also observed in cells that were relatively sensitive to doxorubicin treatment such as MiaPaCa cells 
(p=<0.005) (figure 48H). Cell lines studied included PEA1/PEA2 (p=<0.05) (figure 48A), 
PEO14/PEO23 (p=<0.005) (figure 48B), SKOV3 (p=<0.0001) (figure 48C), IGROV1 (p=<0.0001) 
(figure 48D), OVCAR4 (p=<0.0003) (figure 48E), pancreatic cancer cell lines, Panc-1 (p=<0.005) (figure 
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48F), Aspc1 (p=<0.0005) (figure 48G), TKCC6 (p=<0.0036) (figure 48I), CS1 (p=<0.005) (figure 48J) 
and sarcoma cell line, SK-UT-1 (p=<0.05) (figure 48K). There was a response with API-2 in combination 
with doxorubicin in the SK-UT-1 cells, however the effect was not as striking as with NU7441.  
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Figure 48: DNA-PKcs inhibition significantly sensitizes cells to doxorubicin treatment. 	
Apoptosis assay presented as a fold change in caspase 3/7 induction normalised to cell viability assessed by MTT. Cells 
were treated with either NU7441 at 10µM or API-2 at 20µM and incubated for 1 hour prior to doxorubicin treatment. 
Then, cells that were receiving combination treatment were treated with 1.5µM doxorubicin and incubated for 24h. 
Combination treatment significantly induced apoptosis in PEA1/PEA2 (p=<0.05) (A), PEO14/PEO23 
(p=<0.005) (B), SKOV3 (p=<0.0001) (C), IGROV1 (p=<0.0001) (D), OVCAR4 (p=<0.0003) (E), Panc-1 
(p=<0.005) (F), Aspc1 (p=<0.0005) (G), MiaPaCa (p=<0.005) (H), TKCC6 (p=<0.0036) (I), CS1 
(p=<0.005) (J), SK-UT-1 (p=<0.05) (K). Statistical significance was determined using Student’s t test, where p=<0.05 
was considered significant. 	 	
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5.4	DNA-PKcs	knockdown	by	siRNA	sensitizes	platinum	resistant	PEA2	cells	to	
doxorubicin	treatment	
The effect of inhibiting DNA-PKcs by NU7441 treatment in combination with doxorubicin treatment 
has been clearly demonstrated. To establish a mechanism behind this effect, given that it appears to be 
AKT-independent, further functional studies were carried out. Initially, DNA-PKcs was knocked down 
using siRNA as it was important to ascertain whether this was indeed a DNA-PKcs specific effect. 
Isogenic paired cell lines PEA1 and PEA2 were utilised for this study. Knocking down DNA-PKcs 
sensitized platinum resistant PEA2 cells to doxorubicin treatment when assessed using the caspase 3/7 
glo assay normalised to viability using MTT assay, however the induction in apoptosis was an 8-fold 
increase in apoptosis as opposed the 60-fold increase seen with the doxorubicin and NU7441 
combination, suggesting that although part of the effect observed may be mediated by DNA-PKcs, there 
may be other mediators causing the effects observed (figure 49A). There was no significant change in 
knocking down DNA-PKcs in the PEA1 cells with doxorubicin treatment. SKOV3 cells, which had 
DNA-PKcs stably knocked down using shRNA along with the empty vector were also utilised. Similar to 
the PEA2, there was a slight effect, although to a much smaller scale with a 1.8-fold increase in apoptosis 
with doxorubicin treatment in the DNA-PKcs shRNA cells compared to the empty control (figure 49B). 
There was further induction in apoptosis when the cells were treated with NU7441, suggesting that the 
effects being observed are possibly due to off-target effects of NU7441.  Knockdowns were confirmed at 
protein level as detailed in figure 49C.  
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Figure 49: Knockdown of DNA-PKcs sensitizes cells to doxorubicin treatment but doesn’t 
account for the effects observed with DNA-PKcs inhibition using NU7441.		
PEA1 and PEA2 cells were transfected with 25nM pooled DNA-PKcs siRNA and following 48 hour transfection, cells 
were re-seeded and treated with doxorubicin at 1.5µM for 24 hours before assay was conducted (A). SKOV3 DNA-PKcs 
shRNA were generated in the lab and the cells were treated with doxorubicin at 1.5µM and NU7441 at 10µM, along 
with the empty vector control. Statistical significance was determined using student’s t-test with p= <0.05 being considered 
significant. 	  
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5.5	NU7026	does	not	sensitize	ovarian	and	pancreatic	cells	to	doxorubicin	to	
the	same	extent	as	NU7441	
To further confirm if the effects being observed were DNA-PKcs independent, another DNA-PKcs 
inhibitor, NU7026, which is thought to be more selective for DNA-PKcs (Mould et al, 2014) was utilised. 
Similar to NU7441, NU7026 was pre-incubated for an hour prior to treatment with doxorubicin for 24 
hours before the apoptosis assay.  The results show that NU7026 does sensitize some cell lines such as 
the ovarian cancer cell line SKOV3 (p = <0.005), PEA1 (p=0.008) and sarcoma cell line SK-UT-1 
(p=<0.0001) to doxorubicin, however the effect is more comparable to that seen with DNA-PKcs 
knockdown with siRNA rather than the doxorubicin and NU7441 combination treatment. This effect is 
not seen in all cell lines, with there being no advantage in combining NU7026 with doxorubicin 
pancreatic cancer cell line, Panc-1. As seen in previous data, there was significant sensitization observed 
with the doxorubicin and NU7441 combination in PEA1, PEA2 (p=<0.0001) (figure 50A), SKOV3 
(p=<0.005) (figure 50B), Panc-1 (p=<0.0001) (figure 50C), and SK-UT-1 (p=<0.0001) (figure 50D). This 
was independent of AKT, with the exception of SK-UT-1. 
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Figure 50: NU7026 in combination with doxorubicin increases apoptosis induction, however 
not as effectively as NU7441.  
Apoptosis assay presented as a fold change in caspase 3/7 induction normalised to cell viability assessed by MTT. Cells 
were treated with either NU7441 at 10µM or NU7026 at 10µM or API-2 at 20µM and incubated for 1 hour prior to 
doxorubicin treatment. Then, cells that were receiving combination treatment were treated with 1.5µM doxorubicin and 
incubated for 24 hours before the assays. Combination of NU7441 with doxorubicin treatment significantly induced 
apoptosis in PEA1 and PEA2 (p=<0.005) (A), SKOV3 (p=<0.005) (B), Panc-1 (p=<0.0001) (C) and SK-UT-1 
(p=<0.0001) (D). Statistical significance was calculated using Student’s t-test. 	  
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5.6	Novel	DNAPK	inhibitor	(DNAPKi)	treatment	in	combination	with	doxorubicin	
is	an	effective	treatment	in	ovarian	cancer	
To further test if inhibiting DNA-PKcs is beneficial with doxorubicin treatment, other novel DNA-PK 
inhibitors (DNA-PKi) that were synthesised in-house or some obtained commercially were tested in 
combination with doxorubicin treatment. Cells were treated with the DNA-PKi including NU7441 and 
NU7026 for comparison and incubated for 1 hour prior to doxorubicin treatment for 24 hours. The 
results indicated that combining almost every single DNA-PKi studied increased sensitivity to 
doxorubicin by at least 2-fold in both PEA1 and PEA2 cells. The most effective combination was the 
NU7441 with doxorubicin in both PEA1 and PEA2 (both p=<0.005) (figure 51). Interestingly, DNAPKi 
4 also had a significant response with doxorubicin in the PEA2, however it was also toxic as a single 
agent treatment. The other DNAPKi also induced moderate responses when combined with doxorubicin 
which would indicate a benefit in combining a DNA-PK inhibitor with doxorubicin, particularly in 
chemoresistant disease.  
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Figure 51: Several DNAPK inhibitor shows effectiveness in using it in combination with 
doxorubicin in ovarian cancer.  
Apoptosis assay presented as a fold change in caspase 3/7 induction normalised to cell viability assessed by MTT in PEA1 
(A) and PEA2 (B). Cells were treated with either NU7441 at 10µM or NU7026 at 10µM or the novel DNAPKi at 
equimolar concentration of 1µM each, and incubated for 1 hour prior to doxorubicin treatment. The concentration was 
picked so that it had biological relevance and wasn’t too toxic on its own. This was achievable at 1µM for all drugs with the 
exception of DNAPKi 4. Then, cells that were receiving combination treatment were treated with 1.5µM doxorubicin and 
incubated for 24 hours before the assays. All the DNAPKi increased both cell lines sensitivity to doxorubicin (p=<0.005). 
Statistical significance was calculated using Student’s t-test.   
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5.7	Knockdown	of	MDR1	by	siRNA	resensitizes	cells	to	doxorubicin	treatment	
The results presented above indicate that although knockdown of DNA-PKcs by siRNA and shRNA do 
sensitize cells to doxorubicin treatment, the effect is not comparable with that seen with the inhibitor, 
NU7441, suggesting that there may be other targets of the inhibitor responsible for the phenotype being 
seen. Recently, a paper was published reporting that NU7441 was a dual inhibitor of DNA-PKcs and 
MDR1 (p-glycoprotein), which is implicated in resistance to a broad spectrum of chemotherapeutic 
agents (Mould et al, 2014). To assess if MDR1 was responsible for the effects being observed, MDR1 was 
knocked down by siRNA in PEA1 and PEA2 and then treated with doxorubicin to see if the NU7441 
and doxorubicin effects could be recapitulated. The results showed that knocking down MDR1 did 
significantly sensitize both PEA1 and PEA2 cells to doxorubicin treatment with a 2.5-fold (p=0.0005) 
and 4.7-fold (p=0.0006) increase in apoptosis respectively. This effect was more apparent in the platinum- 
resistant PEA2 cells (figure 52). This however, still does not recapitulate the effects seen with the DNA-
PKcs inhibitor.  
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Figure 52: Knockdown of MDR1 sensitizes cells to doxorubicin treatment but doesn’t 
account for the effects observed with NU7441.  
PEA1 and PEA2 cells were transfected with 100nM pooled MDR1 siRNA and following 48 hour transfection, cells 
were re-seeded and treated with doxorubicin at 1.5µM for 24 hours before assay was conducted. Knockdown of MDR1 
sensitized cells, particularly the PEA2 to doxorubicin (A). Knockdown of MDR1 was confirmed at mRNA level by 
qPCR (B). Statistical significance was calculated using Student’s t-test.  
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5.8	Doxorubicin	in	combination	with	NU7441	causes	loss	of	total	SGK3:	
potential	mechanisms	
Given that the benefits of combining NU7441 and doxorubicin have been extensively demonstrated, it 
was important to try to establish a possible mechanism behind the phenotype being observed.  
It was interesting to note that despite established mechanisms behind NU7441 resensitizing cisplatin 
resistant cells to cisplatin, the mechanism governing the modulation of sensitivity to doxorubicin were 
independent to that of cisplatin. Given the AKT-independent phenotypes being observed with 
doxorubicin, the involvement of an alternative effector of the PI3K pathway, SGK3, discussed in detail in 
chapter 4, was investigated. Ovarian cancer cell lines treated with doxorubicin and NU7441 were lysed for 
protein extraction and then run on a western to detect protein levels of SGK3 and other proteins. It was 
observed that in the isogenic paired cell lines PEA1 and PEA2, whilst treatment with either doxorubicin 
or cisplatin alone did not alter SGK3 protein expression, the combination treatment of doxorubicin and 
NU7441 completely abrogated SGK3 protein levels, specifically in the resistant PEA2 cells. A small 
decrease is seen in the PEA1 cells however this change does not appear to be as pronounced in the PEA2 
(figure 53A). There doesn’t appear to be a change in pAKT S473 levels, the site that DNA-PKcs 
phosphorylates, with the combination treatment, in keeping with the trend that this effect is indeed AKT 
independent. A decrease in SGK3 protein is also observed in ovarian cancer cell line, OVCAR4, however 
this decrease is even more apparent in cells treated with cisplatin in combination with doxorubicin (figure 
53B), suggesting that perhaps the resensitization observed with cisplatin and NU7441 may also be 
mediated by SGK3. Interestingly, a decrease in GSK3b, a known downstream substrate for SGK3 is also 
observed (figure 53B). Similar results were also seen in Panc-1 and SKOV3 cells (figure 53C). 
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Figure 53: SGK3 expression is decreased/lost with doxorubicin and NU7441 treatment  
This effect is seen in PEA1 and particularly in PEA2 cells (A), in OVCAR4 (B), where a decrease in one of SGK3 
substrates, phosphorylated GS3Kb is also shown with decreasing SGK3. Similar reduced SGK3 expression levels were also 
observed in SKOV3 and Panc-1 cells, though the effects are less striking in these cell lines compared to PEA2. 	  
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5.9	DNA-PKcs	may	be	regulating	other	proteins	in	an	AKT-independent	manner,	
identified	using	reverse-phase	protein	array	(RPPA)	
It has thus far been demonstrated that there is a potential therapeutic benefit in combining doxorubicin 
with NU7441. In order to identify the key mediators of the signalling cascades that follow the treatment, 
RPPA experiments were carried out. The experiments were undertaken in isogenic paired cell lines, PEA1 
and PEA2 and pancreatic cell line, Panc-1. The treatment conditions were as follows: vehicle control, 
doxorubicin (1.5µM) alone, NU7441 (10µM) alone, combination of doxorubicin and NU7441, API-2 
(20µM) alone and combination of doxorubicin and API-2. Although the combination of doxorubicin and 
API-2 did not sensitise cells, they were included in the experiment as they would be a good negative 
control along with the vehicle control condition. Cells were treated with the relevant drugs and protein 
lysates were collected 6 hours after treatment and processed for RPPA as detailed in the methods and 
materials. The data presented here are means of three individual experiments.  
5 . 9 . 1 	 B a s e l i n e 	 c h a n g e s 	 i n 	 d o x o r u b i c i n 	 a n d 	 N U 7 4 4 1 	
c o m b i n a t i o n 	 t r e a t m e n t 	 c o m p a r e d 	 t o 	 s i n g l e 	 a g e n t 	 t r e a t m e n t s 	
During the analysis, all the treated conditions were normalised to the untreated control. The baseline fold 
changes (compared to the untreated control) were calculated. To identify proteins that were 
upregulated/downregulated specifically in the combination (doxorubicin + NU7441) treatment versus the 
vehicle control and then compared to the single agent treatment, the fold change values against the 
vehicle control were compared amongst the three treatment conditions.  
In the PEA1, there were a number of upregulated proteins, four of which were exclusive to the 
combination (doxorubicin + NU7441) treatment when comparing with the drugs alone treatments (figure 
54); there were a greater number of downregulated proteins, however only one protein, GAPDH, was 
exclusively downregulated in the combination treatments.  The most differentially upregulated proteins 
that were exclusive to the combination treatment were Puma (1.3-fold, p=0.0332), pEGFR Y1068 (1.3-
fold, p=0.0490), Cyclin E-1 (1.25-fold, p=0.0281) and pATM S1981 (1.25-fold, ns). The most 
differentially downregulated proteins included pS6 S235_S236 (-1.7-fold change, p=0.0482), pS6 
S240_S244 (-1.6-fold change, ns), pNDRG1 T346 (-1.6-fold change, p=0.05), p70 S6 pT389 (-1.5-fold 
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change, p =0.0005), pGSK3b S9 (-1.4-fold change, p=0.0186) and interestingly pAKT S473 (-1.7-fold 
change, p=0.0085) (figure 55). However, these downregulated protein changes were not exclusive to the 
combination treatment but were shared with NU7441 treatment alone too. The only exclusive 
downregulated protein in the combination treatment for PEA1 cells was GAPDH. The full list of 
differentially expressed proteins are detailed in table 16A (for upregulated proteins) and 16B (for 
downregulated proteins). Of note, the downregulated proteins were all phosphorylation modifications, 
presumably due to the short duration of the treatment before lysates were collected for analysis.  
 
 
 
 
Figure 54: Venn diagram showing the distribution of the upregulated and downregulated 
proteins in PEA1 with treatment with either doxorubicin and NU7441 alone or in 
combination.  
 
 
 
 
 
 
 
 
 
 
Figure 55: The highest upregulated or downregulated proteins in doxorubicin and NU7441 
combination treatment in PEA1 cells normalised to the control compared to either drug 
alone. Statistical significance was calculated using student’s t-test where £0.05 was considered to be significant. The cut off 
values for analysis were a 1.2-fold increase or decrease in protein expression.	 
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Table 16: list of all the differentially upregulated (A) and downregulated (B) proteins in 
PEA1, in the combination treatment (doxorubicin + NU7441) compared to either drug alone 
after normalising to vehicle control.  
The cut off values for analysis were a 1.2-fold increase or decrease in protein expression.		
 
In the PEA2 cells, generally more proteins were upregulated compared to the PEA1 counterpart, with 
more exclusive protein changes in the combination treatments compared to the PEA1 cells as observed, 
shown in the Venn diagram in figure 56. Ten proteins were exclusively upregulated and two proteins were 
exclusively downregulated in the combination treatment compared to either drug alone. 
The exclusively upregulated proteins included pPKC-a S657 (1.2-fold change, p=ns), A-raf (1.2-fold 
change, p=0.0046), pBAD S112 (p = 0.05), Bim (1.2-fold change, p=0.0198), Complex-II-subunit (1.2-
fold change, ns), DM-K9-Histone-H3 (1.23-fold change, p=0.0486), pH2AX S139 (1.25-fold, ns), 
Fibronectin (1.27-fold, ns), Mcl-1 (1.3-fold, ns) and Snail (1.3-fold, p=0.0068). The two downregulated 
proteins exclusive to the combination treatment in PEA2 cells were Chk2 (-1.25-fold decrease, p=0.0187) 
Proteins)upregulated PEA1 cells
Doxorbubicin NU7441 Combination
HSP27_pS82 yes yes yes
Chk1_pS345 yes no yes
cGJun_pS73 yes no yes
NFGkBGp65_pS536 yes no yes
Chk1_pS296 yes no yes
p38_pT180_Y182 yes no yes
IRFG1 yes no yes
Snail no yes yes
Axl no yes no
Gys_pS641 no yes yes
Puma no no yes
EGFR_pY1068 no no yes
CyclinGE1 no no yes
ATM_pS1981 no no yes
A	 Proteins)downregulated PEA1)cells
Doxorubicin NU7441 Combination
53BP1 yes no no
Vimentin yes no yes
PKCCbCII_pS660 no yes no
PRAS40_pT246 no yes yes
HifC1Calpha no yes no
Tuberin_pT1462 no yes yes
Rictor_pT1135 no yes yes
PAIC1 no yes no
Elk1_pS383 no yes no
4ECBP1_pS65 no yes yes
cCMyc no yes no
YB1_pS102 no yes no
p90RSK_pT573 no yes yes
cCJun_pS73 no yes no
FRAC1 no yes yes
MAPK_pT202_Y204 no yes no
MDM2_pS166 no yes no
mTOR_pS2448 no yes yes
p70CS6K_pT389 no yes yes
GSKC3aCb_pS21_S9 no yes yes
Pdcd4 no yes no
GSKC3b_pS9 no yes yes
DUSP4 no yes yes
Akt_pT308 no yes yes
NDRG1_pT346 no yes yes
Akt_pS473 no yes yes
S6_pS240_S244 no yes yes
S6_pS235_S236 no yes yes
GAPDH no no yes
B	
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and PLK1 (-1.25-fold decrease, p=0.0211) as detailed in figure 57. The full list of all the proteins 
upregulated and downregulated in the PEA2 cells are detailed in table 17A and 17B respectively.  
 
 
 
 
	
Figure 56: Venn diagram showing the distribution of upregulated and downregulated 
proteins in PEA2 cells with either doxorubicin and NU7441 alone or in combination. All 
conditions were normalised to the vehicle control. 
 
 
 
 
 
 
 
 
 
	
	
 
Figure 57: The highest upregulated or downregulated proteins in doxorubicin and NU7441 
combination treatment in PEA2 cells normalised to the control, compared to either drug 
alone. Statistical significance was calculated using student’s t-test where £0.05 was considered to be significant.  
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Table 17: List of all the differentially upregulated (A) and downregulated (B) proteins in 
PEA2, in the combination treatment (doxorubicin + NU7441) compared to either drug alone 
after normalising to vehicle control. 	
The cut off values for analysis were a 1.2-fold increase or decrease in protein expression.		
 
The Panc-1 cells had the least number of total differentially expressed proteins compared to PEA1 and 
PEA2 cells. As seen in the Venn diagram in figure 58, four proteins were exclusively upregulated in the 
combination condition, namely: c-Jun pS73 (1.5-fold change, p=0.0256), p38 T180_Y182 (1.5-fold 
change, p= 0.0268), Snail (1.4-fold change, p=0.0286) and pMAPK T202_Y204 (1.25-fold change, p = 
0.05). The five downregulated proteins only in the combination treatment were PAR-R (30% decrease; 
ns), pAKT T308 (0.8-fold decrease; p=0.05), pPRAS40 T246, p=0.0456), MIG6 (20% decrease, p= 
0.0386) and pRictor T1135 (0.8-fold decrease; p=0.0080) as shown in figure 59). The full list of all the 
proteins upregulated and downregulated in the Panc-1 cells are detailed in table 18A and 18B respectively.  
 
 
Upregulated+proteins PEA2+cells
Doxorubicin NU7441 Combination
Chk1_pS345 yes no yes
Chk1_pS296 yes no yes
Chk2_pT68 yes no no
NFJkBJp65_pS536 no yes yes
AMPKa_pT172 no yes yes
p38_pT180_Y182 no yes yes
EGFR_pY1068 no yes yes
HSP27_pS82 yes yes yes
ACC_pS79 no yes yes
HER2_pY1248 no yes yes
Notch1 no yes yes
PARJR no yes yes
HistoneJH3 no yes yes
Syk no yes no
YAP_pS127 no yes yes
CaspaseJ7Jcleaved no yes yes
Cox2 no yes yes
cJJun_pS73 no yes yes
Snail no no yes
MclJ1 no no yes
Fibronectin no no yes
H2AX_pS139 no no yes
DMJK9JHistoneJH3 no no yes
ComplexJIIJSubunit no no yes
Bim no no yes
Bad_pS112 no no yes
AJRaf no no yes
PKCJa_pS657 no no yes
A	 Downregulated	proteins PEA2	cells
Doxorubicin NU7441 Combination
Collagen-VI yes no no
NDRG1_pT346 yes yes yes
p90RSK_pT573 yes no no
mTOR_pS2448 no yes yes
HSP27 no yes yes
Tau no yes yes
PRAS40_pT246 no yes yes
ERCC5 no yes yes
4E-BP1_pT37_T46 no yes yes
ER no yes yes
DUSP4 no yes no
Cyclin-D1 no yes yes
GSK-3a-b_pS21_S9 no yes yes
Rictor_pT1135 no yes yes
4E-BP1_pS65 no yes yes
GSK-3b_pS9 no yes yes
Akt_pT308 no yes yes
S6_pS235_S236 no yes yes
S6_pS240_S244 no yes yes
p21 no yes yes
p70-S6K_pT389 no yes yes
Akt_pS473 no yes yes
PLK1 no no yes
Chk2 no no yes
B	
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Figure 58: Venn diagram showing the distribution of upregulated and downregulated 
proteins in Panc-1 cells with either doxorubicin and NU7441 alone or in combination.  
All conditions were normalised to the vehicle control.  
 
 
 
 
 
 
 
 
 
 
 
Figure 59: The highest upregulated or downregulated proteins in doxorubicin and NU7441 
combination treatment in Panc-1 cells normalised to the control, compared to either drug 
alone. Statistical significance was calculated using student’s t-test where £0.05 was considered to be significant.  
 
 
 
 
Upregulatedproteins Panc113cells
Doxorubicin NU7441 Combination
Chk1_pS345 yes no yes
HSP27_pS82 yes yes yes
ATM_pS1981 yes no yes
c1Jun_pS73 no no yes
p38_pT180_Y182 no no yes
Snail no no yes
MAPK_pT202_Y204 no no yes
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Table 18: List of all the differentially upregulated (A) and downregulated (B) proteins in 
Panc-1, in the combination treatment (doxorubicin + NU7441) compared to either drug 
alone after normalising to vehicle control. The cut off values for analysis were a 1.2-fold increase or decrease 
in protein expression.	 
 
5 . 9 . 2 	 N U 7 4 4 1 	 a f f e c t s 	 s e v e r a l 	 p r o t e i n s 	 i n d e p e n d e n t 	 o f 	 A K T 	
t h a t 	 m a y 	 h a v e 	 f u n c t i o n a l 	 c o n s e q u e n c e s 	
To identify true protein changes as a result of combining doxorubicin and NU7441, as opposed to it 
being due to one drug alone, as several commonly upregulated and downregulated proteins were 
observed when comparing baseline changes versus control, analysis was carried out to assess the protein 
changes occurring when normalised to the single drug treatments after being normalised to the control. 
This should highlight any combination specific changes that are likely to be responsible for the 
sensitization effect being observed in the apoptosis assays. This was then compared to similar analysis 
implemented on the doxorubicin and API-2 combination treatment versus either drug alone. The 
proteins that were being highlighted exclusively in the doxorubicin + NU7441 versus doxorubicin alone 
group or doxorubicin + NU7441 versus NU7441 alone group would be of interest as this comparison 
would account for the AKT-dependent effects. As expected, API-2 was a specific AKT inhibitor that 
mainly inhibited only AKT or direct substrates of AKT as shown in 
Downregulated-proteins Panc31-cells
Doxorubicin NU7441 Combination
PAI yes no yes
GAPDH yes no no
4E3BP1_pT37_T46 yes no yes
NDRG1_pT346 yes no yes
GSK33b_pS9 no yes no
mTOR_pS2448 no yes yes
p21 no yes yes
p703S6K_pT389 no yes yes
Akt_pS473 no yes yes
S6_pS240_S244 no yes yes
S6_pS235_S236 no yes yes
Rictor_pT1135 no no yes
MIG6 no no yes
PRAS40_pT246 no no yes
Akt_pT308 no no yes
PAR3R no no yes
B	
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 Supplementary figure 14, where the baseline API-2 changes were restricted mainly to the two AKT 
phosphorylation sites, S473 and T308 or their substrates such as p21.  
Analysis	after	normalising	for	AKT-dependent	effect	
Following the comparisons between the two combination treatments against the drug alone, it was 
observed that NU7441 was also inhibiting AKT and its substrates which may not have been necessarily 
identified when doing the individual comparisons. To identify the protein changes taking place in the 
doxorubicin and NU7441 combination, independent of the NU7441 effects on the AKT pathway, the 
fold changes between the doxorubicin and NU7441 combination against single drug were then 
normalised to API-2 alone to account for the AKT-dependent effects. This may then highlight any 
differential changes that may occur taking into account the fact that AKT substrates (that NU7441 also 
affects) may be driving this phenotype independent of AKT as AKT share substrates with other PI3K 
effectors, and this would be highlighted once normalised to API-2 that selectively inhibits AKT.  
To address this, the fold changes between the combination treatment and either drug alone were then 
normalised to the API-2 treatment alone and the results were represented as a fold change. When 
analysing the dataset using this method, significantly fewer proteins were highlighted as being 
differentially changed. Both PEA1 and PEA2 showed upregulation of both phosphorylation sites of AKT 
(S473 and T308) when normalised to NU7441 and API-2 as detailed in table 19A and 20A. However, 
pAKT S473 was downregulated in the PEA2 when normalised to doxorubicin and API-2 single 
treatments. Interestingly, commonly upregulated proteins across the three cell lines were p38 
pT180_Y182, HSP27, Chk 1 pS296 and Gys pS64 (table 19A, 20A and 21A). Although HSP27, Chk 1 
and Gys were upregulated in all three cell lines, they were not included in the tables below detailing 
significant protein changes because they were not statistically significant due to the variation between 
experiments, although the same trend of upregulation was observed. The significant protein changes are 
visually represented in figure 60 for PEA1 changes, figure 61 for PEA2 changes and figure 62 for Panc-1 
changes. Briefly, in the PEA1, the most upregulated proteins were S6_pS235_S236 (4.9-fold change, 
p=0.0213), pAKT S473 (2.5-fold change, p=0.0255) and HSP27 pS82 (2.1-fold, p=0.0184) with NU7441 
and API-2 single agent normalization. The most downregulated proteins were S6_pS235_S236 (with 
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A	 B	
PEA1%combination%vs%doxorubicin% fold%change%
normalised%to%API:2
PEA1%combination%vs%NU7441%fold%change%
normalised%to%API:2
Upregulated%proteins Fold:change p:value Upregulated%proteins Fold:change p:value
Gys_pS641 1.4 0.0399 S6_pS235_S236 4.9 0.0213
p38_pT180_Y182 1.3 0.0418 Akt_pS473 2.5 0.0255
Puma 1.2 0.0157 HSP27_pS82 2.1 0.0184
c:Jun_pS73 2.0 0.0015
p38_pT180_Y182 1.8 0.0034
Akt_pT308 1.7 0.0422
GSK:3a:b_pS21_S9 1.6 0.031
Chk1_pS345 1.5 0.0187
MDM2_pS166 1.3 0.0389
mTOR_pS2448 1.3 0.0263
Chk1_pS296 1.2 0.0489
SOD2 1.2 0.045
PEA1%combination%vs%doxorubicin% fold%change%
normalised%to%API:2
PEA1%combination%vs%NU7441%fold%change%
normalised%to%API:2
Downregulated%proteins Fold:change p:value Downregulated%proteins Fold:change p:value
Hif:1:alpha 0.8 0.0401 53BP1 0.8 0.051
MAPK_pT202_Y204 0.8 0.0438
Elk1_pS383 0.8 0.0038
MDM2_pS166 0.8 0.041
FRA:1 0.8 0.0017
mTOR_pS2448 0.8 0.0004
c:Myc 0.7 0.0046
4E:BP1_pS65 0.7 0.0268
Rictor_pT1135 0.7 0.0307
YB1_pS102 0.7 0.0141
GSK:3b_pS9 0.7 0.018
p70:S6K_pT389 0.5 0.0045
DUSP4 0.4 0.0364
NDRG1_pT346 0.4 0.043
S6_pS235_S236 0.3 0.0552
doxorubicin normalization) (70% decrease, p=0.05), NDRG1 (60% decrease, p=0.04) and DUSP4 (60% 
decrease, p=0.04). In the PEA2, the highest upregulated proteins are PAR (when normalized to both 
doxorubicin and NU7441) (3.7-fold and 3-fold change, p=0.0117 and p=0.0086 respectively) and pAKT 
S473 in the NU7441 normalized group (1.6-fold change, p=0.0199). The downregulated proteins 
included p70-S6K_pT389 (60% decrease, p=0.0167). The Panc-1 cells had the least differentially 
regulated proteins following the normalizations, however common upregulated proteins were p38 
pT180_Y182 (1.4-fold change, p=0.0123) and HSP27 pS82 (1.4-fold change, p=0.03).  
Interestingly, the downregulated proteins that commonly arose were mTOR pS2448, S6_pS240_S244 and 
S6_pS235_S236 and GSK-3b S9 across the three cell lines as detailed in tables 19B, 20B and 21B.  
 
 
Table 19: significantly upregulated (A) and downregulated (B) proteins in PEA1 after 
normalising the doxorubicin and NU7441 combination to doxorubicin and NU7441 single 
agents and then further against API-2 to account for AKT-dependent effects of NU7441.  
Statistical significance was calculated using student’s t-test where £0.05 was considered to be significant 
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Figure 60: significantly upregulated (A) and downregulated (B) proteins in PEA1 after 
normalising the doxorubicin and NU7441 combination to doxorubicin and NU7441 single 
agents and then further against API-2 to account for AKT-dependent effects of NU7441. 
Results were represented as fold changes. Statistical significance was calculated using student’s t-test where 
£0.05 was considered to be significant.  
	
	
 
 
 
 
 
 
Table 20: Significantly upregulated (A) and downregulated (B) proteins in PEA2 after 
normalising the doxorubicin and NU7441 combination to doxorubicin and NU7441 as single 
agents and then further against API-2 to account for AKT-dependent effects of NU7441. 
Statistical significance was calculated using student’s t-test where £0.05 was considered to be significant.  
A	
B	
PEA2%combination%vs%doxorubicin% fold%change%
normalised%to%API:2
PEA2%combination%vs%NU7441%fold%change%
normalised%to%API:2
Upregulated%proteins Fold:change p:value Upregulated%proteins Fold:change p:value
PAR 3.7 0.0117 PAR 3.0 0.0086
EGFR_pY1068 1.7 0.0456 Akt_pS473 1.6 0.0199
p38_pT180_Y182 1.4 0.0169 Caspase:7:cleaved 1.5 0.0165
HER2_pY1248 1.3 0.0162 Akt_pT308 1.4 0.0401
SOD2 1.3 0.002 GSK:3a:b_pS21_S9 1.3 0.0585
Chk1_pS296 1.3 0.007
PEA2%combination%vs%doxorubicin% fold%change%
normalised%to%API:2
PEA2%combination%vs%NU7441%fold%change%
normalised%to%API:2
Downregulated%proteins Fold:change p:value Downregulated%proteins Fold:change p:value
S6_pS240_S244 0.8 0.0044 PLK1 0.8 0.0198
S6_pS235_S236 0.8 0.0001 GAPDH 0.6 0.0216
Akt_pT308 0.7 0.0332
GSK:3b_pS9 0.7 0.0068
Rictor_pT1135 0.7 0.0092
4E:BP1_pS65 0.6 0.0006
Akt_pS473 0.6 0.0212
p70:S6K_pT389 0.4 0.0167
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Figure 61: Significantly upregulated (A) and downregulated (B) proteins in PEA2 after 
normalising the doxorubicin and NU7441 combination to doxorubicin and NU7441 as single 
agents and then further against API-2 to account for AKT-dependent effects of NU7441. 
Results were represented as fold changes. Statistical significance was calculated using student’s t-test where 
£0.05 was considered to be significant.  
	
 
Table 21: Significantly upregulated (A) and downregulated (B) proteins in Panc-1 after 
normalising the doxorubicin and NU7441 combination to doxorubicin and NU7441 single 
agents and then further against API-2 to account for AKT-dependent effects of NU7441.  
Statistical significance was calculated using student’s t-test where £0.05 was considered to be significant.  
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Panc%1'combination'vs'doxorubicin' fold'change'
normalised'to'API2
Upregulated'proteins Fold%change p%value
p38_pT180_Y182 1.4 0.0123
HSP27_pS82 1.4 0.0319
c%Jun_pS73 1.4 0.0323
Gys_pS641 1.3 0.0074
A	 Panc%1'combination'vs'doxorubicin' fold'change'normalised'
to'API2
Panc%1'combination'vs'NU7441'fold'change'
normalised'to'API2
Downregulated'proteins Fold%change p%value Downregulated'proteins Fold%change p%value
mTOR_pS2448 0.8 0.0148 S6_pS240_S244 0.8 0.004
p70%S6K_pT389 0.7 0.0158
S6_pS240_S244 0.2 0.0094
S6_pS235_S236 0.1 0.0046
B	
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Figure 62: Significantly upregulated (A) and downregulated (B) proteins in Panc-1 after 
normalising the doxorubicin and NU7441 combination to doxorubicin and NU7441 as single 
agents and then further against API-2 to account for AKT-dependent effects of NU7441.  
Results were represented as fold changes. There were no upregulated proteins above 1.2-fold when normalised for NU7441 
and API-2 as single agents. Statistical significance was calculated using student’s t-test where £0.05 was considered to be 
significant.  
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5.10	Discussion 
	
It has been shown that the activation of AKT stimulates a pro-survival response to DNA damage and 
that this pathway is active in platinum resistant cells (Stronach et al, 2011). We also know that DNA-PK 
was identified as being an AKT activating kinase at residue S473 in addition to its other roles. DNA-PK 
undergoes autophoshorylation, which is thought to be an important mechanism in regulating DNA-PK 
activity. To assess the role of DNA-PK autophosphorylation on pAKT S743 in response to cisplatin 
treatment and other DNA damaging agents, isogenic paired cell lines PEA1 (platinum sensitive) and 
PEA2 (platinum resistant) were treated with either cisplatin, doxorubicin or gemcitabine over a time 
course and protein was extracted to analyse by western blotting.  
It is thought that autophosphorylation of DNA-PK must occur before the repair of double-strand breaks. 
Two main phosphorylation site clusters have been identified: ABCDE cluster, which includes T2609 and 
a PQR cluster, which includes S2056. It is thought that phosphorylation at the two different sites have 
different functional consequences. Whilst autophosphorylation of the ABCDE cluster promotes end-
processing, autophosphorylation of the PQR cluster (e.g. S2056) retains DNA-PK at the damaged DNA 
ends and thus limits processing of the end by downstream repair factors (Summers et al, 2011). This study 
has focused on the S2056 phosphorylation site of DNA-PK. While some treatments (i.e. cisplatin) show 
that increased expression of pDNA-PK S2056 correlates with phosphorylation of AKT at S473, others 
show the opposite effect where treatment with doxorubicin causes a significant increase in pDNA-PK 
but a corresponding decrease in pAKT.  
pAKT S473 is absent even in the presence of the pDNA-PK S2056 in response to platinum therapy in 
the PEA1 cells which are platinum sensitive cells, which confirms previous findings within the lab that 
show that the AKT is only activated in the platinum resistant cell line. Initially we hypothesized that one 
would expect the autophosphorylation of DNA-PK at S2056 to be present only in the resistant cells too 
given that DNA-PK activates AKT (S473) and this interaction was only observed in the resistant lines. 
The trend from the results however remains unclear. The discrepancies highlight an important point that 
although DNA-PK does indeed activate AKT at S473, it by no means is the only mechanism by which 
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AKT is activated and it is entirely possible that the presence of pDNA-PK S2056 may not necessarily 
result in the phosphorylation of AKT at S473 because it has various functions that may be context 
dependent. Furthermore, Riaz et al have already suggested that the phosphorylation reaction of AKT 
S473 is more complex than depicted in current models and that the mechanism varies depending on the 
stimulated receptors (Riaz et al, 2012).  
As mentioned above, although treating cells with platinum showed the expression of pDNA-PK without 
the corresponding pAKT in the sensitive PEA1 cells, the complete opposite was observed with the 
treatment with doxorubicin, where the sensitive PEA1 cells showed pAKT expression in the absence of 
pDNA-PK. Again, this highlights another key point that the DNA damaging agents being used may 
determine the mechanism of the pro survival activation pathways because different DNA damaging drugs 
induce different types of damage through different mechanisms.  
To further investigate the interesting trend observed with the doxorubicin treatment, where pAKT S473 
expression decreased as pDNA-PKcs S2056 increased in a time dependent manner, apoptosis assays were 
carried out where cells were treated with doxorubicin and a DNA-PK inhibitor, NU7441. Interestingly, it 
was observed that inhibiting DNA-PKcs using NU7441 sensitized cells to doxorubicin treatment (figure 
52A-K) with up to a 60-fold induction in apoptosis in some cells (PEA2, figure 52A). This did not 
depend on initial sensitivity to doxorubicin because it resensitized cells that were resistant to doxorubicin 
such as Aspc1 and further enhanced sensitization in cells such as SK-UT-1 (figure 52K) and MiaPaCa 
(figure 52H) which are already sensitive to doxorubicin treatment as a single agent. Furthermore, given 
that the resensitization to platinum with NU7441 in platinum resistant cells was thought to occur through 
inhibition of AKT, an AKT inhibitor, API-2 was utilized in combination with doxorubicin to see if the 
effects would be recapitulated and surprisingly, the effects seen with doxorubicin and NU7441 
combination treatment were independent of AKT because combining doxorubicin with API-2 did not 
sensitize cells to doxorubicin. Although there was a slight increase in caspase 3/7 induction with 
doxorubicin and API-2 combination treatment, this was very small and not thought to be functionally 
related to the sensitization effect seen with the doxorubicin and NU7441 combination (figure 52A-K) 
because if the enhanced effect of doxorubicin and NU7441 was occurring through AKT, then using API-
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2 to inhibit AKT should recapitulate the effects seen with doxorubicin and NU7441, which is not evident 
in our assays.  
To investigate if this effect is DNA-PK inhibition specific, DNA-PKcs was knocked down transiently 
using siRNA in PEA1 and PEA2 cells and SKOV3 empty and stably transfected DNA-PKcs shRNA 
were also utilized. The results showed that knocking down DNA-PKcs did sensitize PEA2 cells to 
doxorubicin (figure 50A) with no significant effect being observed in the PEA1. The SKOV3 cells also 
showed increased sensitivity to doxorubicin in the DNAPK-shRNA SKOV3 compared to the empty 
vector (figure 53B). Although there was a significant effect, it did not compare to the doxorubicin and 
NU7441 effect seen when previously done in SKOV3 cells. This could be due differences in cellular 
responses due to the nature of transfection of the SKOV3 with the shRNA but given the big difference, 
it does not seem likely. Interestingly, there also appeared to be an effect when combining doxorubicin 
with NU7441 in the DNA-PK shRNA SKOV3 cells, suggesting that other mediators may be responsible 
at least in part for the effects being observed.  
To further investigate this, other DNA-PKcs inhibitors were tested with doxorubicin to see if the effects 
could be reproduced with either DNA-PK inhibitor. Another DNA-PK inhibitor, NU7026 was utilized 
in the first instance. NU7026 and NU7441 are structurally different, so if differential effects were 
observed, then this would be indicative of an off-target effect being responsible for the phenotype seen. 
Treatment with NU7026 in combination with doxorubicin showed that there was small benefit using that 
combination in the paired cell lines PEA1 and PEA2 or Panc-1 (figure 50A and 50C respectively) 
however there appeared to be a greater benefit in the SKOV3 (figure 50B) and the sarcoma cell line SK-
UT-1 (figure 50D) with increased sensitivity to doxorubicin with NU7026. However, these effects were 
still not comparable to those observed previously with NU7441. Furthermore, additional novel DNAPK 
inhibitors synthesized in-house and obtained commercially were tested with doxorubicin to see if similar 
effects were seen. Interestingly, combining doxorubicin with any DNAPK inhibitor increased the 
sensitivity of doxorubicin significantly (p=<0.005) when compared to the relevant inhibitor or 
doxorubicin alone, however the responses were quite varied between the inhibitors (figure 51A-B). This 
strongly suggests that there is a benefit with combining doxorubicin and a DNAPK inhibitor because 
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although the responses vary to different degrees, every DNAPK inhibitor tested was able to increase 
sensitivity of the cells to doxorubicin.  
Recently, it was shown that NU7441 is a dual inhibitor of DNA-PK and MDR1 (p-glycoprotein) (Mould 
et al, 2014), therefore to investigate if the effects being seen were being modulated through MDR1, 
MDR1 was knocked down in the PEA1 and PEA2 cells using siRNA. The results showed that knocking 
down MDR1 also significantly (p=<0.0006) sensitized cells to doxorubicin in both PEA1 and PEA2, 
however the effects were greater in PEA2 cells (figure 52). Again, although the cells do sensitize to 
doxorubicin, the doxorubicin and NU7441 effects are not recapitulated. This could be due to fact that 
only MDR1 was knocked down and perhaps both DNA-PKcs and MDR1 need to be knocked down 
together to see similar responses to that seen with NU7441 and doxorubicin. This could have particular 
relevance for doxorubicin treatment which is a p-glycoprotein substrate because it has been shown that 
high p-glycoprotein expression correlates with doxorubicin resistance due to p-glycoprotein-mediated 
nuclear translocation (Bao et al, 2011). However, as mentioned earlier, given that doxorubicin sensitive 
cells (SK-UT-1 and MiaPaCa) also respond with enhanced sensitivity to the combination treatment, it is 
likely that either inhibition of p-glycoprotein is only relevant in the context of doxorubicin resistant cells 
or it may not be relevant.  
The experiments to elucidate the responsible target being inhibited remained unclear. To further explore 
the observation that this effect was AKT-independent, protein lysates from cells treated with doxorubicin 
and NU7441 alone along with a combination of both were run on a western blot and initially probed for 
SGK3, an AKT-independent effector of the PI3K pathway, discussed extensively in chapter 4. 
Interestingly, in the isogenic paired cell lines PEA1 and PEA2, there appeared to be a slight decrease in 
SGK3 protein levels in the doxorubicin and NU7441 combination treatment in the PEA1 cells, however 
this effect was significant in the PEA2 cells, with complete abrogation of SGK3 protein expression. The 
data supports a role for SGK3 as the responsible kinase for the phenotype seen because the PEA2 cells 
had a complete abrogation of SGK3 protein and it also showed a larger sensitization effect compared to 
the PEA1 cells. pAKT S473 expression remain unchanged across treatments, further confirming that this 
effect is AKT-independent. Similar results were also observed in Panc-1 and SKOV3 cells.  
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Although this was an indication, more robust experiments were necessary to identify the effectors 
responsible for the increased induction of apoptosis in various cancer cell line models. To address this 
further, RPPA experiments were carried out to identify the activated signaling cascades following 
treatment with doxorubicin and NU7441. The experimental design also included API-2 alone and 
doxorubicin in combination with API-2 to act as a negative control because all the commonly changed 
proteins would likely be irrelevant to the mechanism because both combinations have very different 
responses when assessed by apoptosis and viability assays.  
At first glance, there appeared to be distinct protein signatures to distinguish PEA1 from the PEA2 cells, 
whilst the resistant cell lines PEA2 and Panc-1 clustered together when assessing the unsupervised 
hierarchical clustering (Supplementary figure 10). When assessing baseline changes of doxorubicin and 
NU7441 alone and in combination versus the control, the PEA1 cells had few proteins upregulated, 
particularly in the NU7441 alone treatment in contrast to the number of proteins downregulated (figure 
60). Interestingly, although it has been shown that AKT is not activated in PEA1 with cisplatin treatment, 
NU7441 alone appears to downregulate both phosphorylation sites of AKT when compared to control. 
Although there were many proteins downregulated in the combination treatment versus the control, all of 
them (with the exception of GAPDH) were shared with NU7441 alone too, suggesting that most of the 
changes are NU7441 dependent, irrespective of the doxorubicin treatment (table 22).  
In the PEA2 cells, similar trends were observed, where majority of the upregulated or downregulated 
proteins were shared with NU7441 alone and combination treatment when compared to the control. Of 
interest, proteins upregulated in PEA2 cells included pBAD S112 (p = 0.05), Bim (1.2-fold change, 
p=0.0198), which are pro-apoptotic factors and this is also accompanied with an upregulation of pH2AX 
S139 (1.25-fold change) (figure 61 and table 23), indicative of persistence of DNA damage, which if 
prolonged, would lead to cell death. Most proteins downregulated in the combination treatment in the 
PEA2 cells were shared with NU7441 alone treatment when both were compared to control. These 
included pAKT S473 (70% decrease, p=0.011) and pAKT T308 (50% decrease, p=0.0023) along with 
other PI3K components such as p70 S6K T389 (60% decrease, p=0.005) (table 23).  
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The Panc-1 cells, had the least number of proteins differentially expressed compared to the other two cell 
lines studied, with there being considerably fewer proteins downregulated with NU7441 in this cell line, 
suggesting the ones that have indeed changed may have functional importance. Some of the common 
downregulated proteins between Panc-1 and PEA2 were p70 S6K T389, pS6 S235, pS6 S240, mTOR 
pS2448 and GSK-3b S9 (table 23B and 24B). Their roles in explaining the effects observed with 
combination treatment will be discussed next.  
Overall, when studying the baseline changes, not many proteins were upregulated across the three cell 
lines, however, NU7441 dowregulates more proteins, which when compared to API-2/control shows 
that API-2 specifically inhibits AKT and direct substrates such as p21 as shown in table 25.  
Following comparisons between differentially expressed proteins just with doxorubicin, NU7441 and the 
combination of both, the analysis was extended to see what protein changes were exclusive to the 
doxorubicin + NU7441 combination treatment that was not present in the doxorubicin and API-2 
combination.  
Overall, in PEA1 cells, not many proteins were upregulated or downregulated in the API-2 alone or in 
combination with doxorubicin treatments, which may not be surprising because although with cisplatin, it 
has been shown that inhibiting AKT using API-2 alone or with cisplatin does not have an effect in the 
PEA1 cells. In contrast, in the PEA2 cells, a significant number of proteins were upregulated in the API-2 
condition particlarly, with majority of them overlapping between API-2 alone and in combination with 
doxorubicin conditions as seen in figure 61. The doxorubicin and NU7441 combination highlighted 
exclusive changes after normalising to the single agent treatment conditions that were absent in the API-2 
conditions. These included pEGFR Y1068 (1.9-fold p=0.0016, and p38 pT180_Y182 (1.4-fold, 
p=0.0231), which was also upregulated in the Panc-1 (1.3-fold, p=0.009) when same comparisons were 
made. Similar to the changes observed when analysing baseline changes, the common proteins that were 
downregulated in at least two out of the three cell lines studied were S6 pS235_S236, S6 pS240_S244, 
GSK-3b S9 and mTOR pS2448.  
Lastly, it was evident that NU7441 on its own was downregulating a lot of targets, mainly AKT and its 
substrates so to account for the AKT-dependent effects of NU7441, the fold changes between 
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combination (doxorubicin and NU7441) versus either drug alone were then normalised to API-2. Any 
protein changes resulting from the API-2 treatment is also not thought to contribute to the effects 
observed. Not surprisingly, the results obtained from this slightly altered analysis was not very different to 
the previous one, with the exception that significantly less proteins were highlighted as being differentially 
expressed when normalised to API-2 alone, suggesting that these are the truly differentiated proteins that 
may have functional consequences in the context of this study.  
The recurrent proteins upregulated across the resistant cell lines were p38 pT180_Y182, HSP27 pS82 and 
GSK-3a-b S21_S9, whilst the downregulated proteins were S6 pS235_S236, S6 pS240_S244, GSK-3b S9 
and mTOR pS2448, identical to the previous analysis.  
Interestingly, although the significantly downregulated proteins, S6 and GSK-3b are known AKT 
substrates, they are also shared with SGK3 due to similar functions and substrate specificities. Given that 
they are differentially downregulated even in the context of increased pAKT S473 and pAKT T308 in 
both PEA1 and PEA2 as a result of normalisation to API-2 suggests that perhaps AKT alone is not 
enough to maintain expression.  
The combination of upregulated and downregulated proteins highlighted in this analysis gives an insight 
into the signalling cascades that occur following treatment. p38, which is consistently upregulated in the 
combination treatment has been shown to be involved in mediating apoptosis through its activation. This 
is thought to occur through various mechanisms, one of them being phosphorylation and translocation of 
proteins from the Bcl-2 family which leads to the release of cytochrome c from the mitochondria,
 
the 
transforming growth factor-β-induced activation of caspase 8, as well as the regulation of membrane 
blebbing and nuclear condensation (Olson et al, 2004; Lenassi and Plemenitas, 2006). This is further 
supported by the observation of increased pBad and Bim in the combination treatment in the PEA2 cells.  
HSP27 is also commonly upregulated in the combination treatment and given its usual anti-apoptotic, pro 
survival functions in concert with AKT activation, it was surprising that this protein was significantly 
upregulated. However, in the context of NU7441, the answer may be more complex. As mentioned 
before, it has been shown that NU7441 also inhibits p-glycoprotein, which usually mediates 
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chemoresistance particularly with doxorubicin through drug efflux. It has been shown however, that with 
respect to p-glycoprotein, overexpression of HSP27 significantly reversed drug resistance by inhibiting p-
glycoprotein expression and sensitizing cells to doxorubicin, consequently inducing cell death by 
increased G2/M population and apoptosis (Kanagasabai et al, 2011). Therefore, it is possible that the 
doxorubicin in combination with NU7441 either causes the overexpression of HSP27, which attenuates 
p-glycoprotein or that other unknown mechanisms cause an upregulation in HSP27, which in 
combination with the inhibitory effect that NU7441 already has on p-glycoprotein results in a significant 
induction of apoptosis.  
There is increased expression of GSK-3a-b S21_S9, which detects either or both phosphorylation sites 
(i.e. GSK-3a at S21 or GSK-3b at S9), which then promotes the degradation of the relevant isoform.  The 
antibody used detects either of the two isoforms of GSK: GSK-3a at S21 and GSK-3b at S9. Given that 
GSK-3b S9 is frequently downregulated under the same conditions, strongly suggests that the expression 
being upregulated is specific to the GSK-3a S21 isoform. For GSK-3a and -3b, phosphorylation results in 
inactivation and subsequent degradation of the protein. The two isoforms are thought to have differential 
effects in apoptosis. GSK-3a is thought to phosphorylate anti-apoptotic Mcl-2, so the upregulation of 
phosphorylated GSK-3a suggests that there is no activation of anti-apoptotic Mcl-2, thus contributing to 
promoting apoptosis. This is just one possible contributing mechanism in the resulting effect.  
Phosphorylation of GSK-3b S9 on the other hand is attenuated in the combination treatment resulting in 
active GSK-3b. One of the effects of doxorubicin is suppression of phosphorylation GSK-3b S9 which 
results in increased activity as observed in the RPPA dataset; there is evidence that consistent activation 
of GSK-3b sensitises cells to mTOR inhibition (Koo et al, 2014) and that higher basal levels of GSK-3b 
correlated with enhanced responses. Supporting this is another observation showing reduced mTOR 
pS2448 expression in the combination treatments in PEA1 and Panc-1, suggesting that NU7441 may also 
be inhibiting mTOR either directly or indirectly. GSK3b is also though to promote apoptosis by 
inhibiting pro survival transcription factors such as CREB and heat-shock factor 1 (Jacobs et al, 2012).  
Collectively, the data suggests that doxorubicin and NU7441 combination have therapeutic benefit by 
mediation and crosstalk between several pathways, notably the MAPK/PI3K pathway along with a 
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combination of NU7441 effects on p-glycoprotein and possibly mTOR. Given that this effect appears to 
be AKT independent, interestingly a lot of known AKT substrates have been highlighted as having 
differentially expression in the combination treatments. The most likely reason for this is an AKT-
independent effector such as SGK3 is being affected which would then result in downstream substrates 
shared by both SGK3 and AKT such as GSK3b also being affected. There is emerging evidence to 
suggest that there may be a basis for this speculation, for example, the observation of loss of SGK3 
protein in the combination treatments, which does not affect pAKT S473 levels. Also, proximity ligation 
assays show that pDNA-PK and pSGK3 S486 co-localise in the cytoplasm (Supplementary figure 11) 
indicative of their interaction, suggesting the possibility of a novel mechanism for SGK3 activation by 
DNA-PK in the cytoplasm given the endosomal location of SGK3, similar to that seen with AKT at S473 
in the nucleus.  Another important point to consider is that perhaps one of the off-target effects of 
NU7441 include PI3K inhibition, which might explain why the downstream AKT substrates were 
differentially expressed in the RPPA analysis. This could be addressed by using a PI3K specific inhibitor 
such as LY294002 with doxorubicin to see if the effects on apoptosis are recapitulated to that seen with 
NU7441 and doxorubicin combination treatment.  
The present study highlights the benefit of using a DNA-PKcs inhibitor in combination with doxorubicin 
in a range of cancer cell line models. Further studies to investigate the functional mechanism behind this 
phenotypic effect indicated that some of the proteins that may be responsible for these effects are PI3K-
dependent such as GSK3b but AKT-independent, supporting the role for an AKT-independent effector 
such as SGK3 in modulating this phenotype. Ultimately, whilst these results look promising, further 
validation must be carried out in the laboratory using suitable cell line models before any definitive 
conclusions can be made. 
Although doxorubicin is a highly effective agent, its use is limited due to resistance as well as due to its 
narrow therapeutic window (e.g. cardiac toxicity) (Shi et al, 2011), so any treatment strategy that would 
result in increased sensitivity to this drug would be highly beneficial in the clinical management of this 
disease. This is especially true for pancreatic cancer, which does not respond to multiple treatment 
strategies, including those that contain doxorubicin. In addition, pegylated liposomal doxorubicin (caelyx) 
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is used as a single agent to treat platinum-sensitive recurrent ovarian cancer for patients who cannot 
tolerate platinum-based treatments and also in platinum resistant patients following relapse. Although 
evidence for the use of caelyx is weak, there are few treatment options available to patients who cannot 
take a platinum-based drug so combining doxorubicin with a DNA-PK inhibitor may be a reasonable 
clinical alternative to enhance treatment efficacy in these patients. Furthermore, the combination of 
doxorubicin with NU7441 also sensitizes leiomyosarcoma cells compared to either drug alone; ifosfamide 
and doxorubicin are the most commonly used drugs as first-line therapy suggesting that a DNA-PKcs 
inhibitor may also be useful for treating a subset of sarcomas to enhance the efficacy of doxorubicin.   
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CHAPTER	6:	RESISTANCE	TO	DNA	DAMAGING	
CHEMOTHERAPY	IN	CANCER	IS	ASSOCIATED	WITH	SPECIFIC	
NUCLEAR	ALTERATIONS		
6.1	Introduction	and	Aims	
Resistance to chemotherapy is a major obstacle in successful cancer treatment. It is evident from our 
laboratory’s work and other published data that there appears to be a shuttling of proteins from the 
nucleus to the cytoplasm and the subcellular localization of some of these proteins may determine 
resistance to certain DNA damaging agents (Su et al, 2010; Koster et al, 2010). An example of this is AKT, 
normally a cytoplasmic protein, whose activation in the nucleus in response to DNA damage by cisplatin 
is thought to be critical in driving resistance, which is DNAPK dependent (Stronach et al, 2011). 
Additionally, this is thought to be a resistance-specific occurrence as when analysing the isogenic paired 
cell lines, PEA1 and PEA2, this activation is only observed in the platinum resistant PEA2, not the 
platinum sensitive PEA1 cells.  Another example is p21, a nuclear protein, whose translocation from the 
nucleus to the cytoplasm in response to cisplatin is thought to be a critical step in inducing platinum 
resistance (Koster et al, 2010). It is known that DNA-PKcs activates AKT in the nucleus following DNA 
damage with cisplatin, and it was also demonstrated in this thesis (chapter 5) that there is a benefit in 
inhibiting DNA-PKcs in combination with doxorubicin treatment. Therefore, we wished to examine what 
other proteins may be involved in the induction of chemoresistance through changing their subcellular 
localization and whether this effect is DNAPK dependent, similar to AKT. This was addressed using the 
technique of stable isotope labelling of amino acids in cell culture (SILAC) mass spectrometry, where 
different cell populations were labelled with a ‘light’, ‘heavy’, or ‘extra heavy’ version of an amino acid. 
This technique relies on the metabolic incorporation of these differentially labelled amino acids into newly 
synthesized proteins during cell growth and division. Following approximately 5-7 doublings, proteins are 
enriched with the exogenous labelled amino acids in cell culture. The cells were then harvested and the 
heavy, extra heavy and light cell populations were mixed in a 1:1:1 ratio and protein was extracted for 
further processing. This is followed by enzymatic digestion to form a peptide pool and these samples are 
then analysed via mass spectrometer. The mass spectrometry (MS) analysis quantification is based on the 
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relative intensities of the heavy, extra heavy or light counterparts. The SILAC proteomics allows different 
cell populations to be compared at protein level.  
The aims for this study were: 
1. Following up on existing work showing the DNA-PK/AKT-mediated cytoplasmic translocation 
of p21 correlating with poor prognosis in ovarian cancer, we wished to investigate the effect, if 
any of inhibiting this nuclear export of p21 as a strategy to resensitize cells to chemotherapy 
2. To further address the nuclear/cytoplasmic shuttling dynamic by utilizing SILAC proteomics by 
analyzing for protein changes following treatment with DNA damaging agents such doxorubicin 
or cisplatin alone or in combination with the DNAPK inhibitor NU7441 to assess the 
involvement of DNAPK in the signalling modulation. This will hopefully elucidate which proteins 
change their subcellular localization with treatment of the cytotoxic agent alone and/or with the 
combination treatment. The candidate proteins would then be filtered based on relevance and 
functionally validated in the laboratory.  
 
6.2	Inhibiting	p21	nuclear	export	as	a	therapeutic	strategy	to	resensitize	cells	to	
platinum	therapy		
AKT phosphorylates and/or interacts with several molecules, one of them being p21 at two sites 
(Threonine 143 and Serine 146). One of the molecular predictors of cisplatin resistance is p21, which is 
involved in mediating cell cycle arrest and apoptosis. It has been shown that the presence of cytoplasmic 
p21 confers resistance to platinum therapy in ovarian, breast and testicular cancers (Winters et al, 2003; 
Koster et al, 2010; Xia et al, 2011). It is thought that this localization of p21 is a crucial step in inducing 
platinum resistance as it determines its ability to protect cells from apoptosis (Asada et al, 1999; Koster et 
al, 2010). Given that the presence of cytoplasmic p21 levels correlated with platinum resistance and that 
this effect could be reversed if p21 remained in the nucleus via AKT inhibition (Koster et al, 2010), we 
initially sought to examine if inhibiting the nuclear export of p21 to the cytoplasm would resensitize 
platinum resistant cells to cisplatin treatment. To address this, leptomycin B (LMB), a generic nuclear 
export inhibitor was utilized.  
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To demonstrate the functional effect of LMB, nuclear/cytoplasmic fractionated lysates were made for 
western blot analysis. Western blot analysis for pp21 (Threonine 145) was carried out on the lysates along 
with specific nuclear/cytoplasmic markers to confirm clean fractionations.  
The western blots in figure 63 show that LMB functions to block nuclear export of p21 phosphorylated 
at T145 in PEA1 cells as pp21 is seen in the nucleus and cytosol in the control and cisplatin treatments, 
however is absent from cytosolic fractions in LMB treatments. The same is seen in PEO1 cells at 5nM, 
however this effect is not seen at the lower concentration (1nM). The PEO4 cells show the presence of 
pp21 in the cytosol in all treatment conditions. The levels of pp21 are particularly elevated in the 
combination treatments and this is accompanied with a corresponding decrease in pp21 levels in the 
nucleus. This may not be surprising as this data corroborates the phenotypic assays in figure 64, which 
showed that PEO4 cells were not sensitive to treatment with LMB at any concentration.  
Figure 63 : LMB functions as a nuclear export inhibitor. 
Western blots showing the localization of pp21 in the cytoplasm and nucleus following treatment with cisplatin +/- LMB in 
PEA1 (A), PEO1 (B) and PEO4 (C). Lamin A and b-tubulin were used to confirm nuclear/cytosolic fractionations.  
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Combination treatment of LMB and cisplatin was assessed by apoptosis assays using caspase 3/7 glo 
assay and cell viability using MTT assay. The two isogenic paired ovarian cancer cell lines (PEA1/PEA2 
and PEO1/PEO4) were treated with cisplatin +/- LMB at either 1nM or 5nM for 24 hours as described 
in chapter 2.  
Treating the PEA1/PEA2 cells with LMB in combination with cisplatin results in an increased apoptotic 
signal in both cell lines. The 1nM concentration of LMB appears less toxic to the cells but when 
combined with cisplatin, enhanced sensitivity is observed in the resistant PEA2 cells. LMB at 5nM 
appears to be relatively toxic on its own especially in the PEA1 cell line; even though increased apoptotic 
signal can clearly be seen in the 5nM plus cisplatin combination relative to either single agent, it may be 
that most of the effect is due to LMB alone rather than a synergistic effect.  
 
Figure 64: the effects on apoptosis of treating two ovarian cancer paired cell lines, 
PEA1/PEA2 and PEO1/PEO4 with cisplatin (25µm) alone and in combination with LMB at 
5nM and 1nM. The cell lines were treated with LMB for 1 hour prior to cisplatin treatment and then in 
combination with cisplatin for 24 hours.  
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Following this, immunofluorescent staining was carried out on PEA1 and PEA2 cells to observe any 
nuclear/cytoplasmic changes in pp21 following treatment with cisplatin at 4 hours and 24 hours in the 
presence/absence of the nuclear export inhibitor, LMB.  
After 4 hours of treatment, the untreated controls for both cell lines appear to have more phosphorylated 
p21 than any other treatment condition and whilst pp21 appears to be present in both the cytoplasm and 
the nucleus, its localization is more nuclear in the PEA2 cells (figure 65E). For the cisplatin, LMB alone 
and combination treatments, pp21 expression although present, appears to be limited and mainly in the 
nucleus in both cell lines.  
After 24-hour cisplatin treatment, there is increased pp21 expression in both cell lines. PEA1 cells appear 
to have pp21 in both the nucleus and cytoplasm in the untreated controls; this expression is slightly 
elevated in the nucleus compared to the PEA2 cells. Both cell lines show slightly lower expression in the 
cytoplasm in the cells treated with LMB (5nM) (figure 65J and 65N). Treating cells with cisplatin causes 
an increase in pp21 localization in the cytoplasm, which is evident in both cell lines. The combination 
treatments show accumulation of pp21 in the nucleus in both cell lines, though this accumulation is a lot 
higher in the PEA1 cells. Comparing the immunofluorescent images to the fractionations, similar trends 
are observed. The only two conditions that show the presence of pp21 in the cytosol are the control and 
cisplatin conditions, which also correspond to the two conditions that show clear cytosolic pp21 
localization (Figure 65 I and 65K). Although the combination treatment does show some presence of 
pp21 in the cytosol, nuclear accumulation is clearly evident. It may be that the concentration of pp21 that 
is visible in the immunofluorescence images is not sufficient for detection by western blotting.  
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Figure 65 : IF images of PEA1 (A-D, I-L) and PEA2 (E-H, M-P) cells showing the 
localization of pp21 following treatment with LMB 5nm (B, F, J, N), cisplatin at 25µm 
(C,G,K,O) and combination treatment (D,H,L,P) 4 hours (A-H) and 24 hours (I-P) after the 
addition of cisplatin. Immunofluorescence images presented show nuclei stained with DAPI (blue) and pp21 
staining (cyan) to detect p21 subcellular localization. 
When looking at the results collectively, whilst it may be that the cytoplasmic localization of p21 may 
modulate platinum resistance, it is clear that this by no means is the main or only mechanism which 
induces platinum resistance. This is evident even in the confocal images, where at 24 hours, although the 
combination treatment which shows increased apoptotic activity in the phenotypic assays which 
corresponds to increased nuclear accumulation (shown in figure 65) in the images, there is also a 
significant amount of p21 expressed in the cytoplasm. This would seem to suggest that it may be a 
number of molecules that shuttle in and out of the nucleus and it is a combination of interactions that 
result in this resistant phenotype. Furthermore, this idea is supported by previous findings from the lab, 
Control	 5nM	LMB	 25µM	cisplatin	 LMB	+	cisplatin	
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which show that nuclear AKT is seen post-cisplatin treatment, which is unexpected (Stronach et al, 2011). 
It is hypothesized that induction of DNA damage (by chemotherapy) is detected by DNA-PK, which 
leads to activation of AKT pro-survival signalling at the site of damage, presumably to allow repair to 
occur. However, inevitably this is only part of the story and there may be other pro survival mediators 
which need to be investigated. The p21 data suggests that the nuclear/cytoplasmic signalling data may be 
an important event in its contribution to poor prognosis, so it would be interesting to know the extent of 
nuclear signaling occurring in response to DNA damage which will be addressed next.  
6.3	Using	SILAC	proteomics	to	identify	novel	nuclear	changes	that	may	be	
predictive	of	chemoresistance	in	ovarian	and	pancreatic	cancers	
To assess the shuttling dynamic occurring in response to treatment in chemoresistant cells compared to a 
sensitive model, a SILAC proteomic approach was utilized. The isogenic paired cell lines PEA1 (platinum 
sensitive) and PEA2 (platinum resistant) along with a resistant pancreatic cell line, Panc-1 were studied. 
The experiment was designed to answer several questions: firstly, we were interested in observing any 
chemoresistance specific nuclear changes in response to chemotherapy treatments (doxorubicin and 
cisplatin). This would be possible by comparing the two resistant cell lines, PEA2 and Panc-1 to the 
sensitive cell line, and see which changes occur exclusively in the resistant cell lines. Also, it has been 
demonstrated in the previous chapter that combining doxorubicin with a DNA-PK inhibitor (NU7441) 
significantly sensitizes cells to doxorubicin and previous work in the laboratory also demonstrated a 
significant benefit in combining NU7441 with cisplatin (Stronach et al, 2011). These combination 
treatments were also included in the experimental design because they may shed light on possible 
mechanisms and changes occurring in each cellular compartment that may prove beneficial in predicting 
chemoresistance and/or response to treatment. Ideally, as an example, any upregulated proteins identified 
in the nucleus with the chemotherapy alone treatment would then be downregulated in the nucleus with 
the addition of a DNAPK inhibitor, NU7441 and the chemotherapeutic agent as this would indicate that 
the protein in question is a likely biomarker for chemoresistance and a predictive marker for response to 
combination treatment with a DNAPK inhibitor.  
A triple SILAC approach was utilized to answer the questions explained above. Cell populations were 
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labelled with either a “light”, “heavy” or “extra-heavy” version of an amino acid (full details of amino 
acids altered are in chapter 2 for reference). After 5 doublings, the cells were considered to be fully 
incorporated and experiments could be undertaken using these cells. The incorporations of the cells were 
tested prior to experiments and all the labelled cell population had at least 95% incorporation of the 
amino acids. For the experiment, each cell population was either a control (light label), or treated with 
doxorubicin or cisplatin alone (heavy label) or treated with combination treatment with either 
doxorubicin or cisplatin with the addition of NU7441. Cells were treated for 24 hours, following which 
the three treatments per cell line, per drug (doxorubicin or cisplatin) were combined in a 1:1:1 ratio and 
then fractionated to collect nuclear and cytoplasmic fractions to assess nuclear specific changes.  
The data was normalized to the mean of the distribution as this represents the ratio at which the light, 
heavy and extra heavy cells were mixed initially and is used as a normalization factor for all the proteins. 
The parameters used to identify the differentially expressed proteins were protein score, number of 
peptides identified, the standard deviation of the distribution and the ratios between the different labelled 
populations. Ratios of ³1.2 and £0.8 were used at cut offs for identification of biologically relevant 
changes.  
6 . 3 . 1 	 N o v e l 	 r e s i s t a n c e - s p e c i f i c 	 n u c l e a r 	 c h a n g e s 	 i n 	 r e s p o n s e 	
t o 	 D N A 	 d a m a g e 	
First, the data was analysed for any nuclear changes occurring in response to DNA damage. More 
specifically, any changes occurring in the resistant cells PEA2 and Panc-1 but were absent in the sensitive 
PEA1 cells would be of interest. The Venn diagram in figure 66 highlights the distribution of the 
differentially expressed proteins between the cell lines. The figure represents protein differences with 
either cisplatin or doxorubicin treatment.  
Generally, there were more changes in protein expression/distribution in the resistant PEA2 and Panc-1 
individually when compared to PEA1, which had 6 proteins differentially expressed based on the defined 
cut offs compared to 10 and 19 proteins for PEA2 and Panc-1 respectively. There were 7 proteins 
commonly changed in the PEA2 and Panc-1: AHNK, PRKDC, DDX5, HSP7C, NUCL, ROA1 and 
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SRSF6. Details of the functions of the proteins highlighted are in Table 23.  
 
 
 
 
 
 
 
Figure 66: Venn diagram showing the distribution of proteins differentially expressed with 
either cisplatin or doxorubicin treatment in PEA1, PEA2 and Panc-1.  
Nuclear changes of proteins that were either upregulated or downregulated with a cut-off fold change of 1.2 in cells 
that were treated with either cisplatin or doxorubicin alone were included in the analysis.  
 
When looking at the protein changes individually in each cell line, the PEA1 cells had the least number of 
proteins altered. There were proteins such as vimentin that were upregulated in all three cell lines, or H15, 
which was downregulated in all cell lines, but they were disregarded because they were not considered 
chemoresistant specific changes. The highest upregulated protein common between PEA2 and Panc-1 
was SRSF6 with 2.4-fold and 1.7- fold change respectively. PRKDC (DNA-PKcs) was also upregulated in 
PEA2 (1.2-fold change), which was an expected result as increased levels of DNA-PKcs has been 
observed previously in our laboratory in the platinum resistant PEA2 cells, and so could act as a positive 
control.  
Generally, the ribonucleoproteins such as ROA1, ROA2, ROAA, HNRPD, HNRPK, HNRPM, HNRDL 
were differentially expressed with chemotherapy treatment (tables 22A-C). Similarly, deadbox proteins 
such as DDX5 and DDX17 were also upregulated in the resistant cell lines (table 22B and 22C).  These 
changes were not observed in the sensitive PEA1 cells and so were interesting.   
Resistance)specific)changes
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Table 22: the ratio of drug/control changes in isogenic ovarian cancer paired cell lines 
PEA1 (A) and PEA2 (B) and pancreatic cancer cell line, Panc-1 (C).  
 
 
 
 
 
 
 
 
Table  23: functions of the proteins identified as being commonly altered in PEA2 and Panc-
1 with chemotherapy (doxorubicin or cisplatin) alone treatment.   
B	 Panc%1'nuclear'changes
Protein
Doxorubicin/control'
(H/L'ratio) Protein'
Cisplatin/control'
(H/L'ratio)
Upregulated'proteins
KRI1 2 SRSF6 1.7
ABCF1 1.6 AHNK 1.4
ARI1A 1.6 HSP71 1.3
PHF5A 1.5 NUMA1 1.3
RRBP1 1.4 VIME 1.3
PSD5A 1.4 RBMX 1.2
LC7L3 1.4 HSP7C 1.2
RL12 1.3
ZFR 1.3
HNRDL 1.3
ROA1 1.3
DDX5 1.3
NUCL 1.3
DDX17 1.2
Downregulated'proteins
K2C1 0.003 HNRPK 0.6
HSP71 0.5 ROAA 0.7
HMGA2 0.5 HNRPD 0.7
BTF3 0.5 ROA2 0.8
BASP1 0.6 MDHM 0.8
HSP7C 0.7 NUCL 0.8
H15 0.7
TP53B 0.7
TBA1C 0.7
PRKDC 0.8
C	PEA2%nuclear%changes
Protein
Doxorubicin/control%
(H/L%ratio) Protein%
Cisplatin/control%
(H/L%ratio)
Upregulated%proteins
SRSF6 2.4 IF2B 1.7
HNRDL 1.8 PARP1 1.6
ROA1 1.4 G3P 1.4
ROAA 1.4 SRSF6 1.3
NUCL 1.3 MATR3 1.3
HNRPM 1.3 DDX5 1.3
ROA2 1.2 ROA1 1.2
RBMX 1.2 ALDOA 1.2
AHNK 1.2 AHNK 1.2
DDX21 1.2
NPM 1.2
HSP7C 1.2
PRKDC 1.2
Downregulated%proteins
ALDOC 0.5 HNRPK 0.4
ALDOA 0.7 SPTN1 0.8
EF1A3 0.8 NONO 0.8
H15 0.8 RS14 0.8
RS14 0.8 SFPQ 0.8
Protein Function
SRSF6 Role in mRNA splicing; acts as an oncoprotein that regulates proliferation and
cell survival in lung and colon cancers
HSP7C Companion protein that trafficks other proteins into different compartments;
shown to be upregulated in colon cancer; regulates cell survival and is involved
in AKT signalling
DDX5 Important role in G1/S phase progression; amplified in a subset of breast
tumours
ROA1 Influences preKmRNA processing and mRNA metabolism and transport;
overexpression of gene encoding ROA1 promotes tumour invasion and confers
a poor prognosis in hepatocellular carcinoma patients
NUCL Thought toOplayOaOroleOinOpreKmRNAOtranscriptionOandOribosomeOassembly
PRKDC DNAOdoubleOstrand breakOrepairOandOrecombinationOprotein;OmediatesOAKTO
activationOandOapoptosisOinhibitionO inOclinicallyO acquiredOplatinumOresistance
AHNK NeuroblastOdifferentiationOassociatedOprotein;OmayObeOrequiredO forOneuronalOcellO
differentiation
PEA1%nuclear%changes
Protein
Doxorubicin/control%
(H/L%ratio) Protein%
Cisplatin/control%
(H/L%ratio)
Upregulated%proteins
VIME 1.9 EF1A3 1.3
RBMX 1.3 SRSF8 1.3
HNRPK 1.4 ALDOC 1.2
ROA2 1.5 ZYX 1.4
RS14 1.4
Downregulated%proteins
HMGA2 0.7 ROA2 0.7
ENOA 0.4 ROAA 0.6
H12 0.7 HNRPD 0.8
H15 0.8 DHX9 0.8
MATR3 0.7
MAP4 0.5
A	
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6 . 3 . 2 	 P r o t e i n 	 c h a n g e s 	 t h a t 	 m a y 	 b e 	 d e t e r m i n a n t s 	 o f 	 r e s p o n s e 	
t o 	 t r e a t m e n t 	 w i t h 	 N U 7 4 4 1 	
When analyzing the combination treatment versus the drug alone, several protein changes were observed, 
more specifically, six proteins were altered in PEA2 and Panc-1 exclusively, however only two proteins 
appeared to be of interest when comparing to the single drug analysis (figure 67). The previous analysis in 
figure 70, highlighted seven proteins whose upregulation/downregulation was restricted to the 
chemoresistant cell lines. Two of these proteins, SRSF6 and HSP7C, which were upregulated in response 
to chemotherapy, now appeared to be decreased in the nucleus with the addition of NU7441. SRSF6 
protein expression was downregulated in Panc-1 with the cisplatin /NU7441 combination and in PEA2 
with both doxorubicin and cisplatin in combination with NU7441. HSP7C was also downregulated in the 
same conditions as stated for SRSF6 (table 24B and 24C). Importantly, these changes were not observed 
in the PEA1, suggesting that these proteins may be functionally contributing to chemoresistance with the 
chemotherapy alone and then the sensitization effect seen with NU7441. The other four proteins altered 
were ROA3, H13, NUCL and G3P. Although NUCL was also upregulated in the chemotherapy alone 
treatment, it remained upregulated with NU7441 treatment too. ROA3, H13 and G3P did not show any 
obvious patterns between the Panc-1 and PEA2 because it appeared upregulated in one cell line and 
downregulated in the other. Details can be seen in table 24B and 24C. 
 
 
 
 
 
 
Figure 67: Venn diagram showing the distribution of proteins differentially expressed with 
NU7441 in combination with either cisplatin or doxorubicin normalized to cisplatin or 
doxorubicin treatment alone in PEA1, PEA2 and Panc-1.  
Upregulated or downregulated proteins with a cut off of 1.2-fold change were included in the analysis.  
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Table 24: the ratio of drug/control changes in isogenic ovarian cancer paired cell lines 
PEA1 (A) and PEA2 (B) and pancreatic cancer cell line, Panc-1 (C).  
	 	
PEA2%nuclear%changes
Protein
Combination/doxorubicin%
(EH/H%ratio) Protein%
Combination/cisplatin%
(EH/H%ratio)
Upregulated%proteins
H13 1.5 AHNK 1.5
H15 1.3 HNRPK 1.3
NUCL 1.3 H13 1.3
YBOX1 1.2 H11 1.3
DDX21 1.3
FUBP2 1.2
Downregulated%proteins
ANXA2 0.8 ROA3 0.8
TAGL2 0.8 TBA1C 0.8
HNRPM 0.8 ALDOA 0.8
HSP7C 0.7 SRSF6 0.8
COR1C 0.7 HSP7C 0.8
SRSF6 0.6 G3P 0.8
TAGL2 0.8
LEG1 0.8
IF2B 0.7
PRKDC 0.7
B	 Panc%1'nuclear'changes
Protein
Combination/doxor
ubicin'(EH/H'ratio) Protein'
Combination/cisplatin'
(EH/H'ratio)
Upregulated'proteins
H12 2 ROAA 2.6
TP53B 1.9 HNRDL 2.2
RL18 1.6 RS14 2
RS3 1.6 HNRPD 1.8
H15 1.5 ROA1 1.5
RL30 1.5 ROA2 1.4
NUCL 1.4 HNRPK 1.4
G3P 1.3 NUCL 1.4
HNRPU 1.3 ROA3 1.3
LAP2A 1.2 NPM 1.3
Downregulated'proteins
HSP71 0.8 ANXA2 0.8
ANXA2 0.8 SRSF1 0.8
VIME 0.8 MDHM 0.8
LC7L3 0.8 H15 0.8
PHF5A 0.8 HSP7C 0.8
HNRPR 0.8 SRSF8 0.8
SEP'T2 0.7 LIMA1 0.8
KRI1 0.7 EF1A3 0.7
ABCF1 0.6 HMGA2 0.7
ARI1A 0.6 HSP71 0.7
HS90A 0.6 H13 0.6
FEN1 0.6 SRSF6 0.5
SEP111 0.6 VIME 0.4
INT3 0.6
C	
PEA1	nuclear	changes
Protein
Combination/doxorubicin	
(EH/H	ratio) Protein	
Combination/cisplatin	
(EH/H	ratio)
Upregulated	proteins
H12 2.5 FUS 2.7
NPM 1.5 ROAA 2
RS14 1.5 MATR3 2
SRSF1 1.4 RS19 1.9
ACTB 1.3 YBOX1 1.8
SFPQ 1.3 HNRPU 1.8
H15 1.3 DDX17 1.7
ROA2 1.2 HNRPD 1.6
ROA2 1.5
ROA1 1.4
HNRPK 1.3
Downregulated	proteins
EF1A3 0.8 ANXA2 0.8
LAP2A 0.8 BASP1 0.8
TBA1C 0.8 RBMX 0.8
Vimentin	 0.5 MYH9 0.8
EF1A3 0.7
LAP2A 0.7
ALDOC 0.7
ALDOA 0.7
A	
 240 
6.4	PRELIMINARY	VALIDATION	OF	SILAC	SCREEN	TARGETS	
	
Given that SRSF6 and HSP7C appeared to be of interest when analyzing both the single chemotherapy 
treatment and the combination treatments, they were first validated in the laboratory using siRNA. We 
observed nuclear upregulation of the two proteins with chemotherapy treatment, which then decreased 
with the addition of NU7441. If these proteins were functionally responsible for chemoresistance, then 
knocking them down should resensitize cells to chemotherapy alone treatments.  
PEA2 and Panc-1 cells were transiently knocked down with two siRNAs each for SRSF6 and HSP7C. 
Following 48-hour transfection of the relevant siRNAs, the cells were re-seeded into 96-well plates and 
were treated with either doxorubicin or cisplatin alone and in combination with NU7441 for 24 hours. 
Apoptosis and viability assays were carried out to determine treatment effect. The data represented is a 
fold change of induction of caspase 3/7 normalised to the viability assessed by MTT assay. Knockdowns 
for all targets studied here were confirmed at mRNA level, as detailed in Supplementary figure 13. 
The results showed that knocking down SRSF6 did not show any significant benefit with any treatment in 
either PEA2 or Panc-1 cells (figure 68A and 68B). Similar to SRSF6, knocking down HSP7C did not 
appear to alter apoptosis in either PEA2 or Panc-1 in all treatments tested as shown in figure 69. There 
appeared to be a difference in responses between the two siRNAs used for HSP7C; however knockdown 
of HSP7C by either siRNA did not significantly sensitize cells to the chemotherapy alone. The NU7441 
treatment alone did appear to induce apoptosis 2-fold compared to the non-targeting, however this was 
only observed in one of the siRNAs used in the PEA2 cells and was not statistically significant. Given 
that the top two candidates from the SILAC screen data thought to have a role in modulating response to 
therapy did not affect apoptosis/viability, some of the candidate proteins identified in the chemotherapy 
alone versus control condition were analysed. NUCL, DDX5 and ROA1 were also knocked down by 
siRNA and apoptosis was determined after treatment with chemotherapy alone or in combination with 
NU7441.  
Knocking down DDX5 did not appear to alter apoptotic signal induction in the Panc-1 cells in any 
condition, however, in the PEA2 cells it appeared to significantly sensitize cells to cisplatin alone 
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treatment, NU7441 alone and combination treatment of NU7441 with doxorubicin. The sensitization 
with DDX5 knockdown was only observed in one siRNA for the cisplatin treatment, however the 
significant effect in the combination treatment and NU7441 alone treatment was observed in both 
siRNAs used as detailed in figure 70B.  
Knocking down ROA1 appeared to a have a significant effect on apoptosis induction in the pancreatic 
cancer cell line, Panc-1 in every single treatment condition, with up to a 30-fold induction in apoptosis in 
the cisplatin and NU7441 combination treatment. Again, although the two siRNAs did not display the 
same apoptotic responses, both showed a benefit in knocking down ROA1 in response to therapy (figure 
71A). No significant differences were observed with ROA1 knockdown and non-targeting control in 
PEA2 (figure 71B).  
Finally, knocking down NUCL enhanced sensitivity to NU7441 alone and in combination with cisplatin 
in Panc-1 (figure 72A). Combining NU7441 with doxorubicin however had altered apoptosis induction 
when compared to the non-targeting control. No significant effect was observed with any treatment in 
the PEA2 cells (figure 72B). 
Collectively, the preliminary data shows that there may be benefit in knocking down some targets in 
combination with chemotherapy, however nothing stands out as being a suitable target that is beneficial 
in both cell lines. Validation of other targets may reveal one such candidate protein that may be a suitable 
biomarker of chemoresistance or determinant of response to treatment. 
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Figure 68: knockdown of SRSF6 does not affect apoptosis in PEA2 and Panc-1 with either 
treatment with doxorubicin (1.5µM) or cisplatin (25µM) alone or in combination with 
NU7441 (10µM).  
  
 
 
Figure 69: knockdown of HSP7C does not affect apoptosis in Panc-1 (A) and PEA2 (B) with 
treatment with either doxorubicin (1.5µM) or cisplatin (25µM) alone or in combination with 
NU7441 (10µM).  
	
 
Figure 70: Knockdown of DDX5 does not significantly alter apoptotic signal in Panc-1 (A), 
however does resensitize PEA2 cells (B) to cisplatin (25µM) and combination treatments 
with NU7441 (10µM).  
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Figure 71: knockdown of ROA1 significantly sensitizes Panc-1 cells to all treatments (A) 
however does not have a significant effect in the PEA2 cells (B).  
 
  
 
 
Figure 72: knockdown of NUCL significantly sensitizes Panc-1 cells to all treatments (A) 
however does not have a significant effect in the PEA2 cells (B).  
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6.5	Discussion	
It has previously been shown that the presence of p21 in the cytoplasm is associated with 
chemotherapeutic resistance in several cancers including ovarian cancer. Although p21 was previously 
known to be a cancer cell proliferation inhibitor as well as a cell cycle regulator, several studies have 
demonstrated that p21 promotes tumour progression when accumulated in the cytoplasm (Xia et al, 2011; 
Koster et al, 2011). Additionally, there seem to be contrasting reports of the role of p21 in cancer. Whilst 
some studies have suggested that loss of p21 correlates with carcinogenesis and poor prognosis in small-
cell lung carcinoma, colorectal, cervical and head and neck cancers (Komiya et al, 1997; Zirbes et al, 2000; 
Kapranos et al, 2000) others have suggested that increased p21 expression correlated with poor prognosis 
in ovarian, cervical and breast cancer amongst others. P21 has two phosphorylation sites, Ser 146 and Thr 
145; it is thought that the phosphorylation of the two sites have distinct consequences. Studies have 
reported that phosphorylation at Thr145 inhibits the interaction between p21 and PCNA, which is 
thought to be critical in its function of inducing G1/G2 arrest, independent of its inhibition of 
cyclin/CDK complexes (Cayrol C et al, 1998) and furthermore, phosphorylation at Thr145 significantly 
increases p21 protein stability. Phosphorylation at Ser146 however, causes p21 to localize mainly in the 
cytoplasm and the effect on its stability is minimal (Zhang et al, 2007). The results presented here are all 
investigations on pp21 Thr 145. Although it has been demonstrated that inhibiting nuclear export of p21 
in the PEA1/PEA2 paired cell line does indeed induce more apoptosis in the resistant line compared to 
cisplatin and LMB alone, this effect is not seen in the platinum resistant line from the PEO1/PEO4 pair. 
There is a marginal increase in apoptotic signal in the PEO4 cells but the effect is not significant. 
Furthermore, the western blot, data corroborates the phenotypic assays in that in the PEA1 cell line, 
administering LMB inhibited nuclear export of p21, which was evident by the absence of p21 in the 
cytoplasm at 5nM. Levels of p21 in the PEA2 cells could not be detected in the nucleus or the cytoplasm 
but this could be due to low protein concentrations obtained following fractionation. The same effect as 
seen in PEA1 is observed in the PEO1 western blot, however, in the PEO4 cells, the addition of LMB 
even at 5nM does not appear to prevent the nuclear export of p21. This confirms the phenotypic assays, 
which show that combination treatment does not affect apoptosis in this cell line. This would confirm 
existing data suggesting that the localization of p21 does influence (at least in part) response to platinum 
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therapy because the presence of p21 in the cytoplasm correlated with lack of resensitization of the PEO4 
cells. This is said with caution because LMB is a general nuclear export inhibitor not specific to p21; it is 
possible that the effect of this drug on the localization of other proteins in combination with p21 is 
exerting this effect.  
Having demonstrated the importance of the subcellular localization of p21 in combination with published 
data, the SILAC experiment aimed to better understand the cytoplasmic/nuclear shuttling dynamic and 
how re-localizations of some proteins may be critical in determining response to therapy. We hoped to 
gain similar results to the p21 studies with other proteins that may be involved in the modulation of 
response to chemotherapy. The DNA damaging agents used were the commonly used chemotherapy 
agents, cisplatin and doxorubicin alone and with the addition of a DNAPK inhibitor, NU7441. These 
treatments would elucidate which proteins change subcellular localization with a focus on nuclear changes 
in response to DNA damage, and which of these are DNAPK dependent. It has been observed from 
previous phenotypic experiments that the combination (either chemotherapeutic drug and NU7441) 
treatment resensitizes the resistant PEA2 (ovarian) and Panc-1 (pancreatic) cells to both drugs. Collecting 
subcellular fractionated lysates following such treatments was hypothesized to help us determine 1) which 
proteins change subcellular localization or expression levels when cells are treated with the cytotoxic 
agent (compared to control) and 2) which proteins re-localize with the addition of NU7441 compared to 
cytotoxic drug alone, that are otherwise unaffected in the control and the drug alone treatment. These 
proteins may be of potential interest because their localization and expression may be important in 
determining response to therapy and may be modulated by DNAPK.  
The analysis mainly focused on nuclear changes and the analysis revealed that most of the proteins that 
were either upregulated or downregulated were either exclusively nuclear proteins or proteins that were 
present in both cellular compartments. The PEA2 and Panc-1 cell lines had more differentially expressed 
proteins compared to the PEA1, however only seven proteins were commonly changed only in the 
resistant cell lines (PEA2 and Panc-1) and not the sensitive cell line (PEA1). The most upregulated 
protein common in PEA2 and Panc-1 was SRSF6, a splicing factor, which interestingly was also 
downregulated with NU7441 treatment combination. This was interesting because the trend suggested 
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that perhaps SRSF6 was involved in chemoresistance, as it was upregulated with DNA damage in the 
resistant cells and may be DNA-PK dependent because it was downregulated in the combination 
treatment, also suggesting that it may modulate the resensitization effect. Increasing evidence is 
implicating the process of alternative splicing with cancer development and progression. One study 
specifically shows that SRSF6 is an oncoprotein that regulates survival and proliferation of colon and lung 
cancer cells (Cohen-Eliav et al, 2013). This led us to focus on SRSF6, and was therefore one of the first 
targets to be verified in the laboratory using siRNA to assess its functional role. Unfortunately, as seen in 
figure 68, knockdown of SRSF6 did not alter apoptotic signal when compared to the non-targeting 
control. It has been reported that alternative splicing is not only implicated in tumourigenesis, but can 
also be modulated by chemotherapeutic agents such as cisplatin and doxorubicin via the PI3K/AKT 
pathway, promoting survival and therefore resistance to these agents. Despite this, recently a report has 
suggested that knockdown of SRSF6 and SRSF4 in breast cancer cell lines actually promoted resistance to 
cisplatin treatment (Gabriel et al, 2015). The situation regarding the role of SRSF6 (if any) in contributing 
to chemoresistance of treatment is likely to be more complex than previously thought given the vast 
number of splicing regulators along with the various combinations they can work in along with their wide 
repertoire of targets. Whilst interesting trends were observed, SRSF6 in particular did not appear to be 
important in the cell line models studied using common apoptosis/viability assays.  
A second protein HSP7C also appeared to be an interesting target, for similar reasons to that with SRSF6 
in terms of the trends observed. HSP7C expression was upregulated in the chemotherapy alone treatment 
and this was decreased in the nucleus with the addition of NU7441. Interestingly, the decrease in the 
nucleus with the doxorubicin and NU7441 combination also correlated with an increase in cytoplasmic 
expression (1.2-fold). Also, HSP7C is thought to be involved in evading apoptosis (Higareda-Almaraz et 
al, 2011), so its upregulation with chemotherapy drugs alone in the resistant cell lines was unsurprising. 
However, knockdown of HSP7C did not alter apoptotic signal with any treatment in both cell lines as 
seen in figure 69.   
Given that SRSF6 and HSP7C did not prove to be suitable targets in our system, further validations of 
novel targets focused on proteins identified as being commonly upregulated with the chemotherapy alone 
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treatment. These were DDX5, NUCL and ROA1.  
Knockdown of DDX5 appeared to have a significant effect in the PEA2 cells with cisplatin alone 
treatment, in combination with NU7441 and the doxorubicin and NU7441 combination. This may not be 
surprising because DDX5 has been implicated in promoting proliferation and tumourigenesis in non-
small cell lung cancer through b-catenin pathway activation and has been implicated as having potential as 
a therapeutic target in that model (Wang et al, 2015).  
Another candidate protein chosen for validation as a potential target in our system was a heterogeneous 
nuclear ribonucleoprotein, ROA1. It was shown in figure 71 that knockdown of ROA1 had a significant 
effect in inducing apoptosis with every single treatment in the Panc-1 cells. The loss of ROA1 appeared 
to make the Panc-1 cells vulnerable to any therapeutic insult. This could be through FGF-mediated pro-
survival signaling (Roy et al, 2014). It has been reported that ROA1 is involved in promoting the 
translation of anti-apoptotic proteins. Upon phosphorylation, ROA1 increases its association with Bcl-xl 
and XIAP mRNA to promote their nuclear export. Once in the cytoplasm, it dissociates from them, 
consequently de-repressing their IRES-mediated translation (Roy et al, 2014). Similarly, in this experiment, 
increased protein levels of ROA1 may have contributed to the lack of response with chemotherapy 
through increased translation of anti-apoptotic proteins. Given that the occurrence of chemoresistance 
isn’t a “one theory fits all”, it isn’t necessarily surprising that knockdown of ROA1 did not affect PEA2 in 
a similar manner to Panc-1 even though it was upregulated in both cell lines. Also, the effect of ROA1 
depletion appeared to be DNA-PK independent because inhibiting DNA-PK also enhanced sensitivity in 
the ROA1 knockdown condition.  
The final target to be validated was NUCL, nucleolin. Nucleolin is thought to be involved in stabilizing 
Bcl-2, leading to its overexpression, thus allowing genetically unstable cells to evade apoptosis (Otake et 
al, 2007).  Knockdown of NUCL significantly increased cells sensitivity to NU7441 treatment alone and 
in combination with cisplatin in Panc-1. Nucleolin is also thought to be involved in recognition of DNA 
lesions, where it is recruited to sites of DNA breaks via RAD50 binding where it removes histones H2A 
and H2B from the break site consequently facilitating the repair of the DNA break. NUCL knockdown 
only appeared to have an effect with NU7441 treatment. However, a previous report showed that 
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knockdown of NUCL actually decreased DNA-PK phosphorylation and suppressed its activity (Xu et al, 
2015). So, NUCL in combination with a DNA-PK inhibitor may result in complete suppression of DNA-
PK activity, thus further sensitizing cells.  
In summary, this study has utilized SILAC proteomics to identify novel resistance specific alterations in 
the nuclear compartment of ovarian and pancreatic cancer cell lines treated with either cisplatin or 
doxorubicin alone and in combination with NU7441. Preliminary validation studies have highlighted that 
knockdown of some targets resensitizes resistant cells to at least one chemotherapeutic agent in the cell 
line models studied, however, further work is required to characterize other candidates highlighted in the 
analysis. One of the main limitations of the study is that it was an analysis of one biological experiment. It 
would be more robust to have done at least two independent experiments to have some confidence about 
the proteins highlighted. Further experiments addressing this would be useful to strengthen the data and 
further highlight common proteins differentially expressed across experiments.  
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7.0	CONCLUSIONS	
 
This study aimed to determine the molecular mechanisms behind resistance, one of the major causes of 
poor prognosis in cancer patients. This usually occurs through acquired resistance to treatment, 
particularly in HGS ovarian cancer, where patients initially respond well to chemotherapy and then 
majority eventually relapse with platinum resistant disease, at which point treatment options are limited 
and prognosis is poor. The initial response rates to chemotherapy are poorer in PDAC and STS making 
this problem relevant to all three tumour types. All three tumour types were known to be DDR defective, 
suggesting that genes related to this process may be driving genomic instability and resistance and that 
this would be an avenue to therapeutically exploit. The study focused on identifying new potential 
candidates that drive poor prognosis and to further evaluate an existing identified target, DNA-PKcs, 
which has already been demonstrated in contributing to poor prognosis in HGS ovarian cancer.  
In addition to chemo-resistance, another major contributor to poor prognosis is metastasis. This study 
identified SGK3 as being commonly amplified in HGSOC, PDAC and sarcomas with complex 
karyotypes, and SGK3 amplification correlating with poor prognosis using PFS data in HGSOC patients. 
Further functional studies demonstrated that although SGK3 did not have any short-term impact on 
survival, it did affect long term survival in specific genomic contexts. Additionally, it was demonstrated 
that SGK3 was able to modulate the migratory capacity of ovarian and pancreatic cancer cell lines as well 
as the adhesion and invasion capabilities of the cells. The mechanism was thought to occur at least in part 
through the regulation of the CXCR4-CXCL12 signalling axis, which is known to promote metastasis. 
Further work also demonstrated a potential role for SGK3 in transcriptional regulation of several EMT 
markers, further supporting the role of SGK3 in metastasis also via EMT. This work also has clinical 
impact because currently there are no specific SGK3 inhibitors; the work here demonstrates that there 
may be a benefit in developing an SGK3 specific inhibitor in patients that have low AKT and high SGK3 
levels as these patients are likely to benefit from SGK3 inhibition. This is particularly relevant for 
HGSOC, where metastatic peritoneal dissemination is inevitable.  
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The study also demonstrated that in addition to published data demonstrating a benefit inhibiting DNA-
PKcs in combination with cisplatin (Stronach et al, 2011), DNA-PKcs inhibition was also an effective 
therapeutic strategy in combination with doxorubicin as it enhanced apoptosis in a range of ovarian, 
pancreatic and sarcoma cancer cell line models. Interestingly, although the effect observed with DNA-
PKcs inhibition and cisplatin treatment appeared to be mediated through AKT inhibition, the effect 
observed with doxorubicin treatment appeared to be not solely dependent on AKT. Although there 
appeared to be variability between different DNA-PKcs inhibitors tested in our assays, they all 
significantly induced more apoptosis than either drug alone. Additionally, RPPA analysis to determine the 
molecular mechanism behind this enhanced sensitivity suggested that this effect was being mediated 
through MAPK/PI3K cross-talk. Several of pro-survival factors belonging to the PI3K pathway were 
downregulated even after correcting for AKT inhibition suggesting an AKT-independent effector being 
responsible for the effects observed, further highlighting the complexity and cross-talk between pathways 
at different levels. Furthermore, using SILAC proteomics, the study also demonstrated that a 
nuclear/cytoplasmic shuttling dynamic exists and resistance-specific nuclear changes were observed with 
DNA-damaging agents, highlighting these proteins as potential biomarkers for resistance. Changes were 
also observed with DNA-PKcs inhibition in combination with DNA-damaging agents. The finding of 
DNA-PKcs enhancing effect of not only cisplatin but also doxorubicin has significant clinical impact 
because currently the use of doxorubicin is limited in pancreatic cancer due to enhanced toxicity and is 
used in platinum-resistant ovarian cancer, where prognosis is already poor. Additionally, it is also used as 
first line therapy in sarcomas; combining it with a DNA-PKcs inhibitor would have some clinical benefit 
by enhancing therapeutic efficacy.  
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8.0	FUTURE	WORK	
This study has confirmed and demonstrated an important role for the PI3K pathway in mediating poor 
prognosis in HGSOC, PDAC and leiomyosarcomas. This was demonstrated with a focus on SGK3, an 
AKT-independent PI3K effector, and what is sometimes referred to as a class IV PI3K enzyme, DNA-
PKcs. This study has shown that SGK3 promotes poor prognosis through its role in mediating the 
metastasis process, with SGK3 modulation affecting tumour cell migration, adhesion and invasion. 
Furthermore, SGK3 also appeared to be involved in transcriptional regulation of several key EMT 
markers as well as the CXCR4-CXCL12 signalling axis, a possible mechanism through which SGK3 is 
acting. This study also raises several questions that would be interesting to investigate further.  
Firstly, although it was demonstrated that SGK3 may be acting through the CXCR4-CXL12 signalling 
axis to promote the metastatic phenotypes, this was demonstrated through knockdowns of AIP4 and 
CXCR4. Therefore, it would be useful to overexpress these proteins in the same system to confirm these 
effects. Whilst investigating the effects of SGK3 specific to phosphorylation site modulation, interestingly 
it was observed that the constitutively active S486 site inhibited migratory capacity of the cells while the 
constitutively active T320 site promoted migratory capacity of cells. Following this, the next logical 
question would be to investigate the effects of both sites in concert with each other as both 
phosphorylation sites result in active SGK3. Given the opposing effects each phosphorylation site has on 
its own, it would be interesting to observe how this dynamic changes when both or either site is 
constitutively active/inactive in the presence of the other.  
Another interesting observation was that SGK3 was able to affect long-term survival in a specific ovarian 
cancer cell line (IGROV1) with high endogenous SGK3 and low AKT levels. It would be useful to 
address this further and investigate the role of SGK3 in long-term survival in other cell lines either with 
simultaneous high SGK3 and low AKT or with either high SGK3 alone or low AKT alone. This would 
be beneficial because it would answer several questions: 1) are both SGK3 and AKT levels important in 
determining the function of SGK3 in the particular cell line model? 2) are the effects reproducible in 
several cell line models with presumably different genetic backgrounds other than SGK3 and AKT? If 
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not, then one could further tease out the genetic alterations that might be responsible for observing a 
benefit with SGK3 knockdown/inhibition.  
SGK3 was also shown to either directly or indirectly regulate several EMT markers at the transcriptional 
level assessed by qPCR. It would also be interesting to see if this regulation also occurs at the translational 
(protein) level as seen with CXCR4, where SGK3 modulation affects CXCR4 at both transcriptional and 
translational level. Additionally, the RPPA experiments carried out to further elucidate the signalling 
changes occurring with SGK3 overexpression highlighted several key proteins thought to be important in 
this system, namely myosin-IIa-pS1943 along with EMT markers such as vimentin. Thus, suggesting that 
the regulation of EMT markers may also occur at the translational level, however this requires 
confirmation. Furthermore, the highlighted proteins could also be validated to assess their interaction 
with SGK3 and how it may explain the phenotypes seen.  
Also, with respect to the SGK3 studies, it would be interesting to assess the prognostic value of SGK3 in 
poor prognosis. To address this, patient samples from the SCOTROC4 clinical trial, which tested fixed 
dose vs escalating dose of carboplatin only in front line treatment of ovarian cancer have been stained for 
SGK3 and will be correlated to clinical data of these patients. This is particularly relevant in ovarian 
cancer, where it has been reported that several tumours with PIK3CA mutations have low AKT levels, 
suggesting a role for an effector like SGK3 in these tumours. The patient samples have also been stained 
with AKT so a comparison will be made to assess the role of SGK3 as a prognostic biomarker. Due to 
time constraints these results are not in the thesis but will no doubt prove beneficial when assessing the 
role of SGK3 in predicting poor prognosis.  
This study also focused on the role of DNA-PKcs in mediating poor prognosis, where it was 
demonstrated from previous published data and this study that inhibition of DNA-PKcs enhances 
sensitivity to DNA-damaging chemotherapy in HGSOC, PDAC and leiomyosarcoma cells. More 
specifically, it was demonstrated that DNA-PKcs inhibition significantly sensitized cells with doxorubicin 
treatment. Proteomic experiments (RPPA and SILAC) were utilized to assess the signalling changes 
occurring either at whole proteome level or at subcellular (nuclear) levels. Both studies identified several 
proteins that were significantly differentially expressed such as the p70-S6 kinases, splicing factors and 
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dead-box proteins. Further validation needs to be performed with the significant differentially expressed 
proteins tested in suitable cell line models and suitable phenotypic assays. Additionally, although some of 
the SILAC targets were validated, they were validated using apoptosis/viability assays relevant to our 
research question, but perhaps the targets have a functional relevance in poor prognosis through other 
mechanisms as seen with SGK3. This would need further investigation using other suitable phenotypic 
assays more relevant to their functions.  
ZBTB32, another target identified in the copy number analysis was also initially validated. Given that 
platinum resistant ovarian cancer cell line resensitized to cisplatin following ZBTB32 knockdown, it 
would be interesting to further characterize this gene to assess its role in chemoresistance because the 
initial data indicates that it may have an important role that remains to be elucidated.  
Finally, an indication of an interesting relationship between DNA-PKcs and SGK3 was identified, where 
inhibition of DNA-PKcs in combination with doxorubicin decreased SGK3 protein levels, suggesting a 
role for DNA-PKcs in the regulation of SGK3. This appeared to be even more likely due to the 
interaction of SGK3 and DNA-PKcs observed using the proximity ligation assay, duolink 
(Supplementary figure 11), and the observations with the RPPA experiments identifying PI3K signalling 
components being differentially expressed that were not dependent on AKT, suggesting an AKT-
independent effector. Furthermore, both SGK3 and DNAPK are in close proximity on the same 
chromosome (chromosome 8) and therefore are frequently amplified together within the same amplicon; 
bioinformatic analysis indicated a trend where both genes are required in the same amplicon for the poor 
prognosis phenotype seen (Supplementary figure 13). DNAPK amplification confers a poor prognosis 
that is statistically significant when including SGK3 overexpression. When SGK3 amplifications are 
excluded, the significant effect of poor prognosis is lost. The same is observed when examining SGK3 
amplifications, where excluding DNAPK amplifications results in the loss of the significant effect of poor 
prognosis, suggesting interactions between the two that may be functionally significant. We hypothesize 
that DNAPK activates SGK3 in a DNA damage dependent context (similar to the action of DNAPK on 
AKT as detailed in Stronach et al, 2011). This would be an interesting avenue to pursue to establish a 
relationship between DNA-PKcs and SGK3 as it may have clinical benefit because if DNA-PKcs is the 
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activating kinase of SGK3, perhaps DNA-PKcs inhibition would be sufficient to prevent the SGK3 
oncogenic effects observed in this study.  
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9.0	SUPPLEMENTARY	DATA	
SUPPLEMENTARY FIGURE 1: LIST OF GENES INVOLVED IN DDR/REPAIR 
AND APOPTOSIS USED FOR THE BIOINFORMATICS ANALYSIS 
 
  
AATF EXO1 MRPL3 PSMD8 TNP11
ABL1 EYA1 MRPS11 PSMD9 TONSL
ACD1 EYA2 MRPS12 PSME1 TOP2A
ACLY EYA3 MRPS26 PSME2 TOPBP1
ACTL6A1 EYA4 MRPS35 PSME3 TOPORS
ACTR51 EZH2 MRPS9 PSME4 TP53
ACTR81 C17orf70 MSH2 PSMF1 TP53BP1
AEN C19orf40 MSH3 PTEN TP53TG1
AHCY FAM175A MSH4 PTMA TP63
AIFM1 FAN1 MSH5 PTTG1 TP73
AKT1 FANCA MSH6 LOC100133315 TPX2
AKT2 FANCB MSX11 RAD1 TRANK1
AKT3 FANCC MTHFD2 RAD17 TRDMT1
ALKBH1 FANCD2 MUM1 RAD18 TREX1
ALKBH2 FANCE MUS81 RAD211 TREX2
ALKBH3 FANCF MUTYH RAD23A TRIP131
ALKBH8 FANCG MYO6 RAD23B TSTA3
APBB1 FANCI NAE11 ERCC6L TTC5
APC FANCL NAIP1 ERCC6L2 TUBB
APEX1 FANCM NBN RAD50 TYMS
APEX2 FAP NCBP2 RAD51 UACA1
APITD1 FBXO18 NCOA6 RAD51AP1 UBA52
APLF FBXO31 NEDD4 RAD51C UBB
APTX FBXO45 NEIL1 RAD51L1 UBC
ASF1A FBXO6 NEIL2 RAD51D UBE2A
ASH2L FEM1B NEIL3 RAD52 UBE2B
ASTE1 FEN1 NEK11 RAD54B UBE2D3
ATAD5 FGF10 NEK11 RAD54L UBE2N
ATM FN1 NFATC2 RAD9A UBE2S
ATMIN FNIP2 NFATC4 RAD9B UBE2T
ATR FOLR1 NFRKB1 RASSF1 UBE2V1
ATRIP FOXM1 NGFR1 RBBP8 UBE2V2
ATRX FOXN3 NHEJ1 RBM14 UBR5
ATXN3 FOXO1 NIPBL RBM38 UCHL51
AXIN1 FOXO3 NME1 RBM4 UHRF1
AXIN21 FOXO4 NONO RBX1 UIMC1
BABAM1 FOXO6 NPM1 RDM1 UNG
BARD1 FSBP1 NSMCE1 RECQL UPF11
BAZ1B FTO NSMCE2 RECQL4 USP1
BCCIP FZR1 NTHL1 RECQL5 USP10
BLM G3BP1 NUDT1 REV1 USP28
BOK1 GADD45A NUP205 REV3L USP3
BRCA1 GADD45G NABP1 RFC1 USP47
BRCA2 GEN1 NABP2 RFC2 UVRAG
BRCC3 GML OGG1 RFC3 VAV3
BRE GNL1 OGT RFC4 VCP
BRIP1 GRB2 KIAA0101 RFC5 VEGFA
BRSK1 GTF2H1 PAFAH1B3 RFWD2 VEGFB
BTG2 GTF2H2 PAICS RFWD3 WAC
PARPBP GTF2H2C1 PALB2 RIF1 WDR331
C16orf5 GTF2H3 PAPD71 RINT1 WNT1
SPRTN GTF2H4 PARG RIPK1 WRN
AP5S1 GTF2H5 PARP1 RNF168 WRNIP1
CANX GTSE1 PARP2 RNF8 XAB2
CARM1 H2AFX PARP3 ROCK1 XPA
CBX3 H2AFZ PARP4 RPA1 XPC
CCNA2 HDAC1 PAXIP1 RPA2 XRCC1
CCNB1 HDAC10 PCNA RPA3 XRCC2
CCND1 HDAC11 PGAP2 RPA4 XRCC3
CCNG1 HDAC2 PHLDA3 RPAIN XRCC4
CCNH HDAC4 PIPSL1 RPL13 XRCC5
CCNO HDAC6 PLK1 RPL27 XRCC6
CCT4 HELQ PMAIP11 RPL35 XRCC6BP11
CCT5 HERC2 PML RPS27A YAP1
CD271 HINFP PMS1 RPS27L YY1
CD274 HIPK2 PMS2 RPS3 ZBTB32
CD401 HLTF PMS2CL1 RRM2B ZBTB401
CD44 HMGB1 PMS2P11 RTEL1 ZDHHC17
CD74 HMGB2
DTX2P1IUPK3BP1I
PMS2P11 RUVBL11 ZFYVE26
CDC14B HMOX1 PMS2P3 RUVBL2 ZMAT3
CDC451 HNRPA2B1 PMS2P51 SDHC ZSWIM7
CDC61 HSP90B1 PNKP SESN1 TRIAP1
CDCA51 HSPD1 POLA1 SETD7 CFLAR
CDK1 HSPE1 POLB SETD8 CRADD
CDK2 HUS1 POLD1 SETMAR DAXX
CDK7 HUWE11 POLD2 SETX1 DIABLO
CDKN1A IARS POLD3 SFN MCL11
CDKN1B IFI16 POLD4 SFPQ XIAP
CDKN2A IFNGR2 POLE SGK1 TNFRSF10A
CDKN2D IGHMBP2 POLE2 SGK2 TNFRSF10B
CDKN3 IKBKE POLG SGK3 TNFRSF10C1
CDT11 IKBKG POLG2 SHFM1 TNFRSF10D1
CEBPG IL6 POLH SHPRH TNFRSF12A1
CEP164 IL8 POLI SIRT1 TNFRSF141
CEP63 ILF2 POLK SLC30A91 TNFRSF171
CETN2 ING41 POLL SLK1 TNFRSF181
CHAF1A INO80 POLM SLX1A TNFRSF191
CHAF1B INO80B1 POLN SLX4 TNFRSF1A
CHD1L INO80C POLQ SMARCA4 TNFRSF1B
CHEK1 INO80D1 POLR2A SMARCA51 TNFRSF211
CHEK2 INO80E1 POLR2B SMC1A TNFRSF251
CHRNA4 INTS3 POLR2C SMC3 TNFRSF41
CIB1 JMY POLR2D SMC5 TNFRSF6B1
CIDEA KAT5 POLR2E SMC6 TNFRSF81
CIDEB KDELR2 POLR2F SMG1 TNFRSF91
CINP KDM1A POLR2G SMUG1 TRADD
CKS2 KIAA0415 POLR2H SMYD2 TRAF2
CLSPN KIAA20221 POLR2I SND1 TRAF4
COL1A2 KIF22 POLR2J SNRPE GZMB
COPB2 KIN POLR2K SNRPF HRK
CRIP2 KPNA2 POLR2L SOD11 FAS
CRY1 LARP1 PPP1R15A SOX4 CASP10
CRY2 LARP1B PPP2R5C SP100 CASP8
CSNK1D LDHA PPP4C1 SPATA18 CASP9
CSNK1E LIG1 PPP4R21 SPDYA BAD
CTLA4 LIG3 PRDX2 SPO11 BAG6
CTNNB1 LIG4 PRDX4 SRC BAK11
CUL4A LRP5 PRKCG1 INIP BAX1
CUL4B LTBR1 PRKDC SSBP1 BCL2
DCLRE1A LYN PRMT1 SSR1 BCL2A1
DCLRE1B MAD2L2 PRMT61 SSRP1 BCL2L11
DCLRE1C MAEL PRPF19 STAT1 BCL2L10
DDB1 MANF PSEN1 STAT2 BCL2L11
DDB2 MAP2K6 PSMA1 STAT3 BCL2L2
DDIT3 MAPK1 PSMA2 STAT4 BID
DDX11 MAPK12 PSMA3 STAT5A BIK1
DGKZ MAPK14 PSMA4 STAT5B BIRC21
DMC1 MAPK31 PSMA5 STAT6 BIRC31
DNA2 MASTL PSMA6 STRA13 BIRC51
DNAJA1 MBD1 PSMA7 STRA81 BIRC6
DNMT1 MBD2 PSMA8 STUB11 BIRC71
DNMT3A MBD3 PSMB1 SUMO1 BIRC81
DNMT3B MBD4 PSMB10 SUMO2 APAF1
DOT1L MC1R1 PSMB11 SUMO3 BBC3
DTL MCM3 PSMB2 SUMO4 TMBIM6
DTX3L MCM7 PSMB3 SUPT16H TNFRSF11A1
DUT MCRS11 PSMB4 SUV39H1 TNFRSF11B1
DVL3 MCTS1 PSMB5 SUV39H2 TNF
DYRK2 MDC1 PSMB6 SWI5 TNFSF10
E2F1 MDM2 PSMB7 TAF1 FASLG
E2F5 MECOM PSMB8 TAF9 CASP3
EEF1E1 MECP2 PSMB9 TARS CASP7
EEPD1 MEIR5 PSMC1 TCEA1 BCL3
EHMT1 MEN1 PSMC2 TDG BCL6
EIF4A3 MGMT PSMC3 TDP1
EME1 MICA PSMC4 TDP21
EME2 MIF PSMC5 TERF21
C11orf30 MLH1 PSMC6 TERF2IP1
ENDOG MLH3 PSMD1 TFAP4
ENDOV1 MLL PSMD10 TFPT1
EP300 ZAK PSMD11 TGFB1
EPC2 MMP9 PSMD12 TGIF1
ERCC1 MMS191 PSMD13 C15orf42
ERCC2 MMS22L PSMD14 TIMELESS
ERCC3 MNAT1 PSMD2 TIPIN
ERCC4 MNDA PSMD3 TIPRL
ERCC5 MORF4L1 PSMD4 TLK1
ERCC6 MORF4L2 PSMD5 TLK2
ERCC8 MPG PSMD6 TMEM161A
ESRP1 MRE11A PSMD7 TMEM30A
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SUPPLEMENTARY FIGURE 2: KAPLAN MEIER (KM) PLOTS SHOWING 
THE CORRELATION BETWEEN AMPLIFICATION AND OVERALL 
SURVIVAL (OS) IN ZBTB32, SGK3, C19ORF40 AND MRPS12. 
  
amp	=	122	
not	amp	=	350	
amp	=	150	
not	amp	=	322	
amp	=	114	
not	amp	=	339	
amp	=	128	
not	amp	=	334	
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SUPPLEMENTARY FIGURE 3:  ANTI-APOPTOTIC BCL-2 DECREASES WITH 
SGK3 KNOCKDOWN IN PEO1, PEO4, PEA1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isogenic ovarian cancer paired cell lines were transfected with SGK3 pooled siRNA and protein 
was collected for western blot analysis at the same timepoint as the endpoint of the 
caspase/viability assays utilised to assess the role of SGK3 knockdown on apoptosis and viability.  
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SUPPLEMENTARY FIGURE 4: SGK3 KNOCKDOWN DOES NOT AFFECT 
AUTOPHAGY IN OVARIAN CANCER CELL LINE MODELS.  
 
 
 
 
 
 
Ovarian cancer cell line SKOV3 and sarcoma cell line SKUT-1 were transfected with SGK3 
pooled siRNA or overexpression construct and protein was collected after 48 hours and probed 
for baseline autophagy levels as assessed by the LC3A/B conversion. There appears to be no 
difference in autophagy levels with SGK3 modulation in both cell lines studied.  
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SUPPLEMENTARY FIGURE 5: MODULATING SGK3 S486 
PHOSPHORYLATION SITE AFFECTS ADHESION OF SKOV3 CELLS TO 
COLLAGEN I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overexpression of SGK3 significantly increases adhesion of SKOV3 cells to collagen I; similar 
effects are observed in SGK3 S486 constitutively active overexpressed cells. The inactive SGK3 
S486 overexpressed cells showed adhesion levels comparative to the empty vector, suggesting 
that this site may be responsible for the role that SGK3 has in adhesion. Overexpression of both 
active and inactive constructs of the SGK3 T320 phosphorylation site showed increased 
adhesion to collagen I, comparable with the SGK3 wt and the SGK3 S486A.  
 
* p=<0.05, ** p= <0.01, *** p = <0.001 
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SUPPLEMENTARY FIGURE 6: CONSTITUTIVELY ACTIVE SGK3 S486 
INCREASES SPEED, DISPLACEMENT AND DISTANCE TRAVELLED OF 
SINGLE CELLS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Single-cell migration analysis shows that constitutively active SGK3 S486 increases some 
parameters of single cell migration, namely speed of the single cells, the displacement of an 
individual cell and its speed travelled. This is in contrast to the collective migration results, 
where constitutively active SGK3 S486 represses migratory capacity of cells.  
 
*- p = <0.05 
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SUPPLEMENTARY FIGURE 7: AIP4 TRANSCRIPTIONALLY REGULATES 
CXCR4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
qPCR analysis for CXCR4 expression of SKOV3 AIP4 knockdown lysates showed that there is 
an increase in CXCR4 mRNA level with AIP4 knockdown, suggesting that the level of AIP4-
mediated CXCR4 regulation could also be at the transcriptional level. Knockdowns for the AIP4 
were confirmed as detailed in chapter 4.  
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SUPPLEMENTARY FIGURE 8: SGK3 REGULATES SEVERAL DOWNSTREAM 
TARGETS OF PI3K PATHWAY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Western blot analysis showed that overexpression of SGK3 resulted in an increased expression in 
downstream PI3K targets FOXO3a, p-GSK3b and pPRAS40. Interestingly, PRAS40 is thus far 
known to be an AKT substrate; the results show that SGK3 may also regulate substrates 
previously thought to be regulated exclusively by AKT.  
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SUPPLEMENTARY FIGURE 9: SGK3 OVEREXPRESSION DOES NOT AFFECT 
N-CADHERIN MRNA LEVELS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although SGK3 overexpression causes a significant decrease in E-cadherin mRNA, a key EMT 
marker, this did not correlate with an increase in N-cadherin mRNA, as assessed by qPCR. 
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SUPPLEMENTARY FIGURE 10: UNSUPERVISED CLUSTERING OF DNAPK 
INHIBITION AND DOXORUBICIN TREATED SAMPLES FROM RPPA IN 
PEA1, PEA2 AND PANC-1 CELLS 
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SUPPLEMENTARY FIGURE 11: DNA-PKCS AND SGK3 INTERACT AS 
DETERMINED BY PROXIMITY LIGATION ASSAY.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein interactions between pDNA-PKcs S2056 and pSGK3 S486 were assessed using 
proximity ligation assay, Duolink. This assay utilises a pair of oligonucleotide labelled secondary 
antibodies (PLA probes), which only generate a signal when both PLA probes have bound in 
close proximity by two primary antibodies. The signal from each detected pair of PLA probes is 
visualised as one fluorescent spot. The assay shows that both pDNA-PKcs and pSGK3 interact 
resulting in the red fluorescent spots.  
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SUPPLEMENTARY FIGURE 12: KNOCKDOWN CONFIRMATION FOR SILAC 
TARGETS 
 
Knockdown of all the SILAC targets were confirmed at mRNA level using qPCR analysis 
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SUPPLEMENTARY FIGURE 13: DNA-PK AND SGK3 CO-AMPLIFICATIONS 
ARE ASSOCIATED WITH POOR PROGNOSIS IN OVARIAN CANCER 
 
 
 
 
Kaplan Meier (KM) plots showing the relationship between DNAPK (PRKDC) and SGK3 in 
conferring poor prognosis. Survival analysis shows that both DNAPK (A) and SGK3 (C) 
amplifications confer a poor prognosis which is statistically significant; when SGK3 and 
DNAPK amplifications are excluded (B and D respectively), this significance is lost.  
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SUPPLEMENTARY FIGURE 14: API-2 SELECTIVELY INHIBITS AKT 
	
	
	
	
	
	
	
 
Downregulated proteins with API-2 treatment normalised to control.		
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SUPPLEMENTARY FIGURE 15: RPPA ANTIBODY PANEL 
 
	 	
# Official	Ab	Name	 Official	Ab	Name	 Official	Ab	Name	 Official	Ab	Name	
1 14-3-3	beta COG3 IGF1R	(phospho	Y1135/Y1136) PKC	delta	(phospho	S664)
2 14-3-3	epsilon COL6A1 IGFBP2 PKM2
3 14-3-3	zeta Complex	II	Subunit IGFBP5 PLC	gamma2	(phospho	Y759)
4 4E-BP1 Connexin	43 IGFRb PLK1
5 4E-BP1	(phospho	S65) Coup-TFII INPP4b PMS2
6 4E-BP1	(phospho	T37/T46) Cox	IV IRF-1 PRAS40
7 53BP1 Cox2 IRS1 PRAS40	(phospho	T246)
8 Acetyl	CoA	Carboxylase	(phospho	S79) C-Raf	(phospho	S338) JAB1 PREX1
9 Acetyl	CoA	Carboxylase	1 C-Raf/Raf-1 Jagged1 Progesterone	Repector
10 ACVRL1 CXCR4 Jak2 PTEN
11 ADAR1 Cyclin	B1 JNK/SAPK	(phospho	T183/Y185) Puma
12 Akt Cyclin	D1 JNK2 PYGM
13 Akt	(phospho	S473) Cyclin	E1 LC3A/B Rab11
14 Akt	(phospho	T308) Cyclophilin	F Lck Rab25
15 AMPK	alpha Cytokeratin	19 LDHA Rad50
16 AMPK	alpha	(phospho	T172) Detyrosinated	alpha-Tubulin MAPK	(phospho	T202/Y204) Rad51
17 Androgen	Receptor Dimethyl-Histone	H3	(Lys4) Mcl	1 Raptor
18 Annexin	I Dimethyl-K9	Histone	H3 MDM2	(phospho	S166) Rb
19 Annexin	VII DUSP4/MKP2 MEK1 Rb	(phospho	S807/S811)
20 A-Raf Dvl3 MEK1	(phospho	S217/S221) RBM15
21 ARHI E2F-1 MEK2 Rheb
22 ARID1A E-Cadherin Merlin/NF2 Rictor
23 Atg3 eEF2 MIF Rictor	(phospho	T1135)
24 Atg7 eEF2K Mitochondria Rock-1
25 ATM EGFR MMP2 RPA32
26 ATM	(phospho	S1981) EGFR	(phospho	Y1068) Monocarboxylic	Acid	Transporter	4 RPA32	(Phospho	S4/S8)
27 ATP5A EGFR	(phospho	Y1173) MSH2 RSK
28 Aurora	B/AIM1 eIF4E MSH6 S6	(phospho	S235/S236)
29 Axl eIF4G mTOR S6	(phospho	S240/S244)
30 B7-H3 Elk1	(phospho	S383) mTOR	(phospho	S2448) SCD
31 B7-H4 Epithelial	Membrane	Antigen Myosin	heavy	chain	11 SDHA
32 Bad	(phospho	S112) ErbB2/HER2 Myosin	IIa	(phospho	S1943) SF2/ASF
33 Bak ErbB2/HER2	(phospho	Y1248) NAPSIN	A Shc	(phospho	Y317)
34 BAP1 ErbB3/HER3		 N-Cadherin SHP-2	(phospho	Y542)
35 Bax ErbB3/HER3	(phospho	Y1289) NDRG1	(phospho	T346) SLC1A5
36 Bcl2 ERCC1 NDUFB4 Smac/Diablo
37 Bcl2A1 ERCC5 NF-kappaB	p65	(phospho	S536) Smad1
38 Bcl-xL ERRFI1/MIG6 Notch1 Smad3
39 Beclin Estrogen	Receptor Notch3 Smad4
40 beta	Actin Ets-1 N-Ras Snail
41 beta	Catenin FAK	 p21 SOD2
42 beta	Catenin	(phospho	T41/S45) FAK	(phospho	Y397) p27	KIP	1 Sox2
43 Bid Fatty	Acid	Synthase p27/KIP	1	(phospho	T198) Src
44 Bim Fibronectin p27/Kip1	(phospho	T157) Src	(phospho	Y527)
45 B-Raf FoxM1 p38	MAPK Src	Family	(phospho	Y416)
46 B-Raf	(phospho	S445) FoxO3a p38	MAPK	(phospho	T180/Y182) Stat3
47 BRD4 FoxO3a	(phospho	S318/S321) p53 Stat3	(phospho	Y705)
48 c-Abl FRA-1 p70	S6	Kinase	(phospho	T389) Stat5a
49 Caspase-3	active G6PD p70/S6K1 Stathmin	1
50 Caspase-7	(cleaved	D198) Gab2 p90RSK	(phospho	T573) Syk
51 Caspase-8 GAPDH PAI-1 Tau
52 Caveolin-1 GATA3 PAR TAZ
53 CD171	(L1) GCN5L2 PARK7/DJ1 TFAM
54 CD26 Glutamate	Dehydrogenase1/2 PARP-1 TIGAR
55 CD29 Glutaminase Paxillin Transferrin	Receptor
56 CD31 Glycogen	Synthase P-Cadherin Transglutaminase	II
57 CD44 Glycogen	Synthase	(phospho	S641) PCNA TSC1/Hamartin
58 CD49b GPBB Pdcd-1L1 TSC2/Tuberin	(phospho	T1462)
59 CDK1 GSK-3alpha/beta Pdcd4 TTF1
60 CDKN2A/p16INK4a GSK-3alpha/beta	(phospho	S21/S9) PDGFR	beta Tuberin
61 Chk1 H2AX	(phospho	S140) PDK1 Twist
62 Chk1	(phospho	S296) Heregulin PDK1	(phospho	S241) Tyro3
63 Chk1	(phospho	S345) HES1 PD-L1 UBAC1
64 Chk2 Hexokinase	II PEA-15 Ubiquityl	Histone	H2B
65 Chk2	(phospho	T68) HIAP PED/PEA-15	(phospho	S116) UGT1A
66 c-Jun	(	phospho	S73) Hif-1	alpha PI3	Kinase	p110	alpha VDAC1/Porin
67 c-Kit Histone	H3 PI3K	p110	beta VEGF	Receptor	2
68 Claudin	7 HSP27 PI3K	p85 **VHL**
69 c-Met HSP27	(phospho	S82) PKA	RI	alpha Vimentin
70 c-Met	(phospho	Y1234/Y1235) HSP70 PKC	alpha XBP1
71 c-Myc YAP PKC	alpha	(phospho	S657) XIAP
72 YAP	(phospho	S127) YB1 PKC	beta	II	(phospho	S660) XPA
73 YB1	(phospho	S102) XRCC1 XPF
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